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Abstract 
Lung cancer survival is poorer in more socio-economically deprived patient groups. It 
has been suggested that socio-economic inequalities in receipt of, and time to, 
treatment may contribute to inequalities in cancer outcome. Unintended variations in 
outcome that result from the way that interventions are organised and delivered have 
been described as intervention-generated inequalities. 
The aim of this thesis was to determine if there are socio-economic inequalities in lung 
cancer care and, if so, to identify where on the pathway of care these inequalities 
might occur: looking at receipt of treatment; referral, diagnostic and treatment time 
intervals; and survival. 
A systematic review and meta-analysis was conducted in order to examine the 
published evidence for socio-economic inequalities in lung cancer treatment. A 
secondary analysis of cancer registry data for 65,210 patients diagnosed between 
1999-2010 with a primary diagnosis of lung cancer [ICD10 C33 and C34], linked to 
Hospital Episode Statistics and lung cancer audit data, was conducted. Logistic 
regression was used to examine the likelihood of receipt of treatment; of receiving 
timely referral, diagnosis and treatment within guidelines; and of being alive two years 
after diagnosis, by socio-economic position [SEP]. Cox regression was used to assess 
the likelihood of early referral, diagnosis and treatment and hazard of death, by SEP.  
Socio-economic inequalities in receipt of lung cancer surgery and chemotherapy, but 
not radiotherapy, were found in the systematic review and meta-analysis, and in the 
linked-data analysis. Socio-economic inequalities in the GP referral to first hospital 
appointment time interval were identified. Socio-economic inequalities in survival 
from lung cancer were statistically explained by socio-economic inequalities in receipt 
of treatment, but not by inequalities in timeliness of referral and treatment, in this 
cohort. However high levels of missing stage, performance status and co-morbidity 
data were a limitation. 
Research into the unexplained variance in treatment rates is required in order to 
develop interventions that address socio-economic inequalities in receipt of treatment 
and reduce socio-economic inequalities in survival.   
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Chapter 1. Introduction 
The aim of this thesis is to explore the evidence for intervention-generated inequalities 
(IGIs) in lung cancer treatment: to examine the published evidence for socio-economic 
inequalities in lung cancer treatment; to use routine secondary data to determine if 
there are inequalities in lung cancer care, and to identify where on the pathway of care 
these inequalities might occur – looking at inequalities in receipt of treatment, time to 
treatment, and survival. 
Chapter 1 presents a general introduction to the thesis. Chapter 2 reviews the 
literature on IGIs, and chapters 3, 4 and 5 examine the evidence for IGIs and cancer, 
whilst chapter 6 details the aims and objectives. Chapter 7 examines the published 
evidence for socio-economic inequalities in lung cancer treatment using a systematic 
review and meta-analysis, and chapters 8-12 present the research methods and results 
from the secondary data analysis. Chapter 8 details the methods and chapter 9 
presents descriptive analyses, before going on to explore socio-economic inequalities 
in lung cancer treatment [chapter 10], referral, diagnostic and treatment intervals 
[chapter 11] and survival [chapter 12]. An overall discussion of the thesis findings is 
then presented in chapter 13. 
The general background to the topic will now be examined. 
1.1 Health inequalities  
Despite improvements in living standards, introduction of the welfare state and free 
NHS care for all, socio-economic differentials in health are still observed in the UK (1).  
Health inequalities can be defined as differences in health outcomes between groups 
within populations [or between populations]. Although health inequalities due to 
biological differences are inevitable, it is recognised that inequitable differences in 
health also exist, which are unfair and potentially avoidable (2, 3). Health inequalities 
have been observed using a number of different measures of  socio-economic position 
[SEP] (2, 4).  
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1.1.1 Socio-economic position 
Socio-economic position is a construct used to measure the social and economic 
factors that influence the position of an individual or group within society (5), using 
area-based, household, and individual measures of deprivation, poverty, wealth, 
income and education (6).  
There are advantages and disadvantages to using each of these markers of SEP, which 
need to be taken into account when examining health inequality. Education is easy to 
measure, applicable to all and is generally stable over adulthood. However, it is 
strongly influenced by parental and societal characteristics and there are cohort 
effects. It is a less sensitive measure of SEP than income, but income is often poorly 
reported and excludes non-working groups (5). Household rather than individual 
income can often be a better measure of SEP for women. Poverty is a subjective 
measure and is determined by societal norms. Using a neighbourhood measure of SEP 
means there is danger of ecological fallacy but it can apply to all ages and both sexes 
(6). 
1.2 Intervention-generated inequalities  
Intervention-generated inequalities have been described as health inequalities that 
result from the way that health interventions are organised and delivered (7) so that, 
although overall health may improve as the result of an intervention, differences in 
access to the intervention, differential uptake, delays in uptake, differential 
compliance with, or effectiveness of, an intervention might result in inequalities in 
outcome. 
Inequalities are likely to occur at many different stages of intervention pathways and 
act in a cumulative way. It is also likely that intervention-generated inequalities 
contribute to overall socio-economic inequalities in morbidity and mortality, although 
this has not been conclusively demonstrated (7). 
1.3 Cancer 
Cancer is a term used for a number of diseases in which normal cells change so that 
they grow in an uncontrolled way and are able to invade other tissues. The 
uncontrolled growth causes a tumour to form. Cancer cells can spread to other parts 
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of the body through the blood and lymph systems. There are more than 200 different 
types of cancer and most are named for the organ or type of cell in which they start. 
Most cancers are carcinomas, which are cancers of the epithelial cells [tissue that 
covers and lines the body]. Carcinomas make up about 85% of cancers. There are 
different types of epithelial cells and these can develop into different subtypes of 
carcinoma, including adenocarcinoma and squamous cell carcinoma. 
Staging is a way of describing the size of a cancer and how far it has grown and spread 
to another part of the body, whereas the grade of cancer describes how similar the 
cancer cell is to a normal cell. Staging is important in determining treatment. For 
localised cancer, surgery or radiotherapy could be curative. If a cancer has spread, then 
systemic treatments such as chemotherapy or hormone therapy [that circulate 
throughout the bloodstream] may also be required. 
Cancer patients often suffer from a number of concurrent health conditions which are 
termed co-morbidities. Performance status [PS] is a measure of general well-being and 
ability to care for oneself that is assessed by the care team.  Both these variables may 
be used to help determine the most suitable cancer treatment when patients are 
assessed.  More details on these variables will be presented in chapter 8. 
1.3.1 Cancer incidence, mortality and inequality 
Breast, lung, colorectal and prostate cancer are the top four cancers for incidence and 
mortality in the UK and together account for over 54% of UK cancer incidence (8) and 
47% of cancer mortality (9). Lung cancer is the leading cause of cancer death 
accounting for 22% of cancer mortality followed by colorectal cancer at 10% (9).  
Inequalities in cancer incidence are found for a number of common cancers (8). Higher 
cancer incidence within more deprived populations is associated with higher rates of 
smoking and alcohol consumption, unhealthy diet and lack of exercise, all of which 
contribute to a higher risk of cancer (8). 
A statistically significant association between higher colorectal cancer incidence and 
socio-economic deprivation has been reported for men in England and Wales (10). 
However, this association is not always seen worldwide. A review reported that those 
4 
 
with lower SEP had higher colorectal cancer incidence compared to higher SEP groups 
in the USA and Canada, but that the reverse was true in Europe, where those with 
lower SEP had lower risk (11). However, no UK studies were included and a number of 
European studies did show an increased risk with lower SEP. Conversely higher 
incidence in less deprived populations is found for breast cancer and malignant 
melanoma in England (12).  
Around 63% of cancers are diagnosed in people aged 65 and over, and more than a 
third are diagnosed in the elderly [aged 75 and over]. 
Survival varies markedly by cancer type. Whereas around 50% of those diagnosed with 
colorectal cancer and 80% with breast cancer can expect to still be alive five years after 
diagnosis only around 6% of those with lung cancer can (9). Whilst survival rates have 
greatly improved for most cancers in recent years this improvement has not been seen 
for lung cancer. 
1.3.2 Lung cancer 
Lung cancer is the most common incident cancer, worldwide. In the USA and the UK it 
is the second most incident cancer after breast cancer (8, 13) [and the second most 
common for men after prostate cancer and for women after breast cancer], as well as 
the most common cause of cancer mortality (9, 13). Survival differs internationally. In 
the UK less than 10% of those diagnosed with lung cancer survive for 5 years (9, 14), 
with higher survival rates found in Nordic countries (14, 15), the USA (13, 15), Australia 
and Canada (14). 
A strong socio-economic gradient for lung cancer incidence is seen in the UK, with 
rates 2-3 times higher in the more deprived (8). Higher incidence and mortality is 
found in the north of England compared to the rest of the UK also (8), and the incident 
deprivation gap is wider (12). A systematic review and meta-analysis found that, 
worldwide, lung cancer incidence was associated with low education and low SEP 
[both occupational and income-based] and remained so in subgroup analyses adjusted 
for smoking (16). Smoking has been strongly associated with incidence of small cell 
lung cancer, and also squamous cell non-small cell lung cancer but less so with 
adenocarcinoma tumour type. There is some suggestion that past smoking behaviour 
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may account for much of the socio-economic inequalities in risk of lung cancer (17), 
but not all, as an SEP gradient in incidence remains when smoking status is taken into 
account (16). 
Lung cancers are classified into small cell [SCLC] and non-small cell [NSCLC] cancers, 
with NSCLC accounting for 80% of lung cancers. NSCLC can be further divided into 
squamous cell carcinomas, adenocarcinomas and large cell carcinomas (18). Studies 
have found different proportions of NSCLC subtypes.  
Squamous cell carcinoma has historically been strongly associated with smoking but, 
with the introduction of lower tar and nicotine cigarettes, the incidence of this subtype 
is falling (19). Adenocarcinomas are a morphologically heterogeneous group and 
although they are also associated with smoking [generally of low-tar filtered cigarettes 
(17)] they are also found in those who have never smoked, particularly in women (19). 
Large cell carcinomas are the least common subtype and are often misclassified (19).  
SCLC are thought to account for around 20% of lung cancers although this proportion 
has been reported to be falling in more recent years (20). SCLC is also strongly 
associated with smoking and the decrease in incidence of SCLC over time, similarly to 
the squamous subtype for NSCLC, may be related to the reduced prevalence of 
smoking and type of cigarettes smoked (20). 
1.3.2.1 Lung cancer staging 
Lung cancer stage is determined using the ‘Tumour, Node, Metastasis’ [TNM] staging 
system (21). The TNM staging system describes the size of the primary tumour, 
whether the cancer has spread to the lymph nodes and whether the cancer has spread 
to a different part of the body [metastasised]. 'T' refers to the size of the cancer, going 
from 1 [small] to 4 [large]. The letters A, B or C can be used to further divide the 
number categories. 'N' refers to whether the cancer has spread to the lymph nodes - 
from 0 [no positive nodes] to 3 [many positive nodes]. 'M' refers to whether the cancer 
has spread to another part of the body - either 0 [the cancer has not spread] or 1 [the 
cancer has spread] (21). 
In stage 1 lung cancer the cancer is small [1A: up to 3cm, 1B: 3-5cm] and localised, and 
has not spread to the lymph nodes (21). In stage 2A, the cancer is between 5-7cm and 
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has not spread to the lymph nodes. Stage 2B includes cancers that are 5-7cm and have 
spread to the lymph nodes close to the affected lung; cancers larger than 7cm but with 
no lymph node spread or that have spread to the chest wall, diaphragm, phrenic 
nerve, layers covering the heart, or bronchus; cancers larger than 7cm where part of 
the lung has collapsed; or cancers of any size where there is more than one tumour in 
the same lobe of the lung (21). In stage 3A lung cancer the cancer is larger than 7cm 
and has spread to the lymph nodes close to the affected lung; or any size but spread to 
the heart, trachea, oesophagus, nerve, spinal bone or blood vessel. In stage 3B the 
cancer is in the mediastinum lymph nodes and has spread to the chest wall, 
diaphragm, heart, trachea, oesophagus or major blood vessels. In stage 4 the cancer is 
in both lungs; or has spread to another part of the body; or cancer cells are in a fluid 
collection around the heart or lungs (21). 
1.3.2.2 Lung cancer treatment 
National Institute for Health and Clinical Excellence [NICE] guidelines [2005] 
recommend radical surgery [pneumonectomy or lobectomy] for stage I or II NSCLC. 
Chemotherapy and radical radiotherapy are recommended for stage IIIa, with 
chemotherapy for stage IIIb and stage IV lung cancer patients with good performance 
status. Radiotherapy may be given as a palliative option for stage IV patients with poor 
performance status (18). Figure 1.1 summarises these NICE recommendations. 
Updated guidelines from 2011 now recommend radical radiotherapy for stage I-III 
NSCLC patients (22). Chemotherapy and radiotherapy were the treatments of choice 
for SCLC but surgery is now recommended for early stage SCLC (22). Intervention with 
surgery, chemotherapy or radiotherapy has been shown to improve survival (18). 
Fitness for treatment is assessed using the following NICE guidance pathway [Fig 1.2] 
(22).The type of cancer treatment given is generally determined by cancer stage, but 
also by the performance status of the patient and the number and type of co-
morbidities suffered. Lung cancer sufferers tend to be old [age 70+] and to be smokers 
so that high rates of chronic obstructive pulmonary disease [COPD] and ischaemic 
heart disease are common (23), often making radical surgery unsuitable for these 
patients.  
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Figure 1.1.Treatment matrix for NSCLC (2005 recommendations)
(18) 
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Figure 1.2. NICE guidelines (2011) Fitness assessment clinical pathway: lung cancer (22)  
 
©2011 by British Medical Journal Publishing Group 
 
1.4 Cancer inequalities 
Inequalities in cancer care within the UK have been noted and the NHS Cancer Plan in 
2000 pledged to reduce cancer mortality, reduce delay in diagnosis and treatment and 
increase survival whilst acting to reduce inequalities (24). More recently the National 
Cancer Equality Initiative has been set up to address some of these issues (10) as, 
although the incidence and survival of many common cancers varies with SEP (8, 25, 
26), little is known about inequalities in receipt of, and time to, treatment and how 
these might contribute to inequalities in outcome. However, in a 2006 review that 
summarised a decade of research on the association between SEP and cancer survival, 
it was suggested that socio-economic differences in ‘access to optimal treatment’ (26) 
might at least partially explain survival differences. 
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Lung cancer is the leading cause of cancer death within the UK [with mortality rates 
higher in the North of England and Scotland than in the rest of the UK] and it has been 
suggested that reducing the socio-economic gradient in survival could prevent many 
thousands of avoidable cancer deaths (9). It has been estimated that over 1300 deaths 
could be avoided annually in England and Wales if the survival rate in the more 
deprived socio-economic groups were similar to that of the most affluent (27). 
However, in order to do this it is necessary to identify those factors that may 
contribute to outcome inequalities. Access to treatment may be one such factor. For 
example, resection rates in the north-east are lower than those for England as a whole 
(28) and this might contribute to the poorer survival observed locally. 
Socio-economic inequalities in receipt of cancer care have been found in individual 
studies for a number of cancers and assessed in a review for colorectal cancer (11) but 
there has been no systematic review of the evidence to demonstrate if such 
inequalities in receipt of treatment exist for lung cancer.  
A previous study conducted in the Institute of Health and Society [IHS] at Newcastle 
University explored socio-economic inequalities in the delivery of pancreatic cancer 
care, using Northern and Yorkshire Cancer Registry and Information Service [NYCRIS] 
data, and found evidence of socio-economic differences in time from GP referral to 
first hospital appointment and in receipt of treatment (29). This study will build on 
these findings, using the intervention-generated inequalities framework to explore 
inequalities in cancer care for lung cancer, whilst also undertaking a systematic review 
of the evidence into inequalities in receipt of treatment.  
The next chapter will describe the concept of, and explore the evidence for, 
Intervention-generated inequalities. 
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Chapter 2. Literature review – Intervention-generated inequalities 
This chapter will define intervention-generated inequalities [IGIs], review the evidence 
for IGIs in the literature, as well as exploring the potential reasons for inequalities in 
receipt of healthcare and public health interventions. 
2.1 IGIs - Background and framework 
Health inequalities can be found across a number of dimensions including: place of 
residence [urban/rural], race/ethnicity, occupation, gender, religion, education, socio-
economic position [SEP] and social capital, which have been given the acronym 
PROGRESS (30). If other dimensions such as age, disability and sexual orientation are 
included then this the term PROGRESS–Plus is applied (30). 
The intervention-generated inequalities [IGI] concept was developed by White et al 
[2009], in order to produce a framework for a more evidence-based theory and model 
of intervention inequality (7),  as previous equity ‘laws’ and hypotheses had been used 
in a fairly loose and interpretive way throughout the equity literature. Intervention-
generated inequalities have been described  as health inequalities that result from the 
way that health interventions are organised and delivered (7). Although overall health 
may improve as the result of an intervention, differences in access to the intervention; 
differential uptake; delays in uptake; differential compliance with; or effectiveness of; 
an intervention, may result in inequalities in outcome. There may also be inequalities 
in timeliness of the offer of the intervention and to whom it is offered. 
The IGI framework expands on previous equity hypotheses that have attempted to 
describe variations in the provision and uptake of interventions. The ‘Inverse Care Law’ 
[ICL] first described by Tudor-Hart in 1971 stated that “the availability of good quality 
health care is inversely related to need in the population served” (31). The ICL has 
been cited in a number of studies concerning access to primary care, healthcare 
utilisation (32), GP prescription practices and satisfaction with care (7), but it only 
looks at provision of care in relation to need. Whilst SEP can be seen as a proxy marker 
for ‘need’ [with the assumption that those of lower SEP have more need of care] the 
ICL does not consider intervention effectiveness. The focus is on the organisation and 
delivery of standardised care whereas, in order to address inequalities, it might be 
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more important to consider different types of care and the context in which care is 
delivered.  
The ‘inverse Prevention Law’ suggests that a similar socio-economic gradient also 
exists in disease prevention but this was an idea that appeared within the Acheson 
Report in 1999 (33) without any empirical evidence to back up this claim (7).  
The ‘inverse equity hypothesis’ proposed that public health interventions initially 
widen socio-economic inequalities due to preferential uptake by more advantaged 
groups before the less advantaged follow suit, eventually improving health overall 
(34). Although evidence-based using child health studies from Brazil, it was developed 
for low-income countries but has been used as a framework elsewhere, for example in 
looking at uptake of new cancer treatments in the UK (35).  The hypothesis builds on 
the ‘diffusion of innovation’ theory (34) and makes the assumption that all 
interventions are appropriate for everyone and so could be seen to ascribe blame to 
those who are slower to ‘innovate’ and uptake. It does not consider that some 
interventions may not be suitable for all and so will never diffuse downwards. 
The Tugwell ‘staircase’ model suggests that inequalities at different stages of an 
intervention may combine multiplicatively in order to reduce intervention 
effectiveness in the more deprived (36). Lower access to the intervention [including 
awareness or coverage], inequalities in diagnosis [screening or targeting], provider 
compliance, and consumer adherence in more deprived populations means that this 
staircase effect increases the relative equity-effectiveness gap between rich and poor 
(36). 
None of the above equity laws and models examines how interventions can be 
designed to reduce inequality. It needs to be considered whether it is enough to 
provide a standard level of care to all or whether targeted interventions tailored to 
specific groups might be more effective. Therefore, in order to expand the previous 
equity laws into a framework to address intervention-generated inequalities it is 
necessary to examine all the possible stages where inequalities may be introduced, 
determine which aspects of an intervention may lead to inequalities, and consider 
ways in which these can be reduced or eliminated.  
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2.2 Differential receipt of healthcare 
A number of reasons have been suggested for differential receipt of healthcare, 
ascribed to both patient and system factors (37). However, when considering 
inequalities in access to, and receipt of, care, it is important to first take into account 
the type of healthcare system. 
2.2.1 Healthcare system 
In the UK, the National Health Service [NHS] is free at the point of use. Access to care is 
therefore, in theory, equally available to all UK citizens who require it. Other countries, 
including the United States (US), have a non-universal health care system, where 
access to healthcare is determined by insurance status. Citizens [generally those who 
are in work] can purchase private insurance, and social insurance programmes - 
Medicare [for those aged over 65] and Medicaid [for certain categories of people who 
are on a low income or are disabled] - are also available (38).  
There is a wealth of evidence to show that lack of a universal healthcare system can 
result in disparities in access to treatment (38, 39). In 2002, 17% of Americans were 
uninsured (38), and there is considerable inequity, by income and race, in insurance 
coverage (38).  
2.2.2 Patient and practitioner factors 
Eligibility for healthcare has been described as ‘candidacy’ where it ‘is jointly 
negotiated between individuals and health services’ (40). How individuals identify 
themselves as requiring medical attention may depend on their health expectations 
and how they manage health and recognise symptoms. They must then be able to 
navigate the system and access care (40). Socio-economic barriers to uptake may be 
financial, psychological and educational.  For example, specialist care centres may be 
geographically distant and it may be more difficult to access services for those who 
cannot afford childcare, are unable take time off from work or do not have access to a 
car (37). Lower SEP patients report struggling to navigate a complicated appointments 
system in order to access GP care (41). It may be easier to use emergency services that 
do not involve making an appointment or require a referral, but this could result in 
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patients delaying presenting until symptoms become more severe and when they are 
at a more advanced stage of the disease pathway. 
A realist review [a review method that falls between a systematic and narrative 
review] found evidence that, as middle-class service users tend to be more vocal, this 
may influence their interaction with health services  and the likelihood of referral and 
receipt of treatment, as well as determining the type and quality of information 
provided to them by health professionals (42). 
Differences in communication patterns between health professionals and patients by 
SEP have been described that may influence the treatment prescribed (37). The 
patient must be able to articulate the problem and request help and the ability to do 
so may affect the likelihood of referral (40). Healthcare professionals may make 
treatment decisions based on which patients they consider likely to do well, using 
factors such as age, weight and co-morbidity. There is some evidence that those who 
are in work are more likely to be referred (40) and these subjective judgements may 
disadvantage those of lower SEP. Adherence to treatment protocols has also been 
shown to differ by SEP, as has treatment refusal (40), which may be related to 
understanding of risk.  
2.2.3 Health literacy 
The ability to interpret symptoms, understand risk and effectively navigate the 
healthcare system can be included under the general heading of health literacy. Health 
literacy has been defined as ‘the degree to which individuals have the capacity to 
obtain, process and understand basic health information and services needed to make 
appropriate health decisions’ (43). Health literacy has been proposed as a major 
determinant of population health and health inequalities, although Nutbeam [2008] 
suggests that ‘the corrosive impact’ that poor literacy may have on health remains well 
hidden (43). It is likely that poorer health literacy plays a role in the higher prevalence 
of adverse health behaviours that result in higher disease incidence in more deprived 
SEP populations. 
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Much of the early research examining health literacy and healthcare interactions has 
been conducted in the US.  In a recent systematic review the authors found evidence 
of an association between poor health literacy and reduced ability to manage chronic 
conditions and take medication appropriately, lower use of mammography screening 
and flu vaccine uptake, higher rates of hospital admission and emergency admissions, 
and poorer health outcomes in the elderly,  but the evidence for a relationship 
between health literacy and access to care was judged as insufficient (44). It was also 
suggested that lower health literacy may partially explain racial disparities in some 
health outcomes (44). SEP was not considered but it seems feasible that health literacy 
may also play some role in disparities in health outcome by SEP. 
A recent UK study found that low functional health literacy [the ability to apply basic 
reading skills in a health context] was associated with higher mortality (45). There is 
some evidence to suggest that low health literacy is found at higher rates amongst low 
SEP groups, as well as in older patients and ethnic minorities (46) although much of 
this research has been carried out by UK consumer groups rather than in academia. A 
recent qualitative UK study found that patients from GP practices in low SEP areas did 
appear to have lower health literacy than those from higher SEP areas  and, as well as 
a difference in health knowledge, there was also a difference in role expectation (41). 
Patients’ willingness to actively participate in the consultation depended on their 
cultural and normative expectations of the doctor and patient role. Lower SEP patients 
felt less able to question the doctor and often felt it was not their place to do so (41). 
Patients of higher SEP are more likely to state a preference for involvement in medical 
decision making [as are women and younger patients] (47) but in order to make an 
informed decision patients must be able to understand the information provided. 
Poor understanding of health information is not a minor problem as studies have 
estimated that over 50% of the UK adult population struggle to understand narrative 
health information, and this rises to over 70% when numbers are included in the 
information and where basic numeracy skills are required (46). Patients often do not 
understand complex medical terminology and this problem is compounded by the fact 
that health care professionals in turn do not recognise the extent of the problem and 
tend to over-estimate their patients’ understanding (48). Health literacy can be 
context-specific and, within a healthcare environment, the use of unfamiliar 
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vocabulary and terminology can be stressful and alienating. It is possible that health 
literacy may influence patient choice. If patients have poor capacity to process and 
understand basic health information then they are less able to make appropriate 
health decisions.  
It has been suggested that the current UK government emphasis on patient 
involvement in health decision making may increase health inequalities (46), as only 
those with good health literacy are fully able to participate in effective shared decision 
making.  This might be seen as a further example of an intervention-generated 
inequality. 
2.3 IGIs – examples from the literature 
I will now consider what, if any, evidence exists for the occurrence of intervention-
generated inequalities, the types of interventions that are likely to produce IGIs and 
those which may reduce inequalities.  
2.3.1 Review evidence 
Two early systematic reviews examined interventions to reduce health inequalities (49, 
50), looking at interventions to reduce cancer incidence [screening, smoking cessation] 
and heart disease, accident prevention, reduce risky sexual health behaviour and 
unwanted pregnancy, and improve accessibility of healthcare. Arblaster et al (1996) 
found that successful interventions for reducing health inequalities used systematic 
and intensive health-care delivery approaches, improved access and used prompts to 
encourage service use, designed tailored interventions specifically for the target 
population and used peers to help deliver the intervention (49). However, they also 
found that not all these features were necessary to reduce inequalities but, conversely, 
that these characteristics alone were not enough to ensure equality. The scope of the 
review was quite narrow as it considered only interventions that could be carried out 
by a health service, and the authors were only able to conduct a narrative synthesis of 
the evidence as the settings, populations and outcomes were so diverse. 
A similar review conducted in the same year was wider in scope but included some of 
the same interventions and studies. Gepkens et al [1996] found that structural 
interventions were most effective. Interventions involving health education only 
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seemed to be effective in lower SEP groups when supplemented by personal support 
or structural measures (50). However, the majority of the interventions examined 
aimed to increase knowledge or change behaviour rather than having a specific health 
outcome. And, again, the diversity of the interventions meant that meta-analysis was 
not possible. 
A 2008 systematic review looked at social inequalities [assessed using PROGRESS 
criteria] in tobacco control interventions (51) and identified multiple gaps in the 
evidence base. There was some evidence that workplace restrictions on smoking may 
be more effective in the more affluent (51). However, much of the evidence was from 
the USA and so may not be relevant in other countries. There was little evidence on 
differential effects by SEP, sex or ethnicity and, in order to address this, the authors 
suggested that in population-level studies pre-planned subgroup analyses should be 
carried out to examine inequalities (51).  
A short systematic review of reviews published in 2012 used a limited search strategy 
but employed systematic screening of papers to identify evidence for the types of 
interventions that might generate inequalities (52). However, this ‘rapid review’ did 
not look at interventions involving access to healthcare. The authors again found that 
data was lacking but, the 12 reviews that they were able to include, there was some 
evidence that interventions that involved structural change, pricing and the provision 
of resources appeared to reduce socio-economic health inequalities, whereas those 
that merely provided information, such as media campaigns, increased inequalities 
(52). That is, more ‘upstream’ social, fiscal or policy-level legislative interventions 
appeared more equitable than those that relied on education or information-provision 
to engender voluntary behaviour change. Further evidence has been found to support 
this theory, as is described below. 
2.3.1.1 Interventions that reduce inequalities 
A health voucher scheme in Bangladesh found that the introduction of vouchers for 
maternal health care reduced socio-economic inequalities in service utilisation and, 
contrary to the inverse equity hypothesis, better early uptake was seen in the poorer 
rather than more affluent women (53). Other financially-related interventions have 
also been shown to reduce inequalities; for example, tobacco price increases are more 
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likely to reduce smoking in lower-income adults and those in manual occupations 
whereas smoking cessation services are less effective in these groups (51).  
Legislative changes may also favour the more deprived, as seen in water fluoridation  
(54), and motorbike helmet use (55). The introduction of a mandatory motorcycle 
helmet law in Taiwan reduced regional socio-economic inequality in mortality from 
road traffic accidents and this was most marked for men aged under 25 (55). However, 
inequalities began to increase again 5 years after introduction of the law, so it may 
depend on how strictly a law is enforced as to whether people continue to comply 
equitably. Rear-seatbelt use in the UK is mandatory but a socio-economic gradient in 
compliance is found (56).  
Although not all of these studies may be directly relevant to the UK, they provide 
examples of the principle that the equitable effectiveness of an intervention may 
depend on the level of control and voluntary engagement an individual has.  
2.3.1.2 Interventions that increase inequalities 
Inequalities in uptake of population-based non-mandatory public health interventions 
such as cancer screening and immunisation, were identified in a narrative review of 
evidence for IGIs (7). A UK intervention designed to improve uptake of childhood 
vaccinations improved overall uptake but widened socio-economic inequalities in 
uptake (57).  
A study that examined smoking inequalities in Sweden and Denmark found that, in 
Sweden, where the government had implemented an active, population-based anti-
smoking campaign, overall levels of smoking were lower but inequalities were higher,  
with better educated individuals having responded best to the strategy, compared to 
Denmark (58), where less forceful anti-tobacco policies  had been implemented. 
2.3.2 Gaps in the evidence base 
It does appear that there is a lack of systematic evidence on the type of interventions 
that may result in inequalities in health, as well as in where on the intervention 
pathway that intervention-generated inequalities may be occurring.  
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Equity assessments are rarely conducted as part of systematic reviews and, in a 
random sampling, only one in 95 Cochrane Reviews examined outcome effects across 
PROGRESS factors (30).  In an, as yet unpublished, review on the variations in 
effectiveness of obesity treatment and prevention interventions by SEP it was noted 
that the majority of papers recovered did not detail outcome by SEP in the abstract, 
even if it was detailed in the main text [Martin White, personal communication]. A 
2013 pilot review examining systematic reviews of physical activity interventions found 
that only 26% of these were prospectively designed to examine inequalities (59).  
Comparing the effects of interventions in different populations often requires that 
studies carry out sub-group analyses. However studies may not be suitably powered to 
allow detection of sub-group differences, and if post-hoc subgroup analyses are carried 
out, without suitable consideration of plausibility in relation to inequity theory, then 
researchers may find themselves accused of ‘data-dredging’ by disapproving 
statisticians (60).  
In a methodological study of equity assessment in systematic reviews, of 224 
systematic reviews indexed on Medline in one month, only 13% of these examined 
were found to have conducted subgroup analysis by PROGRESS-plus factors (61). It is 
often difficult, therefore, to assess the effects of interventions on health equity as few 
studies report their results in this way. But it is important to do so, as unequal benefits 
across socio-economic groupings are likely to contribute to decreased health equity 
(30) which can be considered as unethical and unfair, as well as sub-optimally cost-
effective. There are also implications for generalisability, as, if only the more affluent 
take up an intervention, the data may not be applicable at a population-level (62).  
However, this scarcity of evidence means that the contribution of intervention-
generated inequalities to overall socio-economic inequalities in morbidity and 
mortality is still unclear.  
2.4 Summary 
Although the evidence base for intervention-generated inequalities remains limited, it 
does appear that financial and legislative interventions, and those which are 
specifically targeted at particular groups, are less likely to introduce intervention-
generated inequalities than those that rely on voluntary uptake or that provide a ‘one 
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size fits all’ solution for prevention and treatment. However, the patient and system 
factors that influence access to, and uptake of, healthcare and public health 
interventions are also not well evidenced and need to be determined in order to 
eliminate IGIs. 
Chapters 3-5 will examine the evidence for IGIs in cancer care. 
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Chapter 3. Intervention-generated inequalities in cancer care: receipt of 
treatment 
As described in chapter 2, the evidence base for IGIs is somewhat limited. I will now 
look at the evidence for IGIs specifically in relation to receipt of cancer treatment, and 
why these might be found.  
3.1 Introduction 
Previous work looking at inequality in pancreatic cancer care, using NYCRIS data (29), 
found a significant socio-economic trend in receipt of any treatment, with the odds of 
receiving treatment increasing from the most to the least deprived quintile when age, 
sex and co-morbidity were taken into account. This trend was also seen for receipt of 
any radical surgery but not for adjuvant chemotherapy. It was also seen for any 
palliative oncology treatment, any palliative chemotherapy, but not radiotherapy or 
hormone therapy. Differences in access to treatment might be partially explained by 
differences in stage at presentation, but unfortunately staging information was not 
available.  
Time from GP referral to hospital investigation was significantly shorter in the less 
socio-economically deprived groups compared to the most deprived [and for older 
compared to younger patients], but this trend was not seen when looking at time from 
first hospital appointment to diagnosis, or time from diagnosis to any therapy or 
treatment [apart from in time to palliative radiotherapy] (29). Therefore, there is some 
evidence of socio-economically patterned delay in time from referral to first hospital 
appointment for pancreatic cancer. 
Building on this first attempt to examine intervention-generated inequalities in cancer 
care, looking at pancreatic cancer, I will now use the intervention-generated 
inequalities framework to assess where on the pathway of cancer care inequalities 
might occur and why they might occur. The evidence for inequalities in receipt of 
treatment in all cancers is considered in this chapter, including the evidence 
specifically relating to lung cancer. Inequalities in time intervals on the care pathway 
are examined in chapter 4 and inequalities in survival in chapter 5. Socio-economic 
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inequalities in receipt of treatment and in time to presentation, referral, diagnosis and 
treatment may all contribute to inequalities in survival.  
3.2 Inequalities in receipt of treatment 
Existing published evidence for inequalities in receipt of treatment for cancer and why 
these might occur will be examined here. 
3.2.1 Why might socio-economic inequalities in receipt of treatment be found? 
Patient, tumour and system factors may all be relevant for differential receipt of 
cancer care.  
Patients may delay in accessing healthcare, choose not to undergo active cancer 
treatment or to comply with treatment protocols for a number of reasons, often 
involving a complex mixture of financial, psychological, cultural, practical and 
educational factors (37), as previously discussed. Low SEP has been associated with 
colorectal cancer treatment refusal (63) and this may be related to poor health 
literacy. However, a Scottish study of 882 lung cancer patients found no association 
between refusal of treatment and SEP (64). 
Tumour factors such as stage may also be relevant. Later-stage patients are less likely 
to receive surgery and there is some evidence for a socio-economic gradient in stage at 
presentation for some cancers (65-67) but not all (68).  
The use of co-morbidity and PS to determine suitability for treatment may offer a 
partial explanation for socio-economic and age-related inequalities in treatment, as 
the number of co-morbidities and PS vary by SEP (69) and age (70).  Higher co-
morbidity has been associated with older age, female sex and lower SEP in lung cancer 
patients (71) and might reduce the likelihood of surgery for these patients. However, 
another study found that chronological age rather than performance status or the 
number of co-morbidities determined whether elderly patients with lung cancer were 
actively treated. Many doctors adopted a ‘nihilistic approach’ to treatment and 
guidelines were not followed for older patients (72). SEP was not considered in this 
study, but differences in doctor-patient interactions between higher and lower socio-
economic groups (73) have also been suggested as a reason for different socio-
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economic cancer treatment patterns where ‘unrecognised personal biases and beliefs 
may affect recommendations of cancer treatment’ (37). 
Doctor-patient communication has been shown to differ by race in the US. Black lung 
cancer patients and those in ‘racially discordant interactions’ received less information 
and participated less actively in the consultations (74). It is possible that similar 
discrepancies by SEP are also found. 
In the English National Cancer Patient Experience Survey for 2011/12, differences in 
responses from patients were found by SEP. More deprived patients reported that 
their views were taken into account when the clinical team discussed which treatment 
they should have, and possible side effects of treatment were explained in a way they 
could understand (75). However, they also reported delays in diagnosis and that they 
were less likely to receive understandable information or explanations (75). 
Patients in the least deprived quintile were more likely to report a better patient 
experience than the most deprived, for a number of questions that could relate to 
their level of health literacy. They reported ‘being given the right amount of 
information about their condition and treatment, given understandable answers to 
questions by ward nurses all or most of the time, given easy to understand information 
about the type of cancer they had and given easy to understand written information 
about tests beforehand’ (75). These survey results may suggest that there are, indeed, 
differences in the way that doctors communicate, or that differences in health literacy 
between higher and lower SEP groups determine how well understood the information 
given is.  
3.2.2 Evidence for socio-economic inequalities in receipt of treatment 
Socio-economic inequalities in receipt of treatment have been found for some cancers, 
with the majority of evidence from studies looking at colorectal cancer.  
In a 1998 UK study utilising Hospital Episode Statistics [HES] data from patients 
admitted between 1992 and 1995 in south-east England, and using Townsend scores 
as an area-based measure of SEP, patients from less affluent areas were less likely to 
receive surgery for lung and breast cancer but not for colorectal cancer (76), in a 
multivariable analysis adjusted for age and sex. This was a well-conducted study but a 
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number of potentially important confounders such as stage were not included. In a 
similar study in 2010 looking at UK-wide HES data from 1999-2006, patients from 
deprived areas were less likely to receive optimal surgical treatment for breast, lung 
and also rectal cancer, taking into account age, sex and year of admission, but again 
not stage (77). Inequalities in stage at presentation might account for some of these 
socio-economic differences. 
In a UK paper that was primarily concerned with examining geographical access to 
cancer treatment, the authors noted that surgery was less likely for deprived patients 
compared to the more affluent using data for breast, colon, rectum, lung, ovary and 
prostate cancer diagnosed between 1994 and 2002, also taking into account age, sex 
and travel time to hospital, and stage for all except for lung or prostate, as staging 
information was not well recorded for these cancers (78). Deprived patients were also 
less likely to receive chemotherapy [except for breast cancer] and less likely to receive 
radiotherapy [except for colon and rectal cancer] (78). 
3.2.2.1. Colorectal cancer 
There is some evidence to suggest that deprived patients with colorectal cancer are 
less likely to receive treatment (11, 79, 80). According to a 2010 review examining 
socio-economic position and inequalities in risk, treatment and outcome for colorectal 
cancer (11), low SEP colon cancer patients were less likely to receive treatment 
[surgery, radiotherapy and chemotherapy] but results for rectal cancer were less clear 
cut. However, within this review the search terms were narrow and a number of 
relevant papers were not included.  
In the above-mentioned review (11) nine studies conducted multivariate analysis and 
eight included stage. Two only included patients aged 65+ (81, 82). Three (83-85) out 
of seven studies looking at access to radiotherapy (81, 83-88) found a significant 
difference by SEP, as did two(82, 85) out of seven studies looking at access to 
chemotherapy (81-87). Three studies looked at access to surgery (83, 86, 89) but only 
one (83) showed a significant difference in likelihood of receiving treatment for high 
compared to low SEP patients. For colon cancer significant differences in receipt of 
chemotherapy by SEP were found in two (82, 85) out of three papers but, as more 
mixed results were found for rectal and colorectal cancer and for access to surgery and 
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radiotherapy, it is difficult to conclude, as the authors did, that treatment differences 
by SEP can be ‘demonstrated consistently’(11). Also, no meta-analysis was conducted. 
Further studies have also been identified that were not included in the review. 
In a large, good quality UK study, deprived patients were less likely to receive 
treatment within six months of NHS contact [surgery in 95% of cases], adjusted for age 
and stage (79). However, in a Swedish study the odds of receiving any surgical 
treatment or any resection were not associated with income or education level [taking 
into account age, sex, stage, region, hospital type and marital status] (90) and  in a UK 
study deprivation was not associated with lower likelihood of surgery (76) but age, sex, 
stage and co-morbidities were not taken into account. Another UK study using audit 
data also found no association between deprivation and receipt of surgery but did find 
that affluent patients were more likely to undergo curative resection in a univariable 
analysis (91). Therefore the evidence that receipt of colorectal surgery is affected by 
SEP is inconclusive and the quality of the studies variable. However, there is some 
evidence to suggest that the type of surgery received may vary by SEP. 
The traditional treatment for colorectal cancer is excisional surgery. For rectal cancer 
this may require abdomino-perineal excision [APE] which involves the removal of the 
anal sphincter and leaves the patient with a permanent stoma. The preferred 
procedure for colonic or high rectal cancer is anterior resection [AR] which allows 
sphincter retention and appears to improve survival (92).  
A review reported that the chances of undergoing APE were higher if the patient was 
of lower SEP [three UK studies] (11). In a small UK study of 486 patients, those in the 
most deprived group were less likely to undergo surgery and, if they did, were more 
likely to have a permanent stoma (93). However, this was a univariable analysis and so 
other relevant factors were not taken into account. But similar results have been found 
using better quality multivariable analysis studies.  
In a 2010 UK study, patients from deprived areas were less likely to receive anterior 
resection [AR], the preferred procedure for rectal cancer, taking into account age, sex 
and year of admission, but not stage (77). A good quality study using NYCRIS cancer 
registry data also found that a patient was more likely to receive APE  if of deprived 
SEP (92), in a multivariable analysis including stage. In a Swedish study where stage 
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was included, lower income groups were less likely to receive AR compared to the 
highest quartile income group. However, when education level was used as the 
measure of SEP no significant differences were found (90). As education is a less 
sensitive measure of SEP than income (5), this could help explain the different pattern 
of results seen. 
3.2.2.2 Lung cancer 
A systematic review of the published evidence for socio-economic inequalities in 
receipt of lung cancer treatment [surgery, chemotherapy, radiotherapy and any 
unspecified treatment] has been carried out as part of this PhD. See chapter 7 for the 
full protocol, methods and results of this review. 
3.2.3 Evidence for inequalities: other factors 
3.2.3.1 Age  
In a 2001 review (94), it was found that older colorectal patients were less likely to 
receive adjuvant therapy but, as many of the studies included in the review did not 
control for stage or co-morbidities, it is difficult to know how much these factors might 
have impacted on the decision. However, in studies that did take these confounders 
into account older people did appear to receive less intense adjuvant treatment (94). 
Other, more recent, studies also confirm that age is significantly associated with 
receipt of treatment (81-89, 95). Older patients were significantly less likely to receive 
treatment of any sort.  
3.2.3.1.2 Age: Lung cancer 
Under-treatment of lung cancer in elderly patients has now been recognised as a 
worldwide issue (70). Older patients tend to be under-represented in clinical trials and 
so there is less of an evidence base to determine whether treatment would be suitable 
for them. Elderly patients are often less able to tolerate treatment complications and 
more likely to experience chemotherapy toxicity but there is no evidence to suggest 
increased toxicity from radiotherapy, compared to younger patients, and elderly 
patients who undergo surgery do appear to benefit (70). However, decisions to treat 
tend to be made using fairly crude measures of suitability such as number of co-
morbidities or PS which may result in sub-optimal care for older patients, as the 
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interaction between age, co-morbidity, patient well-being and suitability for treatment 
is likely to be complex. 
3.2.3.2 Co-morbidity and performance status 
Higher levels of co-morbidity were significantly associated with a lower likelihood of 
surgery and adjuvant therapy in some colorectal cancer studies (82, 83, 85, 89), but 
not all (81).  
Although co-morbidity and PS measure different things [number of concurrent health 
conditions and general health status respectively] both variables may be used as a 
measure of suitability for lung cancer treatment when patients are assessed.  
However, it is unclear how well co-morbidity and PS capture this ‘fitness for treatment’ 
concept. Where PS is not available co-morbidity score may be being used as a 
surrogate measure of this. In one of the few studies that looked at both co-morbidity 
and PS, the authors found that the number of co-morbidities did contribute to PS but 
were also additionally associated with likelihood of treatment (64). 
A recent study found that PS but not the number of co-morbidities, was associated 
with poorer NSCLC survival (96) suggesting that the presence of co-morbidities is not a 
particularly good measure of how well a patient was likely to do and so should not be 
used as a barrier to receipt of treatment if the patient has a good PS score and appears 
otherwise well.  
Another study found that PS did not appear to be a major influence on receipt of 
treatment according to guidelines, whereas those with a higher number of co-
morbidities were less likely to receive guideline treatment for early stage lung cancer 
(72). Interestingly, they found that co-morbidity was higher in early-stage compared to 
late-stage patients possibly because lung cancer was picked up earlier in patients who 
were regularly monitored for other conditions. However, patient age rather than PS or 
comorbidity appeared to be the main factor on which choice of treatment was based 
(72). 
3.2.3.3 Sex 
Sex has been less consistently associated with access to treatment. In some colorectal 
cancer studies men were found to be more likely to undergo surgery resulting in 
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sphincter loss [APE], probably due to differences in pelvic anatomy between the sexes 
(94). A study using NYCRIS cancer registry data also found that a patient was more 
likely to receive APE if male (92). Women were more likely to receive AR compared to 
men  (77, 90). Sex was also found to be a significant factor in the likelihood of any 
surgery in other studies (83, 86, 89, 90). Sex was not a significant factor in access to 
chemotherapy or radiotherapy in the majority of studies examined (81, 83, 86-88) but 
was in two (84, 85) and in a further study that looked at chemotherapy alone (82).  
3.2.3.4 Ethnicity 
In the USA differences in access to colorectal cancer treatment and outcome have 
been observed by race (94, 97) but some of these differences may also be related to 
differences in income and SEP (85, 97). There are also issues when comparing  
American and UK studies due to the differences in the healthcare systems, as within 
non-universal health care systems the type of insurance held can affect access to 
treatment (85).  
3.2.3.5 System factors 
The introduction of a multidisciplinary team [MDT] to a hospital in Glasgow resulted in 
an increase in the number of non-operable NSCLC patients receiving chemotherapy 
and was also associated with an increased rate of staging, compared to an earlier 
cohort who were assessed only by a medical oncologist (98). 
A 2001 review of patient and provider characteristics on treatment and outcomes in 
colorectal cancer found that patients were more likely to receive sphincter-saving 
surgery [i.e. AR] when they were treated by a surgeon with a high volume caseload or 
who had undergone subspecialty training (94). Removal of sphincter [i.e. APE] was 
more likely if operated on by a surgeon undertaking fewer than seven cases per year 
(92).  
3.3 Summary: Socio-economic inequalities in receipt of treatment 
From this narrative review of socio-economic inequalities in receipt of treatment for a 
number of cancers, it can be seen that there is some evidence that receipt of 
treatment is socio-economically patterned. However, this is not clear cut and many 
studies do not take into account cancer stage at diagnosis, number of co-morbidities or 
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the general health status of the patient, all factors that might potentially vary by SEP 
and thus help explain socio-economic inequalities in treatment. No systematic review 
of the evidence taking into account study quality [including control for appropriate 
confounders] has been conducted and this is required in order to clarify whether 
inequalities in receipt of treatment are found for lung cancer. 
The next chapter will examine the evidence for socio-economic inequalities in time to 
presentation, referral, diagnosis, and treatment for cancer, as well as the potential 
reasons for this. 
 
  
29 
 
Chapter 4. Intervention-generated inequalities in cancer care: time 
intervals 
4.1 Background 
In this chapter, the background relating to the importance of early diagnosis and 
measures to improve this will be described. The evidence for socio-economic 
inequalities in time to presentation, referral, diagnosis and treatment, and the reasons 
for this, will then be examined. 
4.1.1 Delay or interval? 
In the earlier literature the term ‘delay’ appears frequently. However, latterly this 
mostly appears to have been replaced with the term ‘interval’ and the discussion 
centres more around early diagnosis rather than a delay in diagnosis. The use of ‘delay’ 
implies that the time taken is longer than is desirable or acceptable but, within studies 
that use this term, it is not always the case. It may be appropriate to use ‘delay’ when 
a time interval is longer than a specified target time but otherwise the term ‘interval’ 
will be used. However as previous studies have used ‘delay’ the term will still appear in 
this chapter, when referencing these studies.  
4.1.2 Early diagnosis 
Early diagnosis of cancer is thought to be important for improving outcomes, as 
survival is better for those diagnosed with early-stage cancer (99).  Early diagnosis may 
also result in longer intermediate survival for patients with SCLC and later stage NSCLC. 
Early palliative treatment can greatly relieve distressing lung cancer symptoms such as 
pain, breathlessness and persistent cough [Dr M Peake, personal communication]. 
Patient anxiety can also be greatly ameliorated by prompt referral and diagnosis.  
In England the National Awareness and Early Diagnosis Initiative [NAEDI] is a scheme 
designed to encourage early presentation of patients to primary care and to improve 
GP cancer recognition and referral. It proposes that delays may lead to diagnosis at a 
later disease stage and thus result in ‘potentially-avoidable’ deaths (99). It has also 
been suggested that inequalities in delay might contribute to socio-economic 
differences in cancer survival (99). 
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A NAEDI delay pathway has been constructed to suggest why delay at different points 
on the pathway may occur and how these might impact on survival [fig 4.1]. This 
model dovetails in many respects with the proposed model for intervention-generated 
inequalities (7), as it considers access to primary care, as well as uptake of, and delay 
in, care; all of which may result in inequalities in outcome. However, the model does 
not break down into detail the stages in primary and secondary care where delays 
might occur.  
Figure 4.1. The NAEDI pathway (99) 
 
 
4.1.3 Definition of important time points and target times 
In the research to date, poorly defined definitions of the important time points that 
characterise delay periods have resulted in a number of inconsistent and incomparable 
studies. To address this issue, an international consensus working group [CWG] has 
now formulated a standard set of definitions relating to delay intervals and time points 
and a checklist for researchers examining early diagnosis (100). Therefore these will be 
utilised for this present study. 
In the UK the National Cancer Plan [2000] proposed target time intervals of 14 days 
from urgent GP referral to first outpatient assessment, one month [31 days] from 
diagnosis [decision to treat] to treatment, and two months [62 days] from GP referral 
to first treatment, to be in place by 2005 (24). A 2007 study of 342 patients seen in a 
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Manchester hospital between 2003 and 2005 found that although all patients were 
seen within the 14 day referral interval, the 62 day treatment target was not being met 
(101). This was attributed to complex patient pathways and delays in investigations 
and initiation of treatment. 
4.1.4 Theoretical models of delay 
The CWG suggested that there is lack of an underlying theoretical model to explain 
delay (100). However, two delay models have been used in the literature: the Hansen 
and Anderson models. An early model of cancer delay, the Anderson model, attributed 
the majority of delay to patient rather than system factors. However, it has been 
suggested that this may be ‘an artefact of research focus’ and that system delay may 
be an equally important but under-researched area (102).  For example, figure 4.2 
shows the detailed diagnostic and staging clinical pathway for lung cancer [NICE 
guidance 2011] (22). Patients with suspected lung cancer are often initially referred for 
a chest x-ray and the diagnosis confirmed by bronchoscopy. Other investigations 
including CT scans may then be deployed to help determine the most appropriate 
treatment (24). Hence there are a number of system stages where delays can be 
introduced.  
A recent review looked at the application of the Anderson Model of delay in cancer 
diagnosis, as the authors proposed that the use of a robust theoretical framework 
could improve the investigation of delay, and help develop interventions to reduce 
time to presentation, diagnosis and treatment (103). They produced a refined 
Anderson model that took into account system and disease factors, as well as patient 
factors, and split time intervals into appraisal, help-seeking, diagnostic, and pre-
treatment intervals [Fig 4.3]. This results in a model that is fairly similar to the Hansen 
model which also considers patient, doctor and system delay, with further sub-
divisions [Fig 4.4] (104). These models, when used in conjunction with NICE treatment 
decision matrices [Fig 1.1 shows the matrix for lung cancer] (22), can allow 
examination of intervention-generated inequalities at all stages of the cancer care 
pathway. 
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Figure 4.2. Diagnostic and staging clinical pathway for lung cancer (22)  
 
 
Figure 4.3. Updated Anderson model of delay (103) 
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Figure 4.4. Hansen model of delay (104) 
 
 
I will now consider the intervals on the care pathway where delay might occur and the 
potential reasons for this. I will also examine some of the previous problems in 
measuring delay and the different ways that this has been done, with the resultant 
difficulties in comparing studies. Evidence for socio-economic differences in time to 
presentation, referral, diagnosis and treatment within the cancer care pathway, taking 
into account patient and system factors that may influence delay, will also be 
examined, including the evidence specifically relating to lung cancer. 
4.2 Evidence for inequalities in cancer care time intervals  
Table 4.1 summarises the previous evidence from studies examining inequalities in 
lung cancer care time intervals, by SEP. The table details the time interval examined, 
the country of the study, years of diagnosis, size of the study, and the median time for 
the interval in the lowest and highest SEP group [if reported], as well as the type of 
analysis carried out [whether univariable or adjusted for confounders in a 
multivariable analysis].  The evidence from the lung cancer studies included in this 
table, as well as the evidence for other cancers, is discussed in more detail below.  
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Table 4.1. Summary of previous evidence from studies examining lung cancer time intervals and SEP 
Interval        low SEP associated with: 
Specific Interval/ proxy 
measure 
study Country N Years of Diagnosis Median/ mean delay Method Further Info Longer 
delay 
Shorter 
delay 
No 
assoc 
Patient           
Stage at presentation Lyratzopoulos et al 
(2012) (68) 
England 13,286 2006-2009 Not calculated OR of advanced stage at 
diagnosis 
   X 
Stage at presentation Lyratzopoulos et al 
(2012) (66) 
England 16,714 2006-2010 Not calculated OR of advanced stage at 
diagnosis 
   X 
Patient Macleod et al  
(2009) (105) review 
USA 34, 23, 119 Pre 1973, 1975 + 
1990 
Not shown Not detailed  X (1/3)  X (2/3) 
Primary care           
First consultation to 
referral 
Macleod et al  
(2009) (105)  review 
Norway 40 pre1996 Not shown Not detailed  X   
Referral           
Contact with GP – 
hospital appointment 
Neal and Allgar  
(2005) (106) 
England 2950 2002 patient survey 30 (professional) 
30 (unskilled) 
Generalised linear 
modelling 
   X 
Diagnostic           
FHA to diagnosis 
(secondary care delay) 
Neal and Allgar 
 (2005) (106) 
England 3199 2002 patient survey 17 (professional) 
13 (unskilled) 
Generalised linear 
modelling 
   X 
Referral to diagnosis Berglund et al  
(2010) (73) 
Sweden 3370 1996-2004 17 (high education) 
32 (low education) 
Kaplan Meier. Time to 
diagnosis by education 
level 
 X   
Image-diagnosis Yorio et al  
(2009) (107) 
USA 482 2000-2005 16 (6-43) Cox regression    X 
Referral - diagnosis Dalton et al  
(2011) (108) 
Denmark 18,103  2001-2008 Not calculated Logistic regression: OR of 
diagnostic delay > 28 days 
16,713 with stage 
and diag  date 
X   
Treatment           
Referral-treatment Campbell et al 
 (2002) (86) 
Scotland 661 1995-1996 33 (15-104) high SEP 
25 (13-77) low SEP  
Kaplan Meier, Cox 
regression 
   X 
Image-treatment Yorio et al  
(2009) (107) 
USA 397 2000-2005 50 (30-84) high 
income 65 (39-110) 
low income 
Cox regression Sig at uni  but not 
multivariable level 
  X 
Diagnosis-treatment Yorio et al  
(2009) (107) 
USA 299 2000-2005 29 (17-55) high 
income 36 (21-56) low 
income 
Cox regression Sig at uni  but not 
multivariable level 
  X 
Detection- surgery Saint-Jacques et al 
(2008) (109) 
Canada 108 2005 107 (73-141)  
 results by education 
level not shown 
Multifactorial regression Those who 
received surgery  
inc (108 out of 
540 NSCLC) 
  X 
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4.2.1. Patient interval  
4.2.1.1 Definition and background 
Patient delay can be defined as the time between onset of symptoms and initial 
presentation to the GP or other healthcare professional (110). It has recently been 
recommended that the term ‘patient delay’ should no longer be used, and that 
‘patient interval’, split into an ‘appraisal interval’ and help-seeking interval’, is more 
meaningful and so should be adopted (100). However as I am reviewing previous 
literature where only the term ‘patient delay’ has been utilised, it seems appropriate 
to still include this term here. 
It is difficult to measure patient delay as this requires the patient to accurately 
remember when they first noticed the onset of symptoms, which may be subject to 
recall bias. Unlike system delay, which can be examined using secondary data, the 
calculation of patient delay generally requires patients to be interviewed or to 
complete a questionnaire post-diagnosis. Alternatively, stage at diagnosis can be used 
as a proxy measure of late presentation. 
4.2.1.2 Evidence for inequalities in patient interval 
Time to consultation might be influenced by fear or by poor symptom recognition and 
disease awareness, and this awareness may be lower in more deprived socio-economic 
groups (111). In a systematic review summarising risk factors for delayed presentation 
for a number of common cancers an association was found between lower SEP and 
increased delay for upper GI and urological cancer, older age and patient delay for 
breast cancer and lower education level and delay for breast and colorectal cancer 
(105). Generally, not recognising the seriousness of symptoms was found to be a 
significant factor in increasing delay in presenting, especially when symptoms were 
vague and non-specific (105).  
The availability of social support positively influenced time to presentation for breast, 
colorectal and endometrial cancer but did not appear to reduce delay for lung, upper 
GI or urological cancer (105). Older age but not SEP was associated with shorter 
patient delay in a Dutch study including 10 cancer types (104). 
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Systematic review evidence identified co-morbidity, pain and social support as 
potentially important factors in reducing patient delay in presenting with suspected 
colorectal cancer but age and sex were not found to have an influence (112). The 
evidence for SEP was more mixed. A number of older studies found no relationship 
between lower SEP and increased delay. Other studies found that lower levels of 
education and residing in a rural location increased delay (112). Patient delay was 
found to be longer for rectal than for colon cancer (112, 113) possibly because the 
symptoms associated with rectal cancer such as rectal bleeding are often found in 
more benign conditions but embarrassment may also be a factor (112). An Italian 
study found that patients with lower levels of education had non-significantly longer 
time intervals between colorectal cancer symptom onset and first consultation (114). 
4.2.1.2.1 Evidence for inequalities in patient interval: Lung cancer  
A 2009 review of two systematic reviews looking at risk factors for delay in common 
cancers found only three small, old studies that considered SEP and patient delay for 
lung cancer and only one of three found an association (105). Stage at diagnosis can 
also be used as a proxy measure of late presentation. Although socio-economic 
inequalities in stage at diagnosis have been noted for some cancers which might 
suggest that there are differences in timeliness of patient presentation by SEP (66), 
three studies examining socio-economic inequalities in stage at diagnosis for lung 
cancer did not find any significant differences by SEP (66, 68, 115).  
The availability of social support did not appear to reduce delayed presentation for 
lung cancer (105). A small qualitative study of patient delay in lung cancer did however 
find that family support decreased delay in reporting symptoms. Many patients 
delayed going to the GP as they thought that they would be blamed for their illness 
due to their smoking or, if they were not a smoker, they thought that lung cancer was 
highly unlikely (116). Guilt and fear may also be factors that influence delay (102). In a 
Scottish study, more deprived rural-dwelling lung cancer patients did not take longer 
to consult than affluent urbanites. However, living alone and having a long smoking 
history increased delay (117). A small Turkish study that interviewed 48 lung cancer 
patients who delayed presenting found that the most common reason for patient 
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delay was due to ignoring symptoms but that socio-cultural and economic factors were 
also important (118). 
4.2.2 Primary care interval   
4.2.2.1 Definition and background 
Within the primary care setting, the time from first presentation to the GP until the 
referral date can be defined as primary care interval or referral interval. Delays could 
occur in initiating primary-care investigations and ordering tests before ultimately 
referring the patient for secondary-care investigation.  
NICE Cancer referral guidelines were introduced in 2005 and are designed to assist GPs 
to identify patients at risk of cancer (119). However, although lung and colorectal 
cancer are common an average GP is likely to see only one or two new patients each 
year (23, 120) and many patients present with vague symptoms. If symptoms are not 
immediately suggestive of cancer a ‘treat, watch and wait’ period is a suggested 
management option for colorectal cancer (119), which can increase delay. If colorectal 
cancer is suspected then abdominal and rectal examinations and a full blood count 
should be carried out. Patients presenting with co-morbidities can also make diagnosis 
more difficult (102). 
4.2.2.2 Evidence for inequalities in primary care interval 
Higher SEP patients [measured by income or education] had shorter delay from first 
contact with the GP to initiation of primary care investigation [doctor delay] than less 
privileged patients, in a Danish cancer study including but not separating out lung 
cancer (104). The authors suggest that wealthier and better educated patients are 
better able to describe symptoms and thus speed up the investigation process or that 
doctors relate better to these patients and that, possibly unintentionally, these 
patients are given a speedier investigation (104). However patient numbers were small 
and inconsistencies were found between men and women.  
It has been suggested that socio-economic differences in communicating and 
presenting cancer symptoms to health professionals may result in longer delays for 
those who are less ‘convincing’ (111). Some evidence of delay was seen for those 
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(mainly women) who consulted frequently and were subsequently diagnosed with 
colorectal cancer, although SEP was not examined (112). 
A small Italian study of 137 colorectal cancer patients found that patients with lower 
levels of education had longer time intervals from first consultation to surgical referral 
but that this delay was not significant (114). A 2008 review of influences on pre-
hospital delay of colorectal cancer found that ‘initial misdiagnosis, inadequate 
examination and inaccurate investigation increased practitioner delay’ (112). Older 
patients were referred more quickly and there was some evidence of lower SEP 
patients experiencing longer delay but no relationship was shown between sex and 
primary care delay (112). Appropriate use of guidelines may also reduce colorectal 
cancer delay although the evidence was limited (112).  
4.2.2.2.1 Evidence for inequalities in primary care interval: Lung cancer 
No individual lung cancer studies were identified that examined inequalities by SEP 
over the primary care interval. One study identified in a systematic review (105), that 
looked at a number of cancers and included only 40 lung cancer patients, suggested 
that higher education reduced delay. However, lower SEP was not associated with pre-
hospital delay for any of the six cancers [breast, colorectal, lung, ovarian, prostate, 
non-Hodgkin’s lymphoma] looked at in a UK study of over 65,000 patients (106) 
although within this it was not possible to separate-out patient and primary care delay.  
4.2.3 Primary care to secondary care referral interval 
4.2.3.1 Definition and problems 
The date of referral is considered to be the time point where there is a transfer of 
responsibility from primary to secondary care (100). Delay from GP referral date to 
secondary care investigation [generally first outpatient assessment or first hospital 
appointment] can be categorised as primary care to secondary care referral delay or as 
investigation delay. However, within the literature this is mostly just referred to as 
referral delay (121, 122). However, referral delay can also be measured from first 
contact with the GP until first hospital appointment (123), so can include both primary 
care referral delay, which is delay prior to the referral date, as well as post-referral 
delay (11).  
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Patients in England and Wales with suspected cancer should be seen by a specialist 
within two weeks of GP referral (24) but it appears that delays are still experienced in 
waiting for tests and in the use of non-urgent referrals, as well as other delays caused 
by administrative and communication problems.  
4.2.3.2 Evidence for inequalities in referral interval 
Younger age was associated with increased referral delay for lung, breast, colorectal 
and prostate cancer and women experienced longer delays compared to men for 
colorectal cancer but lower SEP was not associated with referral delay [here defined as 
time from first contact with GP to first hospital appointment] for any of the six cancers 
looked at in a UK study (106). However, mean rather than median time was used here 
and as delay intervals tend to be non-normally distributed [right skewed] then the use 
of mean can artificially inflate the delay values seen and so is not necessarily a very 
useful measure. This can be seen in a lung cancer study that reports mean and median 
delay values, where mean delay is much larger than median (121).  
Referral delay was examined in an MPhil thesis looking at pancreatic cancer (29) which 
found that time from GP referral to hospital investigation was significantly shorter for 
less deprived patients in a multivariable analysis including age, sex and co-morbidity. 
In another study, age, sex, ethnicity and marital status did not appear to influence the 
likelihood of urgent referral for lung, colorectal, prostate or ovarian cancer (124). SEP 
was not examined. 
4.2.3.2.1 Evidence for inequalities in referral interval: Lung cancer 
In a small UK study of 247 lung cancer patients, 54% of these were referred from their 
GP and the other 46% were non-GP referrals such as those presenting via casualty. 
Urgent patient referral intervals were short, with a median of 1 day [IQR 1-5]. However 
no time period was reported for non-urgent referrals (125). Median referral delay was 
8 days in a Finnish study (121). 
Although SEP was not examined, age, sex, ethnicity and marital status did not appear 
to influence the likelihood of urgent referral for lung cancer (124). Younger age was 
associated with increased referral delay [here defined as time from first contact with 
GP to first hospital appointment] for lung cancer but lower SEP was not associated 
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with referral delay, in a large UK study (106). However, mean rather than median time 
was used.  
4.2.4 Secondary care interval 
The secondary care interval can be further broken down into diagnostic and treatment 
intervals although both of these measures can also include elements of patient and 
primary care delay, depending on how they have been measured.  
4.2.4.1 Diagnostic interval – definition and problems 
Diagnostic delay is defined as the delay in receiving a diagnosis but there is confusion 
in the literature over the time period measured. It can be measured from onset of 
symptoms (113, 126), referral date (113) and from secondary-care investigation (127) 
to diagnosis. Diagnostic delay may contain elements of both patient delay and 
healthcare delay (113) and it has been suggested that patient and primary care delays 
account for over two-thirds of reported diagnostic delay (128). However, a Cuban 
study [96 patients] estimated that patient delay accounted for 18 days of delay and the 
health-care system for 62 days (126) [but again mean rather than median time was 
used]. The lack of consistency in defining diagnostic delay makes comparison between 
studies difficult. 
The type of referral route might be important in determining diagnostic delay. In a UK 
study using national cancer survey data, patients who were referred via their GP had 
longer diagnostic delay than those who were not (123). 
Date of diagnosis can be defined in a number of different ways and it is not always 
clear within studies how date of diagnosis has been derived. The European Network of 
Cancer Registries uses a priority hierarchy to define date of diagnosis, with 6 
categories; starting off with the date of histological or cytological confirmation of 
malignancy [which can be derived from 3 different hierarchical time points]; then date 
of hospital admission; down to, with lowest priority; date of death if cancer is only 
identified at autopsy (100). Therefore, it is possible that within each study patients 
have a date of diagnosis derived at a number of different time points. In order to 
calculate meaningful diagnostic and treatment intervals it is necessary to exclude 
those who have a diagnosis only after death but, even after excluding these records, a 
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high level of inconsistency in diagnosis date may remain. If differences in diagnostic 
date occur in a random manner then this increases error. However, if there are 
systematic differences in the way that date is recorded according to SEP [although I 
could find no evidence for this] then this may lead to bias and have a serious impact on 
our ability to accurately measure interval inequalities.  
4.2.4.2 Evidence for inequalities in diagnostic interval 
In a UK study lower SEP was associated with increased total diagnostic delay for 
prostate but not colorectal  or breast cancer (106), but again this included an element 
of patient delay. In the same study SEP was associated with secondary care diagnostic 
delay for colorectal, ovarian, prostate and breast cancer (106). However, no 
inequalities in time from first hospital appointment to diagnosis in high compared to 
low SEP groups were found in a pancreatic cancer study in a model including age, sex 
and co-morbidity but not stage (29). 
In a Scottish study diagnostic delay for colorectal cancer was shown to be longer for 
those living in a rural location further from a cancer centre (86).  
4.2.4.2.1 Evidence for inequalities in diagnostic interval: Lung cancer 
Socio-economic position was not associated with secondary care delay [from first 
hospital appointment to diagnosis date] for lung cancer in a UK study of over 3,000 
patients (106). Nor was it associated with increased total diagnostic delay for lung 
cancer (106), but this calculated the time from first symptom to diagnosis, so included 
an element of patient delay. Mean rather than median delay was also used. A small US 
study looking at time from imaging to diagnosis also found no association with SEP 
when using either education or income as the measure (107). 
In contrast, a Swedish study did find that lower SEP lung cancer patients experienced 
longer delays between referral and diagnosis, with a median wait of 32 days for low 
education and 17 days for high education level patients (73). However, this was a 
univariable analysis. But a large, good quality Danish study of over 18,000 lung cancer 
patients also found that those with a higher education level were more likely to have a 
diagnosis within 28 days from referral [the target waiting time] compared to those 
with shorter education, adjusted for age, sex cohabitation status and co-morbidity, in 
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both early and late stage patients (108). A significant association was only found for 
early stage patients when income was used as the measure of SEP however. 
4.2.4.3 Treatment interval – definition and problems 
The treatment interval is generally defined as the time between diagnosis and 
treatment (113, 129). However, it can also be measured as time from first symptoms 
(130), time from first consultation (79) or receipt of referral letter (122) to treatment, 
again making comparison between studies difficult. 
There may be valid reasons why adjuvant therapy is delayed after curative surgery. 
These could include post-operative complications, longer recovery due to cancer 
complications, and poor pre-operative performance status due to presence of co-
morbidities, advanced stage and age (131). Post-operative complications may also 
reduce the likelihood of chemotherapy after surgery.  
4.2.4.4 Evidence for inequalities in treatment interval 
SEP [measured by household income] did not affect time from diagnosis to treatment 
for cancer in a Canadian study. Older patients and women had lower waiting times 
(129). Women with high household income experienced shorter system delays [from 
initial primary care investigation to treatment] than those less economically privileged, 
in a Danish cancer study (104). 
In a large, good quality study using data from over 71,000 patients from 3 UK cancer 
registries and employing an area-based measure of SEP, deprived colorectal cancer 
patients were more likely to receive late treatment (79) [in a model including SEP, 
stage, age and time to treatment from first contact]. In a German study of 86 patients 
treatment delay for colorectal cancer [measured as total time from first symptoms to 
treatment] was associated with SEP [as was type of cancer and marital status but not 
age or sex] (130). However, this measurement of treatment delay included patient as 
well as practitioner delay and the patient delay actually accounted for over 70% of the 
overall delay. A French study found no influence of occupation [as a measure of SEP] 
on time to treatment for colorectal cancer (132). 
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4.2.4.4.1 Lung cancer 
4.2.4.4.1.1 Length of time to treatment interval 
A number of lung cancer studies report time to treatment intervals. One small UK 
study found that the time from GP referral to treatment was a median of 60 days (IQR 
44-85) with the time from secondary care specialist referral to treatment varying by 
treatment type [25 days for surgery, 16.5 days for chemotherapy and 43 days for 
radiotherapy] (101). A small Indian study of 165 patients found that median time from 
diagnosis to treatment was 20 days (133) and, when they looked at a number of older 
studies, these found times varied from 10 to 30 days [but, as they reported, these used 
mean rather than median time so need to be interpreted with caution]. A small UK 
study from 1998 found that median time from receipt of referral letter to treatment 
was 48 days (122). A Finnish study reported lung cancer treatment delay as median 15 
days from diagnosis and 30 days from first visit to specialist (121). 
4.2.4.4.1.2 Evidence for inequalities in treatment interval 
In a Swedish study older patients had longer delay in an unadjusted analysis of time to 
treatment for non-small cell lung cancer. SEP was not measured (134). A small Scottish 
study of time between referral and first treatment for lung cancer found no association 
between SEP and time to treatment (86) in both univariable and multivariable analyses 
[taking into account age, stage and health board]. A small American study found a 
univariable association between income [as a measure of SEP] and time from image to 
treatment, but not when education was used. In the multivariable analysis only type of 
hospital remained significantly associated, with those treated in a public hospital 
having significantly longer delay [median 76 days] than those treated privately [45 
days] (107). A small Canadian study found no association between education level and 
time from detection to surgery (109). 
4.3 Summary: Socio-economic inequalities in time intervals  
The evidence for the influence of SEP on time to consultation, referral, diagnosis, and 
cancer treatment is inconclusive and further investigation is required.  
A review of the current evidence for lung cancer, as discussed in this chapter, is shown 
in table 4.1. Results are contradictory for time to diagnosis [two studies found 
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inequalities in time from referral to diagnosis and two found no association in time 
from FHA to diagnosis and image to diagnosis, with SEP]. No association was found 
between SEP and time to presentation [using stage at diagnosis as a proxy] and time to 
treatment. However, very few studies used median time, most studies were very small 
and had low statistical power [particularly in the time to treatment analyses] and many 
employed only univariable analysis and so were of poor quality. Inconsistent measures 
of time period were also used making comparison between studies difficult. Therefore 
the evidence for socio-economic inequalities in delay for lung cancer is inconclusive. 
The evidence for whether delay contributes to socio-economic differentials in survival 
is considered in section 5.4 of chapter 5, which examines inequalities in survival.  
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Chapter 5. Inequalities in cancer survival 
This chapter examines the evidence for inequalities in cancer survival, why inequalities 
might be found and what factors might influence inequalities in survival. 
5.1 Introduction 
Socio-economic inequalities in survival have been described for most common cancers 
(135) and although introduction of the NHS Cancer Plan in 2000 may have improved 
overall cancer survival there does not appear to be a concurrent reduction in the 
deprivation survival gap in England (136). Three recent studies have looked at relative 
survival for common cancers in England, Wales and Scotland. They all found that 
although cancer survival was improving the deprivation gradient was getting steeper 
(25, 136, 137).  
Cancer survival may be influenced by patient-related factors such as performance 
status and co-morbidities (138), tumour factors relating to stage and aggressiveness of 
the cancer, and to service-related factors such as treatment decisions by the multi-
disciplinary team [MDT] (102). Post-operative complications may also be relevant, as 
might delay.  
5.2 SEP and cancer survival 
5.2.1 Why might socio-economic inequalities in cancer survival be found? 
Variation in co-morbidity, stage at diagnosis and in receipt of treatment have all been 
suggested as potential explanations for socio-economic inequalities in cancer survival, 
although few studies have adjusted for these factors or looked at how they vary by SEP 
(137). Poorer survival is generally attributed to later presentation by lower SEP 
patients. A 2006 review summarised a decade of research on the association between 
SEP and cancer survival (26) and although stage at diagnosis did seem important in 
determining likelihood of survival [particularly for colorectal and breast cancer] the 
authors felt that socio-economic differences in ‘access to optimal treatment’ (26) 
partially explained survival differences.  
One recent study has attempted to examine receipt of treatment and survival by SEP 
for breast and colorectal cancer, using the theoretical framework of the ‘inverse equity 
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law’ to determine whether survival inequalities widen after the introduction of a new 
treatment, on the assumption that it is more likely to be offered to the more affluent 
patients (35). However, as they were not able to determine the actual treatment 
received by patients but were only able to graph the date of introduction of a new 
treatment and the survival trends after that time, it was difficult to draw any clear 
conclusions.  
It has been suggested that social support and being married may lead to better cancer 
survival (26, 139). The less affluent tend to have lower levels of support although the 
effects may differ between the sexes (139). Differences in smoking rates may be 
important. A Norwegian study of women found that smoking status prior to diagnosis 
was a predictive factor for socio-economic variation in cancer survival (140). 
5.2.2 Evidence for socio-economic inequalities in cancer survival 
Stage at diagnosis appears to be the main prognostic factor for colorectal cancer 
survival (141) but survival rates have consistently been shown to be worse for those 
with lower SEP (10, 11, 79, 142-144). A number of studies have also shown that 
survival rates are lower for breast cancer patients who reside in more deprived areas 
(137, 143, 145-148). There is evidence for a socio-economic gradient in survival for 
lung cancer in some studies, with poorer survival in more deprived groups (73, 149-
151), but not in others (143, 152, 153), although no studies found an inverse gradient – 
see table 5.1.The evidence will be explored in more detail below. 
5.2.2.1 Colorectal cancer 
In a UK study looking at five year colorectal cancer survival, area-based socio-economic 
deprivation was associated with increased mortality (142). Age, stage and number of 
co-morbidities were also significant. Similar results were found in a Danish study (144) 
where it was suggested that co-morbidity may partly explain the social gradient in 
survival. However, in another study  it was shown that survival was less likely if co-
morbidities were present but a socio-economic gradient was not found (138).  
Deprived colorectal cancer patients had poorer three-year survival compared to the 
more affluent using data from three UK cancer registries, in a large, good quality study 
(79). However, no differences in survival were seen for those patients who had 
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treatment within one month of diagnosis but the socio-economic survival gradient 
remained in those who had later or no treatment, even when age and stage were 
taken into account (79). Earlier access to treatment attenuated socio-economic 
differences in survival in this cohort suggesting that improved access to treatment for 
all might lead to an overall improvement in outcome (79). Another study appears to 
support this finding, as within a randomised controlled clinical trial of chemotherapy 
and radiotherapy for colorectal cancer, when crude and relative survival at one and 
five years were analysed by socio-economic deprivation then the excess hazard of 
death was not significantly higher in the more deprived groups, adjusted for age, sex, 
stage and cancer site (154), suggesting that equal treatment results in equal outcome, 
regardless of SEP (154). However, it may also be that the type of patient who is 
considered for a clinical trial [generally younger and fitter] may also have an influence 
here. 
A recent study concluded that excess deaths occurred in the first month post-diagnosis 
in more deprived colon cancer patients but this excess persisted for longer in deprived 
rectal cancer patients (155) although stage and co-morbidity were not included in the 
analysis. Lower SEP was associated with a higher risk of 30-day post-operative 
mortality (65) although much of this effect was explained by differences in grade and 
stage of the tumour and by emergency compared to elective surgery. In this study 
more deprived patients presented with later stage cancer (65) in contrast to another 
study which did not find this (156). This small but good quality study (156) found better 
survival for more affluent patients who underwent curative surgery. However, there 
were no socio-economic differences in stage, mode of presentation or treatment 
offered and so they suggested that outcome differences might be related to a more 
compromised tumour-host response in the more deprived patients.   
5.2.2.2 Lung cancer 
Table 5.1 summarises the results from studies located in a review of the literature that 
examined the socio-economic gradient in survival for lung cancer. Details of the 
country of study, study size, years of diagnosis, and confounders included are shown, 
as well as the hazard ratio of survival in the lowest compared to the highest SEP group 
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for univariable and where conducted, multivariable analysis. Some contradictory 
findings can be seen.  
A recent UK study found that three-year survival in 1828 early-stage NSCLC patients 
was 50% in the most affluent group and 39% in the most deprived (157) with a 
univariable HR=1.35 [95% CI 1.07 to 1.70]. However this HR was attenuated and 
became non-significant [HR=1.24 (95% CI 0.98 to 1.56)] in a multivariable model 
including age, sex, co-morbidity and receipt of surgery. A similar result was seen in an 
earlier, smaller UK study that examined one-year survival. A significantly decreased 
univariable OR of survival was found in the lowest compared to the highest SEP group 
and this remained when age, sex, histology, basis of diagnosis, number of symptoms, 
consultant specialty and stage were included in the model but not when receipt of 
treatment was included (158). The authors suggest that poorer survival in more 
deprived patients may therefore be due to differences in receipt of treatment rather 
than case mix variation (158). In a clinical trial education-level was not associated with 
survival when standard treatment was received by all (159) which would support this 
theory. However, two studies using lung cancer audit data did not find socio-economic 
inequalities in survival whether or not treatment was included (152, 153). 
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Table 5.1. Summary of previous evidence from studies examining likelihood of survival by SEP (in most deprived [low SEP] compared to least deprived [high 
SEP] group), for lung cancer 
      Univariable HR Multivariable HR Low SEP associated with: 
Study Country N Years of 
Diagnosis 
Confounders Further information HR (IMD=5) HR (IMD=5) Higher 
HR 
Lower 
HR 
No 
association 
Berglund et al 
(2012) (157) 
England 1,828 2006-2008 Age, sex, co-morbidity, receipt 
of surgery 
3 year survival – early stage 1.35 (1.07 to 1.70) 1.24 (0.98 to 1.56) X  X 
Cheyne et al 
(2013) (115) 
England 1,432 2008-2010  Univariable Kaplan-Meier  only  
1 year survival  
39%  in high SEP  
33% in low SEP 
   X 
Jack et al 
(2006) (158) 
England 695 1998 Age, sex, histology, basis of 
diagnosis, stage, number of 
symptoms, consultant 
specialty, treatment 
OR of survival NOT HR of death 
1-year survival 
0.63 (0.35 to 1.13)  
P for trend = 0.02 
0.84 (0.24 to 2.45) 
P for trend = 0.19 
X  X 
Jones et al 
 (2008) (160) 
England  34,923 1994-2002 Age, sex, stage, histology, 
treated at cancer centre, 
travel time 
Cont measure 
NYCRIS data 
-- 1.001 (1.000 to 1.002) X   
Riaz et al 
(2012) (161) 
England 77,349 2004-2006 Age, sex HR inc with age and derivation in 
full dataset but not by deprivation  
in receipt of surgery dataset 
Data not shown Data not shown X  X 
Rich et al 
(2011) (153) 
England 48,453 2004-2007 Age, sex, PS, histology, stage  1.03 (0.97 to 1.09) 1.00 (0.95 to 1.06)   X 
Rich et al 
(2011) (152) 
England 34,365 2004-2008 Age, sex, stage, PS, ethnicity, 
CCM, surgery, surgery centre, 
radio centre, trial centre 
Clustering by NHS trust 1.04 (1.00 to 1.08) 0.99 (0.94 to 1.05)   X 
Berglund et al 
(2010) (73) 
Sweden 3,369 
(1,405 
women) 
1996-2004 Age, sex, histopathology, PS, 
smoking status, treatment 
Sig diff for women but not men or 
overall. Results for high compared 
to low education in women shown 
 0.76 (0.60 to 0.96) exc 
treatment 
0.84 (0.65 to 1.08) inc 
treatment 
X  X 
Hall et al 
(2004) (162) 
Western 
Australia 
9,080 1982-2001 
and 
1991-2001 
Age, sex, yr of diagnosis, 
marital status, indigenous 
status, histology, surgery, 
insurance status, hospital 
status, remoteness index, 
rural 
5-year survival --- 1.07 (0.94 to 1.20) and 
1.05 (0.93 to 1.20) 
  X 
Hardy et al 
(2009) (163) 
USA – I 
SEER area 
83,101 1991-2002 Age, sex, race, standard 
therapy 
5 year survival 
19,519 early stage, 80,519 late 
stage 
--- 1.38 (1.10 to 1.71) early 
1.09 (1.06 to 1.12) late 
X   
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Table 5.1 (cont). Summary of previous evidence from studies examining likelihood of survival by SEP (in most deprived [low SEP] compared to least deprived 
[high SEP] group), for lung cancer 
      Univariable HR Multivariable HR low SEP associated with: 
Study Country N Years of 
Diagnosis 
Confounders Further information HR (IMD=5) HR (IMD=5) Higher 
HR 
Lower 
HR 
No 
association 
Schrivers et al 
 (1994) (164) 
various    Review inc 3 studies     X 
Yim et al 
 (2012) (165) 
Korea 261 1999-2002 Age, sex, stage, PS, family 
history, no of outpatient visits 
 1.25 (0.87 to 1.80) 1.46 (0.99 to 2.14)   X 
 
 
Table 5.1b. Summary of previous evidence from studies examining the likelihood of survival by SEP (in most deprived compared to least deprived group), for 
lung cancer: relative survival 
      Relative survival (RS) low SEP associated with: 
Study Country N Years of 
Diagnosis 
Confounders Further information  Poorer RS Better RS No association 
Coleman et 
al(2004) 
England and 
Wales 
107,317 
 
1996-1999 Age, sex 5 year relative survival 
Sig in men only 
-1.4%(dep gap in men) X (men)  X (women) 
Rachet et al 
(2010) 
England 303,422 1996-2006 Age, sex 1 year relative survival 
(2006 results shown) 
-1.6%(dep gap in men) 
-3.1%(dep gap in women) 
X   
Shack et al  
 (2007) 
Scotland 20,851 1996-2000 Age, sex 5 year relative survival 
Sig in men only 
-1.6%(dep gap in men) X (men)  X (women) 
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5.3 Other factors influencing survival 
Local variation in cancer management such as access to specialist surgeons might 
affect survival (26). A review found that cancer mortality was lower when treated by a 
specialist surgeon or centre (166) but the poor quality of some of the studies included 
meant that the evidence was not conclusive and no consideration was given to 
outcome differences by age, sex or SEP. In contrast, a 2001 review found that, in the 
majority of studies it examined, surgeon volume or experience did not significantly 
affect colorectal cancer mortality (94). However, there is some more recent evidence 
to suggest that outcomes are better for colorectal patients who are managed by a 
specialist surgeon. The odds of death within 30-days post-operatively and within five-
years were significantly lower for those managed by a specialist, taking into account 
age, sex, stage, SEP, tumour site and whether elective or emergency surgery was 
performed (167).  
Breast cancer survival in the UK is lower than in other European countries with similar 
healthcare systems such as Norway and Sweden, possibly due to more advanced stage 
at presentation (168). Older patients also had poorer survival with a suggestion that 
they may be less likely to receive optimal treatment (168). 
5.3.1 Lung cancer 
Five-year survival for lung cancer is lower in England than in other European countries 
with similar healthcare systems, with a suggestion that this may be due to differences 
in management and access to treatment (169). A recent study found that lung cancer 
survival differences between six countries [including the UK] were partly due to 
differences in stage at diagnosis (170) but it was possible that some of the differences 
observed might also be due to problems with data quality and comparability, and to 
national differences in clinical decision making when dealing with borderline suitable 
patients such as older patients with poor PS and co-morbidities (170).  
A study that simultaneously evaluated the management and  survival of lung cancer 
patients in Teesside in the UK and in Varese in Northern Italy, two areas with similar 
lung cancer incidence, found that the resection rate was higher [24% compared to 7%], 
and three-year survival better [14% compared to 7%], in Italy compared to the UK 
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(171). The lower resection rate in the UK was ascribed to patients presenting with later 
stage cancer, having more aggressive tumours, and higher rates of co-morbidity. SEP 
and time interval delays were not measured, however.  
A review examining the prognostic and predictive role of tumour type on survival 
found contradictory evidence, with some studies showing better survival for those 
diagnosed with adenocarcinoma and others suggesting more favourable outcomes for 
squamous cell cancers (19). Poor general health as measured by PS, but not the 
number of co-morbidities, was associated with poorer lung cancer survival (96) in a 
recent study. Better survival is found for those with good PS.  In a study of 26,957 
patients in Japan, the group with good PS [PS=0] contained the highest percentage of 
non-smokers and over half had stage 1 cancer (172). Smoking status was also found to 
be an independent prognostic factor for survival in this study, as were stage, sex and 
age (172). Women were shown to have better survival than men in a meta-analysis 
although the reasons for this are not clear. For early-stage survival it may be related to 
women being more likely to have a more slow-growing adenocarcinoma subtype. 
However, sex appeared to be an independent prognostic factor when stage, histology 
and smoking status were taken into account (173).  
Age was shown to be strongly associated with early post-operative death [within 90 
days of surgery], as was poor PS in a UK study using lung cancer audit data (174). 
A study conducted using NYCRIS data did not find that increased travel time to hospital 
was associated with poorer survival, in fact the reverse (160). 
There is a correlation between resection rates and survival (175). A recent UK study 
found that patients who were resident in trusts that had high surgical resection rates 
had reduced hazard of mortality compared to those with lower surgical rates, 
suggesting that survival rates could be improved if a higher proportion of patients 
were resected (161). The authors also suggest that as these rates were insensitive to 
adjustment for patient age and SEP then these associations were due to physician or 
hospital-level factors (176). Patients assessed by an MDT had better survival than 
those in a previous cohort, who were not (98). 
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5.4 Delay and survival 
Does delay affect survival? The influence of patient and healthcare delay on cancer 
survival is unclear, according to one review (26). A scoping review identified 47 studies 
looking at 13 different cancers, of which 11 found a positive association, 9 a negative 
association and 29 no association between increased delay and poorer outcome (177). 
If survival is measured from diagnosis or surgery rather than from the onset of 
symptoms then there is a possibility of lead-time bias (178) and many studies on delay 
do not take this into account (177). 
Diagnostic delay has been implicated as a factor that contributes to the poorer survival 
of UK cancer patients compared to the European average (99, 102). However, there 
have been some contradictory findings regarding the importance of delay on survival. 
In some cases it appears that those with shorter system delays may, in fact, have 
poorer survival. This has been termed the Waiting Time Paradox [WTP].  
The WTP suggests that sicker people are referred more quickly and, as they are more 
ill, have shorter survival (179). A small study of colorectal cancer patients found that 
shorter diagnostic interval was associated with higher mortality, but this was only seen 
for those with obvious alarm symptoms and not found for those presenting with vague 
symptoms, although there were only 67 patients in this latter group (179). A 2013 
Korean study found that a delay of greater than 12 weeks from diagnosis to curative 
surgery was associated with increased mortality for colorectal and breast cancer 
patients but not for lung or thyroid cancer (180), so that different effects may be seen 
depending on the specific cancer. However, another study found that an excess wait 
[>62 days from diagnosis to curative surgery] for breast cancer had no impact on 
survival (181) so that contradictory results are also found within cancer types. 
Although some individual studies have shown an association between delay and 
colorectal cancer survival (79) others have not (113). A 2007 review could not reach a 
definitive conclusion as to whether diagnostic and therapeutic delay affected survival 
for colorectal cancer patients (178), although there appeared to be delay differences 
between colon and rectal cancer (178, 182). A weak degree of association was found 
between increased delay and improved survival [which again might support this ‘sicker 
quicker’ WTP theory], but not all the studies considered tumour stage. The review 
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authors also remarked on the scarcity of studies that included other confounding 
factors such as age, sex, SEP and co-morbidities (178). A different review found that 
delaying adjuvant chemotherapy for longer than 8 weeks was associated with poorer 
overall  colorectal survival (131). 
A systematic review of the influence of delay on breast cancer survival found that 
patients with treatment delay had poorer survival but this was not seen when stage at 
diagnosis was taken into account (183). 
5.4.1 Lung cancer 
No association between timely care and survival for lung cancer has been shown in 
two literature reviews, as both found the evidence inconclusive (184, 185). The most 
recent review found three studies where timely care was associated with better lung 
cancer survival, four that found the opposite and eight that found no association. No 
meta-analysis was carried out. The quality of the studies included was mixed and most 
did not adequately control for age, stage, histology and co-morbidity (185). The 
authors suggest that this lack of control for confounding factors is likely to account for 
why those with more timely care had poorer survival, in the studies that found this. 
However, a recent study looking at delays in diagnosis and treatment on survival in 
SCLC patients found that patients who were diagnosed earlier had a poorer prognosis 
that those diagnosed later and they were able to take into account age, sex, stage and 
PS (186).  
5.5 Summary of chapters 3-5 
From the narrative review of inequalities in receipt of treatment for a number of 
cancers, there is some evidence that receipt of treatment and time to treatment is 
socio-economically patterned and that this may impact on socio-economic inequalities 
in survival, but it is not clear cut. The evidence is mixed and there are contradictory 
findings both within and between cancer types. A number of studies look at ‘cancer’ 
but analysing combined cancers is likely to mask any between-cancer differences. 
Differences in tumour development and prognosis may account for some of the 
between-cancer differences in time to, and receipt of, treatment.  
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Even in studies that focus on a particular cancer, the quality of the studies and 
different confounders included make comparisons difficult. A 2007 study noted that 
socio-economic inequalities in co-morbidity, stage at diagnosis and receipt of 
treatment, factors that may be potential explanations for socio-economic inequalities 
in cancer survival, have not been well explored (137). The role that delay may play in 
survival is unclear. In time interval analyses there is a lack of consistency in definitions 
of delay intervals, and a lack of control for potentially important confounders. 
5.5.1 Lung cancer 
Socio-economic gradients in lung cancer survival are found in a number of studies but 
these gradients appear to be attenuated or eliminated in a clinical trial where 
participants received equal treatment and in some observational studies where receipt 
of treatment was included in the model. If access to treatment does influence survival 
it is important to investigate factors such as SEP that might influence whether 
treatment is received.  
Further work is required to determine whether socio-economic inequalities in receipt 
of lung cancer care do occur, what factors may be influencing this, and what role 
treatment inequality and delay might play in survival inequality.  
Having determined the gaps in knowledge regarding the evidence for inequalities in 
lung cancer treatment, time to diagnosis and treatment, and survival, both in the lack 
of research in these areas as well as the poor methodological quality of the studies 
that have been conducted, and the lack of synthesis of the evidence, suitable research 
aims and objectives were developed. These are detailed in chapter 6. 
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Chapter 6. Aims and Objectives 
6.1 Development of aims and objectives 
 The initial narrative literature review identified that further work was required to 
determine whether socio-economic inequalities in receipt of, and time to, lung cancer 
are found; what factors may be influencing this; and what role inequalities in 
treatment and in the referral, diagnostic and treatment intervals might play in survival 
inequality. No systematic synthesis of the evidence for socio-economic inequalities in 
lung cancer treatment, time to diagnosis and treatment, or survival has previously 
been conducted.  
6.2 Aims and objectives 
The following aims and objectives were developed in order to fill the gaps in 
knowledge that had been identified, and to help determine whether IGIs in lung cancer 
care are found: 
Aim:  
• To determine if there are socio-economic inequalities in lung cancer care and, if 
so, to identify where on the pathway of care these inequalities might occur: 
looking at receipt of treatment; referral, diagnostic and treatment intervals; 
and survival 
Objectives: 
• To conduct a systematic review of the literature on socio-economic inequalities 
in receipt of treatment for lung cancer  
• To link routine secondary data in order to identify where on the pathway of 
cancer care inequalities might occur for lung cancer; specifically to describe the 
relationship between SEP and: 
o  receipt of treatment; 
o delay in referral, diagnosis and treatment;  
o survival; 
whilst also taking into account age, sex, cancer stage, performance status, 
presence of co-morbidities and other potential confounding factors  
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This thesis includes two areas of work: a systematic review and meta-analysis of the 
evidence from the published literature on socio-economic inequalities in receipt of 
lung cancer treatment; an analysis of secondary data examining socio-economic 
inequalities in receipt of, and time to, treatment, and survival, for lung cancer.  
Chapter 7 details the systematic review and meta-analysis of socio-economic 
inequalities in lung cancer treatment.  
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Chapter 7. Systematic review and meta-analysis of socio-economic 
inequalities in receipt of lung cancer treatment 
Summary 
Background 
Socio-economic inequalities in treatment may occur for some common cancers. 
Although the incidence and outcome of lung cancer varies with socio-economic 
position, it is not known whether socio-economic inequalities in treatment occur. A 
systematic review and meta-analysis of existing research on socio-economic 
inequalities in receipt of treatment for lung cancer was conducted to investigate this.  
Methods  
MEDLINE, EMBASE and Scopus were searched up to September 2012 for cohort 
studies of participants with a primary diagnosis of lung cancer [ICD10 C33 or C34], 
where the outcome was receipt of treatment (rates or odds of receiving treatment) 
and where the outcome was reported by a measure of socio-economic position.  
Forty six papers met the inclusion criteria and 23 of these papers were eligible for 
meta-analysis.  
Results 
Socio-economic inequalities in receipt of lung cancer treatment were observed. Lower 
socio-economic position was associated with a reduced likelihood of receiving any 
treatment [OR=0.79 (95% CI 0.73 to 0.86), p<0.001], surgery [OR=0.68 (95% CI 0.63 to 
0.75), p<0.001] and chemotherapy [OR=0.82 (95% CI 0.72 to 0.93), p<0.001], but not 
radiotherapy [OR = 0.99 (95% CI 0.86 to 1.14), p=0.89], for lung cancer. The association 
remained when stage was taken into account for receipt of surgery, and was found in 
both universal and non-universal health care systems.  
Conclusions 
Lung cancer patients living in more socio-economically deprived circumstances are less 
likely to receive any type of treatment, surgery and chemotherapy. These inequalities 
cannot be accounted for by socio-economic differences in stage at presentation or by 
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differences in health care system. Further investigation is required to determine the 
patient, tumour, clinician and system factors that may contribute to socio-economic 
inequalities in receipt of lung cancer treatment. 
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7.1 Background 
Socio-economic inequalities in incidence of, and survival from, the majority of cancers 
have been reported (8, 9, 136). The evidence for socio-economic inequalities in cancer 
treatment was explored in chapter 3.  Although a recent non-systematic review found 
some evidence for socio-economic inequalities in receipt of treatment for colorectal 
cancer (11) overall the evidence from studies included in my narrative review was 
inconclusive. Study quality was variable and many studies did not account for 
important confounders.  However, despite the lack of conclusive evidence for socio-
economic inequalities in cancer treatment it has been suggested that socio-economic 
differences in access to treatment might at least partially explain socio-economic 
differences in cancer survival (26).  
Incidence of lung cancer is higher (8, 16), and survival poorer (136), in the most 
deprived patient groups. However, it is not known whether socio-economic 
inequalities in receipt of treatment exist for lung cancer and, if so, what contribution 
they make to overall socio-economic inequalities in outcome. In order to explore the 
first of these questions a systematic review and meta-analysis of cohort studies 
examining the association between socio-economic position (SEP) and receipt of lung 
cancer treatment was undertaken. 
7.2 Review Objectives 
The aim of this review was to summarise the existing literature and to assess the 
published evidence for socio-economic differentials in receipt of treatment for lung 
cancer. 
7.3 Methods 
A protocol [Appendix C-C1] was developed and systematic methods used to identify 
relevant studies, assess study eligibility for inclusion and evaluate study quality. The 
review is reported according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses [PRISMA] guidelines (187) [see Appendix C-C2  for PRISMA 
checklist]. 
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7.3.1 Literature Search 
The online databases of MEDLINE and EMBASE were searched up to September 2012 
to locate studies examining receipt of treatment for lung cancer reported by a 
measure of SEP. This researcher [LF] developed the search strategy, which was refined 
with the help of a medical librarian. Slightly different strategies were required for each 
database [for example MEDLINE recognises the MESH term Lung Neoplasms/ whereas 
EMBASE does not and uses Lung cancer/]. No language restriction was applied [see 
Appendix C C3 for full search strategies]. A search of Scopus uncovered no further 
papers. Additional studies were identified by reviewing the reference lists of all 
included studies and by using a forward citation search to identify more recent studies 
that had cited included studies. EndNote X5 software was used to manage the 
references.  
7.3.2 Study Eligibility 
Studies that met the following criteria were included in the review: primary, cohort 
studies of participants with a primary diagnosis of lung cancer [ICD10 C33 or C34] 
reported separately from other cancers; published in a peer-reviewed journal; where 
at least one reported outcome was receipt of treatment [measured by rates or odds of 
receiving treatment]; and where receipt of this outcome was reported by a measure of 
SEP. Any curative or palliative treatment for lung cancer including surgery, 
chemotherapy and radiotherapy was included.   
Studies where SEP was included as a descriptive variable or potential confounder but 
where outcomes for receipt of treatment by SEP were not presented were not eligible 
for inclusion but the authors were contacted to determine whether relevant data were 
available that might allow for inclusion in the review. 
Studies where multivariable analysis was conducted [and included control for a 
minimum of age and sex as confounders]; receipt of treatment was compared to not 
receiving treatment; odds ratios [ORs] and 95% confidence intervals of receipt of 
treatment in low [most deprived] compared to high [least deprived] SEP was 
calculated; and SEP was not further stratified by another variable, were considered 
suitable for inclusion in meta-analysis. 
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Acceptable measures of SEP were: area-based indices of deprivation [e.g. Index of 
Multiple Deprivation (IMD), Townsend Score, Carstairs Index]; and area or individual 
measures of income; poverty; or education level. 
7.3.3 Study selection and data extraction 
Papers obtained from the database searches were independently assessed by two 
researchers [LF and a fellow PhD student HW] in three phases: title, abstract and full 
paper screening.  
Initial screening of titles was carried out to remove obviously irrelevant papers. 
However, from a preliminary scoping review by LF, the early pilot searches recovered 
studies that, although they conducted analyses of receipt of treatment stratified by 
SEP, did not always mention this in the abstract or title. Therefore, in the title search, 
any titles that referred to uptake or receipt of surgery, chemotherapy and 
radiotherapy for lung cancer were retained. Papers with titles that examined 
disparities in cancer survival/mortality were also included as further checking of the 
abstract was required to determine if inequalities in access to treatment were also 
examined. 
Abstracts were then screened and a subset of studies selected for further review and 
the full article obtained. Abstracts that referred to socio-economic inequalities in 
receipt of treatment were retained. Others that referred to racial, ethnic, geographical, 
sex and age-related disparities in treatment as well as disparities by insurance type 
were also retained as often these papers also looked at SEP, even if this was not 
mentioned in the abstract. Papers that considered delay were not included. Nor were 
studies examining access to hospice care as although some papers were recovered 
that considered this type of care the search was not designed to pick up delay or 
hospice care. Therefore not all papers looking at this are likely to have been found and 
so there was a risk of presenting a selective rather than systematic analysis of these 
areas.   
Papers that were not available through Medline or Embase were obtained from Google 
scholar. Six papers were obtained via Inter-library loans and two were accessed in 
paper format only from Newcastle University library.  
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Two researchers [LF and HW] independently assessed the selected full papers for 
eligibility according to the study-eligibility criteria. Any disagreements at any of the 
screening stages were resolved by discussion between the two researchers in the first 
instance and with a third reviewer [JA] if agreement could not be reached.  
Data extraction was carried out by LF using an Access database pro-forma developed 
for this purpose. Data relating to study authors, journal, study design, year of study, 
data source, number of participants, years of diagnosis, measure of SEP, confounding 
variables included in the analysis [such as age, sex, stage, co-morbidities, cancer 
type/site, vital/performance status, marital status, smoking status, cancer network, 
health board, hospital, emergency or elective treatment, distance from hospital/travel 
time, ethnicity, insurance status], type of treatment received [any, surgery, 
chemotherapy, radiotherapy], statistical tests carries out, outcome measures 
[treatment rates or odds of treatment], comparator used, significance [p values], 
precision [confidence intervals], other variables that were significant; were recorded. 
Data extraction was double-checked by HW in a random sample of 10% of the included 
studies.  
There is evidence to suggest that health-insurance status is an important factor 
relating to access to lung cancer care in countries such as the USA that rely on 
insurance-based health care systems (188). Insurance status is less relevant and rarely 
measured in most other countries. Therefore studies were grouped into three 
categories during analysis: those conducted in a universal healthcare system [UHCS], 
free at the point of access [similar to the UK]; those conducted in countries with 
primarily private insurance healthcare systems [non-UHCS, similar to the USA] (189) 
and those conducted in countries with social insurance healthcare systems [similar to 
many European countries]. No studies were identified that fell into the third category. 
7.3.4 Population definitions 
A number of papers included the same or overlapping study populations or used a 
regional study population that was also analysed in another paper as part of a national 
data-set. Some rules had to be derived in order to define patient populations, deal 
with study data that was being utilised by more than one paper and to choose data 
from the most suitable paper for inclusion. 
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A study population was defined as being determined by the geographical area, the 
source of the data and the time period of diagnosis. If two papers used data from the 
same source and time period then these were defined as fully over-lapping 
populations. If a study presented separate data for early and late stage patients these 
were regarded as separate populations. If a paper contained a regional population that 
was a subset of a paper containing a national population then these were classified as 
separate but over-lapping populations. If papers used populations from the same data 
source where there was only one year of overlapping data and a number of different 
years either side then these were defined as partially over-lapping study populations 
[substantially non-over-lapping]. Appendix C4 examines papers with over-lapping 
populations in more detail, with a breakdown of how the inclusion decisions were 
made.   
Quality score was used to determine the most appropriate paper to choose for 
inclusion in the final meta-analysis.  
7.3.5 Quality 
A quality tool was used to divide eligible papers into six study quality categories with 1 
being the lowest, and 6 the highest, quality [see Appendix C5]. Quality assessment was 
based on internal validity [for measures of SEP and outcome]; type of analysis 
conducted [multivariable or univariable]; population included [population-based or 
selective]; quality of reporting; and adjustment for relevant confounders. Quality 
assessment was carried out by LF and checked by HW.  
7.3.5.1 Existing study quality tools 
A number of existing tools potentially suitable for assessing cohort study quality were 
considered including the Cochrane Tool for Assessment of Risk of Bias (190); three 
other tools recommended by Cochrane Review Groups: the Jadad Scale, the Moncrief 
Scale and the Newcastle-Ottawa Scale (191); the Scottish Intercollegiate Guidelines 
Network [SIGN] methodology checklist for cohort studies (192); the EPHPP Quality 
Assessment Tool for Quantitative Studies (193); and The STROBE [Strengthening the 
Reporting of Observational Studies in Epidemiology] guidelines [a checklist of 22 items 
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that should be included in cohort studies] (194). Details of these tools are found in 
Appendix C6 with a discussion of the suitability of each. 
In a systematic review it is necessary to examine the methodological quality, that is - 
the internal validity, of the primary studies. However, previous systematic reviews 
have used quality tools that defined quality in a number of different ways. Some 
quality scales look at internal validity [risk of bias] but also measure external validity 
and the quality of the reporting, which are not measures of bias within the study. 
Assessment of quality can therefore be sub-divided into a number of categories such 
as internal validity [including selection, confounding, statistical analysis and outcome], 
external validity and reporting. 
If quality scores are employed then they can be used in a number of ways. It is possible 
to include all papers regardless of quality, include only high quality papers or include 
all but use quality to divide papers into sub-groups so that high and low quality papers 
are analysed separately. Quality can also be used as part of a narrative synthesis to 
help explain any differences found (195).  
Having examined a number of potential tools and considered the different ways that 
quality could be utilised, a quality tool was developed for this review. 
7.3.5.2 Development of a quality tool for this review 
As none of the existing tools considered were entirely appropriate for the type of 
studies included in this review and, as has been done for previous reviews (185, 188),  
we devised a suitable tool, adapting and utilising aspects of other available tools. This 
approach has the benefit of producing a quality tool that is highly specific for the type 
of studies examined and there was good agreement between researchers when using 
the tool. 
Quality in this systematic review was appraised using criteria adapted from existing 
quality tools [SIGN, EPHPP and STROBE guidelines].  
In order to be considered for meta-analysis papers had to present adjusted odds ratios 
and report confidence intervals. A quality checklist was constructed with a screening 
question used to split papers into those potentially suitable for meta-analysis [adjusted 
ORs and CIs reported], and those suitable for narrative synthesis [meet inclusion 
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criteria but do not present adjusted ORs]. Then a 19-point scale that examined study 
quality under the following headings: internal validity [selection], external validity, 
quality of reporting of the study, and confounding; with a scoring system, was utilised. 
The scoring system was then used to further sub-divide studies into 6 quality 
categories [with 1 being the lowest, and 6 the highest, quality], with the final score 
determined by the type of population included, internal validity, reporting of the study 
and confounders included.  
Cohort studies reporting only univariable analysis are of lower quality than those 
conducting multivariable analysis, in terms of their ability to control for confounding. 
However, it was decided to include those papers in the narrative analysis, with their 
overall lower quality taken into account. Initially Harvest Plot analysis was considered 
as a method for pictorially displaying the narrative findings, as the authors of this 
method have suggested that the Harvest Plot could be adapted so that, instead of 
looking at suitability of study design, quality can be used to distinguish studies of the 
same design (196). However, the initial Harvest Plot graphs produced were difficult to 
interpret and so it was decided against this approach for the narrative review. 
7.3.6 Statistical analysis 
Trends in receipt of treatment across SEP groups were assessed in the descriptive 
narrative analysis of all studies that met the inclusion criteria. 
Meta-analysis of eligible studies was undertaken using Cochrane Collaboration Review 
Manager 5.1. Only studies reporting multivariable analysis [quality scores 3-6] were 
included in the meta-analysis. Natural logs of the ORs and their standard errors [SEs] 
were calculated for use in Forest plots. Random-effects meta-analysis of the odds of 
treatment in the lowest compared to the highest SEP group was conducted. Where a 
study reported the most deprived class as the comparator then reverse ORs were 
calculated. Studies that presented a single OR as either an OR for a one unit increase in 
deprivation score or incremental quintile increase in income were not included. 
Subgroup analyses by treatment type and healthcare system were conducted. The I2 
statistic was used to examine heterogeneity. In meta-analyses where a ‘substantial’ 
percentage [previously defined as I2 >50%] (197) of the variability appeared to be due 
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to the heterogeneity of the studies rather than to chance, further subgroup analyses 
by stage, histology and quality score were conducted, where appropriate, in order to 
examine potential sources of heterogeneity. A funnel plot was utilised to assess 
potential publication bias.  
Multiple papers using the same or overlapping study data were included. Sensitivity 
analyses were conducted including all eligible papers and using different combinations 
of included-papers but only data from the better quality or more detailed paper in 
each overlapping study group were included in the final meta-analyses to ensure 
independence of results. Sensitivity meta-analyses [showing results including partially- 
overlapping populations, and fully-overlapping populations] are included in Appendix 
C7.  
7.4 Results  
7.4.1 Included studies  
A total of 46 papers met the inclusion criteria and were included in the review [see 
Figure 7.1 PRISMA flow diagram].  
Twenty eight papers were from UHCS countries [tables 7.1-7.2]. Of these, 19 UK 
papers examined 13 study populations, although as these included national and 
regional populations from different sources [cancer registries, Hospital Episode 
Statistics (HES) and lung cancer audit (LUCADA) data], there was some further 
population overlap. One UK paper also compared treatment in Scotland and Canada 
(198). A further nine papers from Canada [2], Sweden [1], Australia [1], Italy [1], France 
[1] and New Zealand [3] were included. The three New Zealand papers all examined 
the same population. These UHCS studies were published between 2001 and 2012, 
and examined populations diagnosed between 1986 and 2008. 
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Figure 7.1. Flow diagram of study selection and exclusion.  
 
 
 
Abbreviations: SEP = socio-economic position, CI = confidence interval 
PRISMA 2009 Flow Diagram 
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Table 7.1. Characteristics of included studies potentially suitable for meta-analysis (universal health care systems). 
        
 Confounders controlled for: 
 
Paper 
Country 
of study 
Data Source (s) 
Population 
included 
Years of 
Diagnosis 
Measure of 
SEP 
No of SEP 
groups 
Treatment 
given 
within 
Age 
range 
Age Sex Stage Histology Other 
Quality 
score 
Berglund 
et al, 
2010(73) 
Sweden 
Regional Lung 
Cancer Register 
(RLCR) - Sweden, 
Cause of Death 
Register and LISA 
(insurance and 
demographics) 
Uppsala/ 
Orebro region 
in central 
Sweden 
1996-
2004 
Education level 
(a) 
3 NR 30+ Yes Yes Yes Yes 
Performance status, year of 
diagnosis, smoking status 
6 
Berglund 
et al, 
2012(157) 
England 
Thames Cancer 
Registry, HES, 
LUCADA 
South-east 
England 
2006-
2008 
IMD 2007 
income domain 
5 NR 0-80+ Yes Yes Yes Yes Co-morbidity 6 
Campbell 
et al, 
2002(86) 
Scotland 
Scottish Cancer 
Registry and 
hospital case notes 
Random 
sample from 
North/NE 
Scotland (with 
hospital record) 
1995-
1996 
Carstairs Index 5 12 months NR Yes Yes Yes Yes 
Health board, distance to 
cancer centre, mode of 
admission 
5 
Crawford 
et al, 
2009(199) 
England 
Northern and 
Yorkshire Cancer 
Registry and 
Information Service 
(NYCRIS) 
Northern and 
Yorkshire 
region 
1994-
2002 
IMD 2004 
(access to 
services 
domain 
removed) 
4 6 months NR Yes Yes No Yes 
Travel time (but overall 
results not stratified by 
travel time used here). 
Histology not included in 
receipt of any treatment 
analysis. 
4 
Erridge et 
al, 
2002(200) 
Scotland 
Scottish Cancer 
Registry and 
medical records 
Scotland (with 
hospital record) 
1995 Carstairs Index 5 6 months 
<60- 
80+ 
Yes Yes Yes Yes 
Health board (not inc in 
receipt of radiotherapy), 
diagnosis by specialist, 
management by oncologist   
6 
Erridge et 
al, 
2009(198) 
Scotland/ 
Canada 
Scottish Cancer 
Registry and 
medical records; 
British Columbia 
Cancer Registry 
Scotland/ 
British 
Columbia 
1995 
Carstairs 
Index/ average 
household 
income 
2 6 months 
<60- 
80+ 
Yes Yes Yes Yes Travel time,  CT scan  4 
Gregor et 
al, 
2001(201) 
Scotland 
Scottish Cancer 
Registry and 
medical records 
Scotland (with 
hospital record) 
1995 Carstairs Index 5 6 months 
<60- 
80+ 
Yes Yes Yes Yes 
Referral to specialist within 6 
months of diagnosis 
6 
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Table 7.1 (cont). Characteristics of included studies potentially suitable for meta-analysis (universal health care systems). 
        
 Confounders controlled for: 
 
Paper 
Country 
of study 
Data Source (s) 
Population 
included 
Years of 
Diagnosis 
Measure of 
SEP 
No of SEP 
groups 
Treatment 
given 
within 
Age 
range 
Age Sex Stage Histology Other 
Quality 
score 
Jack et al, 
2003 (202) 
England 
Thames Cancer 
Registry 
South-east 
England 
1995-
1999 
Townsend 
(median score 
per health 
authority) 
continuous 
(b) 
NR 
<35 -
85+ 
Yes Yes Yes Yes 
First hospital visited is a 
radiotherapy centre, basis of 
diagnosis, incidence.  Health 
authority/hospital used as 
2nd level in multi-level model.   
4 
Jack et al, 
2006 (158) 
England 
Thames Cancer 
Registry and 
medical records 
South-east 
London (with 
hospital record) 
1998 IMD 2000 5 6 months 
<55- 
85+ 
Yes Yes Yes Yes 
                                                                                                                                                                                                 
Consultant specialty, basis of 
diagnosis, (hospital, number 
of symptoms in some 
analyses) 
6 
Jones et 
al,2008(78) 
England 
Northern and 
Yorkshire Cancer 
Registry and 
Information Service 
(NYCRIS) 
Northern and 
Yorkshire 
region 
1994-
2002 
IMD 2004 
(access to 
services 
domain 
removed) 
continuous 
(c) 
NR NR Yes Yes No Yes Travel time to hospital 4 
Mahmud 
et al, 
2003(203) 
Ireland 
National Cancer 
Registry of Ireland 
(NCRI) 
Republic of 
Ireland 
1994-
1998 
SAHRU area-
based material 
deprivation 
index 
3 6 months 15-80+ Yes Yes No Yes 
Health board, year of 
diagnosis 
4/2(d) 
McMahon 
et al, 
2011(204) 
England 
Eastern Cancer 
Registry and 
Information Centre 
(ECRIC) 
East of England 
1995-
2006 
IMD 2004 
(access to 
services 
domain 
removed) 
5 NR 
<60 -
80+ 
Yes Yes No Yes  Year of diagnosis 4 
Pollock  
&Vickers, 
1998(76) 
England HES FCEs  
North/South 
Thames 
(admitted to 
hospital) 
1992-
1995 
Townsend 10 NR <100 Yes Yes No No  Hospital, mode of admission 3 
Raine et 
al, 2010(77) 
England HES FCEs  
England 
(admitted to 
hospital) 
1999-
2006 
IMD 5 NR 
50-- 
90+ 
Yes Yes No No 
Trust, year of admission, 
mode of admission 
3 
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Table 7.1 (cont). Characteristics of included studies potentially suitable for meta-analysis (universal health care systems). 
        
 Confounders controlled for: 
 
Paper 
Country 
of study 
Data Source (s) 
Population 
included 
Years of 
Diagnosis 
Measure of 
SEP 
No of SEP 
groups 
Treatment 
given 
within 
Age 
range 
Age Sex Stage Histology Other 
Quality 
score 
Riaz et al, 
2012(161) 
England 
NCIN/UKACR 
cancer registries 
England 
2004-
2006 
IMD 2004 5 NR 0-- 85+ Yes Yes No No Government Office Region 4 
Rich et al, 
2011(1)(153) 
England 
LUCADA supplied 
by 157 NHS trusts 
England 
2004-
2007 
Townsend 5 NR NR Yes Yes Yes Yes 
Performance status. 
Adjusted for clustering by 
NHS trust 
5 
Rich et al, 
2011(2)(152)  
England LUCADA and HES England 
2004-
2008 
Townsend  5 NR 30-100 Yes Yes Yes Yes 
Co-morbidity, ethnicity, 
surgery centre, radiotherapy 
centre, trial entry. Adjusted 
for clustering by NHS trust 
5 
Stevens et 
al, 
2007(205) 
New 
Zealand 
Regional hospital 
and oncology 
databases checked 
against NZ cancer 
registry 
Auckland-
Northland 
region patients 
managed in 
secondary care 
2004 
NZ Deprivation 
Index 
2 NR 
<60-
80+ 
Yes Yes Yes Yes 
Co-morbidity, private sector 
care, care discussed at MDM 
3 
Stevens et 
al, 
2008(206) 
New 
Zealand 
Regional hospital 
and oncology 
databases checked 
against NZ cancer 
registry 
Auckland-
Northland 
region patients 
managed in 
secondary care 
2004 
NZ Deprivation 
Index 
10 NR 
<60- 
80+ 
Yes Yes Yes Yes 
Co-morbidity, private sector 
care, ethnicity 
5 
(a) Socio-economic index (SEI) and household income also measured but individual education level used in analyses as it contained least missing data 
(b) Odds ratio for 1 unit increase in deprivation score, range unknown   
(c) Odds ratio for 1 unit increase in deprivation score, range 1-80 
(d) Quality score 4 where adjusted OR used and 2 where unadjusted rates used 
 
Quality score ranges from 1 (lowest quality) to 6 (highest quality) 
Abbreviations: HES = Hospital Episode Statistics, HES FCE= Hospital Episode Statistics Finished Consultant Episode, IMD = Index of Multiple Deprivation, LUCADA = Lung Cancer Audit, MDM = multi-disciplinary meeting, 
NCIN/UKACR = National Cancer Information Network/ UK Association of Cancer Registries, NR = not reported, OR = odds ratio, SEP = socio-economic position, UHCS=universal healthcare system
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Table 7.2. Characteristics of included studies not suitable for meta-analysis (universal health care systems). 
         Confounders controlled for:   
Paper 
Country 
of study 
Data Source (s) 
Population 
included 
Years of 
Diagnosis 
Measure of 
SEP 
No of 
SEP 
groups 
Treatment 
given 
within 
Age 
range 
Age Sex Stage Histology Other 
Reason for 
exclusion 
Quality 
score 
Battersby 
et al, 
2004(207) 
England 
HES and East 
Anglian Cancer 
Intelligence Unit 
17 PCTs in Norfolk, 
Suffolk and 
Cambridgeshire 
with  HES record 
1997-2000 
IMD (weighted 
average for 
PCT) 
NR NR NR Yes Yes No Yes Incidence 
Rate 
correlated 
against 
deprivation, 
by sex 
1 
Bendzsak 
et al, 
2011(208) 
Canada 
Ontario Cancer 
Registry linked to 
CIHI hospital data, 
Insurance data and 
RPD database 
Ontario 2003-2004 
Neighbourhood 
income  
5 12 months 
20-
75+ 
Yes Yes No No 
Univariable 
analysis 
Univariable 
rate 
2 
Cartman 
et al, 
2002(209) 
England 
Northern and 
Yorkshire Cancer 
Registry and 
Information Service 
(NYCRIS) 
Yorkshire region 1986-1994 NR NR NR 
<65- 
75+ 
Yes Yes No Yes 
Univariable 
analysis 
Univariable 
rate 
1 
Hui et al, 
2005(210) 
Australia 
NSW Central Cancer 
Registry and 
hospital records 
Residents of 2 
Area Health 
Services 
1996  SEIFA-IRSD 5 NR 
<50- 
70+ 
Yes Yes Yes Yes 
Univariable 
analysis 
Univariable 
rate 
2 
Madelaine 
et al, 
2002(211) 
France 
Manche Dept 
Cancer Registry  
Manche 1997-1999 INSEE  4 NR 
<54 -
75+ 
Yes Yes Yes Yes Urban/rural 
Unemployed 
used as low 
SEP group and 
SEP group 2 
used as 
baseline 
2 
Pagano et 
al, 
2010(212) 
Italy 
Piedmont Cancer 
Registry of Turin 
Turin  2000-2003 Education level  3 12 months 
<65 -
75+ 
Yes Yes Yes Yes Marital status 
Different 
comparator – 
other not no 
treatment 
2 
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Table 7.2 (cont). Characteristics of included studies not suitable for meta-analysis (universal health care systems). 
         Confounders controlled for:   
Paper 
Country 
of study 
Data Source (s) 
Population 
included 
Years of 
Diagnosis 
Measure of 
SEP 
No of 
SEP 
groups 
Treatment 
given 
within 
Age 
range 
Age Sex Stage Histology Other 
Reason for 
exclusion 
Quality 
score 
Patel et al, 
2007(213) 
England 
Thames Cancer 
Registry 
South-east 
England 
1994-2003 IMD 5 6 months 
 0--
100 
Yes Yes Yes Yes 
Cancer 
network, year 
of diagnosis 
Adjusted rates 
with no CIs. 
Possible errors 
in numbers. 
2 
Stevens et 
al, 
2009(214) 
New 
Zealand 
Regional hospital 
and oncology 
databases checked 
against NZ cancer 
Registry listing 
Auckland-
Northland region 
patients managed 
in secondary care 
2004 
NZ Deprivation 
Index  
10 NR 
<60- 
80+ 
Yes Yes Yes Yes 
Univariable 
analysis 
Univariable 
OR. 
Multivariable 
SEP results not 
shown 
2 
Younis et 
al, 
2008(215) 
Canada 
Nova Scotia cancer 
registry and chart 
review 
Nova Scotia 2005 
Median 
household 
income  
2 NR 
65- 
75+ 
Yes Yes Yes Yes 
Co-morbidity, 
PS, hospital, 
surgery type, 
post-op 
complications, 
surgeon, med 
onc, education 
level, distance 
to cancer 
centre, marital 
status, 
smoking 
history 
Univariable 
rate. 
Multivariable 
OR only for 
referral by SEP 
2 
 
Quality scores range from 1 (lowest quality) to 6 (highest quality) 
 
Abbreviations: CI = confidence interval, HES = Hospital Episode Statistics, IMD = Index of Multiple Deprivation, NR = not reported, NSW = New South Wales, OR = odds ratio, PCT = Primary Care Trust, PS=performance status, 
SEIA-IRSD = Socio-economic Indexes for Areas - Index of Relative Social Disadvantage, SEP = socio-economic position, UHCS=universal healthcare system
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Eighteen papers were from non-UHCSs – all of which were from the USA [tables 7.3-
7.4]. The papers were published between 1995 and 2010 and examined populations 
diagnosed between 1978 and 2005. The majority of non-UHCS papers used sub-groups 
of the National Cancer Institute’s Surveillance, Epidemiology and End Results [SEER] 
database population and, again, some population overlap was found. SEER has 
changed in size over the years. In earlier papers SEER covered 9, 10, and mostly 11 
registries and included around 14% of the population but this increased to 16-17 
registries and 26% of the population in later papers. Over half [11/18 = 61%] of the 
non-UHCS papers [7/10 in meta-analysis and 4/8 in narrative analysis] looked at 
receipt of treatment in a Medicare population aged over 65.   
Twenty nine papers met the criteria for meta-analysis, 19 from UHCS (73, 76-78, 86, 
152, 153, 157, 158, 161, 198-206) and 10 from non-UHCSs (216-225). However, six 
studies that examined receipt of treatment in more compared to less deprived SEP 
groups presented the results as a single OR [for a one unit increase or incremental 
quintile increase in deprivation score] and so could not be included in the meta-
analyses. Seventeen studies were included in the final meta-analyses and a further six 
in the sensitivity meta-analyses.  
Seventeen papers did not meet the criteria for meta-analysis and were excluded for 
the following reasons: Five studies did not conduct multivariable analysis and 
calculated only univariable rates (150, 208-210, 214). One paper calculated a rate of 
treatment by deprivation, stratified by sex  (207). A further 11 papers were also 
excluded as, although they did include multivariable analysis, they stratified SEP by 
race (226), calculated but did not report adjusted rates by SEP, but did report 
univariable rates (71, 149, 227, 228), did not report confidence intervals (213, 229), 
had other quality problems (230), or used a different comparator (211, 212, 215).  
In the study including Scottish and Canadian data (198) the numbers in some tables for 
the Scottish data did not appear to add up correctly. It was decided not to exclude this 
paper on quality grounds but to only include data from the Canadian cohort in the 
meta-analysis as this did not contain any apparent errors.  
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Table 7.3. Characteristics of included studies potentially suitable for meta-analysis (non-universal health care systems). 
        
 Confounders controlled for:  
Paper 
Country 
of study 
Data Source (s) 
Population 
included 
Years of 
Diagnosis 
Measure of SEP 
No of 
SEP 
groups 
Treatment 
given 
within 
Age 
range 
Age Sex Stage 
Histo
logy 
Other 
Quality 
score 
Bradley et al, 
2008(216) 
USA 
Michigan Cancer 
Registry and 
Michigan 
Medicare and 
Medicaid data 
Medicare and 
Medicare/ 
Medicaid patients 
in Michigan 
1997-
2000 
Census tract median 
household income 
(high v low) 
2 6 months 66-80+ Yes Yes Yes Yes 
Co-morbidity, insurance 
type, ethnicity, urban/rural 
4 
Davidoff et al, 
2010(217) 
USA 
SEER cancer 
registry linked to 
Medicare data 
Medicare patients 
from 16 SEER 
registries 
1997-
2002 
Census tract median 
household income 
4  90 days 
 66- 
85+ 
Yes Yes Yes Yes 
Co-morbidity, 
performance status, 
ethnicity, marital status, 
rural/urban, prior 
Medicaid, tumour grade  
5 
Earle et al, 
2000(218) 
USA 
SEER cancer 
registry linked to 
Medicare data 
Medicare patients 
from 11 SEER 
registries 
1991-
1993 
Census tract median 
household 
income(increase in 
OR per quintile) 
5  4 months 65-104 Yes Yes Yes Yes 
Co-morbidity, year of 
diagnosis, ethnicity, 
rural/urban, teaching 
hospital, SEER area 
5 
Esnoala et al, 
2008(219) 
USA 
South Carolina 
central cancer 
Registry linked to 
inpatient and 
outpatient 
surgery files 
South Carolina 
1996-
2002 
Income, zip code 
level (poverty/not 
living in poverty) 
2 NR 
<50-
80+ 
Yes Yes Yes Yes 
Co-morbidity, year of 
diagnosis, insurance type, 
ethnicity, rural/urban, 
education, marital status, 
tumour location 
4 
Greenwald et 
al, 1998(220) 
USA 
SEER cancer 
registry 
3 (Detroit, San 
Francisco, Seattle) 
out of 9 SEER 
registries  
1978-
1982 
Census tract median 
household income 
(inc in OR per 
decile) 
10  NR <=75 Yes Yes Yes Yes 
Performance status, 
ethnicity 
6 
Hardy et al, 
2009(221) 
USA 
SEER cancer 
registry linked to 
Medicare data 
Medicare patients 
from 17 SEER 
registries 
1991-
2002 
% individuals below 
poverty line  at 
census tract level  
4 NR 65- 85+ Yes Yes Yes Yes 
Co-morbidity, year of 
diagnosis, ethnicity, 
marital status, SEER area, 
other  treatment  
5 
Hayman et al, 
2007(222) 
USA 
SEER cancer 
registry linked to 
Medicare data 
Medicare patients 
from 11 SEER 
registries 
1991-
1996 
Census tract median 
household income  
5 
4 months/ 
2 years 
65- 85+ Yes Yes Yes Yes 
Co-morbidity, year of 
diagnosis, ethnicity, SEER 
area, hospitalisation, 
teaching hospital, distance 
to nearest RT centre, 
receipt of chemotherapy 
5 
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Table 7.3 (cont). Characteristics of included studies potentially suitable for meta-analysis (non-universal health care systems). 
        
 Confounders controlled for:  
Paper 
Country 
of study 
Data Source (s) 
Population 
included 
Years of 
Diagnosis 
Measure of SEP 
No of 
SEP 
groups 
Treatment 
given 
within 
Age 
range 
Age Sex Stage 
Histo
logy 
Other 
Quality 
score 
Lathan et al, 
2008(223) 
USA 
SEER cancer 
registry linked to 
Medicare data 
Medicare patients 
from 11 SEER 
registries 
1991-
1999 
Census tract median 
household income 
(inc in OR per 
quintile) 
5  NR 65+ Yes Yes Yes Yes 
Co-morbidity, ethnicity, 
SEER registry, urban, non-
profit hospital, patient 
volume, % of black 
patients in hospital 
5 
Polednak, 
2001(224) 
USA 
Connecticut 
Tumor Registry 
(SEER) and 
inpatient hospital 
discharge 
database (HDD) 
Connecticut 
1992 - 
1997 
Census tract poverty 
rate 
5 NR 
<55-
80+ 
Yes Yes Yes No 
Co-morbidity, ethnicity, 
marital status 
4 
Smith et al, 
1995(225) 
USA 
Virginia Cancer 
Registry and 
Medicare claims 
database 
Medicare patients 
from Virginia 
cancer registry 
1985-
1989 
Census tract: 
median household 
income by race and 
age  
 
contin
uous 
(a) 
6 months 65- 85+ Yes Yes Yes Yes 
Co-morbidity, ethnicity, 
county of residence, 
distance to oncologist 
5 
 
(a) Odds ratio for increase per $10,000 income 
Quality scores range from 1 (lowest quality) to 6 (highest quality) 
Abbreviations: CI = confidence interval, non –UHCS = non-universal healthcare system, NR = not reported, OR = odds ratio, SEER = National Cancer Institute’s Surveillance, Epidemiology and End Results database, SEP = socio-
economic position 
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Table 7.4. Characteristics of included studies not suitable for meta-analysis (non-universal health care systems). 
        
 Confounders controlled for: 
 
 
Paper Country 
Data Source 
(s) 
Population 
included 
Years of 
Diagnosis 
Measure of SEP 
No of 
SEP 
groups 
Treatment 
given 
within 
Age 
range 
Age Sex Stage 
Hist 
ology 
Other  
Reasons for 
exclusion 
Quality 
score 
Bach et 
al, 
1999(226) 
USA 
SEER cancer 
registry 
linked to 
Medicare 
data 
Medicare 
patients from 
10 SEER 
registries 
1985-
1993 
Median income in zip 
code of residence 
(lowest quartile 
compared to highest 
3) 
2 NR 
65- 
75+ 
Yes Yes Yes Yes 
Co-morbidity, 
ethnicity, SEER area 
OR of surgery for 
black v white, 
univariable rates 
of surgery used 
here 
2 
Earle et 
al, 
2002(227) 
USA 
SEER cancer 
registry 
linked to 
Medicare 
data 
Medicare 
patients from 
11 SEER 
registries 
1991-
1996 
Census tract median 
household income  
5 any time  NR Yes Yes Yes Yes 
Co-morbidity, 
ethnicity, year of 
diagnosis, teaching 
hospital, seen by 
oncologist, SEER 
area 
SEP non sig in 
multivariable 
analysis but only 
univariable rate 
shown. 
2 
Lathan et 
al, 
2006(230) 
USA 
SEER cancer 
registry 
linked to 
Medicare 
data 
Medicare 
patients from 
11 SEER 
registries 
1991-
1999 
Census tract median 
household income  
5  NR 65+ Yes Yes Yes Yes 
Co-morbidity, 
ethnicity, SEER 
region, teaching 
hospital, rural/urban 
Quality problems  2 
Ou et al, 
2008(149) 
USA 
California 
Cancer 
Registry 
(part of 
SEER) 
California 
1989-
2003 
Composite measure 
(7 indicators of 
education, income 
and occupation)  
5 NR 0--89 Yes Yes Yes Yes 
Ethnicity, tumour 
grade, tumour 
location, histologic 
grade, marital status 
SEP not reported 
in multivariable 
analysis. 
Univariable rate 
shown. 
2 
Suga et 
al, 
2010(229) 
USA 
California 
Cancer 
Registry 
Sacramento 
region in 
northern 
California 
1994-
2004 
Census tract 
composite variable - 
income, education, 
employment, 
poverty, rent, 
housing  value  
5 NR  NR Yes Yes Yes Yes 
Ethnicity, residence 
(urban/rural) 
No CIs 2 
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Table 7.4 (cont). Characteristics of included studies not suitable for meta-analysis (non-universal health care systems). 
        
 Confounders controlled for: 
 
 
Paper Country Data Source (s) 
Population 
included 
Years of 
Diagnosis 
Measure of 
SEP 
No of SEP 
groups 
Treatment 
given 
within 
Age 
range 
Age Sex Stage Histology Other  
Reasons for 
exclusion 
Quality 
score 
Tammemagi 
et al, 2004(71) 
USA 
Josephine Ford 
Cancer Center 
Tumor Registry 
Detroit 
(receiving 
care at Henry 
Ford Health 
System) 
1995-
1998 
Census tract 
median 
household 
income  
continuous  
(a) 
NR NR Yes Yes Yes Yes 
Co-morbidity, 
ethnicity, marital 
status, smoking 
history, alcohol use, 
drug use 
SEP not reported 
in multivariable 
analysis. 
Univariable OR 
shown. 
2 
Wang et al, 
2008(228) 
USA 
SEER cancer 
registry linked 
to Medicare 
data 
Medicare 
patients 11 
SEER 
registries 
1992-
2002 
% below 
census tract 
poverty 
level  
4 4 months 66-85 Yes Yes Yes Yes 
Co-morbidity, 
ethnicity, year of 
diagnosis, grade, 
SEER region, census 
tract education, 
marital status, 
teaching hospital, 
radiation 
SEP not reported 
in multivariable 
analysis.  
OR for 
consultation but 
not treatment 
shown. 
1 
Yang et al, 
2010(150) 
USA 
Florida Cancer 
registry linked 
to inpatient 
and outpatient 
medical 
records 
Florida 
1998-
2002 
Census tract 
poverty 
level  
4 NR 
<45- 
70+ 
Yes Yes Yes Yes 
Univariable analysis 
only 
Univariable rate 2 
 
(a) Odds ratio for increase per $10,000 income 
 
Quality scores range from 1 (lowest quality) to 6 (highest quality) 
 
Abbreviations: CI = confidence interval, non-UHC S= non-universal healthcare system, NR = not reported, OR = odds ratio, SEER = National Cancer Institute’s Surveillance, Epidemiology and End Results database, SEP = socio-
economic position 
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A funnel plot to assess potential publication bias did not appear to show obvious bias 
[figure 7.2]. 
Individual measures of SEP were only available in one study (73) and SEP was 
otherwise measured throughout at an area-based level using a deprivation index, 
income, poverty or education level. The number of SEP groupings utilised varied from 
2 to 10, and again this was taken into account in the quality scores. 
 
Figure 7.2. Funnel plot to assess publication bias. 
 
 
Abbreviations: non-UHCS = non universal health care system, NSCLC = non-small cell lung cancer, UHCS 
= universal health care system  
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7.4.2 Quality Assessment of included studies 
Rates of treatment are not directly comparable between health care systems. Non-
UHCS studies generally included NSCLC-patients only and used as the denominator 
only those patients eligible for treatment [e.g. stage I and II patients for surgery 
analyses].  Many also included details of co-morbidity. The SEER database only includes 
biopsy-confirmed cases of lung cancer and so systematically excludes those patients 
considered too old or unwell for biopsy [and therefore treatment]. UHCS papers rarely 
included co-morbidity, tended to look at rates of surgery for all lung cancers and did 
not stratify by stage.  
In terms of quality the non-UHCS studies that carried out multivariable analysis had 
better control for confounding than UHCS studies, as they tended to stratify by stage 
and histology. However, half of the non-UHCS papers used a Medicare-only population 
where Medicare is a type of social insurance to which those aged over 65 are eligible. 
Non-UHCS studies are therefore less generalizable in population terms than the UHCS 
studies.  
7.4.3 Receipt of treatment 
7.4.3.1 Surgery – overall analysis 
Thirty one papers [29 study populations] included receipt of surgery as an outcome, 18 
UHCS papers [15 study populations] and 13 non-UHCS papers [14 study populations] 
[tables 7.5-7.6]. Of the papers that reported measures of significance [CIs or p-values], 
20 out of 27 [74%] [64% of UHCS (9 /14) and 85% of non-UHCS (11/13) unique-
population studies] reported that lower SEP was significantly associated with lower 
likelihood of surgery when comparing the lowest with the highest SEP group, although 
three of these 20 papers did not find a significant trend across groups. Seven papers 
found no significant association between SEP and receipt of surgery. Four papers did 
not report CIs or p values so were not considered here.  
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Table 7.5. Likelihood of receipt of surgery by SEP group (universal health care systems). 
Study No. 
receiving 
surgery 
Cohort no./  
no. eligible 
Rate Histology OR/rate in 
Q1 (95% CI) 
OR/rate in 
Q2 (95% CI) 
OR/rate in 
Q3 (95% CI) 
OR/rate in 
Q4 (95% CI) 
OR/rate in 
Q5 (95% CI) 
P value Quality 
score 
Meta-
analysis 
Further Information 
Bendzsak et 
al, 2011[49] 
1220 6499 18.77 any 21.1 18.3 19.7 18.8 16.8 0.02 2 N Univariable rate 
Campbell et 
al, 2002[35] 
85 653 13.02 any 1.00 0.76 (0.28 
to 2.09) 
0.70 (0.27 
to 1.84) 
0.88 (0.35 to 
2.22) 
0.59 (0.23 to 
1.53) 
0.423 5 Y  P for trend 
Hui et al, 
2005[51] 
 NR 526   any 29 28 20 27 20 0.19 2 N Univariable rate 
Jack et al, 
2003[39] 
 NR 32818   any         0.98 (0.95 to 
1.01) 
0.7759 4 N  
Jack et al, 
2006[40] 
42 695 6.04 any 1.00 
 
0.82 (0.33 
to 2.07) 
0.89 (0.35 
to 2.25) 
0.16 (0.03 to 
0.73) 
0.75 (0.27 to 
2.09) 
0.1326 6 Y  Subset of Jack et al (2003) pop, p 
for trend 
Jones et 
al,2008[41] 
3552 34923 10.17 any         0.99 (0.99 to 
1.00) 
<0.01 4 N 
 Pollock  
&Vickers, 
1998[44] 
2869 38668 7.42 any 1.00 0.83 (0.69 
to 1.00) 
0.73 (0.61 
to 0.88) 
0.82 (0.68 to 
0.98) 
0.58 (0.48 to 
0.70) 
<0.05 3 Y Hospital population, p for trend 
Raine et al, 
2010[45] 
8790 36902 23.82 any 1.63 (1.49 
to 1.77) 
1.58 (1.46 
to 1.72) 
1.45 (1.35 
to 1.57) 
1.34 (1.25 to 
1.45) 
1.00 <0.001 3 Y Elective admission population 
Raine et al, 
2010[45] 
8923 186741 4.78 any 5.5 5.2 4.8 4.4 4.5 NR 2 N All admissions, univariable rate 
Battersby et 
al, 2004[48] 
387 4092 9.46 NSCLC     -0.10 (-0.55 
to 0.40) 
NR 1 N  Rate by sex correlated with 
deprivation score (men), with 
overall treatment rate 
Battersby et 
al, 2004[48] 
   NSCLC     -0.16 (-0.59 
to 0.35) 
NR 1 N  Rate by sex correlated with 
deprivation score (women) 
Berglund et 
al, 2010[19] 
626 3369 18.58 NSCLC 1.93 (1.25 
to 3.00) 
  1.33 (0.98 
to 1.81) 
  1.00 NR 6 Y   
Berglund et 
al, 2010[19] 
534 932 57.30 NSCLC 2.84 (1.40 
to 5.79) 
  1.53 (1.01 
to 2.31) 
  1.00 NR 6 Y(S) Early stage only - stage IA-IIB 
Berglund et 
al, 2012[22] 
899 1826 49.18 NSCLC 1.00 0.74 (0.51 
to 1.06) 
0.71 (0.49 
to 1.02) 
0.73 (0.52 to 
1.03) 
0.67 (0.48 to 
0.95) 
0.29 6 Y Early stage only – stage IA-IIB, p 
for trend 
Cartman et al, 
2002[50] 
2401 12570 19.10 NSCLC 19.1       18.6 NR 1 N Univariable rate 
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Table 7.5 (cont). Likelihood of receipt of surgery by SEP group (universal health care systems). 
Study No 
receiving 
surgery 
Cohort no / 
no eligible 
Rate Histology OR/rate in 
Q1 (95% CI) 
OR/rate in 
Q2 (95% CI) 
OR/rate in 
Q3 (95% CI) 
OR/rate in 
Q4 (95% CI) 
OR/rate in 
Q5 (95% CI) 
P value Quality 
score 
Meta-
analysis 
Further Information 
Crawford et 
al, 2009[36] 
3335 18324 18.20 NSCLC 1.00 0.90 (0.81 
to 1.00) 
  0.82 (0.74 to 
0.91) 
0.80 (0.72 to 
0.89) 
<0.05, 
<0.01, 
<0.01 
4 Y  Individual P values reported 
Mahmud et 
al, 2003[42] 
866 4451 19.46 NSCLC 19.8   18.0   21.0 NR 2 N Univariable rate 
 
McMahon et 
al, 2011[43] 
2374 18813 12.62 NSCLC 1.00 0.95 (0.83 
to 1.09) 
0.95 (0.83 
to 1.08) 
0.90 (0.79 to 
1.03) 
0.78 (0.65 to 
0.94) 
0.018 4 Y P for trend 
McMahon et 
al, 2011[43] 
            0.96 (0.93 to 
0.99) 
0.018  N Paper presents results in 2 different 
ways 
Riaz et al, 
2012[34] 
 6900 77349  8.92 NSCLC 1.00 0.88 (0.80 
to 0.96) 
0.91 (0.83 
to 0.99) 
0.82 (0.76 to 
0.89) 
0.76 (0.70 to 
0.83) 
<0.01 4 Y(S)  P for trend 
Rich et al, 
2011(1)[46] 
3427 24175 14.18 NSCLC 1.00 1.13 (0.98 
to 1.32) 
1.18 (1.02 
to 1.37) 
1.01 (0.87 to 
1.16) 
1.11 (0.96 to 
1.27) 
0.77 5 Y(S) Subset of Rich et al 2011 (2) pop, p 
for trend 
Rich et al, 
2011(2)[21] 
4481 34436 13.01 NSCLC 1.00 0.99 (0.88 
to 1.11) 
1.04 (0.92 
to 1.19) 
0.98 (0.84 to 
1.13) 
0.86 (0.71 to 
1.04) 
0.132 5 Y(S) P for trend 
 
Q1= high socio-economic position, Q5=low socio-economic position 
 
Some studies reported SEP quintiles but others reported SEP in 2, 3 or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in Tables 1-4 in the column entitled 'No. of SEP groups’  
Quality scores range from 1 (lowest quality) to 6 (highest quality) 
Meta-analysis:  Y=included in final meta-analysis, Y(S) = included in sensitivity meta-analysis, N=not included in meta-analysis 
 
Abbreviations: CI = confidence interval, NR = not reported, OR = odds ratio, pop = population, SEP = socio-economic position , UHCS=universal healthcare system 
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Table 7.6. Likelihood of receipt of surgery by SEP group (non- universal health care systems). 
Study No. 
receiving 
surgery 
Cohort 
no/ no 
eligible 
Rate Stage(s) 
included 
Histology OR/rate 
in Q1 
(95% CI) 
OR/rate in 
Q2 (95% CI) 
OR/rate in 
Q3 (95% CI) 
OR/rate in 
Q4 (95% CI) 
OR/rate in 
Q5 (95% CI) 
P value Quality 
Score 
Meta-
analysis 
Further Information 
Bradley et al, 2008[57] 1336 2626 50.88 I,II,IIIa NSCLC 1.00       0.80  
(0.67 to 0.98) 
<0.05 4 Y  
Esnoala et al, 2008[60]  NR 2791   local NSCLC 1.00       0.67  
(0.51 to 0.88) 
0.005 4 Y   
Greenwald et al, 1998[61] 3053 5157 59.20 I NSCLC         1.076 <0.0001 6 N SE=0.011 (no CIs 
shown) 
Hardy et al, 2009[62] 11834 19658 60.20 I,II NSCLC 1.00 0.92  
(0.84 to 1.14) 
  0.78  
(0.75 to 1.03) 
0.68 
 (0.60 to 0.77) 
>0.05, 
>0.05, 
<0.05 
5 Y Individual  p values 
reported corrected 
OR supplieda  
Lathan et al, 2008[64] 4563 9688 47.10 I,II,III NSCLC        1.06  
(1.02 to 1.11) 
NR 5 N Subset of Lathan et 
al (2006) pop 
Ou et al, 2008[70] 16185 19700 82.16 I NSCLC 86.9 84.8 81.1 79.6 74.5 <0.001 2 N   
Smith et al, 1995[66] 801 2813 28.47 local NSCLC         1.04  
(0.90 to 1.19) 
>0.001 5 N   
Tammemagi et al, 2004[72]  NR 1155   I,II NSCLC         1.19  
(1.03 to 1.30) 
0.02 2 N Univariable OR 
Bach et al, 1999[67] 550 860 63.95 I,II NSCLC 67.5       61.9  NR 2 N Surgery (blacks)  
Bach et al, 1999[67] 7763 10124 76.68 I,II NSCLC 78.0       70.7  NR 2 N Surgery (whites)  
Polednak, 2001[65] 1385 1564 88.55 I,II NSCLC 1.00 1.27  
(0.74 to 2.18) 
1.15  
(0.65 to 2.03) 
1.17  
(0.67 to 2.04) 
1.78  
(1.05 to 3.01) 
>0.05, 
>0.05, 
>0.05, 
<0.05 
4 Y Odds of not 
receiving surgery, 
individual p values 
reported 
Smith et al, 1995[66] 57 2396 2.38 distant NSCLC         1.27 ( 
0.97 to 1.67) 
>0.001 5 N   
Suga et al, 2010[71]  NR 12395     NSCLC         1.17 <0.001 2 N Surgery after 
invasive staging, no 
CIs  
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Table 7.6 (cont). Likelihood of receipt of surgery by SEP group (non- universal health care systems). 
Study No. 
receiving 
surgery 
Cohort 
no/ no 
eligible 
Rate Stage(s) 
included 
Histology OR/rate 
in Q1 
(95% CI) 
OR/rate in 
Q2 (95% CI) 
OR/rate in 
Q3 (95% CI) 
OR/rate in 
Q4 (95% CI) 
OR/rate in 
Q5 (95% CI) 
P value Quality 
Score 
Meta-
analysis 
Further Information 
Suga et al, 2010[71]  NR 12395     NSCLC         1.18 <0.001 2 N Surgery after non-
invasive staging, no 
CIs  
Lathan et al, 2006[69]  NR 14224     NSCLC         1.05  
(1.02 to 1.08) 
NR 2   
Yang et al, 2010[74] NR  NR    all all 24.6 22.2   20.7 18.3 <0.01 2  Univariable analysis 
 
Q1= high socio-economic position, Q5=low socio-economic position       
 
Some studies reported SEP quintiles but others reported SEP in 2, 3 or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in Tables 1-4 in the column entitled 'No. of SEP groups’  
Quality scores range from 1 (lowest quality) to 6 (highest quality) 
Meta-analysis:  Y=included in final meta-analysis, Y(S) = included in sensitivity meta-analysis, N=not included in meta-analysis 
a We are grateful to the authors for supplying a corrected OR to allow inclusion of this study in the meta-analysis 
 
Abbreviations: CI = confidence interval, non –UHCS = non-universal healthcare system, NR = not reported, OR = odds ratio, pop = population, SE=standard error, SEP = socio-economic position
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Meta-analysis of all 16 populations that were suitable for inclusion showed a 
significant negative effect of lower SEP on the likelihood of receiving surgery [OR=0.72 
(95% CI 0.65 to 0.80) I2=80%, p<0.001] [Appendix C, Fig C7.1]. Including only non-
overlapping study populations [n=12] gave a similar result: [OR=0.68 (95% CI 0.63 to 
0.75) I2=53%, p<0.001] [Fig 7.3].  Similar results were also seen for the subgroup of 8 
papers including NSCLC patients only: [OR=0.73 (95% CI 0.68 to 0.80) I2=24%, p<0.001] 
[Appendix C, Fig C7.2] and with further stratification by health care system; NSCLC 
[UHCS]: [OR=0.75 (95% CI 0.66 to 0.85), I2=29%, p<0.001]; NSCLC [non-UHCS, early 
stage only, co-morbidity included]: [OR=0.71 (95% CI 0.64 to 0.78) I2=2%, p<0.001]; [Fig 
7.3].  
Lower SEP was associated with a lower likelihood of receiving lung cancer surgery, in 
both types of health care system, and in studies where histology and stage at diagnosis 
were taken into account.  
Figure 7.3. Meta-analysis of odds of receipt of surgery in low (most deprived) versus high 
(least deprived) SEP. 
 
Abbreviations: CI = confidence interval, non-UHCS = non universal health care system, NSCLC = non-small cell lung 
cancer, OR = odds ratio, SE=standard error, SEP = socio-economic position, UHCS = universal healthcare system 
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7.4.3.1.1 Surgery - detailed analysis by healthcare system: UHCS 
Eight UHCS papers looked at receipt of surgery in any-histology populations [six 
registry studies (including two with overlapping populations) and two HES studies, so 
seven unique populations]. Rates of surgery varied from 4.8 to 18.8% [although a 
higher rate of 23.8% was seen for electively-admitted patients].  A significant 
association was seen between receipt of surgery and higher SEP in the HES studies 
[although neither of the two studies included stage or histology] but was seen in only 
one out of three non-overlapping multivariable-analysis registry studies [in the only 
study that did not include stage] and in one out of two univariable registry studies, 
although all studies showed trends in a reduction in OR as SEP decreased. Three of the 
studies where no association was found were very small [all less than 700 
participants]. All of these studies included patients with SCLC who are rarely eligible for 
surgery. 
Ten UHCS papers looked at receipt of surgery in NSCLC-only populations [seven 
registry studies, one HES and two audit studies]. Rates of surgery varied from 9.5 to 
19.5% [although rates of 49.2% and 57.3% were seen for early stage patients]. All five 
multivariable-analysis registry studies found an association between lower SEP and 
reduced likelihood of receipt of surgery when comparing the lowest SEP group with 
the highest. Two studies looked at surgery for early stage patients only and both found 
higher odds of receiving surgery for patients in the highest SEP compared to the lowest 
but one did not find a significant trend across groups.  
The other two univariable studies calculated rates not odds ratios and did not present 
p values. One study produced a correlated rate by sex. The two LUCADA papers using 
an overlapping study population did not find an association between SEP and receipt 
of surgery.  
Similar meta-analysis results to those seen overall were found with stratification by 
health care system. Eight non-overlapping UHCS studies were suitable for inclusion, 
with an OR=0.67, 95% CI 0.54 to 0.77, I2=65%, p<0.001, [with an OR=0.72, 95% CI 0.63 
to 0.83, I2=85%, p<0.001 when 12 over-lapping studies included], but again 
heterogeneity was high as these included studies that contained eligible NSCLC 
patients and some that also contained ineligible SCLC patients. Not all studies 
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accounted for stage. Including non-overlapping NSCLC-only UHCS studies [n=4] 
reduced the heterogeneity: [OR=0.75, 95% CI 0.66 to 0.85, I2=29%, p<0.001] [fig 7.3].  
In a subgroup analysis of the five partially-overlapping UHCS studies including stage 
[three studies that looked at NSCLC and two studies that looked at any-histology in 
registry and audit populations, all high quality studies, score 5 or 6] the association 
between lower SEP and reduced likelihood of surgery remained [OR=0.72, 95% CI 0.58 
to 0.89, I2=23%, p=0.002]. This was also found using any combination of non-
overlapping studies. 
In the four studies that did not conduct histology-specific analyses [two registry and 
two HES studies, where one HES study looked at receipt of surgery in electively 
admitted patients only] the summary statistic was OR=0.61, 95% CI 0.56 to 0.66, I2=0%, 
p<0.001 [fig 7.3]. The two HES studies included only age and sex as confounders and so 
were of lower quality but accounted for over 98% of the weight in this meta-analysis.  
7.4.3.1.2 Surgery - detailed analysis by healthcare system: non-UHCS 
Ten US papers [11 populations] looked at receipt of surgery for early stage NSCLC. A 
significant association was seen between receipt of surgery and higher SEP in seven 
out of eight papers. However, in two of these studies the pattern across socio-
economic groupings was not significant, only the OR in the lowest compared to the 
highest group was significant. A further 2 papers did not report CIs or p values.  Rates 
of surgery varied from 28.5% to 88.6%.  
Four studies compared the odds of surgery in the lowest compared to the highest SEP 
group. All four studies used different study populations and included co-morbidity as a 
confounder. The meta-analysis summary statistic was OR=0.71, 95% CI 0.64 to 0.78, 
I2=2%, p<0.001; [Fig 7.3].  
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Table 7.7. Likelihood of receipt of chemotherapy by SEP group (universal health care systems). 
Study No 
receivi
ng 
chemo 
Cohort 
no/ no 
eligible 
Rate Hist 
ology 
OR/rate in 
Q1 (95% CI) 
OR/rate in 
Q2 (95% CI) 
OR/rate in 
Q3 (95% CI) 
OR/rate in 
Q4 (95% CI) 
OR/rate in 
Q5 (95% CI) 
P value Quality 
Score 
Meta-
analysis 
Further Information 
Berglund et al, 
2012[22] 
3661 10039 36.47 any 1.00 0.90 (0.77 
to 1.06) 
0.78 (0.67 
to 0.91) 
0.77 (0.66 
to 0.89) 
0.75 (0.65 to 
0.87) 
<0.01 6 Y NSCLC stage IIIA-IV & all stage SCLC, 
p for trend 
Campbell et al, 
2002[35] 
124 653 18.99 any 1.00 0.58 (0.21 
to 1.57) 
0.72 (0.29 
to 1.78) 
0.41 (0.16 
to 1.05) 
0.39 (0.16 to 
0.96) 
0.028 5 Y   
Jack et al, 
2003[39] 
 NR 32818   any         0.96 (0.94 to 
0.98) 
0.0001 4 N Subset of Patel et al (2007) pop 
Jack et al, 
2006[40] 
108 695 15.54 any 1.00 1.04 (0.50 
to 2.16) 
0.81 (0.38 
to 1.70) 
0.89 (0.43 
to 1.85) 
1.04 (0.48 to 
2.25) 
0.9130 6 Y  Subset of Patel et al (2007) pop, p 
for trend 
Jones et 
al,2008[41] 
5783 34923 16.56 any         0.99 (0.99 to 
0.99) 
<0.01 4 N  
Patel et al, 
2007[54] 
11217 67312 16.66 any 18.3 15.7 14.5 12.8 12.8 <0.001 2 N Adjusted rates, no CIs 
Rich et al, 
2011(1)[46] 
14168 59592 23.78 any 1.00 0.97 (0.90 
to 1.04) 
0.89 (0.83 
to 0.96) 
0.83 (0.77 
to 0.89) 
0.85 (0.79 to 
0.91) 
<0.01 5 Y(S)  
Hui et al, 
2005[51] 
 NR 526   any 31 34 36 27 26 0.15 2 N Univariable rate 
Berglund et al, 
2010[19] 
1285 3369 38.14 NSCLC 1.35 (1.00 
to 1.81) 
  1.25 (1.03 
to 1.52) 
  1.00  NR 6 Y   
Pagano et al, 
2010[53] 
430 1231 34.93 NSCLC 1.00   0.98 (0.64 
to 1.50) 
  1.63 (1.08 to 
2.44) 
NR 2 N Odds of receiving chemo +/or radio 
rather than surgery 
Younis et al, 
2008[56] 
29 108 26.85 NSCLC 4.7 (1.3 to 
17.8) 
      1.0 0.015 2 N Odds of referral for adjuvant 
chemo after surgery, stage I,II,III 
Cartman et al, 
2002[50] 
1349 2448 55.11 SCLC 52.1       56.8  NR 1 N Univariable rate 
Crawford et al, 
2009[36] 
3619 5510 65.68 SCLC 1.00 1.10 (0.94 
to 1.30) 
  0.91(0.78 
to 1.08) 
0.94 
(0.80 to 1.11) 
>0.05 4 Y  Individual p values, all  reported as 
>0.05 
Mahmud et al, 
2003[42] 
425 1002 42.42 SCLC 37.8   40.5   50.2  NR 2 N Univariable rate 
Q1= high socio-economic position, Q5=low socio-economic position 
Some studies reported SEP quintiles but others reported SEP in 2, 3 or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in Tables 1-4 in the column entitled 'No. of SEP groups’  
Quality scores range from 1 (lowest quality) to 6 (highest quality) 
Meta-analysis:  Y=included in final meta-analysis, Y(S) = included in sensitivity meta-analysis, N=not included in meta-analysis 
Abbreviations: CI = confidence interval, NR = not reported, OR = odds ratio, pop = population, SEP = socio-economic position , UHCS=universal healthcare system 
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Table 7.8. Likelihood of receipt of chemotherapy by SEP group (non- universal health care systems). 
Study No 
receivin
g 
chemo 
Cohort 
no/ no 
eligible 
Rate Stage Histolo
gy 
OR/rate in 
Q1 (95% 
CI) 
OR/rate in 
Q2 (95% CI) 
OR/rate in 
Q3 (95% CI) 
OR/rate in 
Q4 (95% CI) 
OR/rate in 
Q5 (95% CI) 
P value Quality 
Score 
Meta-
analysis 
Further Information 
Bradley et al, 
2008[57] 
643 2348 27.39 I,II,IIIa NSCLC 1.00       1.09 (0.87 to 
1.37) 
>0.05 4 Y   
Hardy et al, 
2009[62] 
2951 19658 15.01 I,II NSCLC 1.00 0.91 (0.81 
to 1.02) 
  0.96 (0.85 to 
1.09) 
0.85 (0.74 to 
0.98) 
>0.05, 
>0.05, 
<0.05 
5 Y Individual  p values reported  
Ou et al, 
2008[70] 
1175 19700 5.96 I NSCLC 5.3 5.7 5.3 6.9 7.4 0.001 2 N  Univariable analysis 
Davidoff et al, 
2010[58] 
5499 21285 25.84 IIIB, IV NSCLC 1.43 (1.28 
to 1.60) 
1.17 (1.05 
to 1.30) 
  1.11 (1.00 to 
1.22) 
1.00 <0.01, 
<0.01, 
<0.05 
5 Y Individual  p values reported 
Earle et al, 
2000[59] 
1356 6308 21.50 IV NSCLC         1.07 (1.02 to 
1.12) 
0.0077 5 N  Subset of Earle (2002) 
Earle et al, 
2002[68] 
8813 12015 73.35 IV NSCLC 41 41 36 31 27 >0.05 2 N Univariable analysis only. SEP was 
included in multivariable analysis 
but non-sig (figs not reported) 
Hardy et al, 
2009[62] 
26417 51243 51.55 III,IV NSCLC 1.00 0.87 (0.78 
to 0.96) 
  0.76 (0.63 to 
0.90) 
0.60 (0.45 to 
0.79) 
<0.05, 
<0.05, 
<0.05 
5 Y(S) Individual p values reported 
Tammemagi 
et al, 2004[72] 
 NR 1155   III,IV NSCLC         1.09 (1.01 to 
1.18) 
0.03 2 N Univariable OR 
Davidoff et al, 
2010[58] 
749 1946 38.49 IIIB, IV NSCLC 0.86(0.69 
to 1.08) 
0.96 (0.77 
to 1.19) 
  0.99 (0.81 to 
1.22) 
1.00 NR 5 N Odds of single agent compared to 
doublet chemo.  
Wang et al, 
2008[73] 
1521 3196 47.59 II,IIIa NSCLC 1.00 1.08 (0.97 
to 1.21) 
  1.08 (0.97 to 
1.21) 
0.97 (0.85 to 
1.10) 
NR 1 N Odds of receiving oncology 
consultation.  
Yang et al, 
2010[74] 
 NR  NR    All any 32.2 30.7   29.9 30.1 <0.01 2 N Univariable analysis 
 
Q1= high socio-economic position, Q5=low socio-economic position 
Some studies reported SEP quintiles but others reported SEP in 2, 3 or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in Tables 1-4 in the column entitled 'No. of SEP groups’  
Quality scores range from 1 (lowest quality) to 6 (highest quality) 
Meta-analysis:  Y=included in final meta-analysis, Y(S) = included in sensitivity meta-analysis, N=not included in meta-analysis 
Abbreviations: CI = confidence interval, non –UHCS = non-universal healthcare system , NR = not reported, OR = odds ratio, pop = population, SEP = socio-economic position  
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7.4.3.2 Chemotherapy – overall analysis 
Twenty three papers included chemotherapy as an outcome – 14 UHCS papers [12 
populations] and nine non-UHCS papers [10 populations] [tables 7.7-7.8]. Of the 21 
papers that reported measures of significance, 15 [71%] reported that lower SEP was 
significantly associated with lower likelihood of receipt of chemotherapy. 
Meta-analysis of the ten populations that were suitable for inclusion found a 
significant negative effect of lower SEP on the likelihood of receiving chemotherapy: 
[OR=0.81, 95% CI 0.73 to 0.89, I2=68%, p<0.001] [Appendix C, Fig C7.3]. Similarly, in a 
meta-analysis of the eight papers containing non-overlapping populations that were 
selected for inclusion, the odds of receiving chemotherapy were significantly lower for 
those in the most deprived SEP group compared to those in the least deprived 
[OR=0.82, 95% CI 0.72 to 0.93, I2=67%, p=0.003], overall. A similar pattern was found in 
UHCS [OR = 0.80, 95% CI 0.68 to 0.95, I2=46%, p=0.01]; and in non-UHCS settings 
[OR=0.85, 95% CI 0.68 to 1.07, I2=85%, p=0.16], although this did not reach significance 
[Fig 7.4].  
 
Figure 7.4. Meta-analysis of odds of receipt of chemotherapy in low (most deprived) versus 
high (least deprived) SEP.  
 
Abbreviations: CI = confidence interval, non-UHCS = non universal health care system, OR = odds ratio, SE=standard 
error, SEP = socio-economic position, UHCS = universal healthcare system 
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7.4.3.2.1 Chemotherapy - detailed analysis by healthcare system: UHCS 
Eight papers looked at receipt of chemotherapy in any-histology populations but three 
used overlapping populations. One paper included a NSCLC-only population. Rates of 
chemotherapy varied from 15.5% to 38.1% with the highest rate found in the paper 
including only a NSCLC population. Seven out of nine studies found an association 
between SEP and receipt of chemotherapy. Two small studies did not, one of which 
(158) was a subset of a population used in two larger studies where an association was 
seen (202, 231), and one which conducted only univariable analysis (210). 
Three studies looked at receipt of chemotherapy in SCLC patients. Rates here varied 
from 42.4-65.7%. Two studies reported only univariable rates and no CIs but both 
showed a trend for increased rates of chemotherapy in more deprived groups. 
However, in the one study that conducted multivariable analysis no association 
between SEP and receipt of chemotherapy was found, although the trend was for 
reduced likelihood of chemotherapy in deprived populations, in contrast to the 
univariable studies. 
In the meta-analysis five non-overlapping studies [three any histology, one NSCLC, one 
SCLC] reported OR for the lowest compared to the highest SEP group and a significant 
association between SEP and receipt of chemotherapy was seen [OR = 0.80, 95% CI 
0.68 to 0.95, I2=46%, p=0.005].   
7.4.3.2.2 Chemotherapy - detailed analysis by healthcare system: non-UHCS 
Eight non-UHCS papers looked at receipt of chemotherapy in 10 populations. One 
further study looked at the odds of receiving an oncology consultation but didn’t 
report the odds of actually receiving treatment. Six out of 10 found an association 
between low SEP and lower likelihood of chemotherapy as a trend across SEP groups 
and one further study found an association only in the lowest SEP group compared to 
the highest. 
Breaking this down further, eight studies looked at receipt of chemotherapy for NSCLC, 
three for early stage and five for late stage NSCLC. Two out of three early stage studies 
found an association between SEP and receipt of chemotherapy [where one included 
only univariable analysis and one where an association was seen only in the most 
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deprived group]. Only one out of five late stage studies did not find an association and 
this was in a univariable analysis (227). The same authors did find SEP to be significant 
in an earlier paper (218), with a significantly increased OR of receiving chemotherapy 
of 1.07, 95% CI 1.02 to 1.12, for each incremental quintile increase in SEP. 
Three papers [four populations] were potentially eligible for meta-analysis, two had 
data on early stage and two on later stage. Including only the three non-overlapping 
populations gave a non-significant result [OR=0.85, 95% CI 0.68 to 1.07, I2=85%, 
p=0.16]. 
In the two early-stage studies the results were contradictory. One study using 
Michigan registry data found non-significantly increased odds of receiving 
chemotherapy for lower-SEP patients (216) but a much larger study using SEER-linked 
Medicare data (221) found significantly reduced odds. When meta-analysis was 
conducted no association was found for SEP and receipt of chemotherapy [OR=0.95, 
95% CI 0.74 to 1.21, I2=70%, p=0.66]. However, heterogeneity was high and as both 
studies showed contradictory effects meta-analysis may not be suitable. 
In the two studies that looked at late stage NSCLC and compared the odds of receiving 
chemotherapy in high and low SEP, the odds of receiving chemotherapy were 
significantly lower for those in the most deprived SEP group compared to those in the 
least deprived [OR=0.68, 95% CI 0.62 to 0.76, , I2=2%, p<0.001]. Both these studies 
used Medicare-linked SEER data with some overlap in the study populations.  
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Table 7.9. Likelihood of receipt of radiotherapy by SEP group (universal health care systems). 
Study No 
receiving 
radio 
Cohort 
no/ no 
eligible 
Rate Histology OR/rate in 
Q1 (95% CI) 
OR/rate in 
Q2 (95% CI) 
OR/rate in 
Q3 (95% CI) 
OR/rate in 
Q4 (95% CI) 
OR/rate in 
Q5 (95% CI) 
P value Quality 
Score 
Meta-
analysis 
 Further Information 
Berglund et 
al, 2012[22] 
1054 2771 38.04 any 1.00 1.16 (0.88 to 
1.54) 
1.17 (0.90 to 
1.53) 
1.18 (0.91 to 
1.53) 
0.99 (0.77 to 
1.29) 
0.67 6 Y Stage III only, p for trend 
Campbell et 
al, 2002[35] 
412 653 63.09 any 1,00 2.08 (1.11 to 
3.91) 
2.27 (1.24 to 
4.16) 
1.47 (0.83 to 
2.60) 
1.86 (1.05 to 
3.28) 
0.378 5 Y  P for trend 
Jack et al, 
2003[39] 
 NR 32818   any         1.00 (0.99 to 
1.02) 
0.2048 4 N  
Jack et al, 
2006[40] 
338 695 48.63 any 1.00 1.24 (0.76 to 
2.02) 
0.76 (0.46 to 
1.26) 
0.98 (0.60 to 
1.59) 
0.68 (0.41 to 
1.14) 
0.0978 6 Y Subset of Jack et al (2003) 
pop, p for trend 
Jones et 
al,2008[41] 
13857 34923 39.68 any         0.99 (0.99 to 
1.00) 
<0.01 4 N  
Rich et al, 
2011(1)[46] 
12079 59592 20.27 any 1.00 1.08 (1.01 to 
1.16) 
1.12 (1.04 to 
1.20) 
1.12 (1.04 to 
1.20) 
1.02 (0.95 to 
1.09) 
0.80 5 Y(S) P for trend 
Hui et al, 
2005[51] 
 NR 526   any 52 62 51 55 55 0.84 2 N Univariable rate 
Stevens et al, 
2009[55] 
222 555 40.00 any 1.0 0.8 (0.4 to 
1.5) 
0.6 (0.3 to 
1.2) 
0.9 (0.5 to 
1.6) 
0.7 (0.4 to 
1.3) 
>0.05 2 N Hosp pop, univariable OR 
Berglund et 
al, 2010[19] 
863 3369 25.62 NSCLC 0.91 (0.67 to 
1.22) 
  1.12 (0.93 to 
1.36) 
  1.00 NR 6 Y   
Erridge et al, 
2002[37] 
824 3177 25.94 NSCLC/ 
unknown 
1.00 0.94 (0.70 to 
1.26) 
1.04 (0.79 to 
1.38) 
1.33 (1.01 to 
1.75) 
1.13 (0.84 to 
1.51) 
0.10 6 Y  
Mahmud et 
al, 2003[42] 
1265 4451 28.42 NSCLC 26.1   29.0   29.9 NR 2 N Univariable rate 
Cartman et 
al, 2002[50] 
693 2448 28.31 SCLC 37.1       39.5 NR 1 N Univariable rate 
 
Q1= high socio-economic position, Q5=low socio-economic position 
Some studies reported SEP quintiles but others reported SEP in 2, 3 or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in Tables 1-4 in the column entitled 'No. of SEP groups’  
Quality scores range from 1 (lowest quality) to 6 (highest quality) 
Meta-analysis:  Y=included in final meta-analysis, Y(S) = included in sensitivity meta-analysis, N=not included in meta-analysis 
Abbreviations: CI = confidence interval, NR = not reported, OR = odds ratio, pop = population, SEP = socio-economic position , UHCS=universal healthcare system 
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Table 7.10. Likelihood of receipt of radiotherapy by SEP group (non- universal health care systems). 
Study No 
receiving 
radio 
Cohort 
no/ no 
eligible 
Rate Stage Histology OR/rate in 
Q1  
(95% CI) 
OR/rate in 
Q2 
(95% CI) 
OR/rate in 
Q3 
(95% CI) 
OR/rate in 
Q4 
(95% CI) 
OR/rate in 
Q5 
(95% CI) 
P value Quality 
Score 
Meta-
analysis 
Further 
information 
Bradley et al, 
2008[57] 
950 2348 40.46 I,II,IIIa NSCLC 1.00       0.97 (0.79 to 
1.19) 
>0.05 4 Y   
Ou et al, 
2008[70] 
2779 19700 14.11 I NSCLC 11.7 12.6 14.7 16.5 16.6 <0.001 2 N  Univariable 
analysis 
Smith et al, 
1995[66] 
1323 2813 47.03 local NSCLC         0.95 (0.83 to 
1.09) 
>0.001 5 N   
Hardy et al, 
2009[62] 
43519 51243 84.93 III,IV NSCLC 1.00 1.01 (0.96 to 
1.07) 
  0.93 (0.88 to 
0.99) 
0.88 (0.82 to 
0.93) 
0.05, 
<0.05, 
<0.05 
5 Y Individual p 
values reported  
Hayman et al, 
2007[63] 
6436 11084 58.07 IV NSCLC 1.48 (1.17 to 
1.87) 
1.50 (1.17 to 
1.91) 
1.32 (1.01 to 
1.72) 
1.25 (0.93 to 
1.69) 
1.00 <0.001 5 Y(S)   
Smith et al, 
1995[66] 
1438 2396 60.02 distant NSCLC         1.00 (0.90 to 
1.12) 
>0.001 5 N   
Yang et al, 
2010[74] 
 NR  NR    ?? any 32.0 32.1   31.4 33.1 0.02 2 N Univariable 
analysis 
 
Q1= high socio-economic position, Q5=low socio-economic position 
Some studies reported SEP quintiles but others reported SEP in 2, 3 or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in Tables 1-4 in the column entitled 'No. of SEP groups’  
Quality scores range from 1 (lowest quality) to 6 (highest quality) 
Meta-analysis:  Y=included in final meta-analysis, Y(S) = included in sensitivity meta-analysis, N=not included in meta-analysis 
Abbreviations: CI = confidence interval, non –UHCS = non-universal healthcare system , NR = not reported, OR = odds ratio, pop = population, SEP = socio-economic position  
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7.4.3.3 Radiotherapy – overall analysis 
Eighteen papers [18 populations] examined receipt of radiotherapy for lung cancer - 12 
in UHCS settings [11 populations] and six in non-UHCS settings [seven populations - six 
NSCLC-only populations and one study including any-histology] [tables 7.9-7.10]. Only 
one UHCS study found an association between SEP and receipt of radiotherapy. The 
non-UHCS studies had very heterogeneous outcomes. 
Overall, no association between SEP and receipt of radiotherapy was seen in the meta-
analysis of the seven studies with non-overlapping populations selected for inclusion 
[OR = 0.99, 95% CI 0.86 to 1.14, I2=54%, p=0.89] [Fig 7.5], or when all nine studies were 
included [OR = 0.95, 95% CI 0.85 to 1.06, I2=71%, p=0.40] [Appendix C, Fig C7.4]. A 
significant association was seen for non-UHCS studies but only two studies were 
included here, each looking at different stage patients.   
 
Figure 7.5. Meta-analysis of odds of receipt of radiotherapy in low (most deprived) versus 
high (least deprived) SEP.  
 
Abbreviations: CI = confidence interval, non-UHCS = non universal health care system, OR = odds ratio, SE=standard 
error, SEP = socio-economic position, UHCS = universal healthcare system 
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7.4.3.3.1 Radiotherapy - detailed analysis by healthcare system: UHCS 
Eight papers using six registry populations [two with overlapping populations], one 
audit and one hospital-based population looked at receipt of radiotherapy for lung 
cancer in any-histology patients.  A further three registry papers looked at NSCLC only 
and one at SCLC. Only one of these study populations reported an association between 
low SEP and reduced likelihood of receipt of radiotherapy and this study used SEP as a 
continuous variable, although the OR was very close to 1.00 [0.99] and the CI actually 
reached 1.00.  
Five non-overlapping studies looked at the odds of radiotherapy in the lowest 
compared to the highest SEP quintile and the meta- analysis found no association [OR 
= 1.07, 95% CI 0.87 to 1.32]. 
7.4.3.3.2 Radiotherapy - detailed analysis by healthcare system: non-UHCS 
Five non-UHCS NSCLC papers [including six populations] looked at receipt of 
radiotherapy, three for early stage and three for late stage NSCLC. One study examined 
an all-histology population. Two out of three late-stage studies found an association 
between low SEP and reduced likelihood of radiotherapy but one out of three early-
stage [univariable analysis] study and one any-histology [also univariable analysis] 
study found an association between low SEP and increased likelihood of radiotherapy. 
Hence these are contradictory results. However, the univariable studies are of a low 
quality and look at rates of treatment rather than ORs. 
7.4.3.4 Surgery, chemotherapy and radiotherapy summary meta-analysis 
When the surgery, chemotherapy and radiotherapy papers included in the separate 
treatment meta-analyses in this systematic review were analysed together to produce 
an overall summary effect meta-analysis OR, low SEP was associated with a lower 
likelihood of receiving any type of treatment. This was found when including only 
studies with non-overlapping populations [OR = 0.79, 95% CI 0.73 to 0.86, I2=77%, 
p<0.001] [Fig 7.6] and when including all eligible studies [OR = 0.80, 95% CI 0.75 to 
0.86, I2=82%, p<0.001] [Appendix C, Fig C7.5].  
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Figure 7.6. Meta-analysis of odds of receipt of any type of treatment in low (most deprived) 
versus high (least deprived) SEP (non- overlapping populations; n=31).  
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Table 7.11. Likelihood of receipt of any type of unspecified treatment by SEP group (universal health care systems). 
Study No. 
receiving 
treatment 
Cohort 
no/ no 
eligible 
Rate Histology OR/rate in 
Q1 (95% CI) 
OR/rate in 
Q2 (95% CI) 
OR/rate in 
Q3 (95% CI) 
OR/rate in 
Q4 (95% CI) 
OR/rate in 
Q5 (95% CI) 
P value Quality 
score 
Meta-
analysis 
Further Information 
Crawford et al, 
2009[36] 
19667 34923 56.32 any 1.00 0.91 (0.86 
to 0.97) 
  0.82(0.77 
to 0.88) 
0.79 (0.74 to 
0.84) 
<0.01 4 Y  Individual P values, all 
reported as <0.01 
Erridge et al, 2009[18] 2186 3833 57.03 any 1.3 (1.1 to 
1.5) 
      1.00 <0.05 4 Y(S) Scottish pop 
Erridge et al, 2009[18] 1372 2073 66.18 any 1.3 (1.1 to 
1.7) 
      1.00 <0.05 4 Y(S) Canadian pop 
Jack et al, 2003[39]  NR 32818   any         0.98 (0.96 to 
0.99) 
0.0091 4 N  
Jack et al, 2006[40] 414 695 59.57 any 1.00 0.91 (0.53 
to 1.55) 
0.69 (0.40 
to 1.19) 
0.57 (0.34 
to 0.97) 
0.65 (0.37 to 
1.13) 
0.03 6 Y  Subset of Jack et al (2003) 
pop, p for trend 
Stevens et al, 2007[23] 285 565 50.44 any 1.0       0.9 (0.6 to 
1.5) 
0.773 3 Y(S) Hospital pop 
Mahmud et al, 
2003[42] 
2678 4451 60.17 NSCLC 1.0  0.9 (0.8 to 
1.1) 
 1.0 (0.8 to 
1.2) 
0.39, 
0.958 
4 Y(S) Odds of NOT receiving 
treatment – individual p values 
reported 
Mahmud et al, 
2003[42] 
694 1002 69.26 SCLC 1.0  1.0 (0.6 to 
1.5) 
 0.8 (0.5 to 
1.3) 
0.888, 
0.358 
4 Y(S) Odds of NOT receiving 
treatment – individual p values 
reported 
              
 
Q1= high socio-economic position, Q5=low socio-economic position 
Some studies reported SEP quintiles but others reported SEP in 2, 3 or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in Tables 1-4 in the column entitled 'No. of SEP groups’  
Quality scores range from 1 (lowest quality) to 6 (highest quality) 
Meta-analysis:  Y=included in final meta-analysis, Y(S) = included in sensitivity meta-analysis, N=not included in meta-analysis 
Abbreviations: CI = confidence interval, NR = not reported, OR = odds ratio, pop = population, SEP = socio-economic position, UHCS=universal healthcare system  
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Table 7.12. Likelihood of receipt of any type of unspecified treatment by SEP group (non- universal health care systems). 
Study No. 
receiving 
treatment 
Cohort no/ 
no eligible 
Rate Histology OR/rate in 
Q1 (95% CI) 
OR/rate in 
Q2 (95% CI) 
OR/rate in 
Q3 (95% CI) 
OR/rate in 
Q4 (95% CI) 
OR/rate in 
Q5 (95% CI) 
P value Quality 
score 
Meta-
analysis 
Further Information 
Ou et al, 2008[70] 18216 19700 92.47 NSCLC 94.7 94.1 92.2 91.9 87.2 <0.001 2 N Stage I. Univariable analysis 
Smith et al, 
1995[66] 
1697 2396 70.83 NSCLC         1.00 (0.91 to 
1.11) 
>0.001 5 N Distant stage 
Smith et al, 
1995[66] 
2343 2813 83.29 NSCLC         1.00 (0.88 to 
1.13) 
>0.001 5 N Local stage 
 
Q1= high socio-economic position, Q5=low socio-economic position 
 
Some studies reported SEP quintiles but others reported SEP in 2, 3 or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in Tables 1-4 in the column entitled 'No. of SEP groups’  
Quality scores range from 1 (lowest quality) to 6 (highest quality) 
Meta-analysis:  Y=included in final meta-analysis, Y(S) = included in sensitivity meta-analysis, N=not included in meta-analysis 
 
Abbreviations: CI = confidence interval, non –UHCS = non-universal healthcare system , NR = not reported, OR = odds ratio, pop = population, SEP = socio-economic position 
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Table 7.13. Likelihood of receipt of any type of unspecified curative treatment by SEP group (universal health care systems). 
Study No. 
receiving 
treatment 
Cohort 
no/ no 
eligible 
Rate/ 
eligible 
rate 
Histology OR/rate in 
Q1 (95% CI) 
OR/rate in 
Q2 (95% CI) 
OR/rate in 
Q3 (95% CI) 
OR/rate in 
Q4 (95% CI) 
OR/rate in 
Q5 (95% CI) 
P value Quality 
score 
Meta-
analysis 
Further Information 
Erridge et al, 
2009[18] 
548 3833 14.30 any 1.1(0.9 to 
1.4) 
      1.00 >0.05 4 Y (S) Scottish pop – subset of 
Gregor et al (2001) pop 
Erridge et al, 
2009[18] 
546 2073 26.34 any 1.4(1.1 to 
1.8) 
      1.00 <0.05 4 Y Canadian pop 
Gregor et al, 
2001[38] 
627 3855/ 
1423 
16.26/ 
44.06 
any 1.00 1.14 (0.72 to 
1.80) 
1.07 (0.69 to 
1.66) 
0.95 (0.62 to 
1.47) 
0.77 (0.51 to 
1.16) 
0.25 6 Y Eligible = early stage 
Stevens et al, 
2008[47] 
109 565 19.29 any 1.0 3.1 (1.0 to 
9.7) 
1.4 (0.4 to 
4.4) 
1.1 (0.4 to 
0.3) 
0.6 (0.2 to 
1.8) 
0.05, 
0.60, 
0.86, 
0.40 
5 Y Hospital pop - subset of 
Stevens et al (2007) 
pop, individual P values 
reported 
 
Q1= high socio-economic position, Q5=low socio-economic position 
 
Some studies reported SEP quintiles but others reported SEP in 2, 3 or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in Tables 1-4 in the column entitled 'No. of SEP groups’ 
Quality scores range from 1 (lowest quality) to 6 (highest quality) 
Meta-analysis:  Y=included in final meta-analysis, Y(S) = included in sensitivity meta-analysis, N=not included in meta-analysis 
 
Abbreviations: CI = confidence interval, NR = not reported, OR = odds ratio, pop = population, SEP = socio-economic position, UHCS=universal healthcare system 
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7.4.3.5 Treatment type not specified – overall analysis 
Seven papers [eight study populations] examined receipt of unspecified treatment and 
three papers considered receipt of unspecified curative treatment in three populations 
[tables 7.11-7.13]. In the meta-analysis of five non-overlapping studies [all UHCS 
studies], low SEP was associated with a lower likelihood of receiving unspecified 
treatment [OR = 0.78, 95% CI 0.74 to 0.83, I2=0, p<0.001] [Fig 7.7]. This was also seen 
when studies with overlapping populations were included [OR = 0.80, 95% CI 0.77 to 
0.84, I2=17%, p<0.001]. 
Figure 7.7. Meta-analysis of odds of receipt of unspecified treatment in low (most deprived) 
versus high (least deprived) SEP.  
 
Abbreviations: CI = confidence interval, OR = odds ratio, SE=standard error, SEP = socio-economic position 
 
7.4.3.5.1 Treatment type not specified - detailed analysis by healthcare system: UHCS 
Five UHCS papers looked at receipt of any unspecified treatment [table 7.11] in six 
populations [although two contained overlapping populations]. All studies included 
any-histological-type and rates of treatment ranged from 50.4% to 66.2%. A significant 
association was seen between receipt of any treatment and SEP in four out of five non-
overlapping populations, where those with lower SEP were less likely to receive any 
treatment. This association was not seen in one study that included a small hospital 
population.  
Three UHCS papers also looked at receipt of any type of curative treatment [table 7.13] 
in a subset of the any-type-of-treatment populations. One study included a Scottish 
and Canadian population (198) and the Scottish population overlapped with that 
included in a second, better quality, study (201) hence three unique study populations 
102 
 
were examined. In only one out of three non-overlapping study populations was lower 
SEP associated with lower likelihood of any curative treatment.  
Combining the any type of treatment and any type of curative treatment studies gave 
five non-overlapping populations suitable for meta-analysis. Low SEP was associated 
with a lower likelihood of receiving unspecified treatment [OR = 0.78, 95% CI 0.74 to 
0.83, I2=0, p<0.001] [Fig 7.7].  
7.4.3.5.2 Treatment type not specified - detailed analysis by healthcare system: non-
UHCS 
Two studies looked at receipt of unspecified treatment for NSCLC in three populations 
using registry data from California and Virginia [table 7.12]. Rates of treatment ranged 
from 83.3% to 92.5% for early stage patients and 70.8% for late stage. A significant 
association was seen between receipt of unspecified treatment and SEP in one of the 
two studies, where those with lower SEP were less likely to receive any treatment. 
However, this was in an unadjusted analysis. In the study conducting multi-variable 
analysis no significant association was seen in either the early or late-stage population. 
7.5 Discussion 
7.5.1 Principal findings 
To my knowledge, this is the first systematic review and meta-analysis examining 
socio-economic inequalities in receipt of lung cancer treatment. It showed an 
association between low SEP and reduced likelihood of receipt of any type of 
treatment, surgery and chemotherapy but not radiotherapy. The results were 
generally consistent across different health care systems. 
7.5.2 Interpretation of results 
Surgery is only suitable for early stage NSCLC patients and it has been suggested that 
cancer patients with lower SEP are more likely to present later and with later stage 
disease (108). This may help explain why socio-economic inequalities in receipt of 
surgery are observed in some studies. Therefore if stage is not included as a 
confounder then the absence of controlling for stage may account for some of the 
reduced likelihood of receipt of surgery in lower SEP groups. However, presentation 
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with later stage cancer in lower SEP patients has not been consistently observed (73). 
In this review, when receipt of treatment was examined in studies of early-stage 
patients only [from non-UHCS studies] and in UHCS studies where stage was taken into 
account, low SEP remained associated with reduced likelihood of surgery. Thus, the 
association between SEP and receipt of surgery appears to be independent of stage. 
Similar results were seen for NSCLC studies in both health care systems. If SCLC 
patients are included within the surgery denominator and histology is not controlled 
for, as greater levels of SCLC are seen in lower SEP groups due to smoking (17), this 
may be a valid reason for lower rates of surgery in this group. 
Receipt of treatment may also be influenced by clinical suitability for treatment, and 
socio-economic differences in the number of co-morbidities present may explain socio-
economic inequalities in treatment. In the three UHCS studies that took co-morbidity 
into account, SEP was not associated with receipt of surgery (152, 157) or of any 
treatment (205) when the trend across SEP groups was examined, suggesting that co-
morbidity may be a potential mediator of socio-economic inequalities in treatment in 
UHCSs. However, most of the non-UHCS studies did include co-morbidity as a 
confounder and socio-economic inequalities in treatment were still observed, 
suggesting that there may be potential differences between healthcare systems in 
relation to the mediating effect of co-morbidity.  
7.5.3 Strengths and weaknesses of the review and of the available evidence 
This is one of the first equity reviews conducted (51, 61), the first systematic review of 
the literature on intervention-generated inequalities in lung cancer treatment, as well 
as the first cancer equity review to conduct meta-analysis. Extensive searches were 
carried out to identify studies. However, it is possible that not all relevant studies were 
obtained. 
The included studies reported observational data only. The suitability of meta-analysis 
for observational studies has been questioned, as it may produce precise but spurious 
results (232). Examining the possible sources of heterogeneity by conducting 
sensitivity analyses across different sub-groups may be less prone to bias than 
calculating an overall summary effect (232). Here, although an overall summary effect 
OR was calculated, heterogeneity was taken into account. Separate analyses by type of 
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treatment were carried out, with further stratification by stage and histology. 
Universal and non-UHCSs were examined separately and random effects rather than 
fixed effects meta-analyses were conducted. These precautions did not change the 
overall pattern of results seen. 
Significant heterogeneity remained in some cases, which could be considered as a 
limitation, although this is not surprising due to the characteristics of the studies 
included. For studies examining receipt of chemotherapy and radiotherapy it was 
generally not possible to differentiate between curative and palliative treatment and, 
if patterns of care differ for these by SEP, this might explain the high degree of 
heterogeneity seen. However, although there is some suggestion that heterogeneity 
can be considered high at >50% (197), when confidence intervals were calculated 
around the I2 statistic these were wide, and so it was difficult to be confident about the 
degree of heterogeneity present (233).  
Results for receipt of radiotherapy differed in the non-UHCS sub-group compared to 
overall but, as only two studies were included in this sub-group, it is difficult to be sure 
whether different patterns of receipt of radiotherapy by SEP are due to differences in 
healthcare system. 
Many of the non-UHCS studies used over-lapping population sub-groups from the SEER 
database. There was also population overlap between some UHCS datasets. We 
attempted to include only substantially non-overlapping populations within the final 
meta-analyses to ensure independence of results. A judgement had to be made as to 
which was the best quality and most appropriate paper to include, but sensitivity 
analyses using different inclusion combinations [Appendix C, Fig C7.6] did not change 
the overall findings and nor did including all suitable studies regardless of population 
overlap [Appendix C, Figs C7.1, C7.3-C7.5]. 
Included papers contained data for patients diagnosed between 1978 and 2008. As 
treatment guidance has changed over time, older studies may be less applicable to 
current clinical practice. However, the majority of included studies were published 
within the last five years and sensitivity analyses excluding studies published prior to 
2000 did not change the overall findings. 
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Various measures of SEP were utilised and these were categorised differently, which is 
an acknowledged problem in equity reviews (196). All but one study measured SEP at 
area-level. This is a further limitation, as area-based measures of SEP are unlikely to be 
accurate markers of individual-level circumstances and access to resources (234). Area-
based measures of SEP can be calculated using address, making them easy to add to 
disease registers, such as those used in many of the studies synthesised here.  
However, the reliance on area-based markers of SEP may under-estimate the strength 
of the true association between SEP and receipt of treatment.  
Not all studies reported details of stage and histology, both of which influence 
treatment type, and very few UHCS studies took co-morbidity into account. Thus, the 
ORs used in the meta-analyses were not consistently adjusted for the same covariates.  
However, I attempted to take these factors into account in the quality scores and by 
conducting subgroup sensitivity analyses. Examining only high quality studies did not 
alter findings nor did sensitivity analyses [for example, including only NSCLC studies or 
studies adjusting for stage], although consequent reduction in numbers did result in 
loss of significance in some analyses, potentially due to lack of power to detect 
differences.  
In order to conduct meta-analysis it is necessary to compare the odds of treatment in 
the lowest SEP group with the odds in the highest, which simplifies what may be a 
complex relationship across SEP groups. However, studies that reported a change in 
odds ratios across the SEP categories and thus explored trends in receipt of treatment 
generally supported the overall findings of the review. 
A number of existing tools suitable for assessing cohort study quality were considered 
(192, 194). However, none of these tools was entirely appropriate for the type of 
studies included and, as has been done in previous reviews (185, 188),  we devised a 
unique tool, adapting and utilising aspects of other available tools. This approach has 
the benefit of producing a quality tool that is highly specific for the type of studies 
examined. 
As with any systematic review, I was unable to exclude the possibility of publication 
bias. It was considered whether to search the grey literature including published 
abstracts, theses and reports from cancer registries and public health observatories, 
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but time and scope restraints prevented this. Studies reporting null findings are less 
likely to be published or, if they are published, not to report numerical outcomes (197). 
A funnel plot to assess potential publication bias did not appear to show obvious bias 
[Figure 7.2]. However, a number of papers recovered in the search included SEP in the 
description of the study population but did not report receipt of treatment by SEP (64, 
161, 162, 235). Study authors were contacted and asked to provide further 
information, but only one supplied the requested data (161). It is likely that SEP was 
not significantly associated with receipt of treatment in the other studies but this was 
not always clearly reported. However, publication bias is thought to be less important 
than other sources of bias such as confounding, in meta-analyses of observational 
studies (232).  
7.5.4 Implications for policy and practice/ future research 
Socio-economic inequalities in receipt of treatment may exacerbate socio-economic 
inequalities in incidence of lung cancer, which is strongly associated with higher 
smoking rates in more deprived populations, and so may further contribute to the 
poorer outcomes in lower SEP groups. 
Socio-economic inequalities in treatment may be due to differences in access to care. 
Within a non-UHCS it might be expected that socio-economic differences in receipt of 
treatment would be observed due to income-related differences in insurance status. 
Patients with lung cancer in the USA who do not have insurance have been reported to 
have more limited access to care (188). However, as socio-economic inequalities in 
receipt of lung cancer treatment were also observed in UHCS that do not depend on 
ability to pay, this would suggest that other system factors may be contributing to this 
inequality.  
In non-UHCS, studies in younger populations, examining a range of insurance 
providers, are required.  
The extent to which receipt of treatment is influenced by factors such as patient choice 
is not known. Variability at patient, tumour, system and individual clinician level needs 
to be investigated before clear recommendations for changes to policy and practice 
can be made. Further investigation into the factors that might contribute to socio-
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economic inequalities in receipt of lung cancer care is necessary, to help develop 
interventions that ensure equitable receipt of appropriate treatment. This could 
include quantitative exploration of inequalities at each stage of the care pathway as 
well as qualitative work exploring reasons for inequality. It is likely that inequalities in 
receipt of treatment may contribute to inequalities in cancer survival and so cohort 
survival analyses are warranted in order to investigate intervention-generated 
inequalities in lung cancer outcomes. 
7.6 Chapter summary 
This review has demonstrated an association between lower SEP and reduced 
likelihood of receiving surgery, chemotherapy and any type of unspecified treatment, 
but not radiotherapy, for lung cancer.  
If lower SEP patients are more likely to present with later stage cancer [although the 
evidence for this is unclear] they will be ineligible for surgery. Therefore if stage is not 
included as a confounder then the absence of controlling for stage may account for 
some of the reduced likelihood of receipt of surgery in lower SEP groups. Similarly, If 
SCLC patients are included within the surgery denominator and histology is not 
controlled for, as greater levels of SCLC are seen in lower SEP groups due to smoking 
(17), this may be a valid reason for lower rates of surgery in this group. Receipt of 
treatment may be influenced by clinical suitability for treatment, and socio-economic 
differences in the number of co-morbidities present may explain socio-economic 
inequalities in treatment. Better quality UHCS studies, including statistical control for 
co-morbidity, stage and histology, are required. Chapter 10 describes just such a study 
using a secondary linked data-set.  
Chapter 8 now goes on to describe the data-set employed for the secondary data-
analysis and an overview of the analytical methods.  
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Chapter 8. Exploring IGIs in lung cancer care using linked secondary data: 
Methods 
8.1 Introduction 
Socio-economic inequalities in receipt of surgery and chemotherapy for lung cancer 
were found in my systematic review and meta-analysis (236), as described in the 
previous chapter [chapter 7]. However, the quality of the included studies was mixed 
and many did not include important potential confounders such as stage, histology, PS 
and co-morbidity in the analyses.  
To further investigate socio-economic inequalities in receipt of lung cancer treatment 
and the factors that might be influencing this, as well as exploring the role treatment 
inequality and delay might play in socio-economic inequalities in survival, Intervention-
generated inequalities in lung cancer care in the North of England were explored using 
cancer registry [NYCRIS] data linked to Hospital Episode Statistics [HES] data and 
National Lung Cancer Audit [LUCADA] data. These linked secondary data sources were 
used to determine if there were socio-economic inequalities in lung cancer care and to 
identify where on the pathway of care these inequalities might occur – looking at time 
from GP referral to first hospital appointment, diagnosis and treatment; receipt of 
treatment; and survival. This chapter describes the methods employed to do this: the 
data sources used; variables included and the reasons for their inclusion; problems 
with data linkage and missing data; ethical approval; and an overview of the analytical 
methods.  
Potential variables of interest, particularly those that had not previously been well 
explored, were determined from the literature and systematic reviews. An initial 
scoping exercise was then conducted to determine the availability and accessibility of 
data held by NYCRIS and HES that could be supplied in anonymised form. When it 
became clear that all variables of interest were not contained within these two 
datasets further linkage to the lung cancer audit dataset was considered. Tables A1-A3 
in Appendix A show the variables that were included in the initial request and the 
reasons for their inclusion. 
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8.2 Data sources  
The Northern and Yorkshire Cancer Registry and Information Centre [NYCRIS] is one of 
eight English regional cancer registries [11 in the UK] that collect a common minimum 
cancer dataset of information to obtain population-based figures for incidence of, and 
survival from, cancer. It covers a population of 6.6 million and registers approximately 
50,000 incident cancer cases annually. Of these, around 5800 are lung cancer cases 
[2010 data] (237). From 1st April 2013 it became part of Public Health England. 
The National Cancer Dataset uses data collected from all the registries. As well as their 
traditional registry role the registries also provide a cancer information and 
intelligence function. Validity and completeness of the data is also monitored. Active 
cancer treatments given within 6 months of diagnosis [surgery, chemotherapy, and 
radiotherapy] are well recorded in NYCRIS but not always so well recorded in other 
registries (237). Therefore, in order to look at adjuvant and palliative therapy as well as 
surgery, the investigative study uses NYCRIS regional, rather than national, lung cancer 
data.  
Co-morbidity may be a factor determining whether treatment is offered (238) but 
details of co-morbidity are not collected by cancer registries. However, this data can be 
obtained from HES and used to calculate a co-morbidity score. Hospital Episode 
Statistics are stored in a HES ‘data warehouse’ containing details of all admissions to 
English NHS hospitals, and recording episodes of care from 1989 onwards. Other 
details of care including referring GP are also held in HES. The National Cancer Data 
Repository [NCDR] is a merged dataset of cancer registry data linked to an extract of 
HES (239). 
Lack of stage data has been identified as a major limitation of cancer registry data 
(240). Definitive cancer staging requires extensive clinical investigation and levels of 
registry data on stage vary by cancer type. Lung cancer staging data is not routinely 
collected by cancer registries. However, the Lung Cancer Audit [LUCADA], a non-
mandatory register of clinical information on patients diagnosed with lung cancer, 
does collect staging data. The audit initially included only a subset of registry patients 
whose data has been entered into LUCADA, which began in 2004. The audit examines 
the care delivered for patients diagnosed with lung cancer, and is run by The Health 
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and Social Care Information Centre in partnership with the Royal College of Physicians 
on behalf of the Healthcare Quality Improvement Partnership [HQIP].  
8.3 Data  
Data for patients with a primary diagnosis of lung cancer [ICD10 C33 and C34], 
diagnosed between 1997 and 2010 were requested from NYCRIS, and where linked 
data were available, with a linkage to HES [to supply co-morbidity score] and LUCADA 
[for stage and PS data]. The three data sources [NYCRIS cancer registry, HES and 
LUCADA data] were anonymised by NYCRIS and the three data-sets supplied by 
NYCRIS. The Thames Cancer Registry, the lead registry for lung cancer were contacted 
and they informed NYCRIS of the appropriate methods for linking, processing and 
extracting data from LUCADA, to ensure consistent rules were applied by NYCRIS. 
Records were allocated a unique randomly-generated key number, derived from the 
NHS number by NYCRIS, and the HES and LUCADA data were then linked by LF using 
this key.  
8.3.1 Data problems 
8.3.1.1 Delays in obtaining data, and data linkage  
Registry data for patients diagnosed from 1997 to 2010 were supplied by NYCRIS in 
March 2012 but at that point it was still unclear whether HES and LUCADA data would 
be available. A national problem with the way that the co-morbidity score had been 
calculated meant that the data was withdrawn from use and NYCRIS were unclear 
about when this problem would be resolved. After much uncertainty the data 
eventually became available in November 2012. LUCADA data were obtained in 
December 2012. Data from HES and LUCADA were then imported and linked to the 
cleaned NYCRIS dataset.  
8.3.1.2 Data format  
When the initial registry data was received, in order to ensure that the data were non-
identifiable I was not able to have access to the variable ‘date of death’. Instead 
survival time from date of diagnosis was calculated by NYCRIS. However, this was given 
in years, which was not appropriate for meaningful lung cancer survival analysis as 
111 
 
lung cancer has such a short survival period. After some negotiation it was agreed that 
survival time in weeks could be supplied. An estimated survival time in days could then 
be calculated with an accuracy of within 7 days of actual death. However, when the 
‘survival in weeks’ variable did become available it was unfortunately not possible to 
append the new variable onto the existing dataset due to the way that the unique key 
for the dataset had been randomly generated by NYCRIS. Therefore a whole new un-
cleaned dataset had to be sent by NYCRIS, meaning that all data cleaning and the 
generation of new variables had to be carried out again. Luckily as Stata ‘do’ files had 
been created for the initial data cleaning, this was not as big a set-back as it could have 
been. 
8.3.1.3 Missing data 
In the linked dataset the levels of stage, PS and co-morbidity data missing were high.  
Inpatient HES data up until 31/3/2010 were theoretically available. However, although 
linked HES co-morbidity data were available for between 88.4% up to 92.0% of 
patients diagnosed between 1999 and 2008 [figures that are similar to those found in a 
similar study linking Thames cancer registry and HES data (157)], only 1.9% of those 
diagnosed in 2009 and 1.8% diagnosed in 2010 had a linked HES record [Appendix B]. 
National problems with the methodology used to calculate the co-morbidity score 
contained in the National Cancer Dataset meant that these all had to be re-calculated 
and so there was a resultant time-lag in their availability (NYCRIS, personal 
communication).  
Stage and PS data were available from 2006 onwards. However, stage was only 
recorded for 27% of the 2006-2010 cohort, resulting in a large ‘missing’ category. 
Unfortunately the years in which the highest levels of stage and PS data were available 
[2009-2010] were also the years in which HES-linked data [and hence co-morbidity 
score] were not available for over 98% of the cohort. Patients diagnosed between 
2006 and 2008 [n= 17,096] potentially had stage, PS and co-morbidity recorded 
although levels of stage data in these years were low and only 2080 had both details of 
stage and co-morbidity recorded. Those diagnosed between 1999 and 2005 had co-
morbidity score but not stage or PS available.  
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The method for calculating date of diagnosis was changed in 2010 which might 
influence the comparability of the time intervals used in the time to diagnosis and 
treatment analyses for this year.  
Some decisions therefore had to be made regarding which years of data to include in 
the analyses.  
8.3.2 Data-sets  
Data for patients with a primary diagnosis of lung cancer [ICD10 C33 and C34], 
diagnosed between 1997 and 2010 were initially requested from NYCRIS. However, 
patients diagnosed prior to 1999 did not have a valid IMD code and so could not be 
utilised.  
Data for 66,891 patients with a primary diagnosis of lung cancer [ICD10 C33 and C34], 
diagnosed between 1st Jan 1999 and 31st December 2010, were available for use. Of 
these, 1681 had tumour registration based on death-certification only and so were 
excluded from analyses, leaving an eligible cohort of 65,210. 7776 [11.9%] had stage 
recorded in LUCADA [7769 in 2006-2010] and 51,614 [79.2%] had a HES linkage.  
It was decided to split the cohort into two to best deal with missing data. Group 1 
consisted of patients diagnosed between 1999 and 2005 [n=36,477], of whom 32,974 
[90.3%] had a linked HES record. Stage and PS were not available. Patients diagnosed 
between 2006 and 2010 [n= 28,733] made up the 2nd group and, of these, only 18,650 
[64.9%] had a linked HES record, 7769 [27.0%] had stage recorded in LUCADA and 8885 
[30.9%] had a PS score. Analyses with and without the inclusion of co-morbidity were 
also conducted for group 2.  
Multiple imputation for variables with missing data was considered but it is not 
recommended where over 50% of the data in a variable are missing (241). An 
alternative way to address the problem of missing data is  to analyse only complete 
cases, although results from complete-case analyses can be biased (242). It was 
decided to analyse the full 2006-2010 dataset and include a ‘stage missing’ category 
and also to conduct a sub-group analysis of the 7769 staged-patients diagnosed in 
2006-2010.  
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The distribution of each variable in the 1999-2005 and 2006-2010 subgroups and in the 
staged subgroup were compared to the overall cohort and to each other using the Chi 
squared (χ2) test, to determine the representativeness of each of these groups. 
Statistical analyses were performed using STATA v 12.0. 
8.4 Data variables 
8.4.1 Registry data 
8.4.1.1 Socio-demographic factors - SEP 
Socio-economic position [SEP] was calculated according to the agreed methodology for 
all English cancer registries, as the rank of the income domain of the Index of Multiple 
Deprivation [IMD], grouped into quintiles, based on the England-wide distribution of 
this variable.  
IMD is an area-based composite measure of SEP and the UK government’s preferred 
measure of deprivation. The English IMD provides a relative measure of deprivation at 
small area level across England. Areas are ranked from least deprived to most 
deprived, on seven different dimensions of deprivation as follows: income deprivation; 
employment deprivation; health deprivation and disability; education deprivation; 
crime deprivation; barriers to housing and services deprivation; and living environment 
deprivation (243). Postcodes of residence were used to assign individuals to small 
administrative areas known as lower-level super output areas [LSOA], containing an 
average of 1500 individuals.  
To avoid any risk of including an indicator incorporating a health score, some studies 
have previously used the composite measure of IMD with the health domain removed 
(78, 199), but the agreed methodology for all English cancer registries is now to use 
only the income domain of the IMD and not to provide actual deprivation scores per 
LSOA, as scores are not a proportional measure of deprivation. An LSOA with a score of 
40 is not twice as deprived as one with a score of 20 and so raw scores are not 
particularly meaningful (244). IMD is not directly comparable between England, 
Scotland and Wales as there are differences in sub-measures due to differences in 
rules for benefit qualification.  
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IMD quintiles were supplied by NYCRIS, where 5 is the most deprived and 1 the least 
deprived. The income domain of IMD 2010 was used for the most recent years of data, 
which is based on 2008 data and thus populations were derived from 2008 data for 
patients diagnosed between 2007 and 2010. For those diagnosed between 2003 and 
2006 the income domain of IMD2007 was used [derived from 2005 data] and for 1999-
2002 the income domain of IMD2004 [derived from 2001 data]. This changing-
deprivation-score-over-time methodology was thought to be preferable to applying 
deprivation based on 2008 data back in time to much earlier years of diagnosis, as this 
may not properly reflect the deprivation of that area if, for example, there had been 
regeneration over the last decade (244). 
Although data for patients diagnosed in 1997 and 1998 were available, valid IMD data 
were only available from 1999 onwards and so the records for the two earlier years 
were not used. 
8.4.1.2 Other socio-demographic factors 
Age at diagnosis was categorised into 4 groupings: age <60, 60-69, 70-79 and 80+ 
years. 
Sex was categorised as M [male] and F [female]. 
Marital status is recorded by NYCRIS. This variable was requested but due to poor data 
completeness was not able to be supplied. 
Data on ethnicity was supplied. However as ethnicity information was missing for 38% 
of the dataset and, of the 62% that had this variable coded, less than 1% of the dataset 
were characterised as non-white, this variable was not included in the final analyses.  
As inequalities in receipt of treatment may have changed over time and to take into 
account the effect of the introduction of new guidelines for referral in 2005 (18), year 
of diagnosis was split into 4 categories: 1999-2001, 2002-2004, 2005-2007, 2008-2010. 
Individual years were utilised for the 1999-2005 and 2006-2010 datasets. 
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8.4.1.3 Tumour factors 
There were 67 different cancer type codes listed in the registry dataset. Nine codes 
encompassed 96.1% of the records, relating to seven recognisable tumour types [table 
8.1]. The remaining 3.9% had one of 58 different codes and these were classified as 
other-specified carcinomas. 
Lung cancer was therefore categorised into eight morphological subtypes: 
adenocarcinoma, large cell carcinoma, non-small cell carcinoma, squamous cell 
carcinoma, small-cell carcinoma, other specified carcinoma [of which 26.6% were 
carcinoid tumours, codes M82413 and M82463], unspecified carcinoma (20) and 
neoplasm [table 8.1].  The neoplasm subtype included patients with a clinical diagnosis 
only.  
Table 8.1. lung cancer histology and tumour type 
Cancer 
code 
Description N % Tumour type Histology 
M81403 Adenocarcinoma unspecified 9,463 14.5 Adenocarcinoma NSCLC  
M80103 Carcinoma unspecified 4,615 7.1 Unspecified Other 
M80463 Non-small cell carcinoma 8,661 13.3 Non-small NSCLC  
M80123 Large cell carcinoma unspecified 2,140 3.3 Large cell NSCLC  
M80003 Neoplasm malignant 15,390 23.6 Neoplasm Other 
M80413 Small cell carcinoma unspecified 8,599 13.2 Small cell SCLC  
M80723 Squamous cell carcinoma non-
keratinising 
13,831 21.2 
Squamous NSCLC  
M80723 Squamous cell carcinoma NSCLC  
M80713 Squamous cell carcinoma keratinising NSCLC  
 Other cancer type codes (n=54) 
2,511 3.9 
Other specified 
carcinomas 
Other 
Total  65,210 100   
 
Cancer type [histology] was classified as confirmed non-small cell lung cancer [NSCLC], 
including adenocarcinoma, large cell carcinoma, non-small cell carcinoma and 
squamous cell carcinoma subtypes; small cell lung cancer [SCLC]; and Other histology 
[including unspecified carcinoma, neoplasm, and other specified carcinomas (including 
carcinoid tumours)] [table 8.1].  
When including only morphologically-specified lung cancers in analyses then the 
‘unspecified carcinoma/neoplasm’ subtypes were excluded and the ‘other specified 
carcinoma’ subtype was included as probable NSCLC.  
  
116 
 
8.4.1.4 Treatment 
The types of treatment [surgery, chemotherapy and radiotherapy] were used to derive 
a number of different treatment variables: three binary receipt of treatment variables - 
Surgery [y/n], Chemotherapy [y/n], Radiotherapy [y/n]; Type of First Treatment – 
categorised as surgery first, chemotherapy first, radiotherapy first, and no treatment; 
Types of Treatment – categorised as surgery, surgery + chemotherapy/radiotherapy, 
chemotherapy, chemotherapy + radiotherapy, radiotherapy, no treatment. 
8.4.1.5 Dates, interval periods and target times 
8.4.1.5.1 Dates 
Dates of GP referral, first hospital appointment, diagnosis, and treatment received 
[surgery, chemotherapy and radiotherapy], were extracted from the cancer registry 
data.  
For the 1999-2009 NYCRIS data, diagnosis date was determined by searching 
through case notes to collect information. Diagnosis date was determined as the first 
time the tumour was identified either by imaging or histology. From 2010 onwards 
UKACR guidance was followed. The guidance uses a priority hierarchy with 6 categories 
to determine date of diagnosis; the date of histological or cytological confirmation of 
malignancy [which can be derived from 3 different hierarchical time points]; then date 
of hospital admission; down to, with lowest priority, date of death if cancer is only 
identified at autopsy (100).  
In order to calculate meaningful diagnostic and treatment intervals it is necessary to 
exclude those who have a diagnosis only after death. All death certificates that 
mention cancer are returned to the registry so that date of death can be recorded. If 
this cancer has not previously been entered on the register then further details are 
searched for retrospectively, but if medical records cannot be located then the cancer 
is registered as Death Certificate Only [DCO].These cases [n=1681] were excluded from 
analyses. 
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8.4.1.5.2 Intervals and target times 
The following referral, diagnostic and treatment time intervals were potentially 
available for investigation: 
Table 8.2. Referral, diagnostic and treatment intervals 
Interval Definition of interval NCP
*
 target time 
Referral  GP referral date to first hospital appointment date 14 
Diagnostic  GP referral date to diagnosis date 31 (62-31) 
first hospital appointment (FHA) date to diagnosis date 17 (31-14) 
Treatment  diagnosis date to first treatment date 31 
GP referral date to first treatment 62 
*National Cancer Plan  
 
In England, three of these intervals have been the subject of performance 
management. Since 2000, urgent referrals for suspected cancer have been required to 
have a first hospital appointment [FHA] within 14 days from the date of referral 
[referral interval]. Since 2005, intervals of 62 days from date of urgent GP referral to 
first treatment and 31 days from diagnosis/decision to treat to first treatment 
[treatment intervals] have been in place (24). Interim time target periods [italics] can 
be inferred from these stated target times and calculated as follows: GP referral to 
diagnosis [62-31=31 days] and FHA to diagnosis [31-14=17 days].  
Time from GP referral date to FHA was categorised as <=14 days [within target], >14 
days, no referral interval recorded [either no GP referral date or no FHA date]. Time 
from GP referral date to treatment was categorised as <=62 days [within target], >62 
days, no referral interval recorded [either no GP referral date or no FHA date]. Time 
from diagnosis to first treatment was categorised as:  <=31 days [within target], 32-62 
days, >62 days, no treatment. 
8.4.2 HES data – co-morbidity score 
Co-morbidities were derived from diagnostic codes in HES. A calculated co-morbidity 
score was then derived using the Charlson co-morbidity index, a validated instrument 
(245),  and recorded in the National Cancer Registry Dataset. Only patients who had an 
inpatient episode with a condition that counted towards co-morbidity were included. 
Inpatient HES data up until 31/3/2010 were theoretically available. 
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A Charlson co-morbidity [CCM] score was calculated by NYCRIS using the number of 
inpatient HES admissions for 17 specified conditions [other than lung cancer] in the 3- 
18 months prior to diagnosis. Co-morbidities were assigned a weighted score [table 
8.3] and the total score was the sum of weighted scores for the co-morbidities 
experienced.  
No HES data linkage was available for 98.3% of patients diagnosed in 2009-10 as 
national problems in calculating the co-morbidity score meant that there was a time-
lag in their availability. Patients without a CCM score were split into those who did and 
did not have a HES linkage. Those who had a linked HES record but no CCM score 
recorded on HES [CCM missing] were analysed separately from those who had no 
linked HES record and therefore no CCM score [no HES linkage].  
CCM score was categorised as 0, 1-2, 3+, CCM missing, and no HES linkage. 
Table 8.3. Calculation of Charlson co-morbidity (CCM) score 
Charlson 
Group 
Description 
Charlson 
Score 
Notes 
1 Acute Myocardial Infarction 1   
2 Congestive Heart Failure 1   
3 Peripheral Vascular Disease 1   
4 Cerebral Vascular Accident 1   
5 Dementia 1   
6 Pulmonary Disease 1   
7 Connective Tissue Disorder 1   
8 Peptic Ulcer 1   
9 Diabetes 1 
Only highest score is counted 
10 Diabetes Complications 2 
11 Paraplegia 2   
12 Renal Disease 2   
13 Cancer 2 
Derived from cancer registry data rather than HES data. 
14 Metastatic Cancer N/A 
17 Liver Disease 1 
Only highest score is counted 
15 Severe Liver Disease 3 
16 HIV 6   
 
8.4.3 LUCADA data – stage and PS 
Lung cancer staging data is very poorly recorded in NYCRIS. Stage and performance 
status were therefore obtained from LUCADA records. These variables were only 
substantially available for patients who were diagnosed between 2006 and 2010. 
The audit includes only a subset of registry patients whose data has been entered into 
LUCADA, which began in late 2004. Nationally, the percentage completeness varies 
119 
 
from only 40% for those diagnosed in 2005, with gradual increases over the years [66% 
in 2006, 75% in 2007, 85% in 2008, 95% in 2009, 93% in 2010 and 93% in 2011] (246). 
The number with stage recorded was also initially low [55% in 2006, although this is 
55% of the 66% included so is only around 36.3% of the full number diagnosed that 
year] but again is increasing over time [85% in 2010, equivalent to 79% of all those 
diagnosed]. For my linked NYCRIS dataset the numbers were lower than this. Stage 
was recorded for only 11.8% in 2006 and increased to 63.1% in 2010 [see Appendix B]. 
Stage was assigned using the TNM staging system and categorised as I [IA,IB], II 
[IIA,IIB], III [IIIA,IIIB], IV and missing/uncertain. 
Performance status [PS] is a measure of general well-being for cancer patients, as 
assessed by the Multi-Disciplinary Team [MDT], on a scale of 0-4 using the Eastern Co-
operative Group performance status scale [ECOG PS] (18) [table 8.4]. A code of 5 
signifies that PS is missing. 
Table 8.4. Performance status scale 
ECOG/ WHO 
(Zubrod) scale
(119) 
Short Description LUCADA Description 
0 Asymptomatic Able to carry out all normal activity without restriction  
1 Symptomatic but 
ambulatory 
Restricted in physically strenuous activity but able to walk and 
do light work  
2 In bed < 50% of day Able to walk and capable of all self care but unable to carry 
out any work. Up and about 
more than 50% of waking hours 
3 In bed >50& of day Capable of only limited self care, confined to bed or chair 
more than 50% of waking 
hours 
4 Bedridden Completely disabled. Cannot carry on any self care. Totally 
confined to bed or chair  
5 -- Not recorded  
 
8.5 Ethical Approval 
Ethical Approval was applied for through the Integrated Research Application System 
[IRAS] for NHS Research Ethics Committee [REC] approval. The shorter Proportionate 
Review process was used as only anonymised data was requested. The National 
Information Governance Board for Health and Social Care [NIGB], which deals with 
applications to access patient data without consent, were contacted and agreed that, 
providing mechanisms to prevent small numbers being disclosed and thus potentially-
identifying patients were discussed with NYCRIS, NIGB approval was not necessary. 
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Nor was NHS R&D approval required, although I was initially informed that this would 
be required from Leeds Teaching Hospitals NHS Trust, as the trust that holds the 
NYCRIS registry. This did delay the Ethics process whilst this was resolved. 
A favourable ethical opinion was obtained from the Proportionate Review sub-
committee of the NRES Committee East of England REC on the 13th December 2011 
[REC reference 11/EE/0537]. 
Access to NYCRIS data was applied for using the UK Association of Cancer Registries 
[UKACR] Information Request form. The UKACR considers the following to be 
identifiable data items: date of birth, postcode, date or cause of death; therefore I did 
not request these items but rather anonymised data containing variables derived from 
these data items. 
Data items that could be classified as potentially-identifiable are: individual records 
even if they do not contain identifiable information and tables of data with low cell 
counts. However, as I was requesting large datasets for common cancers with all 
identifiable data anonymised, individual patients should not be identifiable. 
8.6 Overview of secondary data analysis analytical methods 
The triple linked dataset was used to examine the factors that may influence socio-
economic inequalities in lung cancer treatment; referral, diagnosis and treatment time; 
and survival. The analytical methods are summarised here and detailed statistical 
methods are given in chapters 9, 10, 11 and 12.  
8.6.1 Socio-economic inequalities in receipt of treatment 
Receipt of treatment by socio-economic position was examined using logistic 
regression. Other variables that were of interest [age, sex, histology, year of diagnosis, 
co-morbidity, stage, PS] were examined in unadjusted analyses and included in the 
adjusted model if significant in the univariable analysis at p<0.05 or if thought to be of 
a priori importance. Outcome was receipt of treatment by SEP for: 
 Surgery  
 Chemotherapy 
 Radiotherapy 
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These results are in chapter 10. 
8.6.2 Socio-economic inequalities in referral, diagnostic and treatment intervals 
Socio-economic inequalities in referral, diagnosis and treatment time for lung cancer 
patients were examined using Cox proportional hazard models. The following intervals 
were considered: 
 Referral [time from referral to secondary care investigation/first hospital 
appointment] 
 Diagnosis [time from first hospital appointment to diagnosis, and time from GP 
referral to diagnosis] 
 Treatment [time from diagnosis to first treatment, and time from GP referral to 
first treatment] 
Multivariable Cox Proportional Hazard models for each time period were constructed 
including variables that were thought to be of a-priori importance, to examine the 
hazard ratio [HR] of early referral, diagnosis and treatment, by SEP. 
Since 2000, urgent referrals for suspected cancer have been required to have a first 
hospital appointment [FHA] within 14 days from the date of referral [referral interval]. 
Since 2005, intervals of 62 days from date of urgent GP referral to first treatment and 
31 days from diagnosis to first treatment [treatment intervals] have been in place. The 
likelihood of referral, diagnosis and treatment within recommended target times by 
SEP was examined using logistic regression, in multivariable models including other 
factors [age, sex, histology, year of diagnosis, co-morbidity, stage, PS] that may impact 
on these time intervals. These results are in chapter 11. 
8.6.3 Socio-economic inequalities in survival 
Survival time was calculated as the interval from the date of diagnosis to the date of 
death or to the end of follow up at 31/12/2011 for those still alive, when data was 
censored. All-cause mortality was analysed using Kaplan-Meier plots and Cox 
proportional hazard models. Kaplan Meier graphs were used to examine univariable 
influences on all-cause mortality. Cox regression models were used to calculate hazard 
ratios [HRs] and 95% CIs for all-cause mortality in relation to SEP in multivariable 
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models. Logistic regression was used to examine the odds of still being alive two years 
[for 2006 to 2009 and 1999-2005 cohorts] after diagnosis, by SEP. 
8.7 Chapter summary 
This chapter has given an overview of the secondary data analysis analytical methods 
and has described the data sources used and variables included, as well as problems 
with data linkage and missing data. In chapter 9 descriptive results for the dataset are 
presented. The demographic and clinical characteristics of the patients are examined, 
as are associations between SEP and a number of variables of interest.  
In chapter 10 multivariable analyses to examine socio-economic inequalities in lung 
cancer treatment are presented. Chapter 11 looks at inequalities in the referral, 
diagnostic and treatment intervals and chapter 12 examines inequalities in lung cancer 
survival. Each chapter presents detailed methods, self-contained results and 
discussion, which places results in context with the literature, discusses the strengths 
and weaknesses of the study and the potential implications for policy and practice and 
further research required. Chapter 13 then summarises the overall findings of the 
thesis, as well as detailing overall methodological strengths and weaknesses of the 
secondary data analysis, detailing any further implications for policy and practice, and 
further research required. 
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Chapter 9. IGIs in lung cancer care – dataset overview and descriptive 
statistics 
9.1 Introduction 
In this chapter a descriptive overview of the dataset is given. The demographic and 
clinical characteristics of the patients in the entire dataset and in the 1999-2005 
cohort, 2006-2010 cohort, and 2006-2010 cohort with stage recorded, are examined 
and compared. Associations between SEP and a number of variables of interest are 
also examined. Time trends and differences between the datasets are considered and 
the implications of these differences for the representativeness of the datasets 
discussed in relation to the proposed multivariable analyses to be carried out.  
9.2 Methods 
Descriptive statistics for the datasets were calculated using the Chi squared [χ2 ] test to 
describe the characteristics and representativeness of each dataset; to describe 
characteristics over time; to examine univariable associations between SEP and other 
patient and tumour characteristics [stage, age, tumour type, PS and CCM score]; and 
to examine univariable associations between stage, PS and CCM score. 
9.3 Results - descriptive statistics 
9.3.1 Characteristics of the datasets 
Table 9.1 shows the demographic and clinical characteristics of patients diagnosed 
with lung cancer between 1999 and 2010 [n=65,210, excluding those patients who 
were recorded as DCO] and comparing them with the subset diagnosed from 1999-
2005 [n=36,477], 2006-2010 [n=28,733] and, within this, the subset in 2006-2010 with 
stage recorded [n=7769]. 
The highest percentage of patients were found in the most deprived quintile [34.8%] 
with the smallest percentage in the most affluent quintile [11.1%] in the full dataset. A 
higher percentage of affluent patients were found in the 2006 to 2010 cohort [11.8%] 
and in the stage subset [12.0%] [table 9.1]. 
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Table 9.1. Demographic and clinical characteristics of patients diagnosed with lung cancer 
(DCO excluded) between 1999 and 2010, and cohorts diagnosed between 1999-2005, 2006-
2010, and 2006-2010 subset with stage recorded  
Variable All patients 
1999-2010 
cohort 1999-2005  cohort 2006-2010 2006-2010 subset 
with stage 
N % N % N % N % 
Deprivation quintile 65210 100 36,477 100 28733 100 7769 100 
1 (least deprived) 7246 11.1 3,857 10.6 3,389 11.8 931 12.0 
2 9265 14.2 5,087 14.0 4,178 14.5 1118 14.4 
3 10853 16.6 6,005 16.5 4,848 16.9 1300 16.7 
4 15163 23.3 8,453 23.2 6,710 23.4 1831 23.6 
5 (most deprived) 22683 34.8 13,075 35.8 9,608 33.4 2589 33.3 
Sex 65210 100 36,477 100 28733 100 7769 100 
Female 28668 44.0 15,414 42.3 13254 46.1 3559 45.8 
Male 36542 56.0 21,063 57.7 15479 53.9 4210 54.2 
Age group 65210 100 36,477 100 28733 100 7769 100 
<60 8905 13.7 5,223 14.3 3,682 12.8 1041 13.4 
60-69 17130 26.3 9,535 26.1 7,595 26.4 2189 28.2 
70-79 24830 38.1 14,582 40.0 10,248 35.7 2843 36.6 
80+ 14345 22.0 7,137 19.6 7,208 25.1 1696 21.8 
Histology 65210 100 36,477 100 28733 100 7769 100 
NSCLC 34095 52.3 18,972 52.0 15,123 52.6 5116 65.9 
SCLC 8599 13.2 5,104 14.0 3,495 12.2 582 7.5 
Other 22516 34.5 12,401 34.0 10,115 35.2 2071 26.7 
Co-morbidity score 65210 100 36,477 100 28733 100 7769 100 
0 10063 15.4 6,053 16.6 4,010 14.0 995 12.8 
1 4968 7.6 2,588 7.1 2,380 8.3 579 7.5 
2 2316 3.6 1,165 3.2 1,151 4.0 278 3.6 
3+ 1639 2.5 705 1.9 934 3.3 226 2.9 
CCM score missing 32,628 50.0 22,453 61.6 10,175 35.4 1,977 25.5 
No HES link 13,596 20.9 3,513 9.6 10,083 35.1 3,714 47.8 
Stage 65210 100 36,477 100 28733 100 7769 100 
I -- -- -- -- 1,186 4.1 1186 15.3 
II -- -- -- -- 552 1.9 552 7.1 
III -- -- -- -- 2,273 7.9 2273 29.3 
IV -- -- -- -- 3,758 13.1 3758 48.4 
Missing/ unknown -- -- -- -- 20,964 73.0 -- -- 
Performance Status 65210 100 36,477 100 28733 100 7769 100 
0 -- -- -- -- 1,842 6.4 1,493 19.2 
1-2 -- -- -- -- 4,865 16.9 3,870 49.8 
3+ -- -- -- -- 2,178 7.6 1,763 22.7 
Missing/unknown -- -- -- -- 19,848 69.1 643 8.3 
Surgery 65210 100 36,477 100 28733 100 7769 100 
Yes 6407 9.8 3,513 9.6 2,894 10.1 1001 12.9 
No 58803 90.2 32,964 90.4 25,839 89.9 6768 87.1 
Chemotherapy 65210 100 36,477 100 28733 100 7769 100 
Yes 15996 24.5 7,648 21.0 8,348 29.1 2732 35.2 
No 49214 75.5 28,829 79.0 20,385 71.0 5037 64.8 
Radiotherapy 65210 100 36,477 100 28733 100 7769 100 
Yes 22216 34.1 12,602 34.6 9,611 33.5 3069 39.5 
No 42994 65.9 23,875 65.5 19,122 66.6 4700 60.5 
GP referral date 65210 100 36,477 100 28733 100 7769 100 
Yes 32,140 49.3 16,688 45.7 15,452 53.8 5,351 68.9 
No 33,070 50.7 19,789 54.3 13,281 46.2 2,418 31.1 
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Table 9.1(cont). Demographic and clinical characteristics of patients diagnosed with lung 
cancer (DCO excluded) between 1999 and 2010, and cohorts diagnosed between 1999-2005, 
2006-2010, and 2006-2010 subset with stage recorded 
Variable All patients 
1999-2010 
cohort 1999-
2005 
cohort 2006-2010 2006-2010 subset 
with stage 
 N % N % N % N % 
Year of Diagnosis 65210 100 36,477 100 28733 100 7769 100 
1999 5,154 7.9 5,154 14.1 -- -- -- -- 
2000 5,227 8.0 5,227 14.3 -- -- -- -- 
2001 5,200 8.0 5,200 14.3 -- -- -- -- 
2002 5,219 8.0 5,219 14.3 -- -- -- -- 
2003 5,221 8.0 5,221 14.3 -- -- -- -- 
2004 5,216 8.0 5,216 14.3 -- -- -- -- 
2005 5,240 8.0 5,240 14.4 -- -- -- -- 
2006 5,533 8.5 -- -- 5,533 19.3 671 8.6 
2007 5,712 8.8 -- -- 5,712 19.9 866 11.2 
2008 5,851 9.0 -- -- 5,851 20.4 1,556 20.0 
2009 5,871 9.0 -- -- 5,871 20.4 2,140 27.6 
2010 5,766 8.8 -- -- 5,766 20.1 2,536 32.6 
Tumour type 65210 100 36,477 100 28733 100 7769 100 
Adenocarcinoma 9,463 14.5 5,001 13.7 4,462 15.5 1473 19.0 
squamous 13,831 21.2 8,602 23.6 5,229 18.2 1850 23.8 
Large-cell 2,140 3.3 1,372 3.8 768 2.7 169 2.2 
non-small cell 8,661 13.3 3,997 11.0 4,664 16.2 1624 20.9 
Small cell 8,599 13.2 5,104 14.0 3,495 12.2 582 7.5 
Other specified 2,511 3.9 1,356 3.7 1,155 4.0 298 3.8 
Unspecified carcinoma 4,615 7.1 4,095 11.2 520 1.8 93 1.2 
neoplasm 15,390 23.6 6,950 19.1 8,440 29.4 1680 21.6 
Alternative histology 65210 100 36,477 100 28733 100 7769 100 
Probable NSCLC 36,606 56.1 20,328 55.7 16,278 56.7 5,414 69.7 
SCLC  8,599 13.2 5,104 14.0 3,495 12.2 582 7.5 
Unspecified/neoplasm 20,005 30.7 11,045 30.3 8,960 31.2 1,773 22.8 
Note: stage and performance status data only available for patients diagnosed between 2006 and 2010 
 
Table 9.1b. Comparison of variable distribution in the datasets 
Variables 2006-10 cohort v 1999-2005 cohort Staged subset v non-staged  
2006-10 cohort 
 χ
2
 P χ
2
 P 
SEP 54.16 <0.001 0.86 0.930 
Age 328.21 <0.001 62.65 <0.001 
Sex 97.78 <0.001 0.44 0.511 
Histology 48.73 <0.001 765.53 <0.001 
CCM 244.22 <0.001 39.02 <0.001 
Surgery 3.53 0.06 92.99 <0.001 
Chemotherapy  567.80 <0.001 192.96 <0.001 
Radiotherapy 8.76 0.003 175.30 <0.001 
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Rates of treatment were higher in the 2006-2010 sub-group that had stage recorded, 
compared to the 2006-2010 cohort. However, the population distribution by SEP and 
sex was similar. The age distribution amongst the cohorts was significantly different 
[table 9.1b]. A higher percentage of patients were diagnosed at an older age in 2006-
2010 [25.1% were aged 80+] compared to the earlier years cohort [19.6% were 
diagnosed at age 80+ in 1999-2005]. However in the cohort with stage recorded higher 
percentages of younger patients were found [table 9.1].  
The sub-population with stage had a much higher percentage of patients diagnosed 
with NSCLC [65.9% compared to 52.6% in the full 2006-10 cohort]. This is not 
surprising as staging is not generally carried out for SCLC. 
In my systematic review of published research [chapter 7], rates of surgery in UK 
studies ranged from 4.8% to 13.0% [table 7.5]. Higher rates were found in NSCLC only 
studies [8.9 to 19.1%]. Chemotherapy rates [any histology] ranged from 15.5 to 23.8% 
and radiotherapy rates from 20.3 to 63.1%. Any type of treatment rates ranged from 
56.3 to 59.6 [table 7.11]. The results from this dataset fall within these ranges for 
surgery [9.6% in 1999-2005, 10.1% in 2006-2010], chemotherapy [21.0% in 1999-2005, 
29.1% in 2006-2010] and radiotherapy [34.6% on 1999-2005 and 33.5% in 2006-2010] 
[table 9.1]. 
9.3.2 Time trends 
Looking at distribution by SEP over time, in 1999 8.5% of patients were in the highest 
SEP group and 38.7% in the lowest, in 2006 this was 11.2% and 33.5% respectively, and 
in 2010 this had changed to 12.0% and 32.2% respectively. When looking at the full 
1999-2010 dataset these differences were significant [χ2=225.53, p<0.001] with a 
higher percentage of people in a higher social class in later years. However, when 
looking at only the 2006-10 subset there were no significant differences in SEP 
distribution over this timescale [χ2 =20.15, p=0.21]. 
Rates of surgery have increased slightly in recent years but there has been a near 
doubling of rates of chemotherapy from 1999 [15.2%] to 2010 [29.9%] [table 9.2]. 
Radiotherapy rates have fallen slightly over time but overall treatment rates have 
changed little, with rates consistently between 52- 55%. 
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Table 9.2. Rates of treatment over time 
Year Surgery Chemotherapy Radiotherapy Total 
 N % N % N % N 
1999 494 9.6 784 15.2 2,059 40.0 5,154 
2000 508 9.7 937 17.9 2,013 38.5 5,227 
2001 489 9.4 923 17.8 1,881 36.2 5,200 
2002 513 9.8 1,048 20.1 1,730 33.2 5,219 
2003 505 9.7 1,170 22.4 1,639 31.4 5,221 
2004 480 9.2 1,291 24.8 1,615 31.0 5,216 
2005 524 10.0 1,495 28.5 1,665 31.8 5,240 
2006 505 9.1 1,506 27.2 1,857 33.6 5,533 
2007 547 9.6 1,667 29.2 1,865 32.7 5,712 
2008 502 8.6 1,681 28.7 1,865 31.9 5,851 
2009 682 11.6 1,773 30.2 2,060 35.1 5,871 
2010 658 11.4 1,721 29.9 1,964 34.1 5,766 
Total 6,407 9.8 15,996 24.5 22,213 34.1 65,210 
 
9.3.3 SEP and patient and tumour characteristics  
Table 9.3 shows the percentage of patients in each SEP group by stage at diagnosis, 
age at diagnosis, tumour type, PS, and CCM score, as well as the percentage who were 
recorded as DCO, for the 1999-2005 and 2006-2010 cohorts. 
There was a significant association between IMD quintile and being DCO [χ2 =26.89, 
p<0.001] in the 1999-2005 cohort, with 1.6% of those in the highest SEP group 
reported as DCO compared to 3.1% in the lowest. This was not found in the 2006-10 
dataset however, where 2.1% of high and low SEP patients were DCO [χ2 = 6.88, 
p=0.14] [table 9.3]. 
IMD quintile was significantly associated with age at diagnosis in both cohorts where 
those in the most deprived quintile had a younger age at diagnosis [χ2 = 116.19, 
p<0.001] in 2006-2010, with 11.4% of those in the most affluent SEP quintile diagnosed 
at <60 years old compared to 14.2% in the lowest SEP quintile. Similar results were 
found in 1999-2005 [13.9% compared to 15.3%, χ2=149.27, p<0.001] [table 9.3]. 
For the 7769 patients diagnosed in 2006-2010 who had stage recorded, although the 
percentage who were diagnosed with stage 1 cancer was slightly higher in the highest 
SEP group compared to the lowest [16.1% compared to 15.0%] and the percentage 
diagnosed with stage 4 cancer lower [46.6% compared to 49.3%], overall no significant 
difference in stage at diagnosis was found by SEP [χ2=4.87, p=0.96] [table 9.3]. Stage 
was not available for the 1999-2005 cohort. 
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Table 9.3. Percentage of patients in each SEP quintile (1=least deprived, 5=most deprived), by age at diagnosis, stage at diagnosis, tumour type, CCM score, PS, 
referral route, and percentage recorded as death-certificate only (DCO) 
 SEP quintile: 1999-2005 SEP quintile: 2006-2010 
Variables: 1 2 3 4 5 1 2 3 4 5 
DCO           
DCO=yes 1.6 2.5 2.8 2.8 3.1 2.1 2.2 2.0 2.6 2.1 
Age at diagnosis           
<60 13.9 13.9 14.2 13.3 15.3 11.4 11.4 11.6 13.4 14.2 
60-69 23.8 24.7 24.8 25.9 28.2 25.8 25.4 25.5 25.8 28.0 
70-79 39.8 39.5 39.8 40.9 39.7 34.8 36.1 35.5 35.8 35.7 
80+ 22.6 21.9 21.1 20.0 16.8 28.0 27.3 27.4 25.0 22.0 
Stage           
I -- -- -- -- -- 16.1 15.9 15.1 14.9 15.0 
II -- -- -- -- -- 7.2 7.2 7.8 7.2 6.7 
III -- -- -- -- -- 30.1 28.2 29.9 29.4 29.0 
IV -- -- -- -- -- 46.6 48.8 47.2 48.6 49.3 
Tumour type           
Adenocarcinoma 16.3 15.5 14.0 13.5 12.2 19.3 17.2 15.6 14.5 14.2 
squamous 19.9 22.6 23.3 23.5 25.2 15.8 17.2 17.6 17.9 20.0 
Large-cell 4.7 4.0 3.8 3.7 3.4 2.9 3.1 2.3 2.9 2.4 
non-small cell 12.2 11.4 10.4 10.6 10.9 16.8 15.9 16.2 16.9 15.8 
Small cell 12.9 13.3 13.2 14.1 14.9 11.8 12.1 12.8 12.3 12.0 
Other specified 5.1 4.0 3.8 3.6 3.2 5.0 4.7 3.9 4.0 3.5 
Unspecified carcinoma 10.2 10.7 12.0 11.6 11.1 2.1 1.6 1.6 2.0 1.7 
neoplasm 18.6 18.5 19.4 19.5 19.0 26.4 28.2 30.0 29.5 30.5 
Co-morbidity score           
0 61.9 60.2 59.5 56.2 55.6 54.5 52.3 50.1 44.8 43.3 
1-2 32.6 33.5 33.9 36.6 37.6 36.7 37.0 40.4 42.9 45.0 
3+ 5.6 6.3 6.7 7.2 6.9 8.9 10.7 9.6 12.3 11.6 
Perf Status           
0 -- -- -- -- -- 26.3 25.9 20.9 19.0 17.7 
1-2 -- -- -- -- -- 53.0 52.8 54.2 55.9 55.7 
3+ -- -- -- -- -- 20.6 21.4 24.9 25.1 26.6 
GP referral            
GP ref date = yes 47.2 47.3 46.7 45.7 44.3 53.6 51.5 53.8 54.7 54.2 
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SEP was associated with histological subtype [tumour]. 16.3% of those in the highest 
SEP group were diagnosed with adenocarcinoma and 19.9% with squamous cell, 
whereas in the lowest SEP group 12.2% had adenocarcinoma and 25.2% squamous cell 
in the 1999-2005 cohort [χ2=173.74, p<0.001]. Similarly, in the 2006-2010 dataset 
19.3% in the highest SEP group were diagnosed with adenocarcinoma and 15.8% 
squamous cell whereas in the lowest SEP group 14.2% have adenocarcinoma and 
20.0% squamous cell [χ2=145.71, p<0.001] [table 9.3].   
There was also an association between tumour type and receipt of surgery. In those 
diagnosed with an adenocarcinoma 22.7% received surgery, compared to 12.6% with 
large cell, and 17.6% with squamous cell tumours [table 9.4].  However, the highest 
rates of surgery were found in the ‘other-specified carcinomas’ group which 
encompassed the 3.9% of the dataset that had 54 different tumour types specified.  
Table 9.4. Tumour type and receipt of treatment (1999-2010) 
 Surgery Chemotherapy Radiotherapy Total 
 N % N % N %  
Adenocarcinoma 2,148 22.7 2,708 28.6 3,154 33.3 9,463 
Squamous 2,437 17.6 3,047 22.0 6,706 48.5 13,831 
Large 270 12.6 539 25.2 948 44.3 2,140 
Non-small 390 4.5 2,654 30.6 4,175 48.2 8,661 
Small 117 1.4 5,783 67.3 3,387 39.4 8,599 
Other specified 956 38.1 726 28.9 574 22.9 2,511 
Unspecified 
carcinoma 67 1.5 271 5.9 1,261 27.3 4,615 
Neoplasm 22 0.1 268 1.7 2,008 13.1 15,390 
Total 6,407 9.8 15,996 24.5 22,213 34.1 65,210 
 
Of the 8885 patients diagnosed in 2006-2010 who had PS recorded, 26.6% in the 
lowest SEP group had poor performance status [PS 3-4] compared to 20.6% in the 
highest SEP group, whereas 26.3% in the highest SEP group had good PS [PS=0] 
compared to 17.7% in the lowest group [table 9.3]. These differences were statistically 
significant [χ2= 69.02, p<0.001].  
Of the 8475 patients who had a CCM score recorded in 2006-2010, 11.6% in the lowest 
SEP group had three or more co-morbidities recorded compared to 8.9% in the highest 
SEP group, whereas 54.4% in the highest SEP group had 0 co-morbidities recorded 
compared to 43.3% in the lowest SEP group [table 9.3]. These differences were 
statistically significant (χ2=63.44, p<0.001). Similar results were seen for the 10,511 
patients who had a CCM score recorded in 1999-2005 [χ2=23.73, p=0.003]. 
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SEP was significantly associated with having a GP referral date [χ2=20.62, p<0.001 for 
1999-2005 cohort and χ2=11.998, p=0.02 for 2006-2010 cohort] although contrasting 
patterns of results were seen in the two cohorts. In 1999-2005 those in the lowest SEP 
group had lower rates of GP referral date recorded compared to those in the highest 
but for 2006-2010, in contrast to what might have been expected, those in the lowest 
SEP group had a higher rate of GP referral date recorded than those in the highest SEP 
group. 
9.3.4 Stage, PS and co-morbidity 
In the 2006-2010 dataset 7126 patients had stage and PS recorded. A significant 
association between stage and PS was found [χ2 = 436.95, p<0.001] with high levels of 
good PS in those with early stage cancer compared to late stage lung cancer [table 
9.5].  
Only 2078 patients had both stage and co-morbidity score recorded. A slightly higher 
rate of recorded co-morbidity was found in those who had early stage cancer [of those 
with stage 1 cancer 56.8% had co-morbidity compared with 49.4% for those with stage 
4 cancer] but no significant association between stage and co-morbidity was found [χ2 
= 10.17, p=0.12] [table 9.5].  
Table 9.5. Percentage rates of PS and co-morbidity by stage 
% PS (n=7126) Co-morbidity Score (n=2078) 
Stage 0 1-2 3-4 0 1-2 3+ 
1 35.9 51.0 13.1 43.2 43.7 13.1 
2 29.0 54.5 16.5 41.8 48.4 9.8 
3 22.7 59.0 18.3 48.3 40.7 11.0 
4 14.1 52.4 33.5 50.5 39.4 10.0 
 
Both co-morbidity and PS can be used as surrogate measures of suitability for lung 
cancer treatment. The number of co-morbidities was significantly associated with PS 
score, where those with good PS had lower rates of high co-morbidity [χ2 =78.53, 
p<0.001]. Only 2434 patients had both a PS and CCM score recorded and 63.0% of 
those who had a PS score of 0 [good health] also had no co-morbidities, 31.5% had 1-2 
co-morbidities and 5.5% had 3+ co-morbidities. However, 36.3% of those with a PS 
score of 3-4 [poor health] also had no co-morbidities recorded [table 9.6].  
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Table 9.6. Percentage rates for number of co-morbidities by performance status score 
% Co-morbidity Score 
Performance Status 0 1-2 3+ 
0 (good PS) 63.0 31.5 5.5 
1-2 48.6 41.1 10.4 
3-4 (poor PS) 36.3 48.6 15.2 
 
9.4 Discussion 
As these are descriptive results only, a general discussion is presented here. 
Implications for policy and practice and further research will be discussed in the next 
four chapters when the multivariable results are presented. 
When the demographic and clinical characteristics of the patients in the different 
cohorts were compared, differences were found. The 2006-2010 cohort was 
significantly different from the 1999-2005 cohort on all variables examined except for 
sex. Rates of treatment were significantly higher in the 2006-2010 sub-group that had 
stage recorded and it had a higher percentage of younger patients and NSCLC patients, 
compared to the full 2006-2010 cohort. The population distribution by SEP and sex was 
not significantly different however. The staged cohort does therefore appear to be 
younger and more likely to undergo treatment. 
Over a third of the northern lung cancer population were in the most deprived SEP 
quintile. National deprivation quintiles are used by cancer registries so that, across 
England, the definition of most and least deprived is consistent (244). Quintiles are 
based on population so that each quintile has an equal number of residents. This does 
mean that, in areas with deprivation higher than the national average [such as NYCRIS] 
there may be low numbers of people within the population in the least deprived 
quintiles. This could be considered a limitation when using regional data. 
Unfortunately the population data for each quintile was not available, to examine any 
skew in population distribution in regional compared to national data. However as 
there were data for over 65,000 patients available, the numbers in all quintiles were 
large.  
In order to determine patient delay [time between onset of symptoms and initial 
presentation to GP], data should ideally be obtained from patients or from GP records. 
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Patient records were not available for this study and as a date is not recorded in the 
Registry dataset for the onset of symptoms it was not possible to look at patient delay 
by SEP unless a proxy measure such as stage of disease at presentation or mode of 
presentation [elective/emergency] was employed. Death within one year of diagnosis 
can be used as a proxy measure of patient delay for some cancers but would not be 
suitable for lung cancer which has short expected survival. 
Mode of presentation was requested but was not available from NYCRIS [due to 
problems with its calculation] but stage at diagnosis was available, as was the number 
of patients recorded as DCO. It has previously been suggested that DCO registrations 
are more common in deprived communities (143) but a study using NYCRIS data did 
not find this, using breast and colorectal cancer data (247). In this study a socio-
economic gradient in DCO cases by SEP was found in the 1999-2005 cohort, with DCO 
rates nearly double in the most deprived quintile compared to the least deprived. 
However this was not found in the 2006-2010 cohort.   
Socio-economic inequalities in stage at diagnosis have been noted for some cancers 
which might suggest that there are differences in timeliness of patient presentation by 
SEP (66), where stage is used as a marker of late presentation and thus as a proxy 
measure of patient delay. However, previous studies examining socio-economic 
inequalities in stage at diagnosis for lung cancer did not find any significant differences 
by SEP (66, 68) suggesting that timeliness of patient presentation to the GP with lung 
cancer does not differ by SEP. We also found no evidence of socio-economic 
inequalities in stage at diagnosis. Results using DCO as a proxy measure of patient 
delay suggest that there were inequalities in time to patient presentation in the early 
years but unfortunately stage at diagnosis was not available for the 1999-2005 cohort 
to confirm this.  However, using both stage at diagnosis and DCO, no evidence for 
inequalities in delay in patient presentation by SEP was found for the 2006-2010 
cohort, although these were univariable analyses.  
A non-significantly higher rate of co-morbidity was found in those who had early stage 
compared to late stage cancer. Other studies have found that patients with severe co-
morbidity were likely to have early-stage lung cancer (157), suggesting that those who 
suffer from a number of different medical conditions may have greater contact with 
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health professionals and so are more likely to have their cancer detected at an earlier 
stage.  
A significant association between stage and PS was found but none was found 
between stage and CCM score. Although co-morbidity and PS measure different things 
[number of concurrent health conditions and general health status respectively], both 
can be used as surrogate measures of suitability for lung cancer treatment. Those with 
good PS were less likely to have severe co-morbidity [65.7% of those who had a PS 
score of 0 had 0 co-morbidities]. However 41.9% of those with a PS score of 3-4 [poor 
health] also had 0 co-morbidities recorded. There is therefore an association between 
the two measures but, as can be seen here, a large percentage of those who have poor 
health do not have any co-morbidities recorded. 
Descriptive statistics for the univariable associations between SEP and receipt of 
treatment, time to referral, diagnosis and treatment, and survival are described in 
chapters 10-12.  
9.5 Chapter summary 
Associations between SEP and a number of variables of interest were examined. SEP 
was univariably associated with age at diagnosis, tumour type, PS, CCM score and GP 
referral, but not with stage at diagnosis. An association between tumour type and 
receipt of treatment was also found. 
The demographic and clinical characteristics of the patients in the entire dataset and in 
the 1999-2005 cohort, 2006-2010 cohort, and 2006-2010 cohort with stage recorded, 
were examined and compared. Significant differences were found between cohorts. 
The implications of these differences on the representativeness of the cohorts and any 
subsequent differences in outcome observed between cohorts will be considered in 
more detail in the following chapters.  
Chapter 10 now goes on to examine socio-economic inequalities in lung cancer 
treatment.  
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Chapter 10. Socio-economic inequalities in receipt of lung cancer 
treatment 
Summary 
Background 
Socio-economic inequalities in receipt of lung cancer treatment have been 
demonstrated in my systematic review and meta-analysis, in both universal [UHCS] 
and non-universal healthcare systems. These findings could not be explained by type 
of healthcare system or stage at diagnosis. However, not all of the included studies 
reported details of stage and histology, both of which influence treatment type, and 
very few UHCS studies took co-morbidity or performance status into account. The 
review recommended that the reasons for socio-economic inequalities in treatment 
should be more thoroughly investigated.  
Cancer registry [NYCRIS], Hospital Episode Statistics [HES] and lung cancer audit 
[LUCADA] data-sets from the North of England were linked in order to examine the 
influence of stage, histology, performance status and co-morbidity on socio-economic 
inequalities in lung cancer treatment. 
Methods 
Multivariable logistic regression was used to examine the likelihood of receipt of 
surgery, chemotherapy and radiotherapy by socio-economic position [SEP] in patients 
diagnosed between 1999-2005 [n=36,477] of whom 32,974 had a linked HES record, 
and in patients diagnosed between 2006-2010 [n=28,733], and in a subset of whom 
had stage [n=7769] and PS recorded in LUCADA.  
Results (for 2006-2010 cohort) 
Socio-economic inequalities in receipt of surgery and chemotherapy, but not 
radiotherapy, were found after control for age, sex, histology, PS and co-morbidity. 
The odds of receiving surgery were significantly lower in the lowest compared to the 
highest SEP group in the full cohort [OR=0.75, CI 0.65 to 0.86, p<0.001]. Inequalities in 
receipt of surgery were substantially attenuated by adjustment for tumour type 
[OR=0.83, CI 0.71 to 0.96, p=0.01].  
135 
 
Patients in the lowest SEP group were significantly less likely to receive chemotherapy 
in the full cohort [OR= 0.60, CI 0.54 to 0.67, p<0.001], but not in the stage-subset when 
PS was included in the model [OR= 0.84, CI 0.68 to 1.02, p=0.08].  
Conclusions 
Socio-economic inequalities in performance status statistically explain socio-economic 
inequalities in receipt of chemotherapy in the selective subset of patients whose 
cancer was staged but not in the full cohort. 
Socio-economic inequalities in receipt of surgery cannot be statistically explained by 
inequalities in stage, PS or co-morbidity. However, socio-economic inequalities in 
tumour type account for some of the inequalities in surgery by SEP. Patients in lower 
SEP groups are more likely to be diagnosed with squamous cell cancer [a tumour type 
strongly associated with smoking] and are less likely to receive surgery than patients in 
higher SEP groups, who are more likely to be diagnosed with adenocarcinoma. 
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10.1 Introduction 
Socio-economic inequalities in receipt of lung cancer treatment were demonstrated in 
my systematic review and meta-analysis (236), in both universal [UHCS] and non-
universal healthcare systems [chapter 6]. These findings could not be explained by the 
type of healthcare system or by socio-economic inequalities in stage at diagnosis. 
However, not all of the included UK studies reported details of stage and histology, 
both of which influence treatment type (236), and very few UHCS studies took co-
morbidity into account. Performance status [PS], a measure of patient well-being, is 
also a factor that has not been previously well explored. The systematic review 
recommended that the reasons for socio-economic inequalities in treatment should be 
more thoroughly investigated in better quality UHCS studies, including statistical 
control for co-morbidity, stage and histology (236).  
Although co-morbidity and PS measure different things [the number of concurrent 
health conditions and general health status respectively] both variables may be used 
as surrogate measures of suitability for lung cancer treatment when patients are 
assessed. It is unclear how well co-morbidity and PS capture this ‘fitness for treatment’ 
concept but, as the number of co-morbidities and PS vary by SEP, this may help explain 
why inequalities are found. I also wanted to explore whether differences in rates of 
histological subtype by SEP might be important as, in the descriptive analyses [chapter 
9], SEP was associated with tumour type, and different rates of treatment were also 
found by tumour type. 
Cancer registry, Hospital Episode Statistics [HES] and lung cancer audit [LUCADA] data-
sets were linked in order to examine the role that socio-economic inequalities in stage, 
histological subtype, PS and co-morbidity might play in contributing to socio-economic 
inequalities in lung cancer treatment in the North-East of England.  
10.2 Methods 
10.2.1 Data 
For details of data sources and variables see chapter 8, sections 8.2 and 8.4. 
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10.2.2 Regression analyses 
Multivariable logistic regression was used to examine the likelihood of receipt of 
surgery, chemotherapy and radiotherapy by SEP, in the 1999-2005 and 2006-2010 
cohorts. The analyses were conducted as follows: in the 1999-2005 dataset controlling 
for age, sex, histology [or histological subtype], co-morbidity, year of diagnosis and GP 
referral; in the 2006-2010 dataset and, within this, on the subgroup that had stage 
recorded [n=7769], controlling for age, sex, histology [or histological subtype], year of 
diagnosis, GP referral, PS and stage, and including and excluding co-morbidity. 
Interaction between SEP and histology was also explored. The R2 statistic was 
examined to determine the amount of variance in receipt of treatment explained by 
each model. Odds ratios [ORs] with 95% confidence intervals [CIs] for the likelihood of 
receipt of treatment in the lower SEP groups compared to the highest SEP group were 
reported. A likelihood ratio test was performed to determine the overall significance of 
each categorical variable.  
Cancer type [histology] was classified as confirmed non-small cell lung cancer [NSCLC], 
SCLC and other histology as previously described. Sub group analyses including only 
morphologically-specified lung cancers were also carried out. The ‘unspecified 
carcinoma/neoplasm’ subtypes were excluded and the ‘other specified carcinoma’ 
subtype was included as probable NSCLC. Receipt of surgery was examined for 
probable NSCLC-only patients. Receipt of chemotherapy and radiotherapy were 
examined separately in probable NSCLC and SCLC populations.  
10.3 Results 
Table 9.1 shows the demographic and clinical characteristics of the lung cancer 
patients included in the study. 
10.3.1 Surgery 
Socio-economic inequalities in receipt of surgery were found. When age, sex, histology 
or tumour type, year of diagnosis, co-morbidity, performance status, stage and GP 
referral were taken into account, socio-economic inequalities in receipt of treatment 
remained.  
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10.3.1.1 1999-2005 
The rate of surgery in the highest SEP group was 11.7% compared to 8.5% in the 
lowest SEP group, with a univariable OR for receipt of surgery of 0.70, 95% CI 0.62 to 
0.78, p<0.001 in the lowest compared to the highest. 
The odds of surgery were significantly lower in the lowest compared to the highest SEP 
group [OR=0.64, 95% CI 0.57 to 0.73, p<0.001] in a multivariable analysis including age, 
sex, histology, co-morbidity and GP referral [table 10.1]. When histology was further 
broken down into tumour type then the SEP OR was attenuated [OR=0.70, 95% CI 0.61 
to 0.79, p<0.001] and the treatment variance explained by the model greatly improved 
[from R2=13.33 to 22.91] [table 10.1].  
10.3.1.2 2006-2010  
The rate of surgery in the highest SEP group was 11.8% compared to 9.5% in the 
lowest SEP group, with a univariable OR for receipt of surgery of 0.78 [95% CI 0.69 to 
0.89, p<0.001] in the lowest compared to the highest.  
The odds of surgery were significantly lower in the lowest compared to the highest SEP 
group in the multivariable analysis when stage and PS [but not CCM] were included 
[OR=0.75, 95% CI 0.65 to 0.86, p<0.001] [table 10.2]. The addition of co-morbidity to 
the model made no substantial change to this OR. Significant interaction between SEP 
and histology was found. Similarly to the 1999-2005 cohort, when histology was 
further broken down into tumour type then the SEP OR was attenuated [OR=0.83, 95% 
CI 0.71 to 0.96, p=0.0013] and the treatment variance explained by the model greatly 
improved [from R2=24.04 to 35.17].  
Older patients were significantly less likely to receive surgery [OR=0.14, 95% CI 0.12 to 
0.17, p<0.001], for those aged 80+, and [OR =0.65, 95% CI 0.57 to 0.73, p<0.001 for 
those aged 70-79], compared to the youngest group [aged <60] in a multivariable 
model, but when histology was further broken down into tumour type then the OR 
was attenuated [to OR=0.22, 95% CI 0.18 to 0.27, p<0.001, and OR=0.79, 95% CI 0.70 
to 0.91, p=0.001, respectively] [table 10.2]. 56% of those aged 80+ had their tumour 
type recorded as a neoplasm compared to 8% in the youngest age group. Those with 
late stage cancer and those with poor performance status were also significantly less 
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likely to receive surgery. However, even when taking all these factors into account, age 
and socio-economic inequalities in receipt of surgery were still found. 
10.3.1.2.1 2006-2010: subgroup with stage 
In the subgroup that had stage recorded [n=7769], although overall 12.9% of these 
patients received surgery, 51.2% of stage I patients received surgery, with 35.3% in 
stage II, so that receipt of surgery was highly dependent on stage. The odds of 
receiving treatment in the lowest SEP group compared to the highest were significantly 
lower in the univariable [OR=0.67, 95% CI 0.54 to 0.82, p=0.001] and adjusted analysis 
[OR=0.60, 95% CI 0.45 to 0.81, p=0.001] [table 10.3].  
10.3.1.2.2 2006-2010: probable NSCLC only 
When looking at receipt of surgery for those with probable NSCLC only [n=16,278] 
socio-economic inequalities in receipt of treatment were found in the multivariable 
analysis [OR=0.84, 95% CI 0.72 to 0.98, p=0.025], in the lowest compared to the 
highest SEP group [table 10.4]. 
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Table 10.1. OR of receipt of lung cancer surgery, by selected patient, tumour and system 
factors for those diagnosed between 1999 and 2005 (DCO cases excluded)  
Variable Receipt of Surgery Adjusted – selected
1
   
(n=36,477, R
2
=13.33) 
Adjusted – selected
2 
(n=36,477, R
2
=22.91) 
 N % OR  (95% CI) P OR  (95% CI) P 
Deprivation quintile 3,513 9.6    <0.001    <0.001 
1 (least deprived) 452 11.7 1.00    1.00    
2 565 11.1 0.92 0.80 1.06 0.25 0.95 0.83 1.10 0.53 
3 592 9.9 0.81 0.71 0.93 0.002 0.85 0.73 0.97 0.02 
4 794 9.4 0.77 0.67 0.87 <0.001 0.81 0.71 0.93 <0.001 
5 (most deprived) 1,110 8.5 0.64 0.57 0.73 <0.001 0.70 0.61 0.79 <0.001 
Sex 3,513 9.6    0.009    0.05 
Female 1,459 9.5 1.00    1.00    
Male 2,054 9.8 0.91 0.84 0.98 0.009 0.92 0.85 1.00 0.05 
Age group 3,513 9.6    <0.001    <0.001 
<60 852 16.3 1.00    1.00    
60-69 1,296 13.6 0.82 0.75 0.91 <0.001 0.91 0.82 1.00 0.06 
70-79 1,248 8.6 0.50 0.45 0.55 <0.001 0.60 0.54 0.66 <0.001 
80+ 117 1.6 0.10 0.08 0.13 <0.001 0.15 0.12 0.18 <0.001 
Histology 3,513 9.6    <0.001     
NSCLC 2,897 15.3 1.00        
SCLC 63 1.2 0.06 0.05 0.08 <0.001     
Other 553 4.5 0.38 0.35 0.42 <0.001     
Co-morbidity score 3,513 9.6    <0.001    <0.001 
0 740 12.2 1.00    1.00    
1-2 318 8.5 0.75 0.65 0.86 <0.001 0.82 0.70 0.95 0.01 
3+ 58 8.2 0.79 0.59 1.05 0.11 0.92 0.68 1.24 0.57 
CCM missing 2,351 10.5 0.73 0.67 0.80 <0.001 0.78 0.71 0.86 <0.001 
No HES link 46 1.3 0.13 0.10 0.18 <0.001 0.18 0.13 0.24 <0.001 
Year of Diagnosis 3,513 9.6    0.46    0.07 
1999 494 9.6 1.00    1.00    
2000 508 9.7 1.04 0.90 1.19 0.61 1.07 0.93 1.23 0.33 
2001 489 9.4 0.95 0.83 1.09 0.45 1.10 0.95 1.26 0.21 
2002 513 9.8 0.96 0.84 1.10 0.57 1.14 0.99 1.32 0.06 
2003 505 9.7 0.95 0.83 1.09 0.46 1.16 1.01 1.34 0.04 
2004 480 9.2 0.89 0.77 1.02 0.09 1.06 0.92 1.23 0.39 
2005 524 10.0 0.97 0.84 1.11 0.63 1.25 1.08 1.43 0.002 
GP referral  3,513 9.6    <0.001    <0.001 
No 1,560 7.9 1.00    1.00    
Yes 1,953 11.7 1.29 1.20 1.39 <0.001 1.20 1.11 1.30 <0.001 
Histological sub-type 3,513 9.6        <0.001 
Adenocarcinoma 1,150 23.0     1.00    
squamous 1,426 16.6     0.73 0.66 0.80 <0.001 
Large-cell 146 10.6     0.41 0.34 0.49 <0.001 
non-small cell 175 4.4     0.15 0.13 0.18 <0.001 
Other specified 486 35.8     1.81 1.59 2.07 <0.001 
Small cell 63 1.2     0.04 0.03 0.05 <0.001 
Unspecified carcinoma 53 1.3     0.06 0.05 0.08 <0.001 
Neoplasm 14 0.2     0.01 0.01 0.02 <0.001 
1
 Mutually adjusted for SEP, sex, age, histology, co-morbidity score, year of diagnosis and GP referral 
2 Mutually adjusted for SEP, sex, age, co-morbidity score, year of diagnosis, GP referral and histological subtype 
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Table 10.2. OR of receipt of lung cancer surgery, by selected patient, tumour and system 
factors (DCO cases excluded) for 2006-2010 cohort 
Variable Receipt of surgery 
(2894/28733) 
Adjusted – selected
1 
(n=28,733, R
2
=24.04) 
Adjusted – selected
2 
(n=28,733, R
2
=35.17) 
 N % OR  (95% CI) P OR  (95% CI) P 
Deprivation quintile 2,894 10.1    <0.001    0.01 
1 (least deprived) 400 11.8 1.00    1.00    
2 458 11.0 0.92 0.78 1.08 0.32 0.92 0.77 1.09 0.33 
3 512 10.6 0.91 0.78 1.07 0.26 0.97 0.82 1.15 0.75 
4 613 9.1 0.75 0.65 0.87 <0.001 0.81 0.69 0.95 0.009 
5 (most deprived) 911 9.5 0.75 0.65 0.86 <0.001 0.83 0.71 0.96 0.013 
Sex 2,894 10.1    <0.001    <0.001 
Female 1,405 10.6 1.00    1.00    
Male 1,489 9.6 0.80 0.73 0.87 <0.001 0.78 0.71 0.86 <0.001 
Age group 2,894 10.1    <0.001    <0.001 
<60 560 15.2 1.00    1.00    
60-69 1,118 14.7 0.96 0.85 1.08 0.50 1.05 0.92 1.19 0.47 
70-79 1,048 10.2 0.65 0.57 0.73 <0.001 0.79 0.70 0.91 0.001 
80+ 168 2.3 0.14 0.12 0.17 <0.001 0.22 0.18 0.27 <0.001 
Histology 2,894 10.1    <0.001     
NSCLC 2,348 15.5 1.00        
SCLC 54 1.6 0.08 0.06 0.11 <0.001     
Other  492 4.9 0.43 0.38 0.48 <0.001     
Year of Diagnosis 2,894 10.1    <0.001    <0.001 
2006 505 9.1 1.00    1.00    
2007 547 9.6 1.04 0.91 1.19 0.58 1.10 0.95 1.27 0.19 
2008 502 8.6 0.95 0.82 1.09 0.47 0.96 0.82 1.11 0.58 
2009 682 11.6 1.33 1.16 1.52 <0.001 1.33 1.15 1.53 <0.001 
2010 658 11.4 1.38 1.20 1.59 <0.001 1.25 1.08 1.45 0.003 
Stage 2,894 10.1    <0.001    <0.001 
I 607 51.2 1.00    1.00    
II 195 35.3 0.41 0.32 0.53 <0.001 0.43 0.33 0.56 <0.001 
III 144 6.3 0.04 0.03 0.05 <0.001 0.04 0.03 0.06 <0.001 
IV 55 1.5 0.01 0.01 0.02 <0.001 0.01 0.01 0.02 <0.001 
Missing 1,893 9.0 0.12 0.10 0.14 <0.001 0.11 0.09 0.14 <0.001 
Performance Status 2,894 10.1    <0.001    <0.001 
0 583 31.7 1.00    1.00    
1-2 480 9.9 0.30 0.25 0.36 <0.001 0.33 0.28 0.40 <0.001 
3-4 15 0.7 0.03 0.02 0.05 <0.001 0.05 0.03 0.09 <0.001 
Missing/ unknown 1,816 9.2 0.34 0.28 0.41 <0.001 0.41 0.34 0.51 <0.001 
GP referral 2,894 10.1    <0.001    <0.001 
No 979 7.4 1.00    1.00    
Yes 1,915 12.4 1.37 1.25 1.50 <0.001 1.26 1.14 1.39 <0.001 
Histological subtype 2,894 10.1        <0.001 
Adenocarcinoma 998 22.4     1.00    
squamous 1,011 19.3     0.86 0.77 0.97 0.01 
Large cell  124 16.2     0.64 0.51 0.80 <0.001 
Non-small 215 4.6     0.19 0.16 0.22 <0.001 
Other specified 470 40.7     2.40 2.06 2.80 <0.001 
Small 54 1.6     0.06 0.04 0.07 <0.001 
Unspecified carcinoma 14 2.7     0.14 0.08 0.24 <0.001 
Neoplasm 8 0.1     0.01 0.00 0.01 <0.001 
1
 Mutually adjusted for SEP, sex, age, histology, year of diagnosis, stage, PS and GP referral  
2 Mutually adjusted for SEP, sex, age, year of diagnosis, stage, PS, GP referral and histological subtype 
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Table 10.3. OR of receipt of lung cancer surgery, by selected patient, tumour and system 
factors (DCO cases excluded) for 2006-2010 cohort with stage recorded 
Variable Receiving surgery 
(1001/7769) 
Adjusted – selected
1 
(n=7769, R
2
=46.99) 
Adjusted – selected
2 
(n=7676, R
2
=53.61) 
 N % OR  (95% CI) P OR  (95% CI) P 
Deprivation quintile 1,001 12.9    0.0007    0.003 
1 (least deprived) 156 16.8 1.00    1.00    
2 162 14.5 0.79 0.56 1.10 0.16 0.72 0.51 1.04 0.08 
3 177 13.6 0.76 0.55 1.05 0.09 0.77 0.54 1.08 0.13 
4 199 10.9 0.54 0.40 0.74 <0.001 0.53 0.38 0.75 <0.001 
5 (most deprived) 307 11.9 0.60 0.45 0.81 0.001 0.61 0.44 0.83 0.002 
Sex 1,001 12.9    0.02    0.12 
Female 485 13.6 1.00    1.00    
Male 516 12.3 0.81 0.67 0.97 0.02 0.85 0.70 1.04 0.12 
Age group 1,001 12.9    <0.001    <0.001 
<60 179 17.2 1.00    1.00    
60-69 398 18.2 1.00 0.76 1.32 0.99 1.13 0.85 1.51 0.41 
70-79 353 12.4 0.56 0.43 0.75 <0.001 0.66 0.49 0.90 0.007 
80+ 71 4.2 0.15 0.11 0.22 <0.001 0.19 0.13 0.28 <0.001 
Histology 1,001 12.9    <0.001     
NSCLC 852 16.7 1.00        
SCLC 18 3.1 0.25 0.14 0.43 <0.001     
Other 131 6.3 0.48 0.37 0.62 <0.001     
Year of Diagnosis 1,001 12.9    <0.001    0.0001 
2006 84 12.5 1.00    1.00    
2007 116 13.4 1.14 0.77 1.69 0.52 1.09 0.71 1.66 0.70 
2008 162 10.4 1.22 0.84 1.78 0.29 1.11 0.75 1.66 0.60 
2009 311 14.5 1.97 1.39 2.78 <0.001 1.81 1.25 2.62 0.002 
2010 328 12.9 2.13 1.51 3.01 <0.001 1.74 1.20 2.52 0.003 
Stage 1,001 12.9    <0.001    <0.001 
I 607 51.2 1.00    1.00    
II 195 35.3 0.42 0.32 0.53 <0.001 0.43 0.33 0.56 <0.001 
III 144 6.3 0.04 0.03 0.05 <0.001 0.04 0.03 0.05 <0.001 
IV 55 1.5 0.01 0.01 0.01 <0.001 0.01 0.01 0.01 <0.001 
Performance Status 1,001 12.9    <0.001    <0.001 
0 498 33.4 1.00    1.00    
1-2 413 10.7 0.31 0.26 0.38 <0.001 0.36 0.29 0.45 <0.001 
3-4 12 0.7 0.03 0.02 0.06 <0.001 0.06 0.03 0.11 <0.001 
Missing/ unknown 78 12.1 0.33 0.23 0.46 <0.001 0.36 0.25 0.52 <0.001 
GP referral 1,001 12.9    0.29    0.85 
No 243 10.1 1.00    1.00    
Yes 758 14.2 1.12 0.91 1.39 0.29 1.02 0.81 1.28 0.85 
Histological subtype 1,001 12.9        <0.001 
Adenocarcinoma 372 25.3     1.00    
squamous 372 20.1     0.67 0.52 0.85 0.001 
Large cell  32 18.9     0.55 0.31 0.98 0.04 
Non-small 76 4.7     0.19 0.13 0.26 <0.001 
Other specified 130 43.6     2.12 1.44 3.12 <0.001 
Small 18 3.1     0.15 0.09 0.27 <0.001 
Unspecified carcinoma 0 0.0     --    
Neoplasm 1 0.1     0.003 0.00 0.02 <0.001 
1 
Mutually adjusted for SEP, sex, age, histology, year of diagnosis, stage, PS and GP referral  
2 Mutually adjusted for SEP, sex, age, year of diagnosis, stage, PS, GP referral and histological subtype 
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Table 10.4. OR of receipt of lung cancer surgery, by selected patient, tumour and system 
factors (DCO cases excluded) for 2006-2010 cohort with probable NSCLC 
Variable Probable 
NSCLC 
Receiving 
surgery 
Unadjusted Adjusted – selected
1 
(n=16,278, R
2
=23.74) 
 N N % OR  (95% CI) P OR  (95% CI) P 
Deprivation 
quintile 16,278 2,818 17.3    0.001    0.02 
1 (least deprived) 2,024 389 19.2 1.00    1.00    
2 2,430 451 18.6 0.96 0.82 1.11 0.58 0.93 0.78 1.11 0.43 
3 2,696 494 18.3 0.94 0.81 1.09 0.44 0.96 0.81 1.14 0.68 
4 3,768 592 15.7 0.78 0.68 0.90 0.001 0.80 0.68 0.95 0.009 
5 (most deprived) 5,360 892 16.6 0.84 0.74 0.96 0.009 0.84 0.72 0.98 0.03 
Sex 16,278 2,818 17.3    <0.001    <0.001 
Female 7060 1359 19.3 1.00    1.00    
Male 9218 1459 15.8 0.79 0.73 0.86 <0.001 0.79 0.72 0.87 <0.001 
Age group 16,278 2,818 17.3    <0.001    <0.001 
<60 2679 544 20.3 1.00    1.00    
60-69 5126 1085 21.2 1.05 0.94 1.18 0.37 1.05 0.92 1.20 0.50 
70-79 5293 1025 17.3 0.82 0.73 0.92 0.001 0.80 0.70 0.92 0.001 
80+ 2550 164 6.4 0.27 0.22 0.32 <0.001 0.22 0.18 0.27 <0.001 
Year of Diagnosis 16,278 2,818 17.3    <0.001    <0.001 
2006 3141 489 15.6 1.00    1.00    
2007 3269 530 16.2 1.05 0.92 1.20 0.48 1.10 0.95 1.27 0.21 
2008 3285 493 15.0 0.96 0.84 1.10 0.53 0.97 0.83 1.13 0.71 
2009 3358 668 19.9 1.35 1.18 1.53 <0.001 1.34 1.16 1.55 <0.001 
2010 3225 638 19.8 1.34 1.17 1.52 <0.001 1.24 1.07 1.44 0.005 
Stage 16,278 2,818 17.3    <0.001    <0.001 
I 917 595 64.9 1.00    1.00    
II 437 192 43.9 0.42 0.34 0.54 <0.001 0.44 0.33 0.58 <0.001 
III 1701 141 8.3 0.05 0.04 0.06 <0.001 0.05 0.04 0.06 <0.001 
IV 2359 54 2.3 0.01 0.01 0.02 <0.001 0.01 0.01 0.02 <0.001 
Missing 10,864 1836 16.9 0.11 0.10 0.13 <0.001 0.12 0.10 0.16 <0.001 
Performance 
Status 16,278 2,818 17.3    <0.001    <0.001 
0 1528 574 37.6 1.00    1.00    
1-2 3467 470 13.6 0.26 0.23 0.30 <0.001 0.33 0.28 0.40 <0.001 
3-4 835 13 1.6 0.03 0.02 0.05 <0.001 0.04 0.02 0.08 <0.001 
Missing/ unknown 10,448 1761 16.9 0.34 0.30 0.38 <0.001 0.39 0.32 0.48 <0.001 
GP referral 16,278 2,818 17.3    <0.001    <0.001 
No 6304 946 15.0 1.00    1.00    
Yes 9974 1872 18.8 1.31 1.20 1.43 <0.001 1.26 1.15 1.40 <0.001 
Histological sub-
type 16,278 2,818 17.3    <0.001    <0.001 
Adenocarcinoma 4462 998 22.4 1.00    1.00    
squamous 5229 1011 19.3 0.83 0.75 0.92 <0.001 0.86 0.77 0.96 0.009 
Large cell  768 124 16.2 0.67 0.54 0.82 <0.001 0.64 0.51 0.80 <0.001 
Non-small 4664 215 4.6 0.17 0.14 0.20 <0.001 0.19 0.16 0.22 <0.001 
Other specified 1155 470 40.7 2.38 2.08 2.73 <0.001 2.39 2.05 2.79 <0.001 
1
Mutually adjusted for SEP, sex, age, year of diagnosis, stage, PS, GP referral and histological subtype 
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10.3.2 Chemotherapy 
10.3.2.1 1999-2005 
In the adjusted model SEP was strongly associated with receipt of chemotherapy. 
Those in the lowest SEP group were significantly less likely to receive chemotherapy 
[OR=0.60, 95% CI 0.54 to 0.67, p<0.001] [table 10.5]. Older patients were significantly 
less likely to receive chemotherapy, as were those with co-morbidities. Rates of 
chemotherapy increased over time with 15.2% receiving chemotherapy in 1999, 
increasing to 28.5% in 2005. 
Table 10.5. OR of receipt of lung cancer chemotherapy, by selected patient, tumour and 
system factors (DCO cases excluded) for those diagnosed between 1999 and 2005 
Variable Receiving 
chemotherapy 
Unadjusted Adjusted – selected
1 
(n=36,477, R
2
=32.84) 
 N % OR  (95% CI) P OR  (95% CI) P 
Deprivation quintile 7,648 21.0    <0.001    <0.001 
1 (least deprived) 961 24.9 1.00    1.00    
2 1,108 21.8 0.84 0.76 0.93 0.001 0.75 0.67 0.85 <0.001 
3 1,196 19.9 0.75 0.68 0.83 <0.001 0.67 0.59 0.76 <0.001 
4 1,720 20.4 0.77 0.70 0.84 <0.001 0.69 0.61 0.77 <0.001 
5 (most deprived) 2,663 20.4 0.77 0.71 0.84 <0.001 0.60 0.54 0.67 <0.001 
Sex 7,648 21.0    0.001    0.39 
Female 3,356 21.8 1.00    1.00    
Male 4,292 20.4 0.92 0.87 0.97 0.001 0.97 0.91 1.04 0.39 
Age group 7,648 21.0    <0.001    <0.001 
<60 2393 45.8 1.00    1.00    
60-69 2,945 30.9 0.53 0.49 0.57 <0.001 0.48 0.44 0.52 <0.001 
70-79 2,074 14.2 0.20 0.18 0.21 <0.001 0.18 0.17 0.20 <0.001 
80+ 236 3.3 0.04 0.04 0.05 <0.001 0.04 0.04 0.05 <0.001 
Histology 7,648 21.0    <0.001    <0.001 
NSCLC 3,582 18.9 1.00    1.00    
SCLC 3,402 66.7 8.59 8.02 9.20 <0.001 12.87 11.86 13.96 <0.001 
Other 664 5.4 0.24 0.22 0.26 <0.001 0.41 0.37 0.45 <0.001 
Co-morbidity score 7,648 21.0    <0.001    <0.001 
0 1,302 21.5 1.00    1.00    
1-2 556 14.8 0.63 0.57 0.71 <0.001 0.75 0.66 0.85 <0.001 
3-4 68 9.7 0.39 0.30 0.50 <0.001 0.47 0.35 0.63 <0.001 
CCM missing 5,643 25.1 1.22 1.14 1.31 <0.001 1.06 0.97 1.15 0.21 
No HES link 79 2.3 0.08 0.07 0.11 <0.001 0.14 0.11 0.18 <0.001 
Year of Diagnosis 7,648 21.0    <0.001    <0.001 
1999 784 15.2 1.00    1.00    
2000 937 17.9 1.22 1.10 1.35 0.00 1.35 1.19 1.53 <0.001 
2001 923 17.8 1.20 1.08 1.33 0.00 1.46 1.28 1.66 <0.001 
2002 1,048 20.1 1.40 1.26 1.55 0.00 1.70 1.50 1.93 <0.001 
2003 1,170 22.4 1.61 1.46 1.78 0.00 2.20 1.95 2.49 <0.001 
2004 1,291 24.8 1.83 1.66 2.02 0.00 2.64 2.34 2.99 <0.001 
2005 1,495 28.5 2.23 2.02 2.45 0.00 3.56 3.16 4.02 <0.001 
GP referral  7,648 21.0    <0.001    <0.001 
No 3,265 16.5 1.00    1.00    
Yes 4,383 26.3 1.80 1.71 1.90 <0.001 1.86 1.74 1.98 <0.001 
1
Mutually adjusted for SEP, sex, age, histology, co-morbidity score, year of diagnosis and GP referral 
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10.3.2.2 2006-2010 
SEP was associated with receipt of treatment in the 2006-2010 subset when age, sex, 
histology, year of diagnosis, GP referral, stage and PS were included in the model 
[OR=0.60, 95% CI 0.54 to 0.67, p<0.001] [table 10.6]. 
Table 10.6. OR of receipt of lung cancer chemotherapy, by selected patient, tumour and 
system factors (DCO cases excluded) for 2006-2010 cohort 
Variable Receiving 
chemotherapy 
(8348/28733) 
Unadjusted Adjusted – selected
1 
(n=28,733, R
2
=33.01) 
 N % OR  (95% CI) P OR  (95% CI) P 
Deprivation quintile 8,348 29.1    <0.001    <0.001 
1 (least deprived) 1,133 33.4 1.00    1.00    
2 1,275 30.5 0.87 0.79 0.96 0.007 0.83 0.74 0.94 <0.001 
3 1,425 29.4 0.83 0.75 0.91 <0.001 0.78 0.69 0.88 <0.001 
4 1,898 28.3 0.79 0.72 0.86 <0.001 0.67 0.60 0.75 <0.001 
5 (most deprived) 2,617 27.2 0.75 0.69 0.81 <0.001 0.60 0.54 0.67 <0.001 
Sex 8,348 29.1    0.29    0.96 
Female 3,810 28.8 1.00    1.00    
Male 4,538 29.3 1.03 0.98 1.08 0.29 1.00 0.94 1.07 0.96 
Age group 8,348 29.1    <0.001    <0.001 
<60 2,221 60.3 1.00    1.00    
60-69 3,332 43.9 0.51 0.47 0.56 <0.001 0.51 0.46 0.55 <0.001 
70-79 2,452 23.9 0.21 0.19 0.22 <0.001 0.22 0.20 0.24 <0.001 
80+ 343 4.8 0.03 0.03 0.04 <0.001 0.04 0.04 0.05 <0.001 
Histology 8,348 29.1    <0.001    <0.001 
NSCLC 5,366 35.5 1.00    1.00    
SCLC 2,381 68.1 3.89 3.59 4.20 <0.001 5.63 5.12 6.18 <0.001 
Other 601 5.9 0.11 0.11 0.13 <0.001 0.22 0.20 0.25 <0.001 
Year of Diagnosis 8,348 29.1    0.005    0.03 
2006 1,506 27.2 1.00    1.00    
2007 1,667 29.2 1.10 1.02 1.20 0.02 1.17 1.06 1.30 <0.001 
2008 1,681 28.7 1.08 0.99 1.17 0.07 1.06 0.96 1.17 0.27 
2009 1,773 30.2 1.16 1.07 1.25 <0.001 1.11 1.00 1.23 0.05 
2010 1,721 29.9 1.14 1.05 1.23 <0.001 1.11 1.00 1.23 0.05 
Stage 8,348 29.1    <0.001    <0.001 
I 223 18.8 1.00    1.00    
II 163 29.5 1.81 1.43 2.29 <0.001 2.11 1.60 2.78 <0.001 
III 1,032 45.4 3.59 3.04 4.25 <0.001 5.45 4.46 6.67 <0.001 
IV 1,314 35.0 2.32 1.98 2.73 <0.001 4.30 3.54 5.23 <0.001 
Missing 5,616 26.8 1.58 1.36 1.83 <0.001 3.46 2.83 4.24 <0.001 
Performance Status 8,348 29.1    <0.001    <0.001 
0 1,151 62.5 1.00    1.00    
1-2 2,067 42.5 0.44 0.40 0.50 <0.001 0.46 0.40 0.53 <0.001 
3-4 113 5.2 0.03 0.03 0.04 <0.001 0.04 0.03 0.05 <0.001 
Missing/ unknown 5,017 25.3 0.20 0.18 0.22 <0.001 0.29 0.25 0.34 <0.001 
GP referral date 8,348 29.1    <0.001    <0.001 
No 2,566 19.3 1.00    1.00    
Yes 5,782 37.4 2.50 2.37 2.64 <0.001 2.17 2.03 2.32 <0.001 
1
Mutually adjusted for SEP, sex, age, histology, year of diagnosis, stage, PS and GP referral 
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10.3.2.2.1 2006-2010: subset with stage recorded 
In the subset of patients who had stage recorded, in a multivariable analysis including 
age and sex, a significant association was seen [OR=0.72, 95% CI 0.61 to 0.86, P<0.001], 
and this was also observed with the stepwise addition of other variables; histology, 
year of diagnosis, and stage, with a similar OR in the lowest compared to the highest 
SEP group, in all cases [table 10.7]. However, on the addition of performance status to 
the model the OR was attenuated and this association was no longer observed 
[OR=0.84, 95% CI 0.68 to 1.02, p=0.08] [table 10.7]. Including performance status also 
greatly increased the treatment variance explained by the model [R2=25.84 without PS, 
34.58 with]. An identical pattern was also seen in the probable NSCLC-only subset with 
stage recorded [results not shown]. Socio-economic differences in performance status 
appear to account for the observed socio-economic differences in receipt of 
chemotherapy in this staged subgroup. 
10.3.2.2.2 2006-2010: probable NSCLC and SCLC separately 
When chemotherapy was examined separately in probable NSCLC and SCLC 
populations, socio-economic inequalities in receipt of chemotherapy were found for 
NSCLC [OR=0.66, 95% CI 0.58 to 0.74, p<0.001] [table 10.8] and SCLC [OR=0.57, 95% CI 
0.42 to 0.75, p<0.001] [table 10.9]. For probable NSCLC likelihood of chemotherapy 
increased over time but this was not seen for SCLC. 
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Table 10.7. OR of receipt of lung cancer chemotherapy, by selected patient, tumour and 
system factors (DCO cases excluded) for 2006-2010 cohort with stage recorded 
Variable Receiving chemotherapy 
(2732/7769) 
Adjusted – selected
1 
(n=7769, R
2
=25.84) 
Adjusted – selected
2
 
 (n=7769, R
2
=34.58) 
 N % OR  (95% CI) P OR  (95% CI) P 
Deprivation quintile 2,732 35.2    <0.001    0.16 
1 (least deprived) 351 37.7 1.00    1.00    
2 414 37.0 0.97 0.78 1.20 0.76 0.99 0.79 1.24 0.91 
3 445 34.2 0.85 0.69 1.05 0.14 1.01 0.81 1.26 0.94 
4 638 34.8 0.78 0.64 0.94 0.01 0.90 0.73 1.11 0.32 
5 (most deprived) 884 34.1 0.68 0.56 0.82 <0.001 0.84 0.68 1.02 0.08 
Sex 2,732 35.2    0.79    0.80 
Female 1,255 35.3 1.00    1.00    
Male 1,477 35.1 0.98 0.88 1.10 0.79 0.98 0.87 1.11 0.80 
Age group 2,732 35.2    <0.001    <0.001 
<60 690 66.3 1.00    1.00    
60-69 1,103 50.4 0.48 0.40 0.56 <0.001 0.54 0.45 0.65 <0.001 
70-79 821 28.9 0.19 0.16 0.23 <0.001 0.25 0.21 0.30 <0.001 
80+ 118 7.0 0.04 0.03 0.05 <0.001 0.06 0.04 0.07 <0.001 
Histology 2,732 35.2    <0.001    <0.001 
NSCLC 2,140 41.8 1.00    1.00    
SCLC 411 70.6 4.03 3.25 4.99 <0.001 6.21 4.85 7.95 <0.001 
Other  181 8.7 0.20 0.17 0.24 <0.001 0.29 0.24 0.35 <0.001 
Year of Diagnosis 2,732 35.2    0.21    0.07 
2006 211 31.5 1.00    1.00    
2007 323 37.3 1.36 1.06 1.74 0.02 1.44 1.11 1.88 0.01 
2008 556 35.7 1.22 0.97 1.53 0.08 1.37 1.08 1.74 0.01 
2009 758 35.4 1.21 0.97 1.51 0.08 1.29 1.02 1.62 0.03 
2010 884 34.9 1.20 0.97 1.49 0.09 1.30 1.04 1.64 0.02 
GP referral 2,732 35.2    <0.001    <0.001 
No 603 24.9 1.00    1.00    
Yes 2,129 39.8 2.15 1.90 2.45 <0.001 2.01 1.75 2.30 <0.001 
Stage 2,732 35.2    <0.001    <0.001 
I 223 18.8 1.00    1.00    
II 163 29.5 1.83 1.41 2.39 <0.001 2.16 1.64 2.84 <0.001 
III 1,032 45.4 3.94 3.26 4.77 <0.001 5.58 4.55 6.84 <0.001 
IV 1,314 35.0 2.41 2.01 2.89 <0.001 4.43 3.64 5.40 <0.001 
Performance Status 2,732 35.2        <0.001 
0 933 62.5     1.00    
1-2 1,561 40.3     0.39 0.34 0.46 <0.001 
3-4 78 4.4     0.03 0.02 0.04 <0.001 
Missing 160 24.9     0.25 0.19 0.31 <0.001 
1
Mutually adjusted for SEP, sex, age, histology, year of diagnosis, GP referral and stage 
2
Mutually adjusted for SEP, sex, age, histology, year of diagnosis, GP referral, stage and PS 
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Table 10.8. OR of receipt of lung cancer chemotherapy, by selected patient, tumour and 
system factors for those diagnosed between 2006 and 2010 (DCO cases excluded) for 
probable NSCLC  
Variable Unadjusted 
 (n=16,278) 
Adjusted – selected
1
   
(n=16,278, R
2
=18.26) 
 OR  (95% CI) P OR  (95% CI) P 
Deprivation quintile    <0.001    <0.001 
1 (least deprived) 1.00    1.00    
2 0.90 0.80 1.02 0.10 0.88 0.77 1.01 0.08 
3 0.84 0.74 0.94 0.004 0.84 0.74 0.97 0.014 
4 0.80 0.71 0.89 <0.001 0.73 0.64 0.83 <0.001 
5 (most deprived) 0.76 0.68 0.84 <0.001 0.66 0.58 0.74 <0.001 
Sex    <0.001    0.97 
Female 1.00    1.00    
Male 0.96 0.90 1.02 0.18 1.00 0.93 1.07 0.97 
Age group    <0.001    <0.001 
<60 1.00    1.00    
60-69 0.55 0.50 0.61 <0.001 0.54 0.49 0.60 <0.001 
70-79 0.24 0.22 0.27 <0.001 0.23 0.21 0.25 <0.001 
80+ 0.05 0.04 0.06 <0.001 0.05 0.04 0.05 <0.001 
Year of Diagnosis    <0.001    0.007 
2006 1.00    1.00    
2007 1.23 1.10 1.36 <0.001 1.24 1.11 1.39 <0.001 
2008 1.23 1.11 1.36 <0.001 1.14 1.01 1.28 0.03 
2009 1.28 1.15 1.42 <0.001 1.13 1.00 1.27 0.04 
2010 1.35 1.22 1.50 <0.001 1.17 1.04 1.32 0.01 
Stage    <0.001    <0.001 
I 1.00    1.00    
II 1.87 1.46 2.41 <0.001 2.22 1.67 2.94 <0.001 
III 3.71 3.09 4.46 <0.001 6.02 4.88 7.43 <0.001 
IV 2.80 2.35 3.34 <0.001 5.03 4.10 6.16 <0.001 
missing 1.70 1.45 2.00 <0.001 3.30 2.66 4.10 <0.001 
Performance Status    <0.001    <0.001 
0 1.00    1.00    
1-2 0.47 0.42 0.53 <0.001 0.48 0.42 0.56 <0.001 
3-4 0.04 0.03 0.05 <0.001 0.03 0.02 0.05 <0.001 
Missing/ unknown 0.31 0.28 0.34 <0.001 0.38 0.32 0.45 <0.001 
GP referral     <0.001    <0.001 
No 1.00    1.00    
Yes 2.08 1.94 2.23 <0.001 2.08 1.93 2.25 <0.001 
1
Mutually adjusted for SEP, sex, age, year of diagnosis, stage, PS and GP referral  
149 
 
Table 10.9. OR of receipt of lung cancer chemotherapy, by selected patient, tumour and 
system factors for those diagnosed between 2006 and 2010 (DCO cases excluded) for SCLC  
Variable Unadjusted 
(n=3495) 
Adjusted – selected
1
  
(n=3495, R
2
=15.83) 
 OR  (95% CI) P OR  (95% CI) P 
Deprivation quintile    0.06    0.0006 
1 (least deprived) 1.00    1.00    
2 0.73 0.54 0.97 0.03 0.74 0.53 1.02 0.07 
3 0.77 0.58 1.03 0.07 0.70 0.51 0.95 0.02 
4 0.70 0.54 0.91 0.009 0.58 0.43 0.78 <0.001 
5 (most deprived) 0.70 0.54 0.90 0.006 0.57 0.42 0.75 <0.001 
Sex    0.87    0.56 
Female 1.00    1.00    
Male 1.01 0.88 1.17 0.87 0.95 0.81 1.12 0.56 
Age group    <0.001    <0.001 
<60 1.00    1.00    
60-69 0.58 0.45 0.75 <0.001 0.55 0.42 0.71 <0.001 
70-79 0.32 0.25 0.41 <0.001 0.31 0.24 0.40 <0.001 
80+ 0.10 0.07 0.13 <0.001 0.09 0.06 0.12 <0.001 
Year of Diagnosis    0.39    0.13 
2006     1.00    
2007 1.02 0.81 1.28 0.86 1.01 0.79 1.30 0.91 
2008 0.91 0.73 1.14 0.42 0.81 0.63 1.03 0.09 
2009 1.12 0.89 1.40 0.34 1.00 0.77 1.29 0.98 
2010 0.92 0.74 1.15 0.47 0.79 0.61 1.03 0.08 
Performance Status    <0.001    <0.001 
0 1.00    1.00    
1-2 0.40 0.24 0.66 <0.001 0.50 0.30 0.84 0.01 
3-4 0.04 0.02 0.07 <0.001 0.05 0.03 0.10 <0.001 
Missing/ unknown 0.18 0.11 0.29 <0.001 0.22 0.13 0.36 <0.001 
GP referral     <0.001    <0.001 
No 1.00    1.00    
Yes 2.16 1.87 2.49 <0.001 2.24 1.91 2.64 <0.001 
1
Mutually adjusted for SEP, sex, age, year of diagnosis, PS and GP referral
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10.3.3 Radiotherapy 
10.3.3.1 1999-2005 
In the 1999 to 2005 data no association between SEP and receipt of radiotherapy was 
found in the unadjusted analysis or in the adjusted model [table 10.10] when co-
morbidity was included [OR= 0.98, 95% CI 0.91 to 1.06, p=0.67].  
10.3.3.2 2006-2010 
No association between SEP and receipt of radiotherapy was found in the 2006-2010 
cohort [adjusted OR= 1.03, CI 0.94 to 1.13, p=0.48] [table 10.11]. Similarly, in the 
analysis of receipt of radiotherapy in the subset of patients who had stage recorded 
[n=7769], SEP was not associated with radiotherapy [OR=1.01, 95% CI 0.86 to 1.19, 
p=0.88] in the adjusted model including age, sex, year of diagnosis, histology, GP 
referral status, stage and PS [results not shown]. The addition of co-morbidity to the 
model did not change this. The rate of receipt of radiotherapy was higher [39.5%] in 
the staged subset compared to in the full cohort [33.5%].  
10.3.3.2.1 2006-2010: probable NSCLC and SCLC separately 
When radiotherapy was examined separately in probable NSCLC [n=16,278] and SCLC 
[n=3495] populations, socio-economic inequalities in receipt of radiotherapy were 
found for probable NSCLC [OR=1.18, 95% CI 1.06 to 1.31, p=0.003] [table 10.12] but 
not SCLC [OR=0.84, 95% CI 0.66 to 1.07, p=0.16] when comparing OR in the lowest SEP 
group to the highest [table 10.13].  
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Table 10.10. OR of receipt of lung cancer radiotherapy, by selected patient, tumour and 
system factors (DCO cases excluded) for those diagnosed between 1999 and 2005 
Variable Receiving radiotherapy 
(12,602/36,477) 
Unadjusted 
(n=36,477) 
Adjusted – selected
1 
(n=36,477, R
2
=7.23) 
 N % OR  (95% CI) P OR  (95% CI) P 
Deprivation quintile 12,602 34.6    0.65    0.65 
1 (least deprived) 1,312 34.0 1.00    1.00    
2 1,781 35.0 1.04 0.96 1.14 0.33 1.02 0.93 1.12 0.63 
3 2,092 34.8 1.04 0.95 1.13 0.40 1.03 0.94 1.12 0.55 
4 2,875 34.0 1.00 0.92 1.08 1.00 0.99 0.91 1.07 0.76 
5 (most deprived) 4,542 34.7 1.03 0.96 1.11 0.41 0.98 0.91 1.06 0.67 
Sex 12,602 34.6    <0.001    0.16 
Female 5,092 33.0 1.00    1.00    
Male 7,510 35.7 1.12 1.08 1.17 <0.001 1.03 0.99 1.08 0.16 
Age group 12,602 34.6    <0.001    <0.001 
<60 2,354 45.1 1.00    1.00    
60-69 3,815 40.0 0.81 0.76 0.87 <0.001 0.83 0.78 0.90 <0.001 
70-79 4,938 33.9 0.62 0.59 0.67 <0.001 0.71 0.66 0.76 <0.001 
80+ 1,495 21.0 0.32 0.30 0.35 <0.001 0.46 0.43 0.50 <0.001 
Histology 12,602 34.6    <0.001    <0.001 
NSCLC 8,371 44.1 1.00    1.00    
SCLC 1,825 35.8 0.70 0.66 0.75 <0.001 0.68 0.63 0.72 <0.001 
Other 2,406 19.4 0.30 0.29 0.32 <0.001 0.38 0.36 0.40 <0.001 
Co-morbidity score 12,602 34.6    <0.001    <0.001 
0 2,123 35.1 1.00    1.00    
1-2 1,200 32.0 0.87 0.80 0.95 0.002 1.01 0.92 1.10 0.87 
3+ 175 24.8 0.61 0.51 0.73 <0.001 0.77 0.64 0.92 0.005 
CCM missing 8,410 37.5 1.11 1.04 1.18 0.001 1.02 0.96 1.09 0.52 
No HES link 694 19.8 0.46 0.41 0.50 <0.001 0.62 0.56 0.69 <0.001 
Year of Diagnosis 12,602 34.6    <0.001    <0.001 
1999 2,059 40.0 1.00    1.00    
2000 2,013 38.5 0.94 0.87 1.02 0.13 0.96 0.89 1.05 0.40 
2001 1,881 36.2 0.85 0.79 0.92 <0.001 0.83 0.77 0.91 <0.001 
2002 1,730 33.2 0.75 0.69 0.81 <0.001 0.70 0.65 0.76 <0.001 
2003 1,639 31.4 0.69 0.63 0.75 <0.001 0.66 0.60 0.72 <0.001 
2004 1,615 31.0 0.67 0.62 0.73 <0.001 0.65 0.59 0.70 <0.001 
2005 1,665 31.8 0.70 0.65 0.76 <0.001 0.67 0.61 0.73 <0.001 
GP referral 12,602 34.6    <0.001    <0.001 
No 5,581 28.2 1.00    1.00    
Yes 7,021 42.1 1.85 1.77 1.93 <0.001 1.63 1.55 1.70 <0.001 
1
Mutually adjusted for SEP, sex, age, histology, co-morbidity score, year of diagnosis and GP referral
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Table 10.11. OR of receipt of lung cancer radiotherapy, by selected patient, tumour and 
system factors (DCO cases excluded) for 2006-2010 cohort  
Variable Receiving 
radiotherapy 
(9611/28,733) 
Unadjusted 
(n=28,733) 
Adjusted – selected
1 
(n=28,733, R
2
=11.20) 
 N % OR  (95% CI) P OR  (95% CI) P 
Deprivation quintile 9,611 33.5    0.80    0.80 
1 (least deprived) 1,126 33.2 1.00    1.00    
2 1,401 33.5 1.01 0.92 1.12 0.78 1.04 0.94 1.16 0.41 
3 1,612 33.3 1.00 0.91 1.10 0.98 1.03 0.93 1.14 0.60 
4 2,215 33.0 0.99 0.91 1.08 0.83 1.00 0.91 1.10 0.96 
5 (most deprived) 3,257 33.9 1.03 0.95 1.12 0.48 1.03 0.94 1.13 0.48 
Sex 9,611 33.5    <0.001    0.06 
Female 4,258 32.1 1.00    1.00    
Male 5,353 34.6 1.12 1.06 1.17 <0.001 1.05 1.00 1.11 0.06 
Age group 9,611 33.5    <0.001    <0.001 
<60 1,707 46.4 1.00    1.00    
60-69 3,140 41.3 0.82 0.75 0.88 <0.001 0.86 0.79 0.93 <0.001 
70-79 3,330 32.5 0.56 0.52 0.60 <0.001 0.67 0.62 0.73 <0.001 
80+ 1,434 19.9 0.29 0.26 0.31 <0.001 0.49 0.45 0.54 <0.001 
Histology 9,611 33.5    <0.001    <0.001 
NSCLC 6,612 43.7 1.00    1.00    
SCLC 1,562 44.7 1.04 0.97 1.12 0.30 1.06 0.98 1.14 0.15 
Other 1,437 14.2 0.21 0.20 0.23 <0.001 0.30 0.28 0.32 <0.001 
Year of Diagnosis 9,611 33.5    0.003    0.009 
2006 1,857 33.6 1.00    1.00    
2007 1,865 32.7 0.96 0.89 1.04 0.30 0.95 0.88 1.03 0.25 
2008 1,865 31.9 0.93 0.86 1.00 0.06 0.87 0.80 0.94 0.001 
2009 2,060 35.1 1.07 0.99 1.16 0.09 0.99 0.91 1.08 0.78 
2010 1,964 34.1 1.02 0.95 1.11 0.58 0.95 0.87 1.04 0.28 
Stage 9,611 33.5    <0.001    <0.001 
I 370 31.2 1.00    1.00    
II 234 42.4 1.62 1.32 2.00 0.00 1.56 1.25 1.94 <0.001 
III 1,206 53.1 2.49 2.15 2.89 0.00 2.42 2.07 2.83 <0.001 
IV 1,259 33.5 1.11 0.97 1.28 0.14 1.22 1.05 1.42 <0.011 
Missing 6,542 31.2 1.00 0.88 1.14 1.00 1.51 1.29 1.76 <0.001 
Performance Status 9,611 33.5    <0.001    <0.001 
0 832 45.2 1.00    1.00    
1-2 2,375 48.8 1.16 1.04 1.29 0.01 1.43 1.27 1.60 <0.001 
3-4 387 17.8 0.26 0.23 0.30 <0.001 0.52 0.44 0.61 <0.001 
Missing/ unknown 6,017 30.3 0.53 0.48 0.58 <0.001 0.89 0.78 1.01 0.07 
GP referral 9,611 33.5    <0.001    <0.001 
No 3,262 24.6 1.00    1.00    
Yes 6,349 41.1 2.14 2.04 2.25 <0.001 1.70 1.61 1.79 <0.001 
1
Mutually adjusted for SEP, sex, age, histology, year of diagnosis, stage, PS and GP referral 
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Table 10.12. OR of receipt of lung cancer radiotherapy, by selected patient, tumour and 
system factors for those diagnosed between 2006 and 2010 (DCO cases excluded) for 
probable NSCLC  
Variable Unadjusted 
 (n=16,278) 
Adjusted – selected
1
   
(n=16,278, R
2
=2.98) 
 OR  (95% CI) P OR  (95% CI) P 
Deprivation quintile    0.005    0.04 
1 (least deprived) 1.00    1.00    
2 1.07 0.95 1.21 0.24 1.08 0.96 1.22 0.21 
3 1.08 0.96 1.21 0.20 1.08 0.96 1.22 0.20 
4 1.12 1.01 1.25 0.04 1.11 0.99 1.24 0.08 
5 (most deprived) 1.20 1.08 1.33 0.001 1.18 1.06 1.31 0.003 
Sex    0.08    0.09 
Female 1.00    1.00    
Male 1.06 0.99 1.13 0.08 1.06 0.99 1.13 0.09 
Age group    <0.001    <0.001 
<60 1.00    1.00    
60-69 0.94 0.86 1.03 0.21 0.92 0.84 1.02 0.11 
70-79 0.78 0.71 0.86 <0.001 0.77 0.70 0.85 <0.001 
80+ 0.69 0.62 0.77 <0.001 0.70 0.63 0.79 <0.001 
Year of Diagnosis    0.56    0.03 
2006 1.00    1.00    
2007 1.00 0.91 1.10 1.00 0.98 0.89 1.09 0.74 
2008 0.95 0.86 1.05 0.36 0.87 0.79 0.97 0.01 
2009 1.04 0.94 1.15 0.43 0.94 0.84 1.04 0.20 
2010 1.00 0.91 1.11 0.97 0.88 0.79 0.98 0.02 
Stage    <0.001    <0.001 
I 1.00    1.00    
II 1.90 1.50 2.40 <0.001 1.86 1.47 2.36 <0.001 
III 3.09 2.61 3.66 <0.001 3.04 2.55 3.61 <0.001 
IV 1.54 1.31 1.81 <0.001 1.58 1.34 1.86 <0.001 
Missing 1.46 1.27 1.69 <0.001 1.77 1.48 2.12 <0.001 
Performance Status    <0.001    <0.001 
0 1.00    1.00    
1-2 1.47 1.30 1.66 <0.001 1.53 1.34 1.73 <0.001 
3-4 0.60 0.50 0.71 <0.001 0.66 0.54 0.79 <0.001 
Missing/ unknown 0.92 0.82 1.02 0.13 1.03 0.89 1.20 0.71 
GP referral     <0.001    <0.001 
No 1.00    1.00    
Yes 1.63 1.53 1.74 <0.001 1.58 1.48 1.69 <0.001 
1
Mutually adjusted for SEP, sex, age, histology, year of diagnosis, stage, PS and GP referral 
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Table 10.13. OR of receipt of lung cancer radiotherapy, by selected patient, tumour and 
system factors for those diagnosed between 2006 and 2010 (DCO cases excluded) for SCLC   
Variable Unadjusted 
(n=3495) 
Adjusted – selected
1
  
(n=3495, R
2
=6.63) 
 OR  (95% CI) P OR  (95% CI) P 
Deprivation quintile    0.48    0.35 
1 (least deprived) 1.00    1.00    
2 0.84 0.64 1.09 0.19 0.86 0.65 1.13 0.28 
3 1.01 0.78 1.29 0.96 0.98 0.75 1.27 0.85 
4 0.88 0.69 1.12 0.31 0.82 0.64 1.06 0.13 
5 (most deprived) 0.90 0.72 1.13 0.38 0.84 0.66 1.07 0.16 
Sex    0.06    0.04 
Female 1.00    1.00    
Male 0.88 0.77 1.00 0.06 0.86 0.75 0.99 0.04 
Age group    <0.001    <0.001 
<60 1.00    1.00    
60-69 0.69 0.57 0.84 <0.001 0.67 0.55 0.82 <0.001 
70-79 0.46 0.38 0.56 <0.001 0.47 0.39 0.58 <0.001 
80+ 0.31 0.24 0.41 <0.001 0.32 0.25 0.42 <0.001 
Year of Diagnosis    <0.001    0.008 
2006 1.00    1.00    
2007 1.03 0.83 1.28 0.77 1.02 0.82 1.28 0.84 
2008 1.14 0.93 1.41 0.22 1.07 0.86 1.34 0.53 
2009 1.53 1.24 1.89 <0.001 1.45 1.16 1.82 0.001 
2010 1.48 1.19 1.83 <0.001 1.41 1.12 1.77 0.003 
Performance Status    <0.001    <0.001 
0 1.00    1.00    
1-2 0.47 0.34 0.65 <0.001 0.53 0.38 0.75 <0.001 
3-4 0.11 0.07 0.17 <0.001 0.14 0.09 0.22 <0.001 
Missing/ unknown 0.31 0.23 0.42 <0.001 0.41 0.30 0.56 <0.001 
GP referral    <0.001    <0.001 
No 1.00    1.00    
Yes 1.89 1.64 2.16 <0.001 1.78 1.54 2.05 <0.001 
1
Mutually adjusted for SEP, sex, age, year of diagnosis, PS and GP referral 
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10.4 Discussion 
10.4.1 Principal findings 
Socio-economic inequalities in receipt of surgery and chemotherapy but not 
radiotherapy for lung cancer were found in the full cohort analyses [1999-2005 and 
2006-2010]. However, socio-economic inequalities in receipt of chemotherapy were 
not found in the subset with stage recorded when PS was included in the model. 
Socio-economic inequalities in receipt of lung cancer treatment were demonstrated in 
my systematic review and meta-analysis, in both universal [UHCS] and non-universal 
healthcare systems (236). However, the quality of the included studies varied and not 
all of the UK studies reported details of stage and histology, both of which influence 
the type of treatment that is likely to be offered. Factors such as co-morbidity and 
performance status [PS], that might help to explain socio-economic inequalities in 
receipt of treatment, had not been previously well explored. We were able to take all 
these factors into account and still socio-economic inequalities in receipt of surgery 
remained.  
Socio-economic inequalities in performance status appear to account for much of the 
socio-economic inequalities in receipt of chemotherapy in the staged subset. Socio-
economic differences in tumour type may partially account for some of the socio-
economic differences in receipt of surgery observed.  
10.4.2 Strengths and limitations 
To our knowledge this is one of the first studies to use multiple dataset linkage 
[NYCRIS, HES and LUCADA] in order to examine the factors that may influence socio-
economic inequalities in lung cancer treatment in a large dataset. Only one other 
recent 2012 study has used these three datasets but did not include PS or tumour type 
in the analysis (157). In the 1999-2005 cohort I was able to take into account co-
morbidity and in the 2006-2010 analyses I was also able to take into account stage and 
performance status. Therefore I have been able to include a range of potential 
confounders that previous studies have not, and inequalities in receipt of surgery 
remained. The high levels of missing stage, PS and co-morbidity data are, however, a 
limitation. 
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It appeared that those patients referred via the GP were more likely to receive 
treatment. Having a GP referral date recorded was used to determine mode of 
presentation [via the GP or directly to secondary care], as a proxy measure of urgency. 
However, it is possible that some patients may have been referred via their GP, but 
this has not been recorded within the registry dataset.  
When histology was further broken down into histological [tumour] subtypes the OR of 
likelihood of receipt of treatment in the most compared to the least deprived SEP 
group was attenuated. The highest rates of surgery were found in the ‘other-specified 
carcinomas’ group, of which over a quarter were highly-operable carcinoid tumours, 
and the remaining 73% consisted of 52 different tumour-type codes. It may be that 
poor histological classification of non-standard tumour types [by putting these into the 
‘other’ rather than NSCLC histology category] may account for this attenuation, as 
patients in the higher SEP groups had higher rates of these non-standardly coded 
tumour types than did the lowest SEP groups. 
10.4.3 Interpretation of results and comparison with other studies 
10.4.3.1 Receipt of surgery  
Socio-economic inequalities in receipt of surgery may be partially explained by socio-
economic differences in tumour type as, when histology was further broken down into 
histological subtypes, the OR of likelihood of receipt of treatment in the most 
compared to the least deprived SEP group was attenuated. It appears that higher 
levels of more operable tumour types are found in the least deprived SEP group.  
A previous study using Thames Cancer Registry data found that adenocarcinoma is less 
clearly associated with deprivation compared to other histological subtypes, as its 
development is less strongly linked to smoking (248). This current study also found a 
higher proportion of adenocarcinoma and lower proportion of the squamous subtype 
in higher SEP patients compared to the lowest SEP group, with a significant association 
between SEP group and histological subtype.  
In the 2006-2010 cohort, in the highest SEP group 19.3% of patients had 
adenocarcinoma compared to 14.2% in the lowest; and 15.8% had squamous subtypes 
compared to 20.0% in the lowest. As 22.7% of patients with adenocarcinoma received 
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surgery but only 17.6% with squamous cell carcinoma did it does appear that some 
types of tumours are more operable than others and that socio-inequalities in receipt 
of surgery may be partly explained by socio-economic differences in tumour type. 
However, although no other UK studies could be identified  that examined surgery by 
tumour type, a study using Danish cancer registry data for patients diagnosed between 
2005-2010 (249) found similar rates of surgery in patients with adenocarcinoma [24%] 
but found higher rates of surgery in squamous cell patients [23%] than I did, with 
squamous rate similar to their adenocarcinoma rate. They therefore concluded that 
tumour type did not greatly influence the likelihood of receiving surgery in that 
population (249).  
Some further smoking-related confounding could however be occurring as, although I 
was unable to determine smoking status from this study, smokers have generally 
poorer health (71) and it may be this, rather than specifically tumour type, that 
determines receipt of surgery. However, I was able to include PS in the analysis, which 
is a measure of general well-being, as well as co-morbidity score. Smokers have also 
been shown to be less likely to receive treatment even after adjustment for co-
morbidity (250) although the reasons for this are not clear.  
Around 30% of tumour type was recorded as morphologically unspecified [unspecified 
carcinoma and neoplasm] although this is a similar level to that recorded in other UK 
registries (20). Only 0.1% of those diagnosed with a neoplasm received surgery. 
Interestingly, 56% of those aged 80+ had their tumour type recorded as a neoplasm 
compared to 8% in the youngest age group and so this is likely to explain much of why 
those in the older age group did not receive surgery. Neoplasm is a general term for an 
unclassified tumour and is used for those patients who have undergone clinical 
investigation only. This could suggest that older patients do not receive surgery 
because their cancer has not been as thoroughly investigated and classified as those in 
younger patients. It is unclear whether older patients do not receive such thorough 
investigation because they are less well, have poorer PS and so are less able to tolerate 
this, or whether there is genuine bias occurring here, where older patients receive less 
thorough investigation than younger patients due to more nihilistic attitudes from 
clinicians.  
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Previous studies have shown age-related inequalities in histological diagnosis and 
treatment even after co-morbidity and PS were taken into account, which would 
suggest age-discrimination (251). A Scottish study found that the selection of 
investigations initially carried out varied by geographical location and according to 
individual clinician practice rather than being guided by the therapeutic intention. 
Patients who were referred for surgery tended to be younger and had good PS (252). 
Although the study was carried out prior to treatment guidelines being introduced it is 
possible that similar practices still occur. A study in the Netherlands that examined 
lung cancer treatment found that less than half the patients were treated according to 
guidelines and the proportion decreased with age (72). Age inequalities in treatment 
remained in the multivariable analyses here when PS and co-morbidity were taken into 
account which would suggest that older-patients who are fit enough for treatment are 
not receiving it. 
10.4.3.3 Receipt of radiotherapy 
Socio-economic inequalities in receipt of radiotherapy were not found apart from in 
the analysis of NSCLC-only patients, where more deprived NSCLC patients were 
significantly more likely to receive radiotherapy. However, it was not possible to 
distinguish between palliative and radical radiotherapy. Low dose palliative 
radiotherapy is most commonly given, whereas fewer than 10% of patients receive 
high dose radiotherapy with potentially-curative intent. It is possible that differential 
effects by SEP might be seen if these two groups were separated, with more deprived 
SEP patients more likely to get palliative care, and less deprived patients, curative care. 
Potentially, these differential effects could cancel each other out and help explain why 
no overall association was found. However, the low R2 value [2.98] suggests that the 
variables in the model do not well account for the factors that are important 
determinants of receipt of radiotherapy. 
10.4.3.4 Receipt of chemotherapy  
In the multivariable analysis in the subset of patients who had stage recorded, lower 
SEP was associated with a reduced likelihood of receipt of chemotherapy when 
including age, sex, histology and stage in the model. However, on the addition of 
performance status to the model this association was no longer observed, suggesting 
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that socio-economic differences in performance status may therefore account for the 
observed socio-economic differences in receipt of chemotherapy in this subgroup. 
Only two other UK studies [using early LUCADA audit data] have included performance 
status in a multivariable analysis of receipt of treatment (152, 153). They found that 
SEP was not associated with receipt of surgery but was associated with receipt of 
chemotherapy when performance status was included. In contrast we found that, 
when including performance status, SEP remained associated with a lower likelihood 
of receipt of surgery but SEP was no longer associated with receipt of chemotherapy in 
the staged subset. The two previous studies using LUCADA data also found that 
number of co-morbidities was significantly associated with receipt of surgery but other 
studies have not found this (157) and nor did this study. 
Previous studies used national LUCADA audit data [entered from 2004-2007 and 2004-
2008] which, for those early years, included only a small subset of registry patients. 
Although entry of lung cancer stage data in LUCADA was noted to be 85% complete 
nationally for 2008 in the Audit report (246), the validity of the 2005 and 2006 LUCADA 
data has been queried due to the poor entry of staging data (28). In these LUCADA 
studies no association between SEP and receipt of surgery was found in the unadjusted 
and adjusted analyses. This result was in contrast to the majority of other UK studies 
included in a systematic review of inequalities in treatment that found an association 
between SEP and receipt of surgery (236).  It should therefore be queried whether 
patients included in LUCADA in the early years of the audit are representative of the 
full spectrum of patients diagnosed with lung cancer in England. 
One of the previous LUCADA studies concluded that the data within LUCADA were 
unbiased and representative of all lung cancer patients in England, despite the variable 
levels of case ascertainment in the Trusts that supplied data in the early years (153). 
They also suggested that there was little variation in patient demographics across 
participating Trusts with different levels of missing data (153), but this does not seem 
to be quite true. Closer inspection shows that there were significant differences in 
stage at diagnosis, histology and PS when comparing patients from Trusts with high 
levels of missing data against those who had low levels of missing data. Patients from 
Trusts with high levels of missing data were significantly more likely to have early-stage 
disease but these differences were explained away as being proportionately different 
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but small at an absolute level (153). Unfortunately SEP was not examined. However, it 
does appear that results obtained from studies using LUCADA data do differ from 
those using Registry and HES data, and some caution should be employed when 
interpreting data from studies using only early-years LUCADA data, as those patients 
from Trusts with high levels of missing data do appear to be selectively different.  
An NCIN report also noted that although concordance of recording of data on receipt 
of surgery between the combined national registry-HES dataset and the LUCADA 
dataset was high this was not so for chemotherapy and radiotherapy, with 48% of 
patients with chemotherapy and 58.6% with radiotherapy recorded in the former 
having no record in the latter (253), so again this might account for some of the 
differences seen in my results to that found in previous LUCADA studies. 
We were able to include later years of LUCADA data [2009-2010] which are more 
complete. However, we used local registry data whereas previous studies used 
England-wide data, which might explain some of the differences observed. Higher 
levels of missing data for stage and PS were found in our linked dataset than have 
been reported nationally (246). Higher levels of deprivation are found in the north 
compared to England as a whole. Although other regional analyses have found 
inequalities in lung cancer treatment, none have investigated the role of PS and 
tumour type. It would be useful to perform these analyses using other regional or 
national registry data to confirm results. 
10.4.4 Implications for policy and practice, and future research 
The results from this study suggest that socio-economic inequalities in performance 
status substantially explain socio-economic inequalities in receipt of chemotherapy in 
the subset of patients whose cancer was staged. However, this staged subset may not 
be representative of the full regional cohort as patients within this were more likely to 
be younger and of higher SEP. A previous study has shown a socio-economic gradient 
in completeness of data on stage and grade of cancer, which could be interpreted as 
inequality in investigative intensiveness (247). It may be that younger patients receive 
more intensive investigation and so are more likely to be staged (247) and so, although 
PS may explain inequalities in chemotherapy in this group, they are a selective cohort. 
This is a relationship that needs to be clarified in other datasets, ideally with lower 
161 
 
levels of missing data for stage and PS. Later years of data in LUCADA have high levels 
of data completeness and so could be utilised in future. 
Guidelines indicate that chemotherapy should be offered to stage III patients and to 
stage IV patients with good PS [0-1] (18) so that poor PS is a valid reason not to offer 
chemotherapy to patients who would not be able to tolerate this. Chemotherapy can 
be offered to patients who are ambulatory and not bed-bound (18). Socio-economic 
differences in health status may determine whether a patient receives chemotherapy. 
Patients who do not smoke, eat a healthy and balanced diet, are not overweight or 
obese, and undertake exercise are more likely to be in better health and so might have 
a greater chance of being able to undergo chemotherapy. Policy advice regarding 
healthy lifestyle would therefore apply here, although there is clearly a long chain of 
causality from health behaviours earlier in life and their specific implications for health 
status in later life. It is also debateable whether making lifestyle changes once 
diagnosed with cancer is likely to do much to improve PS, although a recent systematic 
review and meta-analysis produced preliminary evidence for improved survival [using 
life table modelling] for early-stage lung cancer patients who quit smoking (254). 
A higher percentage of patients in the lowest SEP group had a squamous cell subtype 
which is strongly associated with smoking. Surgery rates were also lower for this 
histological subtype. Non-smokers are less likely to get lung cancer and if they do then 
it appears that they are more likely to get a histological subtype that is more amenable 
to surgery. This is a further reason, if any other were required, to emphasise why it is 
important not to smoke. However, we cannot rule out uncontrolled confounding 
related to smoking-status, where smokers may be less likely to undergo treatment for 
smoking-related reasons [such as suffering from a serious, smoking-related co-
morbidity such as COPD or heart disease] that we cannot measure within this study. 
Unfortunately smoking status is not recorded in the cancer registry data-set.  
This relationship between tumour type and receipt of treatment was not found in a 
Danish cohort (249) and further UK studies are needed to confirm this association. 
I have been able to investigate a number of factors that may be important in the 
relationship between SEP and receipt of treatment, such as stage and performance 
status, but the high levels of missing data limit the conclusions that can be drawn. 
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Although tumour type may account for some of the socio-economic gradient in surgery 
it does not explain it all. Socio-economic inequalities in PS did not explain inequalities 
in chemotherapy in the full cohort analyses [although it did within the staged subset], 
and nor did stage or number of co-morbidities, suggesting that other factors are at 
play.   
I was unable to look at patient choice. Poorer health literacy may influence patient 
choice and understanding of risk and this may vary by SEP (41). If patients have poor 
capacity to process and understand basic health information then they are less able to 
make appropriate health and treatment decisions (43). It is important that clinicians 
take this into account when discussing treatment options. 
Further research is required to investigate the unexplained variance in treatment 
rates, looking at factors such as patient choice, doctor-patient communication of risk 
and benefit, and possible system variation by trusts or within this, by hospital and 
individual consultant. Previous studies have suggested that there may be variation in 
the level of surgery offered by trusts or, within this, by hospital, so that area-level 
rather than individual factors may account for treatment variation observed (161). 
Multi-level modelling is required to fully investigate the effect of area-level factors 
such as trust, in this data-set. 
10.5 Chapter summary 
Socio-economic inequalities in receipt of surgery, chemotherapy but not radiotherapy 
were found in the full cohort analyses.  
Socio-economic inequalities in performance status statistically explain socio-economic 
inequalities in receipt of chemotherapy in the selective subset of patients whose 
cancer was staged, but not in the full cohort in this study. 
Socio-economic inequalities in receipt of surgery cannot be statistically explained by 
inequalities in stage, PS or co-morbidity. However, socio-economic inequalities in 
tumour type may account for some of the inequalities in surgery by SEP. Patients in 
lower SEP groups are more likely to be diagnosed with squamous cell cancer [a tumour 
type strongly associated with smoking] and are less likely to receive surgery than 
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patients in higher SEP groups, who are more likely to be diagnosed with 
adenocarcinoma. 
In the next chapter socio-economic inequalities in referral, diagnostic and treatment 
intervals are examined. 
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Chapter 11. Inequalities in referral, diagnostic and treatment time 
intervals  
Summary 
Background 
Diagnostic delay has been implicated as a factor that contributes to the poor survival 
of UK cancer patients compared to the European average. In England, urgent referrals 
for suspected cancer are required to have a first hospital appointment [FHA] within 14 
days from the date of GP referral [referral interval], and first treatment within 62 days 
from date of urgent GP referral and within 31 days from diagnosis [treatment 
intervals]. There has been little work conducted on socio-economic inequalities and 
delay in lung cancer. 
Cancer Registry [NYCRIS], Hospital Episode Statistics [HES] and lung cancer audit 
[LUCADA] data-sets were linked in order to investigate socio-economic inequalities in 
system delay for lung cancer. 
Methods 
System delay was examined in patients diagnosed between 1999 and 2005 [n=36,477] 
of whom 32,974 [90.4%] had a linked HES record, and in patients diagnosed between 
2006 and 2010 [n=28,733] a subset of whom had PS and stage [n=7769, 27.0%] 
recorded in LUCADA.  
Socio-economic inequalities in the likelihood of receipt of referral, diagnosis and 
treatment within the target intervals and for the calculated interim date targets were 
explored using logistic regression models.  Cox regression analysis was used to 
examine the influence of SEP on the likelihood of shorter time to first hospital 
appointment, diagnosis and treatment.  
Results (for 2006-2010 cohort) 
In the 2006 to 2010 cohort 70% of patients received a hospital appointment within the 
14 day referral target. Time to treatment targets were only being met for 42.5% when 
measured from diagnosis and for 62% from GP referral. Socio-economic inequalities in 
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time from GP referral to FHA, but not in time to diagnosis or treatment, were found. 
However no linear trend association between SEP and referral time was found.  
Late-stage, poor performance status, and SCLC histology were associated with a higher 
likelihood of a first hospital appointment within 14 days of GP referral. Older patients 
were less likely, whereas late stage and poor PS patients were more likely, to receive 
treatment within guideline time limits. 
Conclusions 
Patients who appeared sick were more likely to receive early referral, diagnosis and 
treatment. However, older patients, who were more likely to have poorer PS, were less 
likely to receive early treatment, indicating possible age-discrimination.    
There is some evidence for socio-economic inequalities in the referral but not in the 
diagnostic or treatment interval. It is possible that the WTP ‘sicker quicker’ effect may 
effectively ‘cancel out’ system inequalities that might result in longer time intervals for 
lower SEP patients.  
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11.1 Introduction 
Delays between the onset of cancer symptoms and the time to treatment may 
contribute to the poor survival of UK cancer patients compared to that found in other 
European countries (99). Early diagnosis of cancer is thought to be important for 
improving outcomes, as survival is better for patients who are diagnosed at an early 
stage, because they are more likely to be suitable for receipt of potentially curative 
treatment (99). Early diagnosis may also result in longer intermediate survival for 
patients with SCLC and later stage NSCLC [Dr M Peake, personal communication]. 
An early model of cancer delay, the Anderson model [Fig 4.3], attributed the majority 
of delay to patient rather than system [primary and secondary healthcare] factors. 
However, it has been suggested that this may be ‘an artefact of research focus’ and 
that system delay may be an equally important but under-researched area (102).   
Current theoretical models of the pathway from first symptom to cancer treatment 
identify key intervals and related health care settings (104). Best practice in the 
definition of key time points demarcating these intervals has also been described 
(100). In England, three intervals have been the subject of performance management. 
Since 2000, urgent referrals for suspected cancer have been required to have a first 
hospital appointment [FHA] within 14 days from the date of referral [referral interval]. 
Since 2005, intervals of 62 days from date of urgent GP referral to first treatment and 
31 days from diagnosis/decision to treat to first treatment [treatment intervals] have 
been in place (24).  
Although some research has been conducted into the factors that might influence 
delay for some common cancers (105, 112) there has been little work conducted on 
socio-economic inequalities and delay in lung cancer. Table 4.1 in chapter 4 
summarises the current evidence. 
In this study cancer registry, Hospital Episode Statistics [HES] and lung cancer audit 
[LUCADA] data-sets were linked in order to investigate system delay, examining socio-
economic inequalities in referral, diagnosis and treatment time for lung cancer 
patients; the likelihood of referral, diagnosis and treatment within recommended 
National Cancer Plan [NCP] guideline target times, by SEP; and to examine the other 
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factors [age, sex, histology, stage, and health status] that may impact on these time 
intervals.  
11.2. Methods 
11.2.1 Data 
For details of data sources and variables see chapter 8, sections 8.2 and 8.4. 
11.2.2 Dates, interval periods and target times 
For details of dates, intervals and target times see chapter 8, table 8.2 and section 
8.4.1. 
Records were excluded from a particular analysis if they had a negative interval for 
that time period e.g. if they had a GP referral date later then diagnosis date, as this 
was likely to be a data entry error. Records were included if they had 0 time between 
dates [e.g. treatment date was recorded on the same day as date as diagnosis. In order 
to include these records in the analysis, 0 time intervals were recoded as 0.1].  
Analysis was also restricted to those cases with interval dates within one year of the 
previous interval endpoint. Records were excluded [table 11.1] if the dates fell out-
with these timeframes, as extremely long gaps between dates were considered likely 
to be data entry errors, such as transposition of numbers on date entry. Some patients 
had very long [one to five year] gaps from GP referral to FHA and these dates might 
refer to other illness episodes. 
Table 11.1. Exclusion of data outliers  
Time period N N interval > 
1 year 
% excluded 
GP referral to FHA  31415 36 0.11 
FHA to diagnosis 31524 20 0.06 
Diagnosis to treatment  15051 57 0.38 
 
11.2.3 Analysis 
NYCRIS data for 28,733 patients diagnosed between 2006 and 2010 and 36,473 
diagnosed between 1999 and 2005 were analysed. As date of diagnosis was 
determined in a different way in 2010 from previous years it was thought that this 
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might affect calculation of the diagnosis to treatment interval. Therefore inequalities in 
time from diagnosis to treatment were also examined in the 2006-2009 cohort. 
The number and percentage of patients referred within guidelines were calculated and 
inequalities in the likelihood of receipt of referral, diagnosis and treatment within the 
targets set by the National Cancer Plan (24) and for the calculated interim date targets 
[see chapter 8 section 8.4.1.4.2], by SEP, adjusted for age, sex, histology, year of 
diagnosis, co-morbidity score, stage, and PS, were explored using logistic regression 
models mutually adjusted for all co-variables. Referral route was also included in the 
models for the FHA to diagnosis and diagnosis to treatment intervals. Type of first 
treatment was included in the models for the FHA to treatment and diagnosis to 
treatment intervals. Receipt of treatment was included in the models for the GP 
referral to diagnosis and FHA to diagnosis intervals. 
 Interactions between SEP and histology were also explored. The R2 statistic was 
examined to determine the amount of variance in receipt of treatment explained by 
each model. Odds ratios [ORs] with 95% confidence intervals [CIs] for the likelihood of 
referral, diagnosis and treatment within target in the lowest compared to the highest 
SEP group were reported. A likelihood ratio test was performed to determine the 
overall significance of each categorical variable.  
The problem with using logistic regression as described above is that one can only look 
at the odds of receiving treatment within one year for those who have received any 
treatment, thus excluding around half of the dataset who are untreated. If Cox 
regression is used, with ‘failure’ defined as receipt of treatment [equivalent to death in 
survival analyses, except it is a positive rather than negative outcome], then it is 
possible to include the whole dataset, even those who did not receive treatment. 
Hazard ratios [HRs] are a measure of time to treatment in the whole dataset, with a 
lower hazard ratio equating to a longer time to treatment. This is only relevant for time 
to treatment analyses as the dates required to calculate time to FHA and diagnosis 
were well recorded and fairly complete for the whole dataset. 
Median time and inter-quartile range [IQR], from GP referral to first hospital 
appointment [FHA], diagnosis and first treatment, and from diagnosis to treatment, 
was calculated. Univariable and multivariable Cox regression analysis [with a hazard 
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ratio of <1.00 indicating longer time to treatment] was used to examine the influence 
of SEP, adjusted for age, sex, stage, performance status, co-morbidity, histology and 
year of diagnosis, on the likelihood of shorter time to first hospital appointment, 
diagnosis and treatment, for those who had dates recorded for those time periods. For 
some analyses receipt of treatment, type of first treatment and whether the patient 
had a GP referral date were also included. Hazard ratios [HRs] with 95% confidence 
intervals [CIs] for the likelihood of early referral, diagnosis and treatment in the lowest 
compared to the highest SEP group were reported. A likelihood ratio test was 
performed to determine the overall significance of each categorical variable. Cox 
regression was also used to assess the likelihood of shorter time to treatment from 
diagnosis and GP referral date, for the whole dataset, including those who did not 
receive treatment. 
11.3 Results 
11.3.1 Descriptive statistics 
Table 9.1 shows the demographic and clinical characteristics of the lung cancer 
patients included in the study.  
Table 11.2 shows the level of data completeness for diagnosis, FHA and GP referral 
date and the number receiving treatment. Of the 28,733 patients diagnosed between 
2006 and 2010, all had a date of diagnosis, 28, 704 [99.9%] had FHA date recorded, 
15,452 [53.8%] had a GP referral date and 15,373 [53.5%] received any treatment 
within one year of diagnosis. Table 11.3 shows the overall median time per interval 
compared to target time, and the numbers included in the analysis for each time 
period.  
Table 11.2. Date completeness for 1999-2005 and 2006-2010 data 
Date 
1999-2005  
(n=36,477) 
2006-2010  
(n=28,733) 
 N % N % 
Diagnosis 36,477 100 28,733 100 
FHA 36,409 99.8 28,704 99.9 
GP referral 16,688 45.7 15,452 53.8 
Treatment (any) 19,516 53.5 15,442 53.7 
Any treatment within 1 year and with first treatment 
date >=diagnosis date 19,510 53.5 15,373 53.5 
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Table 11.3. Median time per interval compared to target time, for 1999-2005 and 2006-2010 
data 
 1999-2005 2006-2010 
Interval Target 
time* 
N Median 
time 
IQR N Median 
time 
IQR 
GP referral date to first 
hospital appointment date 
14 16649 10 6-15 14730 10 6-17 
GP referral date to diagnosis 
date 
31  
 
16644 16 9-33 14865 13 7-24 
First hospital appointment 
date to diagnosis date 
17  
 
36330 3 0-13 28284 0 0-0 
Diagnosis date to first 
treatment date 
31 19510 36 20-62 15373 36 22-56 
GP referral date to first 
treatment date 
62 10844 63 41-98 10090 56 39-79 
 
To avoid repetition of results only the results for 2006-2010 are presented below. The 
pattern of results found was broadly similar in the 1999-2005 cohort [see appendix D 
tables D1-D3] and for the 2006-2009 dataset [results not shown]. No significant 
interactions between SEP and histology were found in any of the models. 
11.3.2 GP referral to first hospital appointment 2006-2010 
11.3.2.1 Hazard ratio of early FHA from GP referral 
Median time from GP referral to FHA was 10 days [IQR 6-17], n=14,730 [table 11.4].  
A linear association between SEP and likelihood of earlier FHA within one year of GP 
referral was not found, although those in the middle SEP groups had significantly 
decreased likelihood [as measured by HR] of early FHA from referral compared to the 
least deprived SEP group. Patients with poorer PS, those subsequently diagnosed with 
later stage cancer and those diagnosed with SCLC all had an increased likelihood [HR] 
of early FHA from referral in the multivariable analysis [table 11.4]. However, median 
referral time was between 8-11 days for these variables and so any ‘delay’ appeared 
short. Those diagnosed in later years were significantly more likely to have an early 
FHA with a median time to FHA of 9 days in 2010 compared to 14 days in 2006. 
A similar pattern was seen for the cohort that had stage recorded [Appendix D, table 
D4] although median referral time was shorter in this sub-group [n=5100, median = 9 
days (IQR 4-14)]. 
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Table 11.4. Hazard ratio of early first hospital appointment from GP referral (for those 
referred within 1 year) in 2006-2010 cohort 
 FHA Median time 
to FHA (days) 
Univariable analysis 
(n=14,730) 
Multivariable analysis
1
  
(n=14,730) 
 N N IQR HR 95% CI P HR 95% CI P 
IMD 14730 10 6-17    0.03    0.08 
1 (least deprived) 1735 9 5-15 1.00    1.00    
2 2054 10 6-17 0.94 0.88 1.00 0.05 0.96 0.90 1.02 0.18 
3 2496 10 6-17 0.93 0.88 0.99 0.03 0.94 0.88 1.00 0.04 
4 3490 11 6-18 0.91 0.86 0.97 0.002 0.93 0.87 0.98 0.008 
5 (most deprived) 4955 10 6-17 0.95 0.90 1.01 0.08 0.96 0.91 1.02 0.15 
Age Range 14730 10 6-17    0.004    0.004 
<60 2043 10 6-17 1.00    1.00    
60-69 4218 10 6-16 1.01 0.96 1.06 0.75 1.00 0.94 1.05 0.89 
70-79 5336 11 6-18 0.94 0.89 0.99 0.02 0.93 0.88 0.98 0.007 
80+ 3133 10 5-17 0.98 0.92 1.03 0.41 0.96 0.90 1.01 0.13 
Sex 14730 10 6-17    0.36    0.96 
Female 6696 10 6-17 1.00    1.00    
Male 8034 10 6-17 0.99 0.95 1.02 0.36 1.00 0.97 1.03 0.96 
Histology 14730 10 6-17    <0.001    <0.001 
NSCLC 8940 11 6-18 1.00    1.00    
SCLC 1929 9 5-14 1.20 1.15 1.26 <0.001 1.20 1.14 1.26 <0.001 
Other 3861 10 4-17 1.03 0.99 1.07 <0.101 1.02 0.98 1.06 0.28 
Year of Diagnosis 14730 10 6-17    <0.001    <0.001 
2006 2498 14 9-25 1.00    1.00    
2007 2603 13 8-21 1.12 1.06 1.19 <0.001 1.12 1.06 1.19 <0.001 
2008 3089 8 5-13 1.72 1.63 1.81 <0.001 1.70 1.61 1.79 <0.001 
2009 3232 8 3-14 1.69 1.61 1.78 <0.001 1.79 1.67 1.91 <0.001 
2010 3308 9 3-14 1.63 1.54 1.71 <0.001 1.69 1.58 1.81 <0.001 
Co-morbidity score 14730 10 6-17    <0.001    <0.001 
0 1,929 11 6-19 1.00    1.00    
1-2 1,418 10 4-19 1.02 0.95 1.09 0.56 0.96 0.90 1.03 0.25 
3+ 298 9 2-20 1.07 0.95 1.21 0.26 0.93 0.82 1.05 0.25 
CCM missing 5,432 11 7-19 1.02 0.96 1.07 0.55 1.14 1.08 1.20 <0.001 
No HES link 5,653 9 4-14 1.23 1.17 1.30 <0.001 1.00 0.94 1.06 1.00 
Stage 14730 10 6-17    <0.001    <0.001 
I 773 11 7-20 1.00    1.00    
II 399 11 5-16 1.21 1.08 1.37 0.002 1.20 1.06 1.35 0.004 
III 1578 9 6-15 1.28 1.17 1.39 <0.001 1.23 1.13 1.34 <0.001 
IV 2350 8 3-14 1.47 1.36 1.60 <0.001 1.36 1.25 1.48 <0.001 
Missing/ unknown 9630 11 6-19 1.08 1.00 1.16 0.04 1.21 1.11 1.32 <0.001 
Performance Status 14730 10 6-17    <0.001    <0.001 
0 1,367 11 6-15 1.00    1.00    
1-2 3,257 9 5-15 1.07 1.01 1.14 0.03 1.05 0.99 1.12 0.13 
3-4 1,230 7 0-13 1.39 1.28 1.50 <0.001 1.33 1.23 1.44 <0.001 
Missing/ unknown 8,876 11 6-19 0.91 0.86 0.96 0.001 1.01 0.94 1.08 0.88 
1 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage, PS
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Table 11.5. Odds of FHA within 14 days from GP referral (for those with FHA within 1 year of 
GP ref) 2006-2010 
 FHA 
within 1 
year 
FHA within 14 
days 
Univariable analysis 
(n=14,730) 
Multivariable analysis
1
  
(n=14,730, R
2
=6.80) 
 N N % OR 95% CI P OR 95% CI P 
IMD 14730 10319 70.1    0.005    0.001 
1 (least deprived) 1735 1274 73.4 1.00    1.00    
2 2054 1439 70.1 0.85 0.73 0.98 0.02 0.85 0.74 0.99 0.04 
3 2496 1738 69.6 0.83 0.72 0.95 0.007 0.81 0.70 0.93 0.003 
4 3490 2385 68.3 0.78 0.69 0.89 <0.001 0.75 0.66 0.86 <0.001 
5 (most deprived) 4955 3483 70.3 0.86 0.76 0.97 0.01 0.83 0.73 0.94 0.004 
Age Range 14730 10319 70.1    0.01    0.03 
<60 2043 1467 71.8 1.00    1.00    
60-69 4218 3005 71.2 0.97 0.87 1.09 0.64 0.96 0.85 1.08 0.49 
70-79 5336 3661 68.6 0.86 0.77 0.96 0.008 0.86 0.76 0.97 0.01 
80+ 3133 2186 69.8 0.91 0.80 1.02 0.12 0.89 0.78 1.02 0.09 
Sex 14730 10319 70.1    0.17    0.80 
Female 6696 4729 70.6 1.00    1.00    
Male 8034 5590 69.6 0.95 0.89 1.02 0.17 1.01 0.94 1.09 0.80 
Histology 14730 10319 70.1    <0.001    <0.001 
NSCLC 8940 6135 68.6 1.00    1.00    
SCLC 1929 1492 77.4 1.56 1.39 1.75 <0.001 1.62 1.43 1.83 <0.001 
Other 3861 2692 69.7 1.05 0.97 1.14 0.22 1.04 0.95 1.14 0.42 
Year of 
Diagnosis 14730 10319 70.1    <0.001    <0.001 
2006 2498 1250 50.0 1.00    1.00    
2007 2603 1484 57.0 1.32 1.19 1.48 <0.001 1.33 1.19 1.49 <0.001 
2008 3089 2491 80.6 4.16 3.69 4.68 <0.001 4.17 3.69 4.70 <0.001 
2009 3232 2543 78.7 3.68 3.28 4.13 <0.001 4.24 3.66 4.91 <0.001 
2010 3308 2551 77.1 3.36 3.01 3.77 <0.001 3.80 3.26 4.43 <0.001 
Co-morbidity 
score 14730 10319 70.1    <0.001    <0.001 
0 1,929 1,291 66.9 1.00    1.00    
1-2 1,418 956 67.4 1.02 0.88 1.18 0.76 0.91 0.78 1.06 0.23 
3+ 298 204 68.5 1.07 0.83 1.39 0.60 0.82 0.62 1.08 0.17 
CCM missing 5,432 3,577 65.9 0.95 0.85 1.06 0.39 1.25 1.10 1.41 <0.001 
No HES link  5,653 4,291 75.9 1.56 1.39 1.74 <0.001 0.95 0.83 1.09 0.46 
Stage 14730 10319 70.1    <0.001    <0.001 
I 773 508 65.7 1.00    1.00    
II 399 286 71.7 1.32 1.01 1.72 0.04 1.33 1.01 1.75 0.04 
III 1578 1182 74.9 1.56 1.29 1.88 <0.001 1.50 1.24 1.83 <0.001 
IV 2350 1870 79.6 2.03 1.70 2.43 <0.001 1.74 1.44 2.10 <0.001 
Missing/ 
unknown 9630 6473 67.2 1.07 0.92 1.25 0.39 1.42 1.17 1.72 <0.001 
Performance 
Status  14730 10319 70.1    <0.001    0.0005 
0 1,367 997 72.9 1.00    1.00    
1-2 3,257 2,422 74.4 1.08 0.93 1.24 0.31 1.01 0.87 1.18 0.88 
3-4 1,230 998 81.1 1.60 1.33 1.92 <0.001 1.38 1.13 1.69 <0.001 
Missing/ 
unknown 8,876 5,902 66.5 0.74 0.65 0.84 <0.001 0.94 0.80 1.12 0.49 
1 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage, PS
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11.3.2.2 Likelihood of FHA within 14 days of GP referral 
Of those referred by their GP [which could include both urgent and non-urgent 
referrals], 70.1% had a first hospital appointment within 2 weeks of referral.  
Low SEP was associated with a lower likelihood of FHA within 2 weeks of referral in the 
multivariable analysis [OR=0.83, CI 0.73 to 0.94, p=0.004] but the lowest likelihood was 
for those in the middle SEP groups. A similar pattern was seen for the 1999-2005 
cohort [Appendix D, table D1]. Late stage cancer, SCLC, poor performance status and 
referral post-2006 were associated with increased likelihood of FHA within 14 days of 
referral, but  older age [80+], sex and number of co-morbidities were not [table 11.5].  
11.3.3 GP referral to diagnosis 2006-2010 
11.3.3.1 Hazard ratio of early diagnosis from GP referral 
In those patients with GP referral and diagnosis dates [n=14,860] median time from GP 
referral to diagnosis was 13 days [IQR 7-24].  
Similarly to the pattern seen in the GP referral to FHA interval, those in the middle SEP 
groups had the lowest likelihood of earlier diagnosis. Patients with poorer PS, co-
morbidities, those subsequently diagnosed with later stage cancer and those with SCLC 
had an increased likelihood [HR] of early diagnosis [table 11.6]. Those who 
subsequently went on to receive treatment had longer median time to diagnosis. 
Similar results were seen for the cohort subset [n=5148] who had stage recorded [data 
not shown]. 
11.3.3.2 Likelihood of diagnosis within 31 days of GP referral 
Neither SEP nor age was associated with likelihood of diagnosis within 31 days of GP 
referral overall, although those in the middle SEP groups had significantly lower 
likelihood of diagnosis within 31 days [table 11.7]. Patients with poorer PS, later stage 
cancer and those with SCLC had an increased likelihood of diagnosis within 31 days of 
GP referral. Those diagnosed in in 2007-2009 appeared to have a higher likelihood of 
diagnosis within 31 days compared to those diagnosed in 2010. However, similar 
overall results were seen for the 2006-2009 data-set [results not shown]. 
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11.3.4 Diagnosis to first treatment 2006-2010 
11.3.4.1 Hazard ratio of early treatment for those treated within 1 year of diagnosis 
Median time from diagnosis to first treatment was 36 days [IQR 22-56], for the 15,373 
patients who had first treatment within 1 year of diagnosis [table 11.8].  
No association between SEP and likelihood [HR] of early treatment was found. Patients 
with late stage cancer, those with SCLC and those with poor performance status were 
more likely to receive early treatment.  
Older patients had longer time to treatment [median time to treatment was 41 days 
for those aged 80+ compared to 33 days for those aged <60]. 
Patients with stage 1 lung cancer waited a median of 51 days for treatment, whereas 
those with stage 4 cancer waited 30 days. This may reflect the type of treatment they 
were likely to receive as patients who received surgery as a first treatment had a 
median waiting time 17 days longer than patients who received chemotherapy and 10 
days longer than those who had radiotherapy first. Patients with poor performance 
status waited a median of 28 days to treatment compared with 37 days for those with 
good performance status. No clear pattern of waiting time was seen for number of co-
morbidities, however. For those treated in 2010 it appeared that time to treatment 
was shorter than in all other years [median =29 days compared to 35-41 days in other 
years]. Again this may be related to how date of diagnosis was calculated in this year. 
11.3.4.2 Hazard ratio of early treatment from diagnosis for entire cohort, including 
untreated 
I also examined the likelihood of receiving early treatment for the whole dataset, 
including those who did not receive treatment [table 11.9]. Using this whole-dataset 
methodology resulted in some contrasting findings compared to including only those 
who received treatment. 
Those with low SEP were significantly less likely to receive early treatment in the 
lowest compared to the highest SEP group [HR=0.83, CI 0.79 to 0.88), p<0.001], as 
were those with co-morbidities. Those with later stage cancer were less likely to 
receive earlier treatment, as were those with poorer performance status whereas the 
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reverse was found in the treatment-only cohort. Those referred via the GP were more 
likely to receive early treatment and, again, the reverse was found in the treatment-
only cohort. Older patients were significantly less likely to receive early treatment as 
were those with co-morbidities. Those diagnosed with SCLC were more likely to 
receive early treatment. 
11.3.4.3 Likelihood of treatment within 31 day of diagnosis 
Of the 15,373 patients who were treated within one year, 42.5% [6,537] were treated 
within the 31 day target time from diagnosis [table 11.10].  
There was no association between low SEP and likelihood of treatment within 31 days 
[OR=0.91, CI 0.81 to 1.02, p=0.11], for those treated within 1 year of diagnosis.  
Although 73.4% of SCLC patients were treated within target, this was true for only 
35.4% of NSCLC patients. Histology appeared the most important factor in the 
likelihood of receiving timely treatment, with a median time of 22 days for SCLC 
compared to 40 days for NSCLC. Patients with SCLC often deteriorate quickly and need 
to receive chemotherapy as soon as possible within a short ‘window of opportunity’ to 
improve survival time. 
Older patients were significantly less likely to receive treatment within the 31 day 
target even when factors such as stage and PS were taken into account [OR=0.78, CI 
0.68 to 0.89, p<0.001]. The type of treatment first received also influenced the 
likelihood of treatment within target. Those receiving surgery were less likely to 
receive treatment within target times. Those with poor performance status and those 
receiving chemotherapy were more likely to do so.  
11.3.5 GP referral to first treatment 2006-2010 
11.3.5.1 Hazard ratio of early treatment from GP referral 
Median time from GP referral to first treatment date was 56 days [IQR 39-79] in the 
10,090 patients who had both dates recorded [table 11.11]. Patients in the middle and 
low SEP groups were less likely to receive early treatment compared to the highest SEP 
group. 
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Early stage patients, older patients and those receiving surgery were significantly less 
likely to receive early treatment, whereas later stage patients, those with poor 
performance status and those receiving chemotherapy as first treatment were more 
likely to do so.  
11.3.5.2 Likelihood of treatment within 62 days of GP referral 
61.8% of those who received treatment were treated within the 62 day target from GP 
referral [although this could include patients who were not urgently referred] [table 
11.12]. No linear trend association between SEP and likelihood of starting treatment 
within the target time was found [p=0.08] although those in the middle SEP groups 
were significantly less likely to start treatment within 62 days. 
Early stage patients, older patients and those receiving surgery were significantly less 
likely to start treatment within 62 days, whereas late stage patients, those with poor 
PS and those receiving chemotherapy were more likely to do so. The likelihood of 
receiving treatment within guidelines significantly improved over time.  
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Table 11.6. Hazard ratio of early diagnosis (for those referred by GP within 1 year and with 
diagnosis date within 1 year from FHA), for 2006 to 2010 cohort 
Variable Diag 
nosis 
Median time 
to diagnosis 
(days) 
Univariable analysis 
 
(n=14,860) 
Multivariable analysis
1 
(n=14,860) 
 N N IQR HR 95% CI P HR 95% CI P 
IMD 14,860 13 7-24    0.04    0.04 
1 (least deprived) 1,746 13 7-21 1.00    1.00    
2 2,074 13 7-24 0.93 0.87 0.99 0.02 0.94 0.88 1.00 0.07 
3 2,519 13 7-25 0.91 0.86 0.97 0.004 0.92 0.86 0.97 0.005 
4 3,521 14 7-25 0.93 0.88 0.98 0.01 0.92 0.87 0.98 0.005 
5 (most deprived) 5,000 13 7-23 0.95 0.90 1.00 0.04 0.95 0.90 1.00 0.06 
Age Range 14,860 13 7-24    0.03    0.04 
<60 2,064 13 7-23 1.00    1.00    
60-69 4,252 13 7-23 1.00 0.95 1.05 0.97 1.01 0.96 1.07 0.70 
70-79 5,394 14 7-24 0.96 0.92 1.01 0.16 0.95 0.91 1.01 0.08 
80+ 3,150 13 7-23 1.03 0.97 1.09 0.34 0.97 0.91 1.03 0.30 
Sex 14,860 13 7-24    0.88    0.63 
Female 6,760 13 7-24 1.00    1.00    
Male 8,100 13 7-23 1.00 0.97 1.03 0.88 1.01 0.98 1.04 0.63 
Histology 14,860 13 7-24    <0.001    <0.001 
NSCLC 9,027 14 8-25 1.00    1.00    
SCLC 1,942 12 7-19 1.28 1.22 1.34 <0.001 1.27 1.21 1.34 <0.001 
Other 3,891 12 6-22 1.11 1.07 1.16 <0.001 1.06 1.01 1.10 0.01 
Year of diagnosis 14,860 13 7-24    <0.001    <0.001 
2006 2,501 16 9-28 1.00    1.00       
2007 2,601 14 8-24 1.15 1.09 1.22 <0.001 1.15 1.08 1.21 <0.001 
2008 3,140 11 6-18 1.49 1.41 1.57 <0.001 1.45 1.38 1.53 <0.001 
2009 3,260 10 5-19 1.51 1.43 1.59 <0.001 1.62 1.52 1.73 <0.001 
2010 3,358 16 8-30 1.01 0.96 1.06 0.81 1.07 1.00 1.14 0.07 
Co-morbidity 
score 14,860 13 7-24    <0.001    <0.001 
0 1,958 14 7-26 1.00    1.00    
1-2 1,430 13 7-27 1.00 0.93 1.07 0.89 0.94 0.88 1.01 0.10 
3+ 303 13 5-29 0.93 0.83 1.05 0.27 0.84 0.74 0.95 0.006 
CCM missing 5,464 13 7-21 1.13 1.08 1.19 <0.001 1.20 1.14 1.27 <0.001 
No HES link  5,705 14 7-25 1.05 1.00 1.11 0.05 1.02 0.96 1.08 0.46 
Stage 14,860 13 7-24    <0.001    <0.001 
I 783 18 10-37 1.00    1.00    
II 403 16 8-28 1.18 1.04 1.33 0.008 1.21 1.08 1.37 0.002 
III 1,592 13 7-22 1.45 1.33 1.58 <0.001 1.38 1.27 1.51 <0.001 
IV 2,369 11 5-19 1.77 1.64 1.92 <0.001 1.64 1.51 1.78 <0.001 
Missing/ unknown 9,713 13 7-24 1.34 1.24 1.44 <0.001 1.29 1.19 1.41 <0.001 
Performance 
Status 14,860 13 7-24    <0.001    <0.001 
0 1,376 14 8-27 1.00    1.00    
1-2 3,287 13 7-23 1.14 1.07 1.21 <0.001 1.08 1.01 1.15 0.02 
3-4 1,240 8 3-17.5 1.54 1.43 1.66 <0.001 1.33 1.23 1.44 <0.001 
Missing/ unknown 8,957 14 7-24 1.07 1.01 1.13 0.03 1.05 0.98 1.13 0.18 
Any treatment 14,860 13 7-24    <0.001    <0.001 
No 5063 12 6-21     1.00    
Yes 9767 14 8-25 0.84 0,82 0.88 <0.001 0.89 0.85 0.93 <0.001 
1 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage, PS, any treatment 
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Table 11.7. Odds of diagnosis within 31 days of GP referral (excluding those with FHA > 1 
year from GP ref and diagnosis> 1 year from FHA) 2006-2010 
 Diagnosis 
within 2 
years 
Diagnosis 
within 31 days 
Univariable analysis 
(n=14,860) 
Multivariable analysis
1
  
(n=14,860, R
2
=4.68) 
 N N % OR 95% CI P OR 95% CI P 
IMD 14,860 12,287 82.7    0.22    0.11 
1 (least deprived) 1,746 1,469 84.1 1.00    1.00    
2 2,074 1,710 82.5 0.89 0.75 1.05 0.17 0.90 0.76 1.07 0.25 
3 2,519 2,061 81.8 0.85 0.72 1.00 0.05 0.84 0.71 0.99 0.04 
4 3,521 2,889 82.1 0.86 0.74 1.01 0.06 0.83 0.71 0.97 0.02 
5 (most deprived) 5,000 4,158 83.2 0.93 0.80 1.08 0.35 0.93 0.80 1.08 0.32 
Age Range 14,860 12,287 82.7    0.57    0.37 
<60 2,064 1,705 82.6 1.00    1.00    
60-69 4,252 3,535 83.1 1.04 0.90 1.19 0.60 1.07 0.93 1.24 0.33 
70-79 5,394 4,431 82.2 0.97 0.85 1.11 0.64 0.98 0.85 1.12 0.74 
80+ 3,150 2,616 83.1 1.03 0.89 1.19 0.68 0.98 0.83 1.15 0.81 
Sex 14,860 12,287 82.7    0.09    0.009 
Female 6,760 5,550 82.1 1.00    1.00    
Male 8,100 6,737 83.2 1.08 0.99 1.17 0.09 1.12 1.03 1.23 0.009 
Histology 14,860 12,287 82.7    <0.001    <0.001 
NSCLC 9,027 7,330 81.2 1.00    1.00    
SCLC 1,942 1,714 88.3 1.74 1.50 2.02 <0.001 1.76 1.51 2.05 <0.001 
Other 3,891 3,243 83.4 1.16 1.05 1.28 0.004 1.04 0.93 1.17 0.47 
Year of Diagnosis 14,860 12,287 82.7    <0.001    <0.001 
2006 2,501 1,925 77.0 1.00    1.00    
2007 2,601 2,159 83.0 1.46 1.27 1.68 <0.001 1.47 1.28 1.70 <0.001 
2008 3,140 2,782 88.6 2.33 2.01 2.69 <0.001 2.29 1.98 2.65 <0.001 
2009 3,260 2,853 87.5 2.10 1.82 2.41 <0.001 2.44 2.06 2.90 <0.001 
2010 3,358 2,568 76.5 0.97 0.86 1.10 0.66 1.04 0.88 1.24 0.64 
Co-morbidity 
score 14,860 12,287 82.7    <0.001    <0.001 
0 1,958 1,575 80.4 1.00    1.00    
1-2 1,430 1,137 79.5 0.94 0.80 1.12 0.50 0.86 0.73 1.03 0.11 
3+ 303 229 75.6 0.75 0.57 1.00 0.05 0.67 0.50 0.90 0.008 
CCM missing 5,464 4,664 85.4 1.42 1.24 1.62 <0.001 1.53 1.33 1.77 <0.001 
No HES link  5,705 4,682 82.1 1.11 0.98 1.27 0.11 1.12 0.96 1.31 0.14 
Stage 14,860 12,287 82.7    <0.001    <0.001 
I 783 553 70.6 1.00    1.00    
II 403 312 77.4 1.43 1.08 1.89 0.01 1.53 1.15 2.04 0.003 
III 1,592 1,343 84.4 2.24 1.83 2.75 <0.001 2.11 1.71 2.61 <0.001 
IV 2,369 2,111 89.1 3.40 2.78 4.16 <0.001 2.93 2.38 3.62 <0.001 
Missing/ 
unknown 9,713 7,968 82.0 1.90 1.61 2.23 <0.001 1.64 1.33 2.03 <0.001 
Performance 
Status  14,860 12,287 82.7    <0.001    0.005 
0 1,376 1,089 79.1 1.00    1.00    
1-2 3,287 2,754 83.8 1.36 1.16 1.60 <0.001 1.23 1.04 1.45 0.02 
3-4 1,240 1,107 89.3 2.19 1.76 2.74 <0.001 1.66 1.30 2.12 <0.001 
Missing/ 
unknown 8,957 7,337 81.9 1.19 1.04 1.37 0.01 1.19 0.98 1.44 0.08 
Any treatment 14,860 12,287 82.7        <0.001 
No 5,063 4,328 85.5 1.00    1.00    
Yes 9,797 7,959 81.2 0.74 0.67 0.81 <0.001 0.75 0.66 0.84 <0.001 
1 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage, PS, any treatment 
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Table 11.8. HR of early treatment from diagnosis (for those treated within 1 year of diagnosis 
and excluding those untreated) 2006 to 2010 
 Treated Median time 
to treatment 
(days) 
Univariable analysis  
 
(n=15,373) 
Multivariable analysis
1
  
 
(n=15,373) 
 N N IQR HR 95% CI P HR 95% CI P 
IMD 15,373 36 22-56    0.70    0.25 
1 (least deprived) 1,928 35 21-55 1.00    1.00    
2 2,298 35 21-56 1.00 0.94 1.06 0.89 1.00 0.94 1.06 0.95 
3 2,605 36 22-57 0.98 0.92 1.03 0.41 0.97 0.92 1.03 0.35 
4 3,510 36 22-56 0.97 0.91 1.02 0.22 0.95 0.90 1.00 0.07 
5 (most deprived) 5,032 36 22-56 0.98 0.93 1.03 0.38 0.97 0.92 1.02 0.25 
Age Range 15,373 36 22-56    <0.001    <0.001 
<60 2,941 33 20-50 1.00    1.00    
60-69 5,322 35 21-54 0.93 0.89 0.97 0.002 0.96 0.92 1.01 0.10 
70-79 5,360 38 23-61 0.79 0.75 0.82 <0.001 0.84 0.80 0.88 <0.001 
80+ 1,750 41 23-61 0.74 0.70 0.79 <0.001 0.86 0.81 0.92 <0.001 
Sex 15,373 36 22-56    <0.001    0.07 
Female 6,918 35 21-55 1.00    1.00    
Male 8,455 36 22-57 0.94 0.91 0.97 <0.001 0.97 0.94 1.00 0.07 
Histology 15,373 36 22-56    <0.001    <0.001 
NSCLC 10,638 40 26-59 1.00    1.00    
SCLC 2,615 22 14-33 2.17 2.08 2.27 <0.001 1.96 1.87 2.05 <0.001 
Other 2,120 38.5 20-64 0.94 0.89 0.98 0.005 0.98 0.94 1.03 0.45 
Diagnosis year 15,373 36 22-56    <0.001    <0.001 
2006 2956 35 21-54 1.00    1.00    
2007 3006 36 22-57 0.96 0.92 1.01 0.15 0.95 0.90 1.00 0.06 
2008 3010 41 25-62 0.87 0.82 0.91 <0.001 0.83 0.79 0.88 <0.001 
2009 3262 40 24-60 0.89 0.85 0.94 <0.001 0.88 0.83 0.94 <0.001 
2010 3139 29 16-46 1.25 1.19 1.32 <0.001 1.26 1.17 1.35 <0.001 
Co-morbidity 
score 15,373 36 22-56 
 
  <0.001    0.34 
0 2,323 37 22-57 1.00    1.00       
1-2 1,617 40 24-63 0.93 0.87 0.99 0.02 0.94 0.89 1.01 0.08 
3+ 352 37.5 20-69 0.92 0.82 1.02 0.12 0.98 0.87 1.09 0.68 
CCM missing 5,996 36 22-56 1.02 0.97 1.07 0.40 1.00 0.95 1.05 0.96 
No HES link  5,085 34 20-52 1.11 1.06 1.17 <0.001 0.97 0.91 1.03 0.32 
GP referral date 15,373 36 22-56    0.28    0.21 
No 5,253 35 19-58 1.00    1.00    
Yes 10,120 36 23-55 1.01 0.99 1.05 0.28 1.02 0.99 1.06 0.21 
Stage 15,373 36 22-56    <0.001    <0.001 
I 922 51 32-74 1.00    1.00    
II 403 48 32-69 1.07 0.95 1.20 0.27 1.00 0.89 1.12 0.95 
III 1,602 39 27-57 1.33 1.22 1.44 <0.001 1.16 1.07 1.26 0.001 
IV 2,009 30 20-44 1.84 1.70 1.99 <0.001 1.52 1.40 1.65 <0.001 
Missing/ 
unknown 10,437 35 21-56 1.37 1.28 1.47 <0.001 1.30 1.20 1.41 <0.001 
Performance 
Status 15,373 36 22-56    <0.001    <0.001 
0 1,673 37 24-57 1.00    1.00    
1-2 3,594 35 22-54 1.05 0.99 1.11 0.11 1.06 1.00 1.13 0.05 
3-4 466 28 15-48 1.27 1.15 1.41 <0.001 1.31 1.18 1.46 <0.001 
Missing/ 
unknown 9,640 
36 21-57 
0.97 0.92 1.02 0.23 0.95 0.88 1.01 0.12 
Ist treatment 15,373 36 22-56    <0.001    <0.001 
Chemotherapy 6863 30 21-45 1.00    1.00    
Surgery 2830 47 20-68 0.65 0.62 0.68 0.65 0.83 0.79 0.87 <0.001 
Radiotherapy 5680 40 24-63 0.64 0.62 0.67 0.64 0.75 0.73 0.79 <0.001 
1 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage, PS, first treatment  
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Table 11.9. Hazard ratio of early treatment for 2006-2010 cohort, including those who did 
not receive treatment, looking at time from diagnosis to first treatment ( n treated =15,373) 
 Univariable analysis  
(n=28,664) 
Multivariable analysis
1
   
(n=28,664) 
Multivariable analysis
2
   
(n=28,664) 
 HR 95% CI P HR 95% CI P HR 95% CI P 
IMD    <0.001    <0.001    <0.001 
1 (least deprived) 1.00    1.00    1.00    
2 0.96 0.90 1.01 0.14 0.95 0.90 1.01 0.13 0.95 0.89 1.01 0.09 
3 0.91 0.86 0.97 0.003 0.90 0.85 0.95 <0.001 0.91 0.86 0.96 0.002 
4 0.88 0.83 0.93 <0.001 0.84 0.80 0.89 <0.001 0.85 0.80 0.90 <0.001 
5 (most deprived) 0.88 0.83 0.93 <0.001 0.82 0.78 0.86 <0.001 0.83 0.79 0.88 <0.001 
Age Range    <0.001    <0.001    <0.001 
<60 1.00    1.00    1.00    
60-69 0.76 0.73 0.79 <0.001 0.81 0.78 0.85 <0.001 0.82 0.78 0.86 <0.001 
70-79 0.47 0.45 0.49 <0.001 0.57 0.54 0.59 <0.001 0.58 0.56 0.61 <0.001 
80+ 0.18 0.17 0.19 <0.001 0.29 0.27 0.31 <0.001 0.31 0.29 0.32 <0.001 
Sex    0.002    0.21    0.29 
Female 1.00    1.00    1.00    
Male 1.05 1.02 1.09 0.002 0.98 0.95 1.01 0.21 0.98 0.95 1.01 0.29 
Histology    <0.001    <0.001    <0.001 
NSCLC 1.00    1.00    1.00    
SCLC 1.50 1.44 1.57 <0.001 1.55 1.49 1.62 <0.001 1.64 1.57 1.72 <0.001 
Other 0.21 0.20 0.22 <0.001 0.30 0.28 0.31 <0.001 0.33 0.31 0.34 <0.001 
Diagnosis year    <0.001    <0.001    <0.001 
2006 1.00    1.00    1.00    
2007 0.97 0.92 1.02 0.20 0.98 0.93 1.03 0.35 0.97 0.92 1.02 0.24 
2008 0.91 0.87 0.96 0.00 0.88 0.83 0.92 <0.001 0.86 0.82 0.91 <0.001 
2009 1.02 0.97 1.07 0.39 1.14 1.07 1.22 <0.001 1.10 1.03 1.17 0.004 
2010 1.09 1.04 1.15 0.00 1.37 1.28 1.47 <0.001 1.35 1.26 1.44 <0.001 
Co-morbidity score    <0.001    <0.001    <0.001 
0 1.00    1.00    1.00    
1-2 0.71 0.66 0.75 <0.001 0.85 0.80 0.91 <0.001 0.86 0.81 0.92 <0.001 
3+ 0.56 0.50 0.62 <0.001 0.75 0.67 0.84 <0.001 0.77 0.69 0.86 <0.001 
CCM missing 1.03 0.98 1.08 0.27 1.00 0.95 1.05 1.00 1.01 0.96 1.06 0.76 
No HES link 0.84 0.80 0.89 <0.001 0.77 0.73 0.82 <0.001 0.78 0.74 0.83 <0.001 
GP referral    <0.001    <0.001    <0.001 
No 1.00    1.00    1.00    
Yes 2.02 1.95 2.09 <0.001 1.64 1.58 1.70 <0.001 1.58 1.52 1.63 <0.001 
Stage    <0.001        <0.001 
I 1.00        1.00    
II 0.92 0.82 1.04 0.17     0.85 0.75 0.95 0.005 
III 0.94 0.87 1.02 0.16     0.87 0.80 0.95 0.001 
IV 0.68 0.63 0.73 <0.001     0.78 0.72 0.85 <0.001 
Missing/unknown 0.58 0.54 0.62 <0.001     0.84 0.77 0.91 <0.001 
Performance Status    <0.001        <0.001 
0 1.00        1.00    
1-2 0.70 0.66 0.74 <0.001     0.90 0.85 0.96 0.001 
3-4 0.13 0.12 0.15 <0.001     0.27 0.24 0.30 <0.001 
Missing/ unknown 0.36 0.34 0.38 <0.001     0.65 0.61 0.70 <0.001 
1 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, GP referral 
2
Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, GP referral, stage, PS 
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Table 11.10. Odds of receiving any treatment within 31 days of diagnosis (for those treated 
within 1 year of diagnosis) 2006-10 
 Treated Treated within 
31 days 
Univariable analysis  
(n=15,373) 
Multivariable analysis
1
   
(n=15,373, R
2
=9.43) 
N N % OR 95% CI P OR 95% CI P 
IMD 15,373 6,537 42.5    0.39    0.29 
1 (least deprived) 1,928 849 44.0 1.00    1.00    
2 2,298 993 43.2 0.97 0.86 1.09 0.59 0.97 0.85 1.11 0.67 
3 2,605 1,089 41.8 0.91 0.81 1.03 0.13 0.89 0.78 1.01 0.06 
4 3,510 1,504 42.9 0.95 0.85 1.07 0.40 0.94 0.84 1.06 0.34 
5 (most deprived) 5,032 2,102 41.8 0.91 0.82 1.01 0.09 0.91 0.81 1.02 0.11 
Age Range 15,373 6,537 42.52    <0.001    <0.001 
<60 2,941 1,409 47.9 1.00    1.00    
60-69 5,322 2,355 44.3 0.86 0.79 0.94 0.001 0.89 0.81 0.98 0.02 
70-79 5,360 2,111 39.4 0.71 0.65 0.77 <0.001 0.75 0.68 0.83 <0.001 
80+ 1,750 662 37.8 0.66 0.59 0.75 <0.001 0.78 0.68 0.89 <0.001 
Sex 15,373 6,537 42.5    0.001    0.27 
Female 6,918 3,045 44.0 1.00    1.00    
Male 8,455 3,492 41.3 0.89 0.84 0.95 0.001 0.96 0.90 1.03 0.27 
Histology 15,373 6,537 42.5    <0.001    <0.001 
NSCLC 10,638 3,765 35.4 1.00    1.00    
SCLC 2,615 1,920 73.4 5.04 4.58 5.55 <0.001 4.38 3.94 4.86 <0.001 
Other 2,120 852 40.2 1.23 1.11 1.35 <0.001 1.26 1.14 1.39 <0.001 
Co-morbidity 
score 15,373 6,537 42.5    <0.001    0.24 
0 2,323 940 40.5 1.00    1.00    
1-2 1,617 598 37.0 0.86 0.76 0.98 0.03 0.91 0.79 1.04 0.17 
3+ 352 145 41.2 1.03 0.82 1.29 0.80 1.08 0.85 1.38 0.52 
CCM missing 5,996 2,482 41.4 1.04 0.94 1.15 0.44 1.02 0.92 1.14 0.68 
No HES link  5,085 2,372 46.7 1.29 1.16 1.42 <0.001 1.05 0.92 1.19 0.46 
Diagnosis year 15,373 6,537 42.5    <0.001    <0.001 
2006 2,956 1,314 44.5 1.00    1.00    
2007 3,006 1,250 41.6 0.89 0.80 0.99 0.03 0.88 0.79 0.98 0.02 
2008 3,010 1,071 35.6 0.69 0.62 0.77 <0.001 0.64 0.57 0.71 <0.001 
2009 3,262 1,196 36.7 0.72 0.65 0.80 <0.001 0.68 0.59 0.79 <0.001 
2010 3,139 1,706 54.4 1.49 1.34 1.65 <0.001 1.54 1.32 1.79 <0.001 
GP referral 15,373 6,537 42.5    <0.001    <0.001 
No GP referral  5,253 2,384 45.4 1.00    1.00    
FHA<=14 days 7,178 3,081 42.9 0.91 0.84 0.97 0.006 0.89 0.83 0.97 0.006 
FHA >14 days 2,942 1,072 36.4 0.69 0.63 0.76 <0.001 0.73 0.66 0.81 <0.001 
1st treatment 15,373 6,537 42.5        <0.001 
Chemotherapy 6,863 3,563 51.9 1.00    1.00    
Surgery 2,830 903 31.9 0.43 0.40 0.48 <0.001 0.77 0.69 0.86 <0.001 
Radiotherapy 5,680 2,071 36.5 0.53 0.49 0.57 <0.001 0.77 0.71 0.84 <0.001 
Stage 15,373 6,537 42.5    <0.001    <0.001 
I 922 229 24.8 1.00    1.00    
II 403 98 24.3 0.97 0.74 1.28 0.84 0.86 0.65 1.14 0.28 
III 1,602 580 36.2 1.72 1.43 2.06 <0.001 1.33 1.09 1.61 0.005 
IV 2,009 1,065 53.0 3.41 2.87 4.06 <0.001 2.48 2.05 3.00 <0.001 
Missing/unknown 10,437 4,565 43.7 2.35 2.02 2.75 <0.001 1.77 1.45 2.14 <0.001 
Performance 
Status 15,373 6,537 42.5    <0.001    0.0001 
0 1,673 647 38.7 1.00    1.00    
1-2 3,594 1,551 43.2 1.20 1.07 1.36 0.002 1.10 0.96 1.25 0.15 
3-4 466 256 54.9 1.93 1.57 2.38 <0.001 1.68 1.33 2.12 <0.001 
Missing/ 
unknown 9,640 4,083 42.4 1.17 1.05 1.30 0.005 1.01 0.87 1.17 0.92 
1 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, GP referral, 1st treatment, 
stage, PS 
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Table 11.11. HR of early treatment from GP referral (for those treated within 1 year of 
diagnosis and excluding those untreated) 2006 to 2010 
 Treat 
ment 
Median time to 
treatment 
(days) 
Univariable analysis  
 
(n=10,090) 
Multivariable analysis
1
  
 
(n=10,090) 
 N N IQR HR 95% CI P HR 95% CI P 
MD 10,090 56 39-79    0.09    0.049 
1 (least deprived) 1,250 54 36-75 1.00    1.00    
2 1,460 55 38-79 0.94 0.87 1.01 0.10 0.95 0.88 1.03 0.22 
3 1,696 56 39-80.5 0.92 0.85 0.99 0.02 0.92 0.86 0.99 0.03 
4 2,306 56 38-79 0.91 0.85 0.98 0.009 0.90 0.84 0.97 0.005 
5 (most deprived) 3,378 56 39-79 0.92 0.86 0.98 0.01 0.92 0.86 0.98 0.01 
Age Range 10,090 56 39-79    <0.001    <0.001 
<60 1,861 51 35-71 1.00    1.00    
60-69 3,512 55 37-76 0.94 0.89 0.99 0.02 0.97 0.92 1.03 0.27 
70-79 3,531 59 41-84 0.79 0.75 0.84 <0.001 0.85 0.81 0.90 <0.001 
80+ 1,186 59 41-85 0.76 0.71 0.82 <0.001 0.86 0.80 0.93 <0.001 
Sex 10,090 56 39-79    0.24    0.83 
Female 4,508 56 38-78 1.00    1.00    
Male 5,582 56 39-79 0.98 0.94 1.02 0.24 1.00 0.97 1.04 0.83 
Histology 10,090 56 39-79    <0.001    <0.001 
NSCLC 7,241 59 43-82 1.00    1.00    
SCLC 1,646 36 26-51 2.19 2.07 2.31 <0.001 1.94 1.83 2.05 <0.001 
Other 1,203 62 41-92 0.86 0.80 0.91 <0.001 0.91 0.86 0.97 0.005 
Diagnosis year 10,090 56 39-79    0.0001    0.02 
2006 1,682 57 40-83 1.00    1.00    
2007 1,756 56 39-79 1.09 1.02 1.16 0.01 0.90 0.82 0.98 0.01 
2008 2,090 55 37-77 1.10 1.03 1.18 0.003 0.87 0.74 1.03 0.11 
2009 2,262 56 39-78 1.12 1.05 1.19 0.001 1.07 1.01 1.15 0.04 
2010 2,300 55 38-76 1.16 1.09 1.24 <0.001 1.02 0.94 1.10 0.69 
Co-morbidity 
score 10,090 56 39-79 
 
  <0.001    <0.001 
0 1,408 57 40-80 1.00    1.00    
1-2 892 62 41-89.5 0.90 0.82 0.98 0.01 1.06 0.99 1.13 0.11 
3+ 163 56 40-89 0.88 0.75 1.04 0.14 1.07 1.00 1.14 0.05 
CCM missing 3,943 55 38-77 1.07 1.01 1.14 0.03 1.15 1.06 1.26 0.001 
No HES link  3,684 55 38-76 1.11 1.05 1.18 0.001 1.16 1.06 1.28 0.001 
Stage 10,090 56 39-79    <0.001    <0.001 
I 665 71 57-100 1.00    1.00    
II 332 67 54-92 1.14 1.00 1.30 0.05 1.07 0.94 1.22 0.30 
III 1,239 56 42-74 1.60 1.46 1.76 <0.001 1.27 1.16 1.41 <0.001 
IV 1,454 44 31-61 2.23 2.04 2.45 <0.001 1.69 1.53 1.86 <0.001 
Missing/ 
unknown 6,400 56 38-80 1.46 1.35 1.59 <0.001 1.26 1.14 1.39 <0.001 
Performance 
Status 10,090 56 39-79 
   
<0.001    <0.001 
0 1,305 58 42-76 1.00    1.00    
1-2 2,629 54 38-73 1.07 1.00 1.14 0.05 1.03 0.96 1.10 0.44 
3-4 311 42 25-64 1.39 1.23 1.57 <0.001 1.37 1.20 1.55 <0.001 
Missing/ 
unknown 5,845 
57 39-82 
0.95 0.89 1.00 0.07 0.97 0.89 1.05 0.40 
1st treatment 10,090 56 39-79    <0.001    <0.001 
Chemotherapy 4715 48 34-65 1.00    1.00    
Surgery 1856 70 56-94 0.54 0.51 0.57 <0.001 0.69 0.65 0.74 <0.001 
Radiotherapy 3519 58 40-85 0.65 0.63 0.68 <0.001 0.80 0.76 0.84 <0.001 
1
Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage, PS, 1
st
 treatment 
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Table 11.12. Odds of receiving any treatment within 62 days of GP referral (for those with 
FHA within 1 year of referral, diagnosis within 1 year of FHA and treated within 1 year of 
diagnosis)  
 Treat 
ment 
Treated 
within 62 
days 
Univariable analysis  
 
(n=10,090) 
Multivariable analysis
1
   
 
(n=10,090, R
2
=8.75) 
 N  N  % OR 95% CI P OR 95% CI P 
IMD 10,090 6,232 61.8    0.22    0.08 
1 (least deprived) 1,250 806 64.5 1.00    1.00    
2 1,460 902 61.8 0.89 0.76 1.04 0.15 0.89 0.75 1.05 0.16 
3 1,696 1,033 60.9 0.86 0.74 1.00 0.05 0.84 0.71 0.98 0.03 
4 2,306 1,399 60.7 0.85 0.74 0.98 0.03 0.80 0.69 0.94 0.005 
5 (most deprived) 3,378 2,092 61.9 0.90 0.78 1.03 0.11 0.88 0.76 1.01 0.07 
Age Range 10,090 6,232 61.8    <0.001    <0.001 
<60 1,861 1,263 67.9 1.00    1.00    
60-69 3,512 2,241 63.8 0.83 0.74 0.94 0.003 0.88 0.78 1.00 0.06 
70-79 3,531 2,033 57.6 0.64 0.57 0.72 <0.00 0.70 0.62 0.80 <0.001 
80+ 1,186 695 58.6 0.67 0.58 0.78 <0.00 0.77 0.65 0.91 0.002 
Sex 10,090 6,232 61.8    0.53    0.11 
Female 4,508 2,769 61.4 1.00    1.00    
Male 5,582 3,463 62.0 1.03 0.95 1.11 0.53 1.07 0.98 1.17 0.11 
Histology 10,090 6,232 61.8        <0.001 
NSCLC 7,241 4208 58.1 1.00    1.00    
SCLC 1,646 1393 84.6 3.97 3.44 4.57 <0.001 3.05 2.62 3.55 <0.001 
Other 1,203 631 52.5 0.80 0.70 0.90 <0.001 0.87 0.76 0.99 0.03 
Co-morbidity 
score 10,090 6,232 61.8    <0.001    0.0002 
0 1,408 838 59.5 1.00    1.00    
1-2 892 469 52.6 0.75 0.64 0.89 0.001 0.78 0.65 0.94 0.008 
3+ 163 89 54.6 0.82 0.59 1.13 0.23 0.83 0.59 1.17 0.29 
CCM missing 3,943 2,443 62.0 1.11 0.98 1.25 0.11 1.13 0.98 1.30 0.10 
No HES link  3,684 2,393 65.0 1.26 1.11 1.43 <0.001 1.07 0.91 1.25 0.44 
Diagnosis year 10,090 6,232 61.8        0.0003 
2006 1,682 983 58.4 1.00    1.00    
2007 1,756 1,032 58.8 1.01 0.88 1.16 0.85 1.01 0.87 1.16 0.90 
2008 2,090 1,305 62.4 1.18 1.04 1.35 0.01 1.13 0.99 1.30 0.08 
2009 2,262 1,410 62.3 1.18 1.03 1.34 0.01 1.24 1.04 1.50 0.02 
2010 2,300 1,502 65.3 1.34 1.18 1.52 <0.001 1.39 1.14 1.69 <0.001 
1
st
 treatment 10,090 6,232 61.8        <0.001 
Chemotherapy 4,715 3,441 73.0 1.00    1.00    
Surgery  1,856 718 38.7 0.23 0.21 0.26 <0.001 0.38 0.34 0.44 <0.001 
Radiotherapy 3,519 2,073 58.9 0.53 0.48 0.58 <0.001 0.76 0.69 0.85 <0.001 
Stage 10,090 6,232 61.8        <0.001 
I 665 257 38.7 1.00    1.00    
II 332 147 44.3 1.26 0.97 1.65 0.09 1.07 0.81 1.41 0.64 
III 1,239 799 64.5 2.88 2.37 3.50 <0.001 1.56 1.27 1.93 <0.001 
IV 1,454 1,136 78.1 5.67 4.65 6.92 <0.001 2.74 2.20 3.41 <0.001 
Missing/unknown 6,400 3,893 60.8 2.47 2.09 2.90 <0.001 1.63 1.31 2.03 <0.001 
Performance 
Status 10,090 6,232 61.8 
    
   0.01 
0 1,305 790 60.5 1.000    1.00    
1-2 2,629 1,747 66.5 1.29 1.13 1.48 <0.001 1.07 0.92 1.24 0.40 
3-4 311 226 72.7 1.73 1.32 2.28 <0.001 1.31 0.97 1.77 0.08 
Missing/ 
unknown 5,845 3,469 59.4 0.95 0.84 1.08 0.43 0.88 0.73 1.05 0.16 
1
Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage, PS, 1
st
 treatment 
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11.4 Discussion 
11.4.1 Principal Findings 
Socio-economic inequalities in the time intervals from GP referral to FHA, diagnosis, 
and treatment were found, but socio-economic inequalities were not found in the time 
intervals from FHA to diagnosis [results not shown], or from diagnosis to treatment. 
This would suggest that interval inequalities originate from the GP referral to FHA 
interval. However, a linear trend was not seen. Patients in the middle SEP groups were 
less likely to receive early FHA, diagnosis or treatment from GP referral, compared to 
the highest SEP group, but this was not consistently observed for the lowest SEP group.  
Generally, those with SCLC, those with poorer PS and those with more advanced stage 
cancer were more likely to receive FHA, diagnosis and treatment within guidelines. 
Older patients were less likely to receive first treatment within guidelines. Patients 
undergoing surgery and radiotherapy as their first treatment had longer time to 
treatment than those receiving chemotherapy as a first treatment. 
11.4.2 Strengths and weaknesses 
To my knowledge this is the first study to examine factors associated with timely care 
within UK guidelines for referral, diagnosis and treatment for lung cancer.  
In order to accurately determine whether there are inequalities in referral, diagnostic 
and treatment intervals consistent recording of dates is required. It is likely that FHA 
and treatment dates are accurately recorded but as a number of different dates can be 
used for the diagnosis date then, unless there is consistent application of the rules, this 
could affect calculation of the diagnostic and treatment intervals and thus introduce 
error. There is no evidence to suggest that the accuracy of recording date of diagnosis 
is likely to vary by SEP and introduce bias, however.  
As the results for time from GP referral to diagnosis and from diagnosis to treatment 
for those diagnosed in 2010 seemed markedly different to those of earlier years it may 
be that the different methodology used for determining date of diagnosis in 2010 
contributed to these observed differences. It is difficult to say, therefore, whether the 
likelihood of receiving quicker first treatment in 2010 is a genuine system 
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improvement or not. However, using the 2006-2009 dataset gave similar results 
overall.  
I examined the interim time interval from FHA to diagnosis. However, the FHA and 
diagnosis date often appeared to be recorded as the same date [there was a median 
interval of 0 with 0-0 IQR for 2006-2010 data], which may relate to problems with 
variability in recording of date of diagnosis in the registry dataset. There did not 
appear to be socio-economic inequalities within this diagnostic interval but it was 
difficult to draw any firm conclusions from this analysis when the median time interval 
in all SEP groups was 0. 
It is of course possible that, for those without a GP referral date, the FHA may be an 
emergency hospital visit where diagnosis is made on that day. Patients who are 
diagnosed clinically may also have their first clinical appointment date as the date of 
diagnosis. A UK study also found that the median time from FHA to diagnosis was 0 
days [with mean =11.5 days] for lung cancer and was also 0 days in the five other 
cancer types they looked at, which would suggest that the majority of patients do find 
out their diagnosis at the FHA (123). 
The type of referral route may influence time to diagnosis and treatment. More than 
half of patients did not have a GP referral date recorded but it was not possible to 
determine from this data how many of these patients had been referred via a different 
route and how many may have had a GP referral for which the date was missing. 
However a large study examining routes to diagnosis found that only 41% of lung 
cancer patients were referred via their GP and a high proportion of cases (39%) 
presented as an emergency (255).  It was also not possible to determine which patients 
were urgent GP referrals. However, those who did have a GP date had longer time to 
treatment than those who did not [a finding similar to that seen in one other study 
that looked at this for lung cancer (123)], which does suggest that those without a GP 
date may be presenting as emergency cases and thus receive more urgent 
investigation and treatment.  
In this study I was not able to examine inequalities in the primary care interval [from 
first patient presentation to the GP until the referral was made], as date of first 
presentation to GP is not recorded within the registry dataset. I was able to look at 
186 
 
patient delay by using stage at diagnosis and number of DCO cases as proxy measures 
of patient delay. No evidence for inequalities in delay in patient presentation by SEP 
was found for the 2006-2010 cohort (chapter 9), in a univariable analysis.  
11.4.3 Interpretation of results and comparison with other studies 
11.4.3.1 Diagnostic delay 
Two studies from Sweden (73) and Denmark (108), (which have similar healthcare 
systems to the UK), found socio-economic inequalities in time from referral to 
diagnosis, with higher SEP patients having more timely diagnosis. I found socio-
economic inequalities from GP referral to diagnosis and, within this interval, from GP 
referral to FHA but not from FHA to diagnosis. A similar result was found in a study 
which examined socio-economic inequalities in these intervals for pancreatic cancer 
(29) and a UK study of over 3,000 lung cancer patients also found that socio-economic 
position was not associated with time from FHA to diagnosis (106). Therefore the 
evidence does suggest that socio-economic diagnostic inequalities are found in the 
referral to FHA interval rather than the secondary care FHA to diagnostic interval. 
11.4.3.2 Referral delay 
Patients in England and Wales with suspected cancer should be seen by a specialist 
within two weeks (24), as an urgent referral. A small 2007 study of 247 UK lung cancer 
patients found that all patients were referred within this 2 week interval (125). In my 
study, the median time from GP referral to first hospital appointment was 10 days and 
70% of patients were seen in secondary care within the 14 day guideline target, 
although I did not have details on what type of GP referral these were.  
A non-linear trend in socio-economic inequalities in the likelihood of being referred to 
secondary care within time interval guidelines was found. Those in the middle SEP 
groups were less likely to receive timely referral than those in the top SEP group, but 
this was not seen for those in the lowest SEP group.  
The Waiting Time Paradox [WTP] suggests that sicker people are referred more quickly 
and, as they are more ill, actually have shorter survival (179). In our study we found 
that poorer performance status did result in increased likelihood of earlier referral and 
diagnosis. This may help to explain why those in the lowest SEP group were not 
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significantly less likely to receive a timely referral or diagnosis compared to the highest 
SEP group. Patients with lower SEP had poorer PS [see chapter 9] and so were likely to 
be in generally poorer health. The results of this ‘sicker quicker’ effect may, therefore, 
act to effectively ‘cancel out’ any system inequalities that might result in longer 
referral and diagnosis time intervals for lower SEP patients. Those in the bottom SEP 
group are more likely to receive earlier referral due to being more ill and presenting as 
an emergency, whereas those at the top are better able to seek urgent referral.  
It has been suggested that socio-economic differences in communicating and 
presenting cancer symptoms to health professionals may result in longer delays for 
those who are less ‘convincing’ (111). Lower SEP patients may be less articulate 
whereas more educated cancer patients are better able to describe symptoms and 
thus speed up the referral process (104). Differences in health literacy of patients by 
SEP may contribute to this, where better-educated, more health-literate patients have 
looked up their symptoms on-line, found out the correct vocabulary and what might 
be important to mention to the doctor.  Doctors may also relate better to wealthier, 
better educated patients [as they are more similar to themselves in terms of social 
class and culture] and this may result, possibly unintentionally, in a more rapid 
investigation process (104). 
In a previous study age, sex, ethnicity and marital status did not appear to influence 
the likelihood of urgent referral for lung cancer (124).  We also found that sex was not 
associated with likelihood of early referral and no clear pattern of referral by age was 
found. 
Patients subsequently diagnosed with earlier-stage cancer and those with good PS had 
a lower likelihood of being referred within 14 days. It could be argued that it is not 
appropriate to include stage as a variable in the analysis of time from referral to FHA, 
as stage is not yet known at this time. A similar argument can also be made for the 
inclusion of performance status here as, again, this is only ascertained post-FHA.  
However, stage, PS and co-morbidity score can all be considered as proxy measures for 
how ill a patient is. Those with earlier stage cancer may not have so many obvious 
clinical symptoms as patients with later stage cancer. A GP will be prompted to 
investigate or refer by signs and symptoms of possible cancer. Urgent referral requires 
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the presence of ‘alarm’ symptoms that are more likely to be present as the disease 
advances.  
A previous study found that co-morbidity delayed diagnosis in around 20% of lung 
cancer patients seen by GPs (256). In patients with a number of co-morbidities, lung 
cancer may not be suspected possibly because symptoms (for example cough, weight 
loss breathlessness) may be ascribed to a known comorbidity [for example COPD] 
rather than lung cancer. There is some evidence to suggest that those with lower SEP 
are likely to have more co-morbidity. One study found that more deprived cancer 
patients had a 50% higher risk of serious co-morbidity compared to less deprived [high 
SEP] patients (69). Patients in the lowest SEP group in this study had more co-
morbidity and poorer PS than those in the higher SEP groups [table 9.3]. However, no 
clear-cut pattern was observed in referral or diagnosis time by co-morbidity score in 
this study, but those with poorer performance status had increased odds of timely FHA 
and diagnosis.  
Both CCM score and PS can be used as proxy measures of general wellbeing/sickness 
and it is difficult to say how well they capture this. It may be that the number of co-
morbidities is not a particularly sensitive measure and PS may be a better marker. 
However, it may also depend on a patient’s prior history as to how a GP interprets 
their symptoms.  If someone regularly visits their GP presenting with multi-morbidities 
[as measured by CCM score] then the GP may be reluctant to refer that person for yet 
more testing and the patient may also be reluctant to do so. However if someone with 
few or no previous comorbidities appears very ill [as measured by performance status] 
then they may be more likely to be referred for investigation. 
11.4.3.3 Treatment delay 
A previous study that looked at time to treatment targets for lung cancer found that 
these were not being achieved (101) (125). We found that time to treatment targets 
were only being met for 43% of patients when measured from diagnosis and 62% 
when measured from GP referral date [although the type of referral route was not 
known and could include those not referred under the two-week wait route]. 
However, some of the reasons for longer delay may be valid. Those who receive 
curative surgery may undergo a longer period of preliminary investigation with a 
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greater number of diagnostic and staging procedures, as well as an assessment for 
fitness for surgery (125). In this study patients who underwent surgery as a first 
treatment waited a median of 47 days from diagnosis compared to 30 days for 
chemotherapy and 40 days for radiotherapy. Lower SEP was associated with a longer 
time to treatment when including both those who did, and did not, receive treatment. 
This may be because higher SEP patients are more likely to receive treatment. Socio-
economic inequalities in receipt of lung cancer treatment were found in my systematic 
review and meta-analysis (236) and have also been shown for this dataset [see chapter 
10]. Late stage and poor performance status were also associated with longer time to 
treatment. Again, this may be because those with late stage and poorer performance 
are less likely to receive treatment and thus the time interval appears long as this is 
censored at the end of the time period rather than treatment being obtained in the 
interim.  
However, when only those patients who received treatment were included in the 
analysis then SEP was not associated with early treatment from diagnosis. However, in 
the GP referral to treatment interval, those in the middle SEP groups appeared less 
likely to receive treatment within the 62 day guidelines, compared to the highest SEP 
group.  Those with later stage cancer and poorer PS were more likely to receive timely 
treatment within guidelines. Again my previous explanation may be relevant where 
those in the bottom SEP group are more likely to receive earlier referral and treatment 
as, due to poorer general health, they are more likely to proceed more speedily 
through the system and undergo quicker, non-curative treatment such as 
chemotherapy, whereas those in the top SEP group are more likely to receive curative 
surgery for which there is a longer interval but they are able to obtain this earlier. 
Those in the middle groups who are either not so obviously ill or are less able to 
communicate thus wait the longest for referral and treatment.  
11.4.4 Implications for policy and practice, and further research 
The consistent and accurate recording of GP referral, FHA, diagnosis and first 
treatment dates by cancer registry staff is important if inequalities in referral, 
diagnosis and treatment intervals are to be identified. The interval from FHA to 
diagnosis could not be examined. Due to changes in the way that date of diagnosis was 
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calculated it was difficult to be sure that any differences seen over time were system 
changes as a result of the introduction of targets or just due to the change in rules for 
determining date of diagnosis.  Similar studies using other data would be useful to 
verify this. 
Our findings suggest that lower SEP patients are likely to appear more ill [as measured 
by PS] and the WTP ‘sicker quicker’ effect may neutralise any patient and system 
inequalities that might result in longer referral and diagnosis time intervals for lower 
compared to higher SEP patients, potentially relating to poorer communication and 
health literacy. Better evidence of inequalities in health literacy by SEP is required. It 
would also be useful to know more about patient and primary care delay prior to GP 
referral, and to determine whether socio-economic inequalities are found in these 
intervals. As around 40% of lung cancer patients present as emergency admissions and 
there is some evidence that lower SEP patients are more likely to present via this route 
(77), further investigation into SEP and route to diagnosis is also required. 
11.5 Chapter summary 
Socio-economic inequalities in the time intervals from GP referral to FHA, diagnosis, 
and treatment were found, but socio-economic inequalities were not found in the 
interim intervals from FHA to diagnosis or from diagnosis to treatment. This would 
suggest that interval inequalities originate from the GP referral to FHA interval. 
However, a linear trend was not seen. Patients in the middle SEP groups were less 
likely to receive early FHA, diagnosis or treatment from GP referral, compared to the 
highest SEP group, but this was not consistently observed for the lowest SEP group. It 
is possible that the WTP ‘sicker quicker’ effect may effectively ‘cancel out’ system 
inequalities that might result in longer time intervals for lower SEP patients.  
The main factors that determined early referral, diagnosis and treatment appeared to 
be how sick patients appeared, as patients with poor PS and late-stage cancer were 
more likely to receive early referral and treatment. However, older patients, who were 
more likely to have poor performance status, were less likely to receive early 
treatment, indicating possible age-discrimination.    
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Socio-economic inequalities in lung cancer survival will now be examined in chapter 
12.  
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Chapter 12. Inequalities in survival 
Summary 
Background 
Lung cancer survival is socio-economically patterned and socio-economic inequalities 
in receipt of treatment have been demonstrated. In England, target waiting times for 
the referral interval [14 days] and treatment intervals [31 days from diagnosis and 62 
days from GP referral] have been set and socio-economic inequalities in the time 
intervals from GP referral have been found. The contribution of these inequalities to 
socio-economic inequalities in lung cancer survival is unclear. 
Cancer registry [NYCRIS], Hospital Episode Statistics [HES] and lung cancer audit 
[LUCADA] data-sets were linked in order to investigate the factors that may influence 
socio-economic inequalities in survival. 
Methods 
NYCRIS data for 36,477 patients diagnosed between 1999 and 2005 and 28,733 
diagnosed between 2006 and 2010 were analysed. Survival time [in weeks] was 
calculated as the interval from the date of diagnosis to the date of death or to the end 
of follow up at 31/12/2011 for those still alive. Cox regression models were used to 
calculate hazard of death, in relation to SEP for those diagnosed in 1999-2005 and 
2006-2010. Logistic regression was used to examine the likelihood of still being alive 
two years after diagnosis for those diagnosed in in 1995-2005 and in 2006-2009. 
Results 
Those in the lowest SEP group had a significantly higher risk of death. Socio-economic 
inequalities in survival were no longer found when treatment was included in the 
model. 
Only 15.3% of patients were still alive 2 years after diagnosis but this increased to 70% 
for those who had surgery. Patients in the lowest SEP group were significantly less 
likely to still be alive after 2 years, compared to the highest SEP group, in a 
multivariable analysis adjusted for age, sex, histology, year of diagnosis, GP referral 
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date, co-morbidity, stage and PS [OR=0.78, 95% CI 0.69 to 0.88, p<0.001]. Adding 
timely-referral did not substantially change this. However if treatment was included 
the association no longer remained significant [OR=0.87, 95% CI 0.75 to 1.00, p=0.06] 
but further addition of timeliness-of-treatment made no difference to the outcome. 
Patients treated later than the treatment target times had better 2 year survival and 
lower risk of death than those who received timely treatment. 
Conclusions 
Socio-economic inequalities in survival are statistically explained by inequalities in 
receipt of treatment but not by time to treatment in this cohort. However, patients 
who were treated within the time-to-treatment guideline targets had poorer survival 
compared to those who had later treatment. Sicker patients had quicker referral 
through the care pathway and this ‘sicker quicker’ effect may mask any system 
inequalities that might otherwise result in longer time intervals in lower SEP patients. 
Interventions that address socio-economic inequalities in receipt of treatment are 
likely to reduce socio-economic inequalities in survival and thus improve survival rates 
overall.  
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12.1 Introduction 
Survival from lung cancer is socio-economically patterned (135). Socio-economic 
inequalities in receipt of lung cancer treatment have been demonstrated in a 
systematic review and meta-analysis (236) conducted as part of this PhD thesis 
[chapter 7] as well as in the secondary data analysis [chapter 10]. It has been 
suggested that inequalities in receipt of treatment may at least partially contribute to 
inequalities in outcome (26) although there is little definitive evidence to support this. 
Socio-economic inequalities in the time intervals from GP referral to FHA, diagnosis 
and treatment have also been found [chapter 11] but no linear pattern by SEP 
emerged. Again it is not known what role inequalities in referral, diagnostic and 
treatment time may play in survival inequalities.  
Cancer registry [NYCRIS], Hospital Episode Statistics [HES] and lung cancer audit 
[LUCADA] data-sets were linked in order to investigate the factors that may influence 
socio-economic inequalities in survival for lung cancer patients, specifically examining 
the influence of socio-economic inequalities in receipt of treatment, and in timely GP 
referral and treatment, taking into account age, sex, histology, year of diagnosis, co-
morbidity, stage and performance status. 
12.2 Methods 
12.2.1 Data 
For details of data sources and variables see chapter 8, sections 8.2 and 8.4. The 
following variables were included in multivariable analyses: SEP, age, sex, histology, 
year of diagnosis, co-morbidity, stage, PS, type of treatment [no treatment, surgery, 
surgery + chemotherapy or radiotherapy, chemotherapy, chemotherapy and 
radiotherapy, radiotherapy], timely GP referral [FHA within 14 days of GP referral, 
FHA>14 days from GP referral, or no GP referral date], timely first treatment [first 
treatment within 31 days of diagnosis, or first treatment >31 days from diagnosis].  
12.2.2 Analysis 
Kaplan Meier graphs were used to examine univariable influences on all-cause 
mortality. Cox regression models were used to calculate hazard ratios [HRs] and 95% 
CIs for all-cause mortality in relation to SEP, in multivariable models for those 
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diagnosed in 1999-2005 and 2006-2010. As date of diagnosis was determined in a 
different way in 2010 from previous years then analysis of the 2006-2009 dataset 
[n=22,967] and of the 2006-2009 dataset with stage recorded [n=5233] was also 
carried out. Nelson-Aalen plots were used to check the proportional hazard 
assumptions for the potential explanatory variables in each model.  
Logistic regression was used to examine the likelihood of still being alive two years 
after diagnosis, by SEP, in the 1995-2005 cohort and in the 2006-2009 dataset. 
Interactions between SEP and histology, and SEP and type of treatment received, were 
explored. The R2 statistic was examined to determine the amount of variance in 
survival explained by each model. 
12.3 Results 
12.3.1 Descriptive statistics 
Similar results were found in the 1999-2005 cohort compared to those for 2006-2010 
and 2006-2009 and so to avoid repetition the 1999-2005 tables are found in appendix 
D.  
Figs 12.1 – 12.13 show univariable Kaplan-Meier survival curves for patients diagnosed 
between 2006 and 2010, plotting proportion of patients surviving [y axis] over time [x 
axis]. Results for 1999-2005 and for 2006-2009 all showed similar patterns [results not 
shown].  
Median survival was 24 weeks in the least deprived SEP group and 21 in the most 
deprived [table 12.1]. Although survival inequalities by SEP were found [Fig 12.1] these 
were less pronounced than for survival inequalities by age [Fig 12.2] and sex [Fig 12.3].  
Survival inequalities by tumour type were observed [Fig 12.4] with the best survival 
found for the small number of patients who have a non-standard histology code 
[other-specified histology], with 41% of these still alive at 2 years compared to 25.3% 
for adenocarcinoma and 24% for those diagnosed with squamous cell carcinoma in the 
2006-2009 cohort. Only 8.3% of those diagnosed with SCLC were still alive at 2 years 
[table 12.4]. 
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Figure 12.1. Kaplan-Meier survival curve: SEP 
 
 
Figure 12.2. Kaplan-Meier survival curve: age 
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Figure 12.3. Kaplan-Meier survival curve: sex 
 
 
Figure 12.4. Kaplan-Meier survival curve: tumour type 
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Survival also varied markedly by performance status [Fig 12.5] with a median survival 
of 64 weeks for those with good PS [PS=0] compared to 34 weeks with PS=1-2 and 8 
weeks for those with poor PS [PS=3-4] [table 12.1]. However, survival differences by 
number of co-morbidities was less pronounced [Fig 12.6] with only small median 
survival differences found between those who had no co-morbidities recorded [23 
weeks], 1-2 co-morbidities [20 weeks] and 3 or more co-morbidities [18 weeks] [table 
12.1]. 
Patients who underwent surgery had the best survival [Fig 12.7]. Interestingly survival 
one year after diagnosis was better for those who surgery plus 
chemotherapy/radiotherapy compared to surgery alone, but this reversed shortly 
after, with those having surgery alone having the best overall survival [73.0% at 2 years 
compared to 64.4% in the multiple treatment group for the 2006-2009 data-set] [table 
12.4]. 
Fig 12.8 shows survival by type of, and time to, first treatment. Those who had surgery 
later than 31 days from diagnosis had the best survival although after four years those 
who had surgery within the 31 day target had similar survival. Patients who had 
radiotherapy as a 1st treatment within the 31 day target from diagnosis had similar 
survival to those who had no treatment, after one year. Those who had first treatment 
within 31 days had poorer survival [median survival 32 weeks] compared to those who 
had first treatment later than 31 days from diagnosis [median survival 55 weeks] [Fig 
12.9]. 
Figs 12.10-12.12 show survival by receipt of and time to, surgery, chemotherapy and 
radiotherapy respectively and again it can be seen that those who had treatment later 
than the 31 day target from diagnosis had better survival than those who had timely 
treatment. For chemotherapy and radiotherapy the best survival was found for those 
who had treatment more than 62 days after diagnosis but these graphs do not take 
into account whether any other treatment was also received. 
Fig 12.13 shows survival by stage. Patients with early stage cancer had better survival 
than those with later stage cancer. 
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Figure 12.5. Kaplan-Meier survival curve: PS 
 
 
Figure 12.6. Kaplan-Meier survival curve: co-morbidity 
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     Figure 12.7. Kaplan-Meier survival curve: treatment type 
 
 
Figure 12.8. Kaplan-Meier survival curve: time to, and type of, treatment 
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Figure 12.9. Kaplan-Meier survival curve: time to first treatment 
 
 
Figure 12.10. Kaplan-Meier survival curve: timely surgery 
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Figure 12.11. Kaplan-Meier survival curve: timely chemotherapy 
 
 
Figure 12.12. Kaplan-Meier survival curve: timely radiotherapy 
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Figure 12.13. Kaplan-Meier survival curve: stage 
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Table 12.1. Median survival (weeks), by selected patient, tumour and system factors for the 
cohort diagnosed between 2006 and 2010, and for the 2006-2010 subset with stage (DCO 
cases excluded)  
Variable 2006-2010 
Cohort 
Median survival (weeks) 2006-2010 
Cohort 
with stage 
Median survival (weeks) 
 N N IQR N N IQR 
Deprivation quintile 28,733 21 6-59.3 7769 30 10-68.1 
1 (least deprived) 3389 24 7-64 931 34 11-76 
2 4178 22 6-60.3 1118 33 10-71 
3 4948 21 6-59 1300 30 10-68.6 
4 6710 20 6-58 1831 28 9-64.1 
5 (most deprived) 9608 21 6-58.6 2589 29 9-67.7 
Age group 28,733 21 6-59.3 7769 30 10-68.1 
<60 3682 36 12-78 1041 41 16-77 
60-69 7595 30 8-72 2189 39 12-80 
70-79 10248 21 6-59 2843 28 9-67 
80+ 7208 12 3-37 1696 18 6-51 
Sex 28,733 21 6-59.3 7769 30 10-68.1 
Female 13254 22 6-63 3559 31 11-72 
Male 15479 21 6-56 4210 29 9-66 
Histology 28,733 21 6-59.3 7769 30 10-68.1 
NSCLC 15123 32 11-74.7 5116 38 14-78 
SCLC 3495 24 7-50 582 29 8-54 
Other 10115 9 2-36 2071 14 4-49 
Year of Diagnosis 28,733 21 6-59.3 7769 30 10-68.1 
2006 5533 20 6-57 671 36 12-85 
2007 5712 21 6-60 866 34.5 11-88 
2008 5851 21 6-58 1556 27 10-71 
2009 5871 23 6-67 2140 30 9-85 
2010 5766 22 6-58 2536 29 8-60.7 
Co-morbidity Score 28,733 21 6-59.3 7769 30 10-68.1 
0 4010 23 7-65 995 30 11-75 
1-2 3531 20 6-57 857 28 9-75 
3+ 934 18 4-54 226 21 7-61 
CCM missing 10175 22 7-61 1977 32 11-79 
No HES link 10083 21 5-58.6 3714 30 9-64.6 
Timely GP referral 28,733 21 6-59.3 7769 30 10-68.1 
No GP referral date 13281 12 3-42 2418 19 6-57 
FHA<=14 days 11019 30 9-66 4087 33 11-71 
FHA>14 days 4433 37 13-78 1264 44 17-79.3 
Stage 28,733 21 6-59.3 7769 30 10-68.1 
I 1186 88 56-139.6 1186 88 56-139.6 
II 552 61.5 32-99.6 552 61.5 32-99.6 
III 2273 40 17-72.1 2273 40 17-72.1 
IV 3758 14 5-35 3758 14 5-35 
missing 20964 19 5-55 -- -- -- 
Performance Status 28,733 21 6-59.3 7769 30 10-68.1 
0 1842 64 35-108 1493 65 36-107.6 
1-2 4865 34 14-69.9 3870 35 14-70 
3-4 2178 8 3-21 1763 8 3-20 
Missing 19848 18 5-54 643 22 7-64.6 
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Table 12.1 (cont). Median survival (weeks), by selected patient, tumour and system factors 
for the cohort diagnosed between 2006 and 2010, and for the 2006-2010 subset with stage 
(DCO cases excluded)  
Variable 2006-2010 
Cohort 
Median survival (weeks) 2006-2010 
Cohort 
with stage 
Median survival (weeks) 
 N N IQR N N IQR 
Type of treatment 28,733 21 6-59.3 7769 30 10-68.1 
No treatment 13291 6 2-19 2815 9 4-23 
Surgery 1833 120.4 66-194.3 579 103.1 64.7-153.5 
Surgery + chemotherapy/ 
radiotherapy 
1061 103 64.3-166.4 422 96.5 64.1-150.7 
Chemotherapy 3404 30 15-55 1051 32 16-56 
Chemotherapy+radiotherapy 4117 53 34-84 1329 55 35-82 
Radiotherapy 5027 25 11-57 1573 28 12-63 
Timely 1
st
 treatment 28,733 21 6-59.3 7769 30 10-68.1 
>31 days from diagnosis 8887 55 27-108.6 2979 58 29-104.6 
<=31 days from diagnosis 6555 32 13-65 1975 36 15-67.3 
 
12.3.2.2 Multivariable regression analysis: 2006-2010 cohort 
In the multivariable analysis including age and sex a survival gradient by SEP was seen 
[HR=1.13, 95% CI 1.09 to 1.18, p<0.001]. This remained when histology, year of 
diagnosis, co-morbidity and timely GP referral were taken into account [HR=1.13, 95% 
CI 1.09 to 1.18, p<0.001] [table 12.2] and on addition of stage and PS [HR=1.11, 95% CI 
1.07 to 1.16, p<0.001] [table 12.2] but not once receipt of treatment was included in 
the model [HR=1.02, 95% CI 0.98 to 1.06, p=0.36] [table 12.2]. Addition of timeliness of 
treatment to the model did not change the findings [HR=1.03, 95% CI 0.98 to 1.07, 
p=0.22].  
12.3.2.3 2006-2009 cohort 
An identical pattern of results was seen for the 2006-2009 dataset [results not shown].  
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Table 12.2. Likelihood of mortality (hazard ratio of death), by selected patient, tumour and 
system factors for those diagnosed between 2006 and 2010 (DCO cases excluded)  
Variable Unadjusted  
 
(n=28,733) 
Adjusted – IMD, age, sex, histology, year, CCM, 
timely GP referral  
(n=28,733) 
 HR 95% CI P HR 95% CI P 
Deprivation quintile    0.0002    <0.001 
1 (least deprived) 1.00    1.00    
2 1.06 1.01 1.11 0.02 1.07 1.02 1.12 0.009 
3 1.06 1.01 1.11 0.01 1.06 1.01 1.11 0.02 
4 1.09 1.05 1.14 <0.001 1.12 1.07 1.17 <0.001 
5 (most deprived) 1.10 1.05 1.14 <0.001 1.13 1.09 1.18 <0.001 
Age group    <0.001    <0.001 
<60 1.00    1.00    
60-69 1.09 1.04 1.14 <0.001 1.10 1.05 1.14 <0.001 
70-79 1.33 1.28 1.39 <0.001 1.29 1.24 1.35 <0.001 
80+ 1.83 1.75 1.91 <0.001 1.62 1.55 1.69 <0.001 
Sex    <0.001    <0.001 
Female 1.00    1.00    
Male 1.10 1.07 1.12 <0.001 1.14 1.12 1.17 <0.001 
Histology    <0.001    <0.001 
NSCLC 1.00    1.00    
SCLC 1.39 1.34 1.44 <0.001 1.43 1.37 1.48 <0.001 
Other 1.76 1.71 1.81 <0.001 1.52 1.48 1.57 <0.001 
Year of Diagnosis    <0.001    0.28 
2006 1.00    1.00    
2007 0.97 0.94 1.01 0.15 0.98 0.94 1.02 0.25 
2008 0.97 0.93 1.01 0.14 0.98 0.94 1.02 0.37 
2009 0.90 0.86 0.93 <0.001 0.95 0.91 1.00 0.03 
2010 0.91 0.88 0.95 <0.001 0.95 0.91 1.00 0.07 
Co-morbidity score        <0.001 
0 1.00    1.00    
1-2 1.12 1.06 1.17 <0.001 1.01 0.96 1.06 0.81 
3+ 1.20 1.11 1.29 <0.001 1.02 0.94 1.09 0.70 
CCM missing 1.06 1.02 1.10 0.002 1.13 1.08 1.17 <0.001 
No HES link 1.06 1.02 1.10 0.004 1.07 1.03 1.12 0.002 
Timely GP referral    <0.001    <0.001 
No GP ref date 1.00    1.00    
FHA<=14 days 0.68 0.66 0.70 <0.001 0.73 0.71 0.76 <0.001 
FHA>14 days 0.60 0.57 0.62 <0.001 0.63 0.61 0.66 <0.001 
Stage    <0.001     
I 1.00        
II 1.54 1.35 1.76 <0.001     
III 2.61 2.38 2.87 <0.001     
IV 4.86 4.45 5.31 <0.001     
Missing 3.63 3.34 3.95 <0.001     
Performance Status    <0.001     
0 1.00        
1-2 1.73 1.63 1.85 <0.001     
3-4 4.05 3.77 4.35 <0.001     
Missing 2.34 2.21 2.49 <0.001     
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Table 12.2 (cont). Likelihood of mortality (HR of death), by selected patient, tumour and 
system factors for those diagnosed between 2006 and 2010 (DCO cases excluded)  
Variable Adjusted – IMD, age, sex, histology, year, 
CCM, timely GP referral, stage, PS  
 
(n=28,733) 
Adjusted – IMD, age, sex, histology, year, 
CCM,  timely GP referral, stage, PS, treatment 
type 
 (n=28,733) 
 HR 95% CI P HR 95% CI P 
Deprivation quintile    <0.001    0.51 
1 (least deprived) 1.00    1.00    
2 1.07 1.02 1.12 0.007 1.04 0.99 1.10 0.08 
3 1.05 1.00 1.10 0.05 1.03 0.98 1.08 0.23 
4 1.10 1.05 1.15 <0.001 1.02 0.98 1.07 0.29 
5 (most deprived) 1.11 1.07 1.16 <0.001 1.02 0.98 1.06 0.36 
Age group    <0.001    <0.001 
<60 1.00    1.00    
60-69 1.09 1.05 1.14 <0.001 0.96 0.92 1.00 0.07 
70-79 1.28 1.22 1.33 <0.001 0.91 0.87 0.95 <0.001 
80+ 1.57 1.50 1.65 <0.001 0.85 0.81 0.89 <0.001 
Sex    <0.001    <0.001 
Female 1.00    1.00    
Male 1.15 1.12 1.18 <0.001 1.14 1.11 1.17 <0.001 
Histology    <0.001    <0.001 
NSCLC 1.00    1.00    
SCLC 1.36 1.31 1.42 <0.001 1.52 1.46 1.59 0.00 
Other  1.44 1.40 1.49 <0.001 0.99 0.96 1.03 0.70 
Year of Diagnosis    0.61    <0.001 
2006 1.00    1.00    
2007 0.98 0.94 1.02 0.31 0.99 0.95 1.03 0.63 
2008 0.98 0.94 1.02 0.33 0.98 0.95 1.02 0.43 
2009 0.97 0.93 1.02 0.22 1.14 1.09 1.19 <0.001 
2010 0.96 0.91 1.01 0.12 1.15 1.09 1.21 <0.001 
Co-morbidity score    <0.001    <0.001 
0 1.00    1.00    
1-2 1.01 0.96 1.06 0.77 0.92 0.87 0.96 <0.001 
3+ 1.01 0.94 1.09 0.75 0.89 0.82 0.96 0.002 
CCM missing 1.12 1.07 1.16 <0.001 1.11 1.07 1.16 <0.001 
No HES link 1.07 1.02 1.12 0.003 0.92 0.88 0.96 <0.001 
Timely GP referral    <0.001    <0.001 
No GP ref date 1.00    1.00    
FHA<=14 days 0.75 0.73 0.77 <0.001 0.84 0.82 0.87 <0.001 
FHA>14 days 0.66 0.63 0.68 <0.001 0.75 0.72 0.78 <0.001 
Stage    <0.001    <0.001 
I 1.00    1.00    
II 1.61 1.41 1.84 <0.001 1.42 1.24 1.62 <0.001 
III 2.68 2.44 2.95 <0.001 2.05 1.87 2.25 <0.001 
IV 4.65 4.25 5.08 <0.001 3.29 3.01 3.60 <0.001 
Missing 2.82 2.58 3.09 <0.001 2.26 2.06 2.48 <0.001 
Performance Status    <0.001    <0.001 
0 1.00    1.00    
1-2 1.39 1.30 1.49 <0.001 1.12 1.05 1.20 <0.001 
3-4 2.49 2.31 2.68 <0.001 1.55 1.44 1.67 <0.001 
Missing 1.71 1.60 1.84 <0.001 1.34 1.25 1.44 <0.001 
Type of treatment        <0.001 
No treatment     1.00    
Surgery     0.09 0.08 0.10 <0.001 
Surgery 
+chemo/radiotherapy     0.12 0.11 0.13 <0.001 
Chemotherapy     0.40 0.38 0.42 <0.001 
Chemo+radiotherapy     0.25 0.24 0.26 <0.001 
Radiotherapy     0.50 0.48 0.51 <0.001 
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Table 12.3. Likelihood of mortality (hazard ratio of death), by selected patient, tumour and 
system factors for the subset diagnosed between 2006 and 2010 with stage recorded (DCO 
cases excluded)  
Variable Adjusted – IMD, age, sex, histology, year, CCM, 
timely GP referral  
(n=28,733) 
Adjusted – IMD, age, sex, histology, year, CCM, 
timely GP referral, stage 
(n=28,733) 
 HR 95% CI P HR 95% CI P 
Deprivation quintile    0.0004    0.002 
1 (least deprived) 1.00    1.00    
2 1.06 0.96 1.16 0.27 1.06 0.96 1.17 0.22 
3 1.07 0.97 1.17 0.18 1.08 0.98 1.18 0.13 
4 1.17 1.07 1.27 0.001 1.16 1.06 1.27 0.001 
5 (most deprived) 1.17 1.07 1.27 <0.001 1.16 1.06 1.26 0.001 
Age group    <0.001    <0.001 
<60 1.00    1.00    
60-69 1.02 0.94 1.11 0.65 1.06 0.98 1.16 0.14 
70-79 1.21 1.12 1.32 0.00 1.34 1.24 1.45 <0.001 
80+ 1.49 1.37 1.63 0.00 1.70 1.55 1.85 <0.001 
Sex    <0.001    <0.001 
Female 1.00    1.00    
Male 1.13 1.07 1.19 <0.001 1.13 1.07 1.19 <0.001 
Histology    <0.001    <0.001 
NSCLC 1.00    1.00    
SCLC 1.46 1.33 1.60 <0.001 1.18 1.08 1.30 <0.001 
Other 1.48 1.39 1.57 <0.001 1.55 1.46 1.65 <0.001 
Year of Diagnosis    0.16    0.96 
2006 1.00    1.00    
2007 1.01 0.91 1.12 0.90 0.98 0.88 1.10 0.77 
2008 1.08 0.98 1.19 0.12 0.98 0.89 1.08 0.71 
2009 1.10 0.98 1.23 0.09 1.01 0.90 1.13 0.86 
2010 1.13 1.01 1.27 0.03 1.02 0.91 1.15 0.76 
Co-morbidity score    0.02    0.03 
0 1.00    1.00    
1-2 0.95 0.86 1.06 0.36 1.02 0.92 1.13 0.72 
3+ 1.07 0.92 1.25 0.40 1.18 1.01 1.38 0.04 
CCM missing 1.11 1.01 1.21 0.03 1.04 0.95 1.14 0.43 
No HES link 0.97 0.89 1.05 0.45 0.94 0.86 1.02 0.15 
Timely GP referral    <0.001    <0.001 
No GP referral date 1.00    1.00    
FHA<=14 days 0.78 0.74 0.83 <0.001 0.77 0.73 0.81 <0.001 
FHA>14 days 0.66 0.61 0.71 <0.001 0.70 0.65 0.75 <0.001 
Stage        <0.001 
I     1.00    
II     1.73 1.52 1.98 <0.001 
III     3.16 2.88 3.48 <0.001 
IV     6.54 5.96 7.16 <0.001 
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Table 12.3 (cont). Likelihood of mortality (HR of death), by selected patient, tumour and 
system factors for those diagnosed between 2006 and 2010 with stage recorded (DCO cases 
excluded)  
variable Adjusted – IMD, age, sex, histology, year, 
CCM, timely GP referral ,stage, PS  
 
(n=28,733) 
Adjusted – IMD, age, sex, histology, year, 
CCM, stage, PS, timely GP referral, treatment 
type 
(n=28,733) 
 HR 95% CI P HR 95% CI P 
Deprivation quintile    0.18    0.45 
1 (least deprived) 1.00    1.00    
2 1.05 0.95 1.15 0.37 1.07 0.97 1.18 0.16 
3 1.01 0.92 1.11 0.76 1.03 0.93 1.13 0.61 
4 1.10 1.01 1.20 0.04 1.07 0.98 1.16 0.16 
5 (most deprived) 1.06 0.97 1.15 0.21 1.02 0.94 1.11 0.60 
Age group    <0.001    <0.001 
<60 1.00    1.00    
60-69 1.00 0.92 1.09 0.99 0.95 0.87 1.03 0.20 
70-79 1.13 1.04 1.22 0.005 0.86 0.79 0.94 0.001 
80+ 1.28 1.17 1.40 <0.001 0.81 0.73 0.89 <0.001 
Sex    <0.001    <0.001 
Female 1.00    1.00    
Male 1.15 1.10 1.21 <0.001 1.15 1.09 1.21 <0.001 
Histology    <0.001    <0.001 
NSCLC 1.00    1.00    
SCLC 1.12 1.02 1.23 0.02 1.42 1.29 1.57 <0.001 
Other  1.25 1.18 1.33 <0.001 0.95 0.89 1.02 0.15 
Year of Diagnosis    0.65    0.0009 
2006 1.00    1.00    
2007 0.96 0.87 1.07 0.49 0.98 0.88 1.09 0.65 
2008 0.95 0.86 1.04 0.26 0.98 0.89 1.08 0.66 
2009 1.00 0.89 1.12 0.99 1.17 1.04 1.30 0.008 
2010 1.01 0.90 1.14 0.86 1.18 1.05 1.33 0.005 
Co-morbidity score    0.05    <0.001 
0 1.00    1.00    
1-2 0.95 0.86 1.05 0.34 0.90 0.81 0.99 0.03 
3+ 1.05 0.90 1.23 0.55 0.91 0.78 1.06 0.23 
CCM missing 1.06 0.97 1.17 0.18 1.04 0.95 1.14 0.43 
No HES link 0.93 0.85 1.01 0.09 0.83 0.76 0.91 <0.001 
Timely GP referral    <0.001    <0.001 
No GP referral date 1.00    1.00    
FHA<=14 days 0.80 0.76 0.85 <0.001 0.87 0.82 0.92 <0.001 
FHA>14 days 0.74 0.69 0.80 <0.001 0.81 0.75 0.87 <0.001 
Stage    <0.001    <0.001 
I 1.00    1.00    
II 1.66 1.45 1.90 <0.001 1.54 1.34 1.76 <0.001 
III 2.96 2.69 3.25 <0.001 2.44 2.21 2.70 <0.001 
IV 5.88 5.36 6.45 <0.001 4.52 4.10 4.98 <0.001 
Performance Status    <0.001    <0.001 
0 1.00    1.00    
1-2 1.51 1.40 1.63 <0.001 1.22 1.13 1.32 <0.001 
3-4 3.45 3.15 3.77 <0.001 2.08 1.89 2.28 <0.001 
Missing 1.94 1.75 2.16 <0.001 1.53 1.37 1.70 <0.001 
Type of treatment        <0.001 
No treatment     1.00    
Surgery     0.18 0.15 0.21 <0.001 
Surgery 
+chemo/radiotherapy     0.17 0.14 0.20 <0.001 
Chemotherapy     0.42 0.38 0.46 <0.001 
Chemo+radiotherapy     0.28 0.26 0.31 <0.001 
Radiotherapy     0.59 0.54 0.63 <0.001 
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12.3.2.4 2006-2010 subset with stage recorded 
Median survival in the staged cohort was better than for the full 2006-2010 cohort 
[median of 30 compared to 21 weeks]. 
In the subset with stage recorded [n=7769] socio-economic inequalities in survival 
were found in a univariable analysis [OR=1.13, 95% CI 1.04 to 1.22, p=0.005] and in 
multivariable analyses when age and sex, histology, year of diagnosis, co-morbidity, 
timely GP referral and stage were included in the analysis [OR=1.16, 95% CI 1.06 to 
1.26, p=0.001], but not when PS was added to the model [OR=1.06, 95% CI 0.97 to 
1.15, p=0.21] [table 12.3] and not when receipt of treatment was included [OR=1.02, 
95% CI 0.94 to 1.11, p=0.60]. Further addition of timely treatment did not alter this. 
12.3.2.5 2006-2009 subset with stage recorded 
In the 2006-2009 subset with stage recorded [n=5233] an identical pattern of results to 
the 2006-2010 cohort with stage recorded was again found [results not shown]. 
12.3.3 Two year survival: 2006-2009 data-set 
12.3.3.1 Descriptive analysis 
In the 2006 to 2009 data-set [n=22,967], 15.3% of patients [3513] were still alive two 
years after diagnosis [table 12.4]. In the unadjusted analysis those in the lowest SEP 
group were significantly less likely to still be alive after 2 years, compared to the 
highest SEP group [OR=0.79, 95% CI 0.70 to 0.89, p<0.001] [table 12.5].  
Likelihood of two-year survival was better for patients with high SEP, younger patients, 
women, those diagnosed with NSCLC, those with no co-morbidity, early stage patients, 
those with good PS, those referred by their GP and those receiving treatment. Patients 
who received surgery between 32-62 days after diagnosis had the greatest likelihood 
of two-year survival. For chemotherapy and radiotherapy optimal survival was found 
for those who had treatment more than 62 days after diagnosis [table 12.4]. 
12.3.3.2 Multivariable regression analysis 
In a multivariable analysis adjusted for age, sex, histology, year of diagnosis, timely GP 
referral and co-morbidity, inequalities in survival by SEP were observed, with a  
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reduced likelihood of 2 year survival in the lowest compared to the highest SEP group 
[OR=0.74, 95% CI 0.66 to 0.84, p<0.001] [table 12.5]. The amount of survival variation 
explained by the model was poor [R2=5.77]. Adding stage and PS improved this 
[R2=12.31] but did not substantially change the SEP OR [OR=0.77, 95% CI 0.66 to 0.88, 
p<0.001]. However if treatment type [surgery, surgery plus 
chemotherapy/radiotherapy, chemotherapy, chemotherapy plus radiotherapy, 
radiotherapy] was included in the analysis the association no longer remained 
significant [OR=0.87, 95% CI 0.75 to 1.00, p=0.06]. Receipt of treatment also made the 
greatest contribution to explaining survival variance in the model [R2=27.97]. Further 
addition of timeliness of treatment made no difference to the outcome [OR=0.87, 95% 
CI 0.75 to 1.00, p=0.05]. No significant interactions between SEP and type of treatment 
[or SEP and histology] were found. 
Patients treated later than the referral and treatment target times had better 2-year 
survival than those who received timely treatment. 
Similar results were found for the 1999-2005 cohort. Socio-economic inequalities in 
survival were found in a univariable analysis [OR=0.81, 95% CI 0.73 to 0.90, p=0.006] 
and remained when adjusted for age, sex, year of diagnosis, co-morbidity and timely 
referral [OR=0.84, 95% CI 0.76 to 0.94, p<0.001, R2=5.80] but were no longer found 
when treatment was added to the model [OR=1.06, 95% CI 0.94 to 1.20, p=0.38 
R2=24.60] [appendix D, table D5]. Stage and PS were not available for these years.  
12.3.3.3 2006-2009 subset with stage recorded 
In the 2006 to 2009 subset with stage recorded [n=5233] socio-economic inequalities 
in survival were found in a multivariable analysis including age, sex, histology, year of 
diagnosis, co-morbidity and timely GP referral, with those in the most deprived group 
having a significantly lower likelihood of 2-year survival than those in the most affluent 
[OR=0.76, 95% CI 0.61 to 0.76, p=0.02], but with poor explanation of survival variance 
using this model [R2=3.72]. 
However, the association was no longer significant when stage was added [OR=0.79, 
95% CI 0.61 to 0.82, p=0.07], with a large increase in R2 to 24.39. The addition of PS 
further attenuated the OR (OR=0.90, 95% CI 0.70 to 1.17, p=0.45) [table 12.6] as did 
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the addition of treatment [OR=1.03, 95% CI 0.78 to 1.36, p=0.85]. Stage and receipt of 
treatment contributed most to the explanation for survival variance in the model but 
PS and treatment had the greatest influence on likelihood of survival by SEP. 
 
Table 12.4 Survival at 2 years: descriptive data and univariable ORs for 2006-2009 cohort 
Variable Cohort Survival at 2 years 
 
Unadjusted 
(n=22,967) 
 N N % OR 95% CI P 
Deprivation quintile 22,967 3,513 15.3    0.004 
1 (least deprived) 2,698 474 17.6 1.00    
2 3,303 520 15.7 0.88 0.76 1.00 0.06 
3 3,827 586 15.3 0.85 0.74 0.97 0.02 
4 5,387 815 15.1 0.84 0.74 0.95 0.005 
5 (most deprived) 7,752 1,118 14.4 0.79 0.70 0.89 <0.001 
Age group 22,967 3,513 15.3    <0.001 
<60 3,041 651 21.4 1.00    
60-69 6,016 1,199 19.9 0.91 0.82 1.02 0.10 
70-79 8,219 1,210 14.7 0.63 0.57 0.70 <0.001 
80+ 5,691 453 8.0 0.32 0.28 0.36 <0.001 
Sex 22,967 3,513 15.3    <0.001 
Female 10,510 1,770 16.8 1.00    
Male 12,457 1,743 14.0 0.80 0.75 0.86 <0.001 
Histology 22,967 3,513 15.3    <0.001 
NSCLC 12,152 2,463 20.3 1.00    
SCLC 2,829 236 8.3 0.36 0.31 0.41 <0.001 
Other  7,986 814 10.2 0.45 0.41 0.49 <0.001 
Histology (alternative) 22,967 3,513 15.3    <0.001 
Probable NSCLC 13053 2835 21.7 1.00    
SCLC 2,829 236 8.3 0.33 0.29 0.38 <0.001 
Unspecified 7085 442 6.2 0.24 0.22 0.27 <0.001 
Year of Diagnosis 22,967 3,513 15.3    <0.001 
2006 5,533 783 14.2 1.00    
2007 5,712 844 14.8 1.05 0.95 1.17 0.35 
2008 5,851 861 14.7 1.05 0.94 1.16 0.39 
2009 5,871 1,025 17.5 1.28 1.16 1.42 <0.001 
Co-morbidity 22,967 3,513 15.3    0.0006 
0 3,597 601 16.7 1.00    
1-2 3,125 453 14.5 0.85 0.74 0.97 0.01 
3+ 766 89 11.6 0.66 0.52 0.83 <0.001 
CCM missing 10,133 1,509 14.9 0.87 0.79 0.97 0.009 
No HES link 5,346 861 16.1 0.96 0.85 1.07 0.45 
Stage 22,967 3,513 15.3    <0.001 
I 864 504 58.3 1.00    
II 332 128 38.6 0.45 0.35 0.58 <0.001 
III 1,587 276 17.4 0.15 0.12 0.18 <0.001 
IV 2,450 139 5.7 0.04 0.03 0.05 <0.001 
missing 17,734 2,466 13.9 0.12 0.10 0.13 <0.001 
Performance Status 22,967 3,513 15.3    <0.001 
0 1,298 481 37.1 1.00    
1-2 3,414 635 18.6 0.39 0.34 0.45 <0.001 
3-4 1,415 65 4.6 0.08 0.06 0.11 <0.001 
Missing 16,840 2,332 13.9 0.27 0.24 0.31 <0.001 
Timely treatment 22,967 3,513 15.3    <0.001 
>31 days from diagnosis 7,443 2,346 31.5 1.00    
<=31 days from diagnosis 4,849 708 14.6 0.37 0.34 0.41 <0.001 
No treatment 10,675 459 4.3 0.10 0.09 0.11 <0.001 
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Table 12.4 (cont). Survival at 2 years: descriptive data and univariable ORs for 2006-2009 
cohort 
Variable Cohort Survival at 2 years 
 
Unadjusted 
(n=22,967) 
 N N % OR 95% CI P 
Timely GP referral 22,967 3,513 15.3    <0.001 
No GP referral date 11,014 1,254 11.4 1.00    
FHA<=14 days 8,284 1,456 17.6 1.66 1.53 1.80 <0.001 
FHA>14 days 3,669 803 21.9 2.18 1.98 2.40 <0.001 
Tumour type 22,967 3,513 15.3    <0.001 
Adenocarcinoma 3,409 861 25.3 1.00    
Squamous 4,141 992 24.0 0.93 0.84 1.04 0.19 
Large 640 116 18.1 0.66 0.53 0.81 <0.001 
Non-small 3,962 494 12.5 0.42 0.37 0.48 <0.001 
Other specified 901 372 41.3 2.08 1.78 2.43 <0.001 
Small 2,829 236 8.3 0.27 0.23 0.31 <0.001 
Unspecified carcinoma 442 26 5.9 0.18 0.12 0.28 <0.001 
Neoplasm 6,643 416 6.3 0.20 0.17 0.22 <0.001 
Surgery Y/N 22,967 3,513 15.3    <0.001 
No surgery 20731 1951 9.4 1.00    
Surgery 2236 1562 69.9 22.31 20.15 24.69 <0.001 
Chemotherapy Y/N 22,967 3,513 15.3    <0.001 
No chemotherapy 16340 2104 12.9 1.00    
Chemotherapy 6627 1409 21.3 1.83 1.70 1.97 <0.001 
Radiotherapy Y/N 22,967 3,513 15.3    <0.001 
No radiotherapy 15320 2108 13.8 1.00    
Radiotherapy 7647 1405 18.4 1.41 1.31 1.52 <0.001 
Type of 1
st
 treatment 22,967 3,513 15.3    <0.001 
No treatment 10,675 459 4.3 1.00    
Surgery 1st 2193 1534 70.0 51.81 45.46 59.04 <0.001 
Chemotherapy 1st 5490 892 16.3 4.32 3.84 4.86 <0.001 
Radiotherapy 1st 4609 628 13.6 3.51 3.10 3.98 <0.001 
Type of treatment 22,967 3,513 15.3    <0.001 
No treatment 10,675 459 4.3 1.00    
Surgery 1,427 1,041 73.0 60.02 51.68 69.71 <0.001 
Surgery +chemo/ radiotherapy 809 521 64.4 40.26 33.91 47.80 <0.001 
Chemotherapy 2,759 267 9.7 2.38 2.04 2.79 <0.001 
Chemotherapy+radiotherapy 3,236 701 21.7 6.15 5.43 6.98 <0.001 
Radiotherapy 4,061 524 12.9 3.30 2.89 3.76 <0.001 
Surgery 22,967 3,513 15.3    <0.001 
No surgery 20,731 1,951 9.41 1.00    
Surgery <31 days from 
diagnosis 515 333 64.7 17.61 14.61 21.22 <0.001 
Surgery 32-62 days from 
diagnosis 943 686 72.8 25.69 22.10 29.87 <0.001 
Surgery > 62 days from 
diagnosis 778 543 69.8 22.24 18.95 26.10 <0.001 
Chemotherapy 22,967 3,513 15.3    <0.001 
No chemotherapy 16,340 2,104 12.9 1.00    
Chemotherapy <31 days from 
diagnosis 2,782 324 11.7 0.89 0.79 1.01 0.07 
Chemotherapy 32-62 days 
from diagnosis 2,267 420 18.5 1.54 1.37 1.73 <0.001 
Chemotherapy >62 days from 
diagnosis 1,578 665 42.1 4.93 4.42 5.50 <0.001 
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Table 12.4 (cont). Survival at 2 years: descriptive data and univariable ORs for 2006-2009 
cohort 
Variable Cohort Survival at 2 years 
 
Unadjusted 
(n=22,967) 
 N N % OR 95% CI P 
 
Radiotherapy 22,967 3,513 15.3    <0.001 
No radiotherapy 15,320 2,108 13.8 1.00    
Radiotherapy <31 days from 
diagnosis 1,649 62 3.8 0.24 0.19 0.32 <0.001 
Radiotherapy 32-62 days from 
diagnosis 1,871 268 14.3 1.05 0.91 1.20 0.51 
Radiotherapy > 62 days from 
diagnosis 4,127 1,075 26.1 2.21 2.03 2.40 <0.001 
 
Timely 1
st
 Treatment 22,967 3,513 15.3    <0.001 
No treatment 10,675 459 4.3 1.00    
Chemotherapy 1
st
  >31 days 
from diagnosis 2,775 577 20.8 5.84 5.13 6.66 <0.001 
Chemotherapy 1
st
  <31 days 
from diagnosis 2,715 315 11.6 2.92 2.51 3.39 <0.001 
Surgery 1
st
  >31 days from 
diagnosis 1,678 1,201 71.6 56.04 48.65 64.55 <0.001 
Surgery 1
st
  <31 days from 
diagnosis 515 333 64.7 40.72 33.23 49.91 <0.001 
Radiotherapy  1
st
 >31 days 
from diagnosis 2,990 568 19.0 5.22 4.58 5.95 <0.001 
Radiotherapy  1
st
 <31 days 
from diagnosis 1,619 60 3.7 0.86 0.65 1.13 0.27 
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Table 12.5. Likelihood of still being alive 2 years after diagnosis, by selected patient, tumour 
and system factors for those diagnosed between 2006 and 2009 (DCO cases excluded)  
Variable Adjusted – IMD, age, sex, histology, year, 
CCM, timely referral 
(n=22,967, R2=5.77) 
Adjusted – IMD, age, sex, histology, year, 
CCM, timely referral, stage, PS 
(n=22,967, R2=12.31) 
 OR 95% CI P OR 95% CI P 
Deprivation quintile    <0.001    0.002 
1 (least deprived) 1.00    1.00    
2 0.87 0.76 1.00 0.05 0.87 0.76 1.01 0.07 
3 0.86 0.75 0.98 0.03 0.87 0.75 1.00 0.05 
4 0.80 0.70 0.91 0.001 0.83 0.72 0.95 0.005 
5 (most deprived) 0.74 0.66 0.84 <0.001 0.77 0.68 0.88 <0.001 
Age group    <0.001    <0.001 
<60 1.00    1.00    
60-69 0.93 0.83 1.03 0.17 0.92 0.82 1.03 0.14 
70-79 0.65 0.58 0.73 <0.001 0.64 0.57 0.71 <0.001 
80+ 0.35 0.31 0.41 <0.001 0.34 0.30 0.39 <0.001 
Sex    <0.001    <0.001 
Female 1.00    1.00    
Male 0.74 0.69 0.80 <0.001 0.73 0.67 0.79 <0.001 
Histology    <0.001    <0.001 
NSCLC 1.00    1.00    
SCLC 0.34 0.30 0.40 <0.001 0.36 0.31 0.42 <0.001 
Other 0.60 0.55 0.66 <0.001 0.64 0.58 0.71 <0.001 
Year of Diagnosis    0.08    0.20 
2006 1.00    1.00    
2007 1.06 0.95 1.18 0.30 1.05 0.94 1.18 0.35 
2008 1.06 0.95 1.19 0.27 1.08 0.96 1.21 0.18 
2009 1.19 1.04 1.36 0.01 1.16 1.01 1.33 0.04 
Co-morbidity score    0.007    0.01 
0 1.00    1.00    
1-2 0.95 0.83 1.09 0.50 0.94 0.81 1.08 0.38 
3+ 0.84 0.66 1.07 0.16 0.79 0.61 1.03 0.08 
CCM missing 0.82 0.74 0.92 <0.001 0.83 0.74 0.93 0.001 
No HES link 0.94 0.82 1.07 0.32 0.97 0.85 1.11 0.66 
Timely GP referral    <0.001    <0.001 
No GP referral 1.00    1.00    
FHA<=14 days 1.44 1.32 1.58 <0.001 1.40 1.28 1.53 <0.001 
FHA>14 days 1.98 1.79 2.19 <0.001 1.80 1.62 2.01 <0.001 
Stage        <0.001 
I     1.00    
II     0.38 0.29 0.50 <0.001 
III     0.13 0.11 0.16 <0.001 
IV     0.04 0.03 0.05 <0.001 
missing     0.17 0.14 0.20 <0.001 
Performance Status        <0.001 
0     1.00    
1-2     0.55 0.47 0.65 <0.001 
3-4     0.18 0.14 0.24 <0.001 
Missing     0.45 0.38 0.54 <0.001 
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Table 12.5 (b). Likelihood of still being alive 2 years after diagnosis, by selected patient, 
tumour and system factors for those diagnosed between 2006 and 2009 (DCO cases 
excluded)  
variable Adjusted – IMD, age, sex, histology, year, 
CCM, timely referral, stage, PS, treatment 
type 
 (n=22,967, R2=27.97) 
Adjusted – IMD, age, sex, histology, year, 
CCM, timely referral, stage, PS, treatment 
type, timely 1st treatment 
 (n=22,967, R2=28.74) 
 OR 95% CI P OR 95% CI P 
Deprivation quintile    0.34    0.34 
1 (least deprived) 1.00    1.00    
2 0.88 0.75 1.04 0.13 0.88 0.75 1.04 0.14 
3 0.90 0.77 1.06 0.22 0.90 0.76 1.05 0.18 
4 0.94 0.81 1.09 0.41 0.94 0.81 1.09 0.39 
5 (most deprived) 0.87 0.75 1.00 0.06 0.87 0.75 1.00 0.05 
Age group    0.11    0.04 
<60 1.00    1.00    
60-69 1.04 0.91 1.18 0.60 1.02 0.89 1.16 0.80 
70-79 0.94 0.82 1.07 0.33 0.90 0.79 1.03 0.12 
80+ 0.88 0.74 1.03 0.12 0.84 0.71 1.00 0.05 
Sex    <0.001    <0.001 
Female 1.00    1.00    
Male 0.72 0.66 0.79 <0.001 0.71 0.65 0.78 <0.001 
Histology    <0.001    <0.001 
NSCLC 1.00    1.00    
SCLC 0.46 0.40 0.54 <0.001 0.57 0.49 0.67 <0.001 
Other  1.28 1.14 1.44 <0.001 1.33 1.18 1.50 <0.001 
Year of Diagnosis    0.009    0.009 
2006 1.00    1.00    
2007 1.02 0.90 1.15 0.77 1.00 0.88 1.13 0.95 
2008 1.08 0.95 1.23 0.22 1.02 0.90 1.16 0.75 
2009 0.83 0.71 0.98 0.03 0.80 0.68 0.93 0.005 
Co-morbidity score    <0.001    <0.001 
0 1.00    1.00    
1-2 1.10 0.93 1.29 0.25 1.10 0.93 1.29 0.25 
3+ 0.96 0.72 1.28 0.79 0.96 0.72 1.29 0.81 
CCM missing 0.84 0.73 0.95 0.006 0.83 0.73 0.95 0.006 
No HES link 1.37 1.17 1.60 <0.001 1.38 1.18 1.61 <0.001 
Timely GP referral    <0.001    <0.001 
No GP referral date 1.00    1.00    
FHA<=14 days 1.16 1.05 1.29 0.004 1.14 1.03 1.26 0.02 
FHA>14 days 1.40 1.25 1.58 <0.001 1.36 1.20 1.53 <0.001 
Stage    <0.001    <0.001 
I 1.00    1.00    
II 0.48 0.35 0.68 <0.001 0.49 0.35 0.69 <0.001 
III 0.29 0.23 0.36 <0.001 0.30 0.24 0.38 <0.001 
IV 0.12 0.09 0.15 <0.001 0.13 0.10 0.17 <0.001 
Missing 0.31 0.25 0.38 <0.001 0.33 0.27 0.41 <0.001 
Performance Status    0.001     
0 1.00    1.00    
1-2 0.88 0.73 1.05 0.16 0.89 0.74 1.07 0.20 
3-4 0.59 0.43 0.81 0.001 0.61 0.44 0.83 0.002 
Missing 0.73 0.60 0.90 0.002 0.72 0.59 0.88 0.002 
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Table 12.5 (b, cont). Likelihood of still being alive 2 years after diagnosis, by selected patient, 
tumour and system factors for those diagnosed between 2006 and 2009 (DCO cases 
excluded)  
variable Adjusted – IMD, age, sex, histology, year, 
CCM, stage, PS, timely referral, treatment 
type 
 (n=22,967, R2=27.97) 
Adjusted – IMD, age, sex, histology, year, 
CCM, stage, PS, timely referral, treatment 
type, timely 1st treatment 
 (n=22,967, R2=28.74) 
 OR 95% CI P OR 95% CI P 
Type of treatment    <0.001    <0.001 
No treatment 1.00    1.00    
Surgery 49.77 41.93 59.07 <0.001 60.95 51.12 72.66 <0.001 
Surgery +chemo/ 
radiotherapy 33.00 26.99 40.34 <0.001 40.47 32.96 49.69 <0.001 
Chemotherapy 3.25 2.71 3.91 <0.001 4.19 3.47 5.05 <0.001 
Chemotherapy+radiotherapy 7.83 6.65 9.22 <0.001 10.03 8.48 11.86 <0.001 
Radiotherapy 3.34 2.89 3.87 <0.001 4.12 3.55 4.78 <0.001 
Timely 1
st
 treatment        <0.001 
>31 days from diagnosis     1.00    
<31 days from diagnosis     0.50 0.45 0.56 <0.001 
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Table 12.6. Likelihood of still being alive 2 years after diagnosis, by selected patient, tumour 
and system factors for those diagnosed between 2006 and 2009 (DCO cases excluded) with 
stage recorded 
Variable Adjusted – IMD, age, sex, 
histology, year, CCM, timely GP 
referral 
(n=5233, R2=3.72) 
Adjusted – IMD, age, sex, 
histology, year, CCM, timely GP 
referral, stage  
(n=5233, R2=24.39) 
Adjusted – IMD, age, sex, 
histology, year, CCM, timely GP 
referral, stage, PS 
(n=5233, R2=26.59) 
 OR 95% CI P OR 95% CI P OR 95% CI P 
Deprivation 
quintile 
   0.02    0.07    0.22 
1 (least deprived) 1.00    1.00    1.00    
2 0.92 0.71 1.20 0.54 0.93 0.69 1.25 0.62 0.97 0.72 1.31 0.83 
3 0.92 0.72 1.19 0.53 0.92 0.69 1.23 0.56 1.00 0.75 1.34 0.99 
4 0.72 0.56 0.91 0.007 0.71 0.54 0.93 0.01 0.77 0.58 1.02 0.06 
5 (most deprived) 0.76 0.61 0.96 0.02 0.79 0.61 1.02 0.07 0.90 0.70 1.17 0.45 
Age group    <0.001    <0.001    <0.001 
<60 1.00    1.00    1.00    
60-69 1.06 0.86 1.31 0.60 0.94 0.74 1.20 0.63 1.03 0.81 1.32 0.79 
70-79 0.79 0.64 0.97 0.03 0.60 0.47 0.77 <0.001 0.75 0.59 0.96 0.02 
80+ 0.53 0.41 0.68 <0.001 0.35 0.26 0.47 <0.001 0.49 0.36 0.67 <0.001 
Sex    <0.001    <0.001    <0.001 
Female 1.00    1.00    1.00    
Male 0.75 0.65 0.86 <0.001 0.72 0.61 0.84 <0.001 0.70 0.59 0.82 <0.001 
Histology    <0.001    <0.001    <0.001 
NSCLC 1.00    1.00    1.00    
SCLC 0.32 0.22 0.47 <0.001 0.49 0.32 0.75 0.001 0.49 0.32 0.76 0.001 
Other 0.65 0.54 0.78 <0.001 0.61 0.50 0.76 <0.001 0.80 0.64 1.00 0.05 
Year of 
Diagnosis    0.70    0.29    0.93 
2006 1.00    1.00    1.00    
2007 1.03 0.80 1.33 0.83 1.04 0.78 1.39 0.78 1.07 0.80 1.43 0.66 
2008 0.91 0.72 1.15 0.42 1.04 0.80 1.37 0.75 1.09 0.83 1.44 0.52 
2009 0.95 0.72 1.25 0.70 1.09 0.80 1.49 0.58 1.09 0.79 1.50 0.59 
Co-morbidity 
score    0.07        0.22 
0 1.00    1.00    1.00    
1-2 1.22 0.95 1.58 0.12 1.08 0.81 1.45 0.59 1.21 0.90 1.64 0.20 
3+ 1.00 0.63 1.58 1.00 0.67 0.40 1.13 0.14 0.83 0.49 1.40 0.48 
CCM missing 0.85 0.68 1.07 0.17 0.94 0.73 1.22 0.63 0.93 0.71 1.21 0.58 
No HES link 1.05 0.83 1.34 0.66 1.13 0.86 1.48 0.39 1.19 0.91 1.58 0.21 
Timely GP 
referral    <0.001    <0.001    <0.001 
No GP referral  1.00    1.00    1.00    
FHA<=14 days 1.44 1.22 1.70 <0.001 1.47 1.21 1.78 <0.001 1.36 1.12 1.66 0.002 
FHA>14 days 1.87 1.52 2.30 <0.001 1.45 1.15 1.84 0.002 1.33 1.05 1.70 0.02 
Stage        <0.001    <0.001 
I     1.00    1.00    
II     0.39 0.29 0.51 <0.001 0.40 0.30 0.53 <0.001 
III     0.13 0.11 0.16 <0.001 0.14 0.12 0.17 <0.001 
IV     0.04 0.03 0.05 <0.001 0.04 0.04 0.06 <0.001 
Performance 
Status 
    
       <0.001 
0         1.00    
1-2         0.53 0.44 0.64 <0.001 
3-4         0.18 0.13 0.25 <0.001 
Missing         0.47 0.35 0.64 <0.001 
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Table 12.6 (cont). Likelihood of still being alive 2 years after diagnosis, by selected patient, 
tumour and system factors for those diagnosed between 2006 and 2009 (DCO cases 
excluded) with stage recorded 
Variable Adjusted – IMD, age, sex, histology, year, 
CCM, stage, PS, timely referral, treatment 
type 
(n=5233, R2=31.73) 
Adjusted – IMD, age, sex, histology, year, 
CCM, stage, PS, timely referral, treatment 
type, timely 1st treatment 
 (n=5233, R2=32.04) 
 OR 95% CI P OR 95% CI P 
Deprivation quintile    0.76    0.80 
1 (least deprived) 1.00    1.00    
2 1.02 0.74 1.40 0.92 1.01 0.73 1.39 0.97 
3 1.08 0.79 1.47 0.64 1.07 0.78 1.46 0.67 
4 0.90 0.67 1.21 0.51 0.91 0.67 1.22 0.51 
5 (most deprived) 1.03 0.78 1.36 0.85 1.02 0.77 1.34 0.90 
Age group    0.69    0.67 
<60 1.00    1.00    
60-69 1.12 0.86 1.45 0.41 1.11 0.85 1.44 0.45 
70-79 1.03 0.78 1.34 0.85 1.00 0.77 1.31 0.99 
80+ 0.95 0.68 1.33 0.79 0.94 0.67 1.31 0.71 
Sex    <0.001    <0.001 
Female 1.00    1.00    
Male 0.69 0.58 0.82 <0.001 0.69 0.58 0.82 <0.001 
Histology    0.0005    0.007 
NSCLC 1.00    1.00    
SCLC 0.48 0.31 0.74 0.001 0.55 0.35 0.85 0.008 
Other  1.19 0.93 1.52 0.18 1.18 0.92 1.51 0.19 
Year of Diagnosis    0.43    0.41 
2006 1.00    1.00    
2007 1.02 0.75 1.38 0.91 1.00 0.73 1.36 0.99 
2008 1.02 0.77 1.37 0.87 0.98 0.74 1.31 0.92 
2009 0.82 0.59 1.14 0.24 0.79 0.57 1.11 0.18 
Co-morbidity score    0.02    0.02 
0 1.00    1.00    
1-2 1.35 0.99 1.84 0.06 1.35 0.99 1.84 0.06 
3+ 1.06 0.61 1.83 0.84 1.02 0.59 1.78 0.93 
CCM missing 0.90 0.68 1.18 0.46 0.90 0.68 1.18 0.43 
No HES link 1.40 1.04 1.88 0.03 1.40 1.05 1.89 0.02 
Stage    <0.001    <0.001 
I 1.00    1.00    
II 0.47 0.34 0.63 <0.001 0.47 0.35 0.64 <0.001 
III 0.23 0.18 0.29 <0.001 0.24 0.19 0.30 <0.001 
IV 0.09 0.07 0.12 <0.001 0.10 0.07 0.13 <0.001 
Performance Status    <0.001    <0.001 
0 1.00    1.00    
1-2 0.75 0.61 0.92 0.007 0.76 0.62 0.94 0.01 
3-4 0.44 0.30 0.65 <0.001 0.46 0.31 0.67 <0.001 
Missing 0.70 0.51 0.97 0.03 0.72 0.52 0.99 0.05 
Timely GP referral    0.14    0.16 
No GP referral date 1.00    1.00    
FHA<=14 days 1.23 1.00 1.52 0.05 1.22 0.99 1.50 0.06 
FHA>14 days 1.16 0.90 1.50 0.25 1.15 0.89 1.48 0.29 
Type of treatment    <0.001    <0.001 
No treatment 1.00    1.00    
Surgery 11.24 7.78 16.24 <0.001 12.86 8.84 18.70 <0.001 
Surgery 
+chemo/radiotherapy 13.13 8.78 19.63 <0.001 14.94 9.93 22.49 <0.001 
Chemotherapy 2.48 1.70 3.62 <0.001 2.81 1.92 4.11 <0.001 
Chemo+radiotherapy 4.75 3.41 6.61 <0.001 5.43 3.87 7.60 <0.001 
Radiotherapy 2.24 1.67 3.00 <0.001 2.47 1.83 3.32 <0.001 
Timely 1
st
 treatment        <0.001 
>31 days from diagnosis     1.00    
<31 days from diagnosis     0.63 0.51 0.79 <0.001 
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12.4 Discussion 
12.4.1 Principal findings 
Socio-economic inequalities in receipt of treatment appear to contribute to socio-
economic inequalities in lung cancer survival. Survival inequalities were found when 
patient, tumour and system factors were included in the multivariable model but the 
addition of treatment type significantly attenuated socio-economic inequalities in 
survival. The further addition of time to treatment had no significant effect on socio-
economic inequalities in survival. Time to treatment was, however, significantly 
associated with risk of death and those who received treatment within guidelines 
[within 31 days of diagnosis] had poorer survival than those who had later treatment 
[within 1 year of diagnosis].  
12.4.2 Strengths and weaknesses 
An exact date of death was not available as this was considered a potentially-
identifiable data item. Survival time in weeks was utilised here.  
Inconsistent recording of the date of diagnosis and the different methodology used for 
determining date of diagnosis in 2010, as previously described, might also be a 
problem when calculating survival time from diagnosis to death. However, the 2006-
2009 dataset was used to calculate the likelihood of two-year survival, and both the 
2006-2010 and 2006-2009 datasets were used to determine risk of all-cause mortality 
and similar patterns of results were found in both data-sets. 
12.4.3 Interpretation of results and comparison with other studies 
Inequalities in receipt of treatment [surgery and chemotherapy but not radiotherapy] 
were found for this dataset [chapter 10] and these treatment inequalities appear to 
substantially explain inequalities in survival. This has previously been shown in a small 
study of 695 patients that did not include co-morbidity or PS in the multivariable 
analysis (158). Number of co-morbidities and PS vary by SEP (69) and age (70) and 
might help explain socio-economic inequalities in receipt of treatment and survival. 
But in a multivariable analysis adjusted for stage and PS survival inequalities were still 
observed and it was only on addition of receipt of treatment that the association no 
longer remained significant. However, in the subset with stage recorded PS also 
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substantially accounted for socio-economic inequalities in survival. As previously 
discussed, this staged subset may not be representative of the full cohort, as patients 
within this were more likely to be younger and had higher rates of treatment.  
It has been suggested that the poorer survival of UK cancer patients compared to the 
European average might be related to diagnostic delay (102). However, two literature 
reviews both found the evidence for any association between timely care and survival 
for lung cancer inconclusive (184, 185). Contradictory results were found in the studies 
examined but the quality of the studies included was mixed and most did not 
adequately control for important confounders such as age, stage, histology and co-
morbidity (185). The lack of control for confounding factors may account for why those 
with more timely care actually had poorer survival, due to the Waiting Time Paradox 
[WTP], as previously discussed in chapter 11. 
Adequately controlling for stage, co-morbidity and PS should therefore eliminate this 
‘sicker quicker’ effect. In a small study of colorectal cancer patients, shorter diagnostic 
interval was associated with higher mortality for those who appeared more ill, but not 
for those presenting with ‘vague’ symptoms (179). However, in our study we found 
that a shorter diagnostic to treatment interval resulted in a lower likelihood of survival 
two years after diagnosis and increased hazard of death, compared to those with later 
treatment. Furthermore, those who had a FHA within 14 days of GP referral had 
poorer survival than those who waited longer to be seen in secondary care. These 
associations remained after age, stage, histology, co-morbidity and PS were taken into 
account in the multivariable analysis. It may be that uncontrolled confounding remains 
or that the measures of ‘sickness’ used – PS and co-morbidity - are not particularly 
good. The high levels of missing stage and PS data are also a major limitation. 
However, we also carried out this analysis in the staged subset [which is effectively a 
complete-case cohort for stage and PS] and a similar result was found.  
The NHS Cancer Plan set guideline waiting times for cancer treatment of 31 days from 
diagnosis and 62 days from GP referral. I have previously shown that, in patients who 
received treatment within 1 year of diagnosis, those with later stage cancer, poor PS, 
and those undergoing chemotherapy as a first treatment were more likely to receive 
timely treatment within guidelines [chapter 11]. Those with higher SEP were not 
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significantly more likely to receive treatment within the 31 day guideline from 
diagnosis. It appears that sicker patients with later-stage cancer obtain non-curative 
treatment within guidelines whereas earlier stage, good-PS patients wait longer for 
curative care, but their survival is better.  
Patients who were treated within the guideline targets had poorer survival than those 
who had later treatment, which might bring into question the clinical validity of these 
guidelines. Two year survival was better for those patients who had surgery later than 
the 31 day guideline [72.8% of those who had surgery between 31-62 days after 
diagnosis were still alive compared to 64.7% who had treatment within guidelines] but 
for four-year survival there was higher survival for those treated within guidelines [see 
Fig 12.10]. When I looked at time to surgery and survival for patients with early stage 
cancer [as these are the patients for whom application of the guidelines might improve 
survival] similar patterns were seen, so the evidence for the effectiveness of the 
guidelines in improving survival is unclear.  
I previously found no socio-economic inequalities in the diagnosis to treatment interval 
but some suggestion of inequalities in the GP referral to FHA interval, with those in the 
highest and the lowest SEP groups having quicker referral. As no linear association is 
observed it is perhaps unsurprising that time from diagnosis to treatment had little 
effect on socio-economic inequalities in survival. A study that looked at breast cancer 
survival also found that that time to treatment was not associated with deprivation 
and that adjusting for time to treatment did not attenuate the association of 
deprivation with survival (181). They suggest that lower survival amongst more 
deprived patients may therefore relate to factors prior to their entry into the 
secondary care system although they were not able to consider inequalities in receipt 
of treatment as they looked at only those patients who received treatment. 
The results from chapter 10 suggested that socio-economic inequalities in tumour type 
might account for some of the socio-economic inequalities in receipt of treatment as 
rates of treatment were higher for adenocarcinoma compared to squamous-cell 
tumours. The highest treatment rates were found in the ‘other-specified-histology’ and 
patients in this category had the highest two-year survival. However there was no 
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significant difference in two- year survival rates between patients diagnosed with 
adenocarcinoma and squamous-cell tumours. 
12.4.4 Implications for policy and practice, and further research 
Inequalities in receipt of treatment appear to substantially account for inequalities in 
lung cancer survival. However, clinical guidelines focus on target times for referral and 
treatment. Perhaps a clinical focus on ensuring that those who are eligible for 
treatment actually receive it, rather than on time-interval targets might have a greater 
impact on improving survival, as well as reducing inequalities in survival. 
As patients who were treated within the guideline targets had poorer survival than 
those who had later treatment, the effectiveness of the guidelines on improving 
survival appears unclear. Patients with early stage cancer are likely to be the patients 
for whom application of the guidelines, resulting in earlier referral and treatment, 
might improve survival. Further research on this group of patients is warranted to help 
determine whether delays in referral and treatment lead to poorer lung cancer 
survival, without the confounding effect of the WTP. Further research is also required 
to determine whether this interval effect on survival is also seen in other cancers.  
Further examination of the patient, tumour and system factors that determine 
timeliness of treatment is warranted to determine why those who have later 
treatment have better survival, and to develop interventions to improve cancer 
survival. 
12.5 Chapter summary 
Socio-economic inequalities in lung cancer survival appear to be statistically explained 
by inequalities in receipt of treatment but not by time from GP referral to FHA or from 
diagnosis to treatment. However, patients who were treated within the time-to-
treatment guideline targets had poorer survival compared to those who had later 
treatment, as explained by the WTP.  
Interventions that address socio-economic inequalities in receipt of treatment are 
likely to reduce socio-economic inequalities in survival and thus improve survival rates 
overall. 
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The next chapter will summarise and discuss all the findings from previous results 
chapters on socio-economic inequalities in: receipt of treatment [chapters 7 and 10]; 
referral, diagnostic and treatment intervals [chapter 11]; and survival [chapter 12]; 
discuss the methodological strengths and weaknesses of the study, the implications for 
policy and practice, and the further research required. 
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Chapter 13. Overall summary - discussion and conclusions 
This final chapter presents a summary of the thesis findings, details overall strengths 
and weaknesses of the data and the analyses, and suggests some detailed further 
research that might arise from this work, as well as the specific post-doctoral research 
that I plan to conduct. The findings from each component of the thesis in relation to 
published studies have been discussed in depth in previous chapters and so a summary 
of what the thesis has added to knowledge will be detailed here. 
13.1 Background 
This research examined the evidence for socio-economic inequalities in time to, and 
receipt of, treatment for lung cancer, and the contribution of these inequalities to 
socio-economic inequalities in survival, using the intervention-generated inequalities 
framework. 
13.2 Methods 
To examine the existing evidence for socio-economic inequalities in lung cancer 
treatment a systematic review and meta-analysis of published studies was conducted. 
Cohort studies of participants with a primary diagnosis of lung cancer [ICD10 C33 or 
C34], where the outcome was receipt of treatment [rates or odds of receiving 
treatment] and where the outcome was reported by a measure of socio-economic 
position were examined. A quality tool was used to assess study quality. Studies 
conducting multivariable analysis were considered for meta-analysis. 
Potentially-important confounders that had previously been poorly investigated were 
identified by the systematic review and the results from this were used to determine 
variables to include in the secondary data analyses. Cancer registry [NYCRIS], Hospital 
Episode Statistics [HES] and lung cancer audit [LUCADA] data-sets were linked in order 
to investigate intervention-generated inequalities in lung cancer care. 
NYCRIS data for 65,210 patients diagnosed between 1999 and 2010 with a primary 
diagnosis of lung cancer were analysed. Logistic regression was used to examine the 
likelihood of receipt of treatment by SEP and of receiving timely referral, diagnosis and 
treatment within guideline targets, as well as the likelihood of still being alive two 
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years after diagnosis, by SEP. Cox regression was used to assess the likelihood of early 
referral, diagnosis and treatment and risk [hazard] of death by SEP.  
13.3 Results  
A total of 46 papers were included in the systematic review and 23 in the meta-
analysis. Socio-economic inequalities in receipt of lung cancer treatment [surgery, 
chemotherapy but not radiotherapy] were identified in the meta-analysis. These 
inequalities could not be accounted for by socio-economic differences in stage at 
presentation or by differences in health care system. However, not all of the included 
studies reported details of stage and histology, both of which influence treatment 
type, and very few studies took co-morbidity or performance status into account.  
In the linked database analysis socio-economic inequalities in receipt of surgery and 
chemotherapy, but not radiotherapy, were found after control for age, sex, histology, 
stage, performance status and co-morbidity. The odds of receiving surgery were 
significantly lower in the lowest compared to the highest SEP group. Patients in the 
lowest SEP group were significantly less likely to receive chemotherapy in the full 
2006-2010 cohort but not in the staged-subset when performance status was included 
in the model.  
In the 2006 to 2010 cohort 70% of patients received a hospital appointment within the 
14 day urgent referral target [although patients with non-urgent referrals might also 
be included here]. Time to treatment targets were only being met for 42.5% when 
measured from diagnosis and for 62% from GP referral. Socio-economic inequalities in 
time from GP referral to FHA were identified but a linear trend association by SEP was 
not seen. Late-stage, poor performance status, high SEP and SCLC histology were 
associated with a higher likelihood of a first hospital appointment within 14 days of GP 
referral. Older patients were less likely, whereas late stage and poor PS patients were 
more likely, to receive treatment within guideline time limits. 
Only 15.3% of patients were still alive 2 years after diagnosis. This increased to 70% for 
those who had surgery. Patients referred and treated later than guideline targets had 
higher likelihood of surviving to 2 years and decreased risk of death.  
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Socio-economic inequalities in survival were found in a multivariable analysis 
controlling for age, sex, histology, year of diagnosis, timely GP referral, co-morbidity, 
stage and performance status, with those in the lowest socio-economic group 
significantly less likely to be alive after 2 years, compared to the highest group. 
However, when receipt of treatment was included in the analysis the association no 
longer remained significant. Addition of timeliness of treatment made no difference to 
the conclusion.  
13.4 Discussion 
13.4.1 Principal findings 
This study found socio-economic inequalities in the lung cancer care pathway, with 
inequalities in receipt of surgery and chemotherapy, and in the time interval from GP 
referral to FHA. Socio-economic inequalities in survival from lung cancer were 
statistically explained by socio-economic inequalities in receipt of treatment, but not 
by inequalities in timeliness of referral and treatment, in this cohort.  
Socio-economic inequalities in lung cancer treatment could not be explained by 
inequalities in stage or performance status in the full dataset. However, socio-
economic differences in performance status may account for the observed socio-
economic differences in receipt of chemotherapy in the staged subset. Socio-economic 
inequalities in tumour type may account for some of the socio-economic gradient in 
surgery. 
Socio-economic inequalities in the GP referral to FHA, diagnosis and treatment 
intervals were found but were not seen in the interim intervals from FHA to diagnosis 
or from diagnosis to treatment, suggesting that interval inequalities originate in the GP 
referral to FHA interval. However, no survival benefit of timely referral and treatment 
was demonstrated and patients who were treated within the guideline targets had 
poorer survival than those who had later treatment.  
13.4.2 Methodological strengths and weaknesses  
This is one of the first studies to link three datasets [NYCRIS, HES and LUCADA] in order 
to examine the factors that may influence socio-economic inequalities in lung cancer 
treatment, time to treatment and survival. Using a triple-linked dataset allowed 
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inclusion of co-morbidity, stage and performance status data in the analyses whilst 
also employing the large, comprehensive cancer registry dataset. However, the years 
in which stage and PS were most completely recorded in LUCADA [2009-2010] were 
also the years of registry data which did not yet have a co-morbidity score available. 
Examining receipt of treatment and survival in the 2006-2008 dataset that included all 
three variables gave the same pattern of results [results not shown] as that for 2006-
2009 and 2006-2010, therefore the larger year groups were employed where possible.  
Co-morbidity was included in the 1999-2005 cohort analysis, and stage and PS in the 
2006-2010 cohort, with the addition of co-morbidity to see if this made any difference 
to the outcome. Differences over time between the earlier- and later-year cohorts 
could also be observed. 
A major strength of this study is the completeness of treatment data recorded in the 
large NYCRIS cancer registry dataset particularly for chemotherapy and radiotherapy, 
which are often poorly recorded elsewhere. Treatment was also more 
comprehensively recorded here than in LUCADA (253).  
LUCADA data has been cited as an ideal data source for lung cancer research (153) but 
although LUCADA audit data completeness has improved, nationally this was low in 
the early years [66% entry of patients diagnosed in 2006, increasing to 93% entry in 
2010] (246). The number with stage recorded was also initially low [36% of patients 
diagnosed in 2006] but again is increasing over time [79% in 2010] (246). For my linked 
north of England dataset the numbers were lower than this. Stage and PS were 
available within the linked LUCADA data but only 27% [7769] of the 2006-2010 registry 
cohort had stage recorded in LUCADA. Therefore one major weakness of the analysis 
was the high level of missing stage and PS data.  
Stage was recorded for 11.8% in 2006 and data completeness improved over time. 
However, even in 2010, the year with the most complete stage data, stage was only 
recorded for 43% of participants. Multiple imputation was considered as a way of 
dealing with missing data but it is not recommended where over 50% of the data in a 
variable are missing (241). An alternative way to address the problem of missing data 
is  to analyse only complete cases, although results from complete-case analyses can 
be biased (242). Therefore I looked at the subset of patients who had stage recorded 
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[as an analysis of complete-case stage patients] and I also analysed the full dataset and 
included a ‘stage missing’ category. Differences between the datasets were examined 
and used to help explain any differences in outcome observed.  
Patients with poorer performance status had increased odds of timely FHA, diagnosis 
and treatment but a lower likelihood of receiving treatment. No clear-cut pattern was 
observed in time intervals or receipt of treatment by co-morbidity score in this study. 
Both co-morbidity score and PS can be used as proxy measures of general wellbeing 
and my results would suggest that PS may be a better marker of this. PS is a measure 
of patients’ functional status and need for care measured on an ECOG scale of 0-4, 
determined by the care team. Although it has been shown to have good prognostic 
predictive validity (257) it could be considered a somewhat subjective measure. Only 
moderate inter-observer agreement in allocating PS score was found in an inter-
observer variability study, although there was good agreement when allocating good 
[PS 0-2] compared to poor PS [PS 3-4]  (258).  
Co-morbidity score, obtained from HES data, does not appear to be a particularly good 
measure of patient well-being, and high levels of missing data were an issue. The 
Charlson Co-morbidity [CCM] Index is a validated instrument for measuring co-
morbidity (245) but only contains details of conditions requiring in-patient care. 
Patients who suffer from a relevant condition but are treated by their GP will have a 
score of O, thus resulting in misclassification and underestimation of co-morbidity 
(259). It is also a crude measure of co-morbidity as patients with mild and severe forms 
of a disease receive the same score. This is a problem for conditions such as COPD 
where the severity of the disease is likely to influence the likelihood of surgery (259). 
Details of the particular condition and the severity of this would be a more useful 
measure than a crude score. Details of co-morbidity are included within the LUCADA 
audit dataset although recording of this remains low. One of the key messages of the 
2012 audit report (246) related to improving the recording of co-morbidity so that this 
is a more reliable variable for case-mix adjustment. Future studies may therefore be 
able to utilise this. 
As for most cancer registry-based analyses, an area-based, ecological measure of SEP, 
calculated using postcode, was employed, which is unlikely to be an accurate marker 
230 
 
of individual circumstances and access to resources (234), potentially under-estimating 
the strength of the true association between SEP and receipt of treatment. A changing-
deprivation-score-over-time methodology was used, as this is more likely to accurately 
reflect current area deprivation, rather than previous methods which retrospectively 
applied current deprivation back in time to earlier years of diagnosis (244). 
Lack of smoking status data is a major weakness for any study examining lung cancer 
but is one found for all studies examined as part of this research, as smoking status is 
not routinely recorded as part of the cancer registry dataset. 
The focus of this PhD study was lung cancer. One advantage of focusing on a single 
cancer is that a detailed and in-depth analysis can be carried out within the three-year 
timescale, which would not be possible if the scope of the PhD were broader. 
Conducting analyses on a combined number of different cancers may mask any 
between-cancer differences relating to tumour development and prognosis that might 
influence likelihood and timing of treatment. However, the generalisability of the 
results to other cancers is unclear. 
The systematic review and meta-analysis included studies from UHCS and non-UHCS 
countries and so the results are relevant internationally. However, for the secondary 
data analysis, local north of England data were analysed. Local rather than England-
wide data were requested from NYCRIS following discussion with the NYCRIS Director 
and a number of analysts. This was a pragmatic decision relating to the complexity of 
the linkage, and the manageability and size of the dataset, but affects the potential 
generalisability of these lung cancer results for the whole of England, the UK and 
beyond.  
13.4.3 Interpretation of findings and comparisons with other studies 
I have previously interpreted the findings of each of my study components and done a 
comparison with published studies in the preceding chapters. Here I will make some 
remarks in summary. 
Overall, this study has been able to advance knowledge on the topic of socio-economic 
inequalities in lung cancer care. I have demonstrated socio-economic inequalities in 
lung cancer treatment for surgery and chemotherapy, but not radiotherapy, in both 
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UHCSs and non-UHCSs, in my systematic review and meta-analysis. I have been able to 
include a number of important confounders that have not been previously well 
examined [stage, PS, co-morbidity] in the secondary data analysis, although the levels 
of missing data were a limitation. Inequalities in the referral, diagnostic and treatment 
intervals have not been well explored before. My results suggest that socio-economic 
inequalities are found in the referral interval. I have also been able to show an 
association between socio-economic inequalities in receipt of treatment and 
inequalities in lung cancer survival.  
13.4.4 Implications for policy and practice, and further research 
I have been able to investigate a number of factors that may be important in the 
relationship between SEP and survival such as receipt of, and time to, treatment, stage 
and performance status. However, high levels of missing data and inconsistent data 
recording remain important problems. In order to clearly document the relationships 
between these variables and receipt of treatment and survival, more complete and 
accurate recording of data is required. 
The high levels of missing stage and PS data within the early LUCADA data were a 
major problem. The comparability of the audit data with that held within registries is 
uncertain as differences were found between trusts that supplied high and low levels 
of data to the audit in early years (152) that does appear to have been somewhat 
glossed over in the literature. Data quality and completeness within LUCADA has 
greatly improved over recent years [see appendix B Fig B1] and this is now an excellent 
resource that will allow better investigation into lung cancer inequalities in the future.  
A new single national cancer registration system [Encore] was launched in 2013 in 
order to improve timeliness and quality of the data, reduce data replication and the 
costs involved in this, and to support the improvement of staging information (260). 
The data will be used in conjunction with, or as an alternative to, the existing cancer 
audits including LUCADA. Therefore, Encore appears to be a potential resource that 
will improve the quality of research into inequalities in lung cancer care. 
Smoking status is not recorded in the cancer registry dataset but is available from 
primary care data. Date of first contact with GP, which could be used to calculate the 
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primary care interval [from first patient presentation to GP referral] could also be 
obtained from this source. Further linkage of my secondary care linked-dataset to 
primary care data could allow further exploration of where on the lung cancer care 
pathway inequalities might occur and also allow the inclusion of smoking status in 
analyses, the omission of which is a major weakness in current studies. 
Socio-economic inequalities in were found in the lung cancer care pathway but it is still 
unclear whether these inequalities are also found for other cancers and whether they 
occur at the same points in the care pathway. Similar analyses should, therefore, be 
conducted for other cancers. 
Interventions that address socio-economic inequalities in receipt of treatment are 
likely to reduce socio-economic inequalities in survival and thus improve the overall 
likelihood of survival. Further research is required to investigate the unexplained 
variance in treatment rates, looking at factors such as patient choice, doctor-patient 
communication of risk and benefit, and possible variation by trusts or within this, by 
hospital and individual clinician. I hope to examine these factors in my post-doctoral 
work. 
13.4.4.1 Further research - post-doctoral work 
My systematic review on socio-economic inequalities in lung cancer treatment has 
been published in an international journal (236) and press coverage on this paper 
resulted in an invited editorial (261).  Papers are in preparation on the empirical work 
presented in chapters 10-12 and the preliminary findings have been presented at 
conferences and published in abstract form (262-264). The rapid reviews of the 
evidence on socio-economic inequalities in referral, diagnostic and treatment intervals 
[chapter 4, table 4.1], and in survival [chapter 5, table 5.1], conducted as part of the 
literature review, will also be developed into full systematic reviews for publication. 
As a member of Fuse [UKCRC Centre for Translational Research in Public Health], I 
hope to feedback the findings from this thesis to practitioners and policy makers with 
support from the Fuse Knowledge Exchange Broker, who has an explicit remit for 
knowledge translation. Further qualitative work with healthcare professionals to 
explore potential reasons for inequalities in receipt of treatment, as well as the 
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implications for clinical practice of earlier referral and treatment resulting in poorer 
survival, are also planned.   
A future NIHR Fellowship application, to further investigate intervention-generated 
inequalities in cancer care using a mixed-methods approach, is planned. It is hoped to 
examine doctor-patient communication using a series of vignettes, and to conduct 
multi-level modelling on the linked data-set to take better account of surgeon and 
hospital characteristics in receipt of care. 
It is planned to repeat the secondary-data analyses detailed in this thesis on NYCRIS 
colorectal cancer data linked to HES data. The linked colorectal dataset was obtained 
at the same time as the lung cancer data and ethical approval is in place to begin this 
work immediately. 
13.5 Reflections on the PhD process 
During the PhD I wrote a number of blog posts for the Fuse Open Science blog, 
detailing some of the many highs (265), and lows [problems with obtaining the 
secondary data] (266), of the PhD experience, and also why I decided to undertake a 
PhD (267).  
13.6 Chapter summary and overall conclusions 
Intervention-generated inequalities in lung cancer care were identified from this 
research. Socio-economic inequalities in receipt of surgery and chemotherapy, but not 
radiotherapy, were found in the systematic review and meta-analysis and in the 
secondary data-analysis. Socio-economic inequalities in lung cancer treatment could 
not be explained by inequalities in stage or performance status in the full dataset. 
However, socio-economic differences in performance status may account for the 
observed socio-economic differences in receipt of chemotherapy in the staged subset. 
Tumour type may account for some of the socio-economic gradient in surgery. 
Socio-economic inequalities in the GP referral to FHA interval were found. Socio-
economic inequalities in survival from lung cancer were statistically explained by socio-
economic inequalities in receipt of treatment, but not by inequalities in timeliness of 
referral and treatment, in this cohort.  
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Suggestions have been made for future research that could help confirm these thesis 
findings, with respect to where on the pathway of lung cancer care inequalities occur, 
and also why they might occur. It will then be possible to develop specific 
interventions that address socio-economic inequalities in receipt of treatment and 
reduce socio-economic inequalities in survival.  
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Chapter 14. Appendices 
14.1 Appendix A: Variables requested from NYCRIS 
Table A.1. Variables that are held in the NYCRIS regional dataset, or can be derived from this 
Variable Derived from 
NYCRIS 
variable (by 
NYCRIS) 
Reason for inclusion Analyses to be used in 
IMD ranking Postcode The project is looking at 
inequalities by SEP and so a 
measure of SEP is required 
All analyses, as the measure 
of SEP 
Age at diagnosis Date of birth/ 
Date of 
Diagnosis 
Age has been shown to 
influence receipt of treatment 
and so will be included as a 
confounder. Age at diagnosis is 
required to calculate survival 
time.  
 
Logistic regression analyses 
of rates of treatment, Cox 
proportional hazard models 
of survival and time to 
treatment 
Year of diagnosis Date of 
diagnosis 
Treatment trends may change 
over time 
Logistic regression analyses 
of rates of treatment, Cox 
proportional hazard models 
of survival and time to 
treatment 
Sex Sex Sex is included as a potential 
confounder  
Logistic regression analyses 
of rates of treatment, Cox 
proportional hazard models 
of survival and time to 
treatment 
Marital status Marital status Marital status may affect 
survival and so will be included 
as a confounder 
Logistic regression analyses 
of rates of treatment, Cox 
proportional hazard models 
of survival and time to 
treatment 
Age at death Date of Death/ 
Date of Birth 
Required to calculate survival 
time (age at death – age at 
diagnosis) 
All survival models 
Cause of Death = 
lung cancer (Y/N) 
 
Cause of Death Need to differentiate between 
those who died of cancer of 
interest  and those who died of 
other causes 
Survival models 
DCO (Y/N) DCO Need to differentiate between 
those who were DCO and those 
who weren’t 
Logistic regression analysis 
comparing profile of those 
who are DCO with those who 
are not 
Cancer site (ICD10 
C33, C34 (lung 
cancer) 
Cancer site These are the cancer sites that 
the project will investigate 
Incidence, rates of 
treatment, time to 
treatment and survival 
analyses 
Cancer type  Cancer 
morphology/ 
type 
Cancer morphology may 
influence survival and type of 
treatment received 
Logistic regression analyses 
of rates of treatment, Cox 
proportional hazard models 
of survival and time to 
treatment 
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Table A.1 (cont). Variables that are held in the NYCRIS regional dataset, or can be derived 
from this 
Variable Derived from 
NYCRIS 
variable (by 
NYCRIS) 
Reason for inclusion Analyses to be used in 
Basis of diagnosis Basis of 
diagnosis 
Basis of diagnosis may 
influence time to treatment. 
Want to look at rates of 
treatment for histologically-
confirmed cases. 
Logistic regression analyses 
of rates of treatment, Cox 
proportional hazard models 
of time to treatment 
Date of GP referral Date of GP 
referral 
Required to calculate primary 
care delay and investigation 
delay 
Cox proportional hazard 
models of time to referral 
and 2
0
 care investigation 
Date of first 
hospital appt 
Date of first 
hospital appt 
Required to calculate 
investigation delay and 
diagnostic delay 
Cox proportional hazard 
model of time to 2
0
 care 
investigation and diagnosis 
Date of diagnosis Date of 
diagnosis 
Required to calculate 
diagnostic delay and treatment 
delay 
Cox proportional hazard 
models of time to diagnosis 
and treatment 
Date of first surgery Date of surgery Required to calculate 
treatment delay and therapy 
delay 
Cox proportional hazard 
models of time to treatment 
and therapy 
Date of  first 
chemotherapy 
Date of 
chemotherapy 
Required to calculate therapy 
delay 
Cox proportional hazard 
models of time to therapy 
Date of first 
radiotherapy 
Date of 
radiotherapy 
Required to calculate therapy 
delay 
Cox proportional hazard 
models of time to therapy 
Trust: (in pseudo-
anonymised form 
as trust A,B,C etc) 
 
PCT code Receipt of, and time to, 
treatment may be determined 
by Trust factors and so this will 
be included as a confounder 
Multi-level modelling 
Surgeon: (in 
pseudo-
anonymised form 
as surgeon 1,2,3 
etc) 
Consultant 
code 
Survival may be associated with 
surgeon and so this will be 
included as a confounder 
Multi-level modelling 
All survival analyses 
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Table A.2. Variables that are available from the linked, anonymised, regional subset of 
NYCRIS and HES data, or that can be derived from them 
Variable Derived from 
HES variable 
(by NYCRIS) 
Reason for inclusion Analyses to be used in 
Charlson co-
morbidity  score 
(CCS) 
Charlson co-
morbidity  
score (in 
NCDR) 
Co-morbidity may influence 
receipt of treatment and 
survival and so will be included 
as a confounder 
Logistic regression analyses 
of rates of treatment, Cox 
proportional hazard model 
of survival 
Nature of admission 
(elective/emergency) 
Method of 
Admission 
Nature of admission may 
influence survival. Emergency 
rather than elective admission 
may be a marker of late 
presentation 
Logistic regression analysis 
comparing profile of those 
who are emergency 
admissions with those who 
are not, Cox proportional 
hazard model of survival 
 
Post-operative 
complications 
Diagnostic 
codes ? 
Post-operative complications 
may contribute to delay from 
surgery to adjuvant therapy 
and influence survival 
Cox proportional hazard 
models of survival and time 
to adjuvant treatment 
 
 
Ethnicity Ethnic 
category 
Ethnicity may influence receipt 
of treatment and so will be 
included as a confounder  
Logistic regression analyses 
of rates of treatment, Cox 
proportional hazard models 
of survival and time to 
treatment 
GP(in pseudo-
anonymised form as 
GP a,b,c etc) 
Referring 
general 
medical 
practitioner 
GP may influence referral time 
(primary care delay) 
Cox proportional hazard 
models of time to treatment 
 
Table A.3. Variables available from the linked NYCRIS regional lung cancer and LUCADA 
dataset 
Variable Derived from 
LUCADA variable 
(by NYCRIS) 
Reason for inclusion Analyses used in 
Performance 
status 
Performance status Performance status may 
influence receipt of treatment 
and survival and so will be 
included as a confounder 
Logistic regression analyses 
of rates of treatment, Cox 
proportional hazard model 
of survival 
Stage Stage Stage has been associated 
with receipt of treatment and 
survival and so will be 
included as a confounder 
Logistic regression analyses 
of rates of treatment, Cox 
proportional hazard model 
of survival 
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14.2 Appendix B: Data linkage and data completeness 
Table B.1. Completeness of stage data in the linked dataset, by year 
 Stage  
Year 1 2 3 4 missing Total 
 N % N % N % N % N %  
1999 0 0 0 0 0 0 0 0 5,154 100 5,154 
2000 0 0 0 0 0 0 0 0 5,227 100 5,227 
2001 0 0 0 0 0 0 0 0 5,200 100 5,200 
2002 0 0 0 0 0 0 0 0 5,219 100 5,219 
2003 0 0 0 0 0 0 0 0 5,221 100 5,221 
2004 0 0 0 0 1 0.02 0 0 5,215 99.98 5,216 
2005 2 0.04 0 0 0 0 1 0.02 5,237 99.9 5,240 
2006 129 2.3 45 0.8 229 4.1 268 4.7 4,862 88.2 5,533 
2007 151 2.6 73 1.2 274 4.7 368 6.3 4,846 85.2 5,712 
2008 229 3.8 86 1.4 464 7.8 777 13.0 4,295 74.0 5,851 
2009 355 6.0 128 2.2 620 10.4 1,037 17.4 3,731 64.1 5,871 
2010 322 5.5 220 3.7 686 11.7 1,308 22.2 3,230 56.9 5,766 
Total 1,188 1.8 552 0.8 2,274 3.4 3,759 5.6 57,437 88.4 65,210 
 
 
Table B.2. Completeness of performance status data in the linked dataset, by year 
 Performance Status  
Year 0 1 2 3 4 missing Total 
 N % N % N % N  N % N %  
1999 0 0 0 0 0 0 0 0 0 0 5,154 100 5,154 
2000 0 0 0 0 0 0 0 0 0 0 5,227 100 5,227 
2001 0 0 0 0 0 0 0 0 0 0 5,200 100 5,200 
2002 0 0 0 0 0 0 0 0 0 0 5,219 100 5,219 
2003 0 0 0 0 0 0 0 0 0 0 5,221 100 5,221 
2004 0 0 1 0.02 0 0 0 0 0 0 5,215 99.98 5,216 
2005 1 0.02 1 0.02 1 0.02 1 0.02 0 0 5,236 99.9 5,240 
2006 219 4.0 301 5.4 192 3.5 139 2.5 26 0.5 4,656 84.2 5,533 
2007 253 4.4 374 6.6 214 3.8 152 2.7 48 0.8 4,671 81.8 5,712 
2008 332 5.7 598 10.2 402 6.9 341 5.8 107 1.8 4,071 69.6 5,851 
2009 494 8.4 807 13.8 526 9.0 432 7.4 170 2.9 3,442 58.6 5,871 
2010 544 9.4 883 15.3 568 9.9 539 9.4 224 3.9 3,008 52.2 5,766 
Total 1,843 2.8 2,965 4.6 1,903 2.9 1,604 2.5 575 0.9 56,320 86.4 65,210 
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Table B.3. Completeness of HES linkage in the linked dataset, by year 
 HES link  
 No Yes  
Year N % N % Total 
1999 596 11.6 4,558 88.4 5,154 
2000 600 11.5 4,627 88.5 5,227 
2001 570 11.0 4,630 89.0 5,200 
2002 442 8.5 4,777 91.5 5,219 
2003 474 9.1 4,747 90.9 5,221 
2004 416 8.0 4,800 92.0 5,216 
2005 425 8.1 4,815 91.9 5,240 
2006 490 8.9 5,043 91.1 5,533 
2007 442 7.7 5,270 92.3 5,712 
2008 675 11.5 5,176 88.5 5,851 
2009 5,758 98.1 113 1.9 5,871 
2010 5,663 98.2 103 1.8 5,766 
Total 16,551 25.4 48,659 74.6 65,210 
 
 
Figure B.1. LUCADA case ascertainment, and stage & performance status data completeness, 
for England and Wales, by year (246) 
 
Figures taken from National Lung Cancer Audit Report 2012 
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14.3 Appendix C: Supporting Information for chapter 7  
Appendix C1 Protocol 
Appendix C2 PRISMA checklist 
Appendix C3 Full search strategies (Medline and Embase) 
Appendix C4 Population over-lap and paper selection for inclusion 
Appendix C5 Quality score checklist 
Appendix C6 Assessment of existing quality assessment tools 
Appendix C7 Sensitivity meta-analyses 
Figure C7.1 Sensitivity Meta-analysis of odds of receipt of surgery in low (most 
deprived) versus high (least deprived) SEP (overlapping populations) 
Figure C7.2 Meta-analysis of odds of receipt of surgery for NSCLC in low (most 
deprived) versus high (least deprived) SEP (non-overlapping 
populations) 
Figure C7.3 Sensitivity meta-analysis of odds of receipt of chemotherapy in low 
(most deprived) versus high (least deprived) SEP (overlapping 
populations) 
Figure C7.4 Sensitivity Meta-analysis of odds of receipt of radiotherapy in low (most 
deprived) versus high (least deprived) SEP (overlapping populations) 
Figures C7.5 Sensitivity meta-analysis of odds of receipt of any type of treatment in 
low (most deprived) versus high (least deprived) SEP (overlapping 
populations) 
Figure C7.6 Sensitivity meta-analysis of odds of receipt of surgery in low (most 
deprived) versus high (least deprived) SEP (partially-overlapping 
populations) 
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Appendix C1. Protocol 
Summary 
Background 
Intervention-generated inequalities are health inequalities that result from the way 
that health interventions are organised and delivered and there is some evidence to 
suggest that intervention-generated inequalities in care may occur for some common 
cancers. Although the incidence and outcome of lung cancer varies with socio-
economic position, it is not known whether inequalities in treatment occur and, if they 
do, how these might contribute to inequalities in outcome. 
Review objectives                                                                                                           
To summarise the existing literature and assess whether there are socio-economic 
differentials in receipt of treatment for lung cancer  
Population 
Adults who have a primary diagnosis of lung cancer [ICD10 C33 and C34], participating 
in studies published in a peer-reviewed journal up to 2011, and where the relevant 
outcome is analysed according to a measure of socio-economic position [including an 
individual or area-based measure of socio-economic position, deprivation, income, or 
education]. 
Interventions and comparators: 
Receipt of any curative or palliative treatment for lung cancer including surgery, 
chemotherapy and radiotherapy compared to not receiving surgery, chemotherapy or 
radiotherapy  
Outcomes: 
i) Rates of treatment; or ii) Odds of receiving treatment; looking at low [most deprived] 
compared to high [least deprived] SEP or trends by socio-economic strata 
Study design: 
Cohort, observational studies conducting appropriate univariable or multivariable 
analyses  
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C1.1 Background 
C1.1.1 Lung cancer 
Worldwide, lung cancer is the most common cancer. In the UK it is the second most 
common cancer for incidence overall [the second most common for men and third 
most common for women] (8), as well as the most common cause of cancer mortality 
(9). Less than 10% of those diagnosed survive for 5 years.  
Lung cancers are classified into small cell [SCLC] and non-small cell [NSCLC] cancers, 
with NSCLC accounting for 80% of lung cancers. NSCLC can be further divided into 
squamous cell carcinomas, adenocarcinomas and large cell carcinomas (18). NICE 
guidelines recommend radical surgery [pneumonectomy or lobectomy] for stage I or II 
NSCLC. Chemotherapy and radical radiotherapy are recommended for stage IIIa, with 
chemotherapy for stage IIIb and good performance-status stage IV lung cancer 
patients. Radiotherapy may be given as a palliative option for stage IV patients with 
poor performance status (18). Intervention with surgery, chemotherapy or 
radiotherapy has been shown to improve survival (18). 
The incidence and outcome rates of lung cancer vary with socio-economic position 
[SEP], with incidence and mortality rates 2-3 times higher in the more deprived, within 
the UK (8). A strong deprivation gradient for incidence (16) and mortality is also seen 
worldwide. However, it is not known whether inequalities in investigation and 
treatment occur and, if so, how these might contribute to inequalities in outcome.  
C1.1.2 Intervention-generated inequalities 
Intervention-generated inequalities are health inequalities that result from the way 
that health interventions are organised and delivered (7) so that although overall 
health may improve as the result of an intervention, differences in access to the 
intervention, differential uptake and delays in uptake might result in inequalities in 
outcome. Inequalities are likely to occur at many different stages of intervention 
pathways and act in a cumulative way. It is also likely that intervention-generated 
inequalities contribute to overall socio-economic inequalities in morbidity and 
mortality, although this has not been conclusively demonstrated (7). 
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Inequalities in cancer care within the UK have been noted and the NHS Cancer Plan in 
2000 pledged to reduce cancer mortality, reduce delay in diagnosis and treatment and 
increase survival whilst acting to reduce inequalities (24). More recently the National 
Cancer Equality Initiative has been set up to address some of these issues (10). This is 
an important task as, in a 2006 review that summarised a decade of research on the 
association between socio-economic status and cancer survival, the authors suggested 
that socio-economic differences in ‘access to optimal treatment’ (26) might at least 
partially explain survival differences. 
Inequalities in access to cancer care have been shown in individual studies for a 
number of cancers and in a non-systematic review for colorectal cancer (11) but the 
evidence is inconclusive and there has been no systematic review of the evidence to 
demonstrate if such inequalities in access to care exist for lung cancer.  
C1.2 Review Objectives 
To summarise the existing literature and assess whether there are socio-economic 
differentials in receipt of treatment for lung cancer  
C1.3 Methods 
C1.3.1 Search strategy 
Systematic methods will be used to identify relevant studies, assess study eligibility for 
inclusion and evaluate study quality. A search will be undertaken to locate all studies 
published up to May 2011 examining care and treatment for lung cancer associated 
with socio-economic status. One researcher [LF] will develop the search strategy with 
support from her supervisors, which will then be refined with the help of a medical 
librarian and used to search the online databases of MEDLINE, EMBASE and Scopus. 
Slightly different strategies will be required for each database [for example MEDLINE 
recognises the MESH term Lung Neoplasms/ whereas EMBASE does not and uses Lung 
cancer/. See pp6-8 of this protocol for draft MEDLINE and EMBASE search strategies]. 
Additional studies will be identified by reviewing the reference lists of relevant studies 
identified from the search and by using a forward citation search to identify more 
recent studies that have cited an older, relevant study. EndNote software will be used 
to manage the references. 
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C1.3.2 Study Eligibility 
Cohort studies of adult participants who have a primary diagnosis of lung cancer 
[small-cell lung cancer or non-small-cell lung cancer - ICD10 C33 or C34], published in a 
peer-reviewed journal up to 2011, and where the outcome is receipt of care or 
treatment [measured by rates or odds of receiving care/treatment] and where the 
outcome is analysed by a measure of socio-economic position [such as an individual or 
area-based measure of SEP, deprivation, income or education] will be eligible for 
inclusion. Receipt of any curative or palliative treatment for lung cancer including 
surgery, chemotherapy and radiotherapy will be considered.  
Preliminary independent screening of the titles and abstracts obtained from the 
database searches will be carried out by two researchers [LF and HW]. Initial screening 
of titles will be carried out to remove obviously irrelevant papers. However, from a 
preliminary scoping review by LF, the early pilot searches recovered studies that, 
although they conducted analyses by SEP, did not always mention this in the abstract 
or title. Therefore, in the title search, any titles that refer to surgery, chemotherapy 
and radiotherapy uptake for lung cancer will be retained. Papers that look at 
disparities in cancer survival/mortality will also be included as further checking of the 
abstract is required to see if inequalities in access to treatment are also examined. 
Selected abstracts will then be screened and a subset of studies will be selected for 
further review and the full article obtained. Abstracts that refer to socio-economic 
inequalities in receipt of care/treatment will be retained. Abstracts that refer to racial, 
ethnic, geographical, sex and age-related disparities in treatment as well as disparities 
by insurance type will also be retained as often these papers also look at SEP, even if 
this is not mentioned in the abstract. Papers that look at delay will not be included. 
Two researchers [LF and HW] will then independently assess the selected full papers 
for eligibility according to the study-eligibility criteria detailed above. Any 
disagreements at any of the screening stages will be resolved by discussion between 
the two reviewers in the first instance. If agreement cannot be reached, then a third 
reviewer [JA or MW] will independently review the title, abstract or full paper, as 
appropriate, and a majority decision will be taken on inclusion/exclusion. 
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C1.3.3 Data Extraction 
Data extraction will be carried out by LF and HW using a pro-forma to be developed by 
LF for this purpose. Data relating to study authors, journal, study design, year of study, 
data source, number of participants, years of diagnosis, measure of SEP, confounding 
variables included in the analysis [such as age, sex, stage, co-morbidities, cancer 
type/site, vital/performance status, marital status, smoking status, cancer network, 
health board, hospital, emergency or elective treatment, distance from hospital/travel 
time, ethnicity, insurance status], type of treatment received [any, surgery, 
chemotherapy, radiotherapy], statistical tests carries out, outcome measures 
[treatment rates or odds of treatment], comparator used, significance [p values], 
precision [confidence intervals], other variables that were significant; will be recorded.  
There is evidence to suggest that insurance status is an important factor relating to 
access to lung cancer care in the US system (188) but is less relevant or rarely 
measured in the UK and Europe. Therefore studies will be split into three categories: 
those carried out in a healthcare system free at the point of access [similar to the UK]; 
those based on an insurance system [similar to the USA]; those that include a mixture 
of free care and social insurance-based payment [some European systems] (189).  
C1.3.4 Study Quality 
Study quality will be appraised using criteria based on the SIGN guidelines (192) and 
the STROBE [Strengthening the Reporting of Observational Studies in Epidemiology] 
guidelines (194) that contain a checklist of 22 items that should be included in cohort 
studies. Although the STROBE guidelines are a checklist measure of good reporting 
rather than ‘an instrument to evaluate the quality of observational research’ (194) , a 
number of other lung cancer systematic reviews use a similar scale for quality 
ascertainment (185, 188). 
The quality of reporting on the following criteria will be assessed: study design, size, 
setting, dates, data sources, eligibility criteria, number of participants potentially 
eligible, number actually included, number analysed, missing/incomplete data 
reported, variables included [in terms of outcome, exposure, predictors, confounders],  
type of statistical analysis carried out, unadjusted and adjusted estimates reported, 
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precision [confidence intervals], significance [p values] given, limitations of the study, 
potential bias addressed, external validity of results and funding source. 
C1.3.5 Statistical analysis 
Meta-analysis will be considered if there are sufficient studies available with suitable 
data. If it is not possible to conduct a meta-analysis, due to the heterogeneity of the 
studies, then Harvest Plot methodology will be considered. This is a method that has 
been devised for synthesising evidence from studies looking at the differential effects 
of interventions, where meta-analysis is not suitable (196). Meta-regression may also 
be considered if there are sufficient studies with similar variables available that might 
enable combined analysis of factors associated with combined outcomes. 
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Table C2.1. PRISMA 2009 Checklist  
Section/topic  # Checklist item  
Reported 
in section 
paragraph 
#*  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Para 1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
Para 1-4 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Para 1-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
Para 4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
Para 1 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
Para 2-3 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
Para 2 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Table S1 
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Table C2.1 (cont). PRISMA 2009 Checklist  
Section/topic  # Checklist item  Reported in 
section 
paragraph 
#  
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
Para 3-7 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
Para 8 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
Para 3-7, 9 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
Para 10-11 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Para 13 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
Para 14 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
#*: paragraphs refer to paragraphs within PLoS Medicine paper generated from this research (236) 
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Appendix C3. Search strategies 
Table C3.1. MEDLINE search strategy 05/05/11 
Search Term 
Number  
Retrieved 
1.       Lung Neoplasms/ di, ep, mo, pc, rt, su, 59693 
2.       Exp carcinoma, Non-Small-cell Lung/or exp Carcinoma, Small Cell/ 37049 
3.       Or/1-2 80591 
4.       Social Class/ or Socio-economic Factors/ 110317 
5.       Socio-economic status.mp 4098 
6.       Education/ or exp Education, Continuing 64913 
7.       Income/cl, sn 3109 
8.       Exp Health Status/sn, td  1046 
9.       Exp Poverty/pc, sn, td 2309 
10.   Exp Social Class/ 27097 
11.   Socio-economic position.mp 213 
12.   Inequalities.mp 5837 
13.   Exp Social Environment/td 137 
14.   Social factors.mp 4869 
15.   Income.mp 53934 
16.   Exp Residence Characteristics/cl, sn 3307 
17.   Social Class.mp 29869 
18.   Education.mp 463082 
19.   Exp Health Status Disparities/ 3380 
20.   Inequities.mp 1569 
21.   Deprivation.mp 51228 
22.   Equity.mp 5183 
23.   Inequity.mp 920 
24.   Insurance status.mp 1700 
25.   Or/ 4-24 650350 
26.   surgery.mp 660227 
27.   treatment.mp 255751 
28.   exp Health Services Accessibility/cl, og, st, sn, td, ut 16904 
29.   exp Healthcare Disparities/ 3400 
30.   treatment disparities.mp 69 
31.   exp  “Delivery of Health Care”/ 662295 
32.   exp Primary Health Care/sn, td, ut 6839 
33.   exp Drug Therapy/ 921829 
34.   Chemotherapy.mp or 236003 
35.   Radiotherapy, Adjuvant/  or Radiotherapy/ 45648 
36.   Radiotherapy.mp  145755 
37.   Accessibility.mp 56793 
38.   Access.mp 123272 
39.   Pattern$.mp 767175 
40.   Palliative care/ or Patient care/ or Primary Health care/ 83405 
41.   Care.mp 1154474 
42.   Investigation.mp 282065 
43.   Exp “Quality of Health Care”/st, sn, td, ut 99809 
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44.   Exp Patient Selection/ or exp Eligibility Determination/or exp 
Medicaid/ 60372 
45.   Exp “Referral and Consultation”/ st, sn, td, ut 9243 
46.   Receipt.mp or exp “Patient Acceptance of Health Care”/ 137892 
47.   Provision.mp 33164 
48.   Attendance.mp 11676 
49.   Or/26-48 5529748 
50.   3 and 25 and 49 484 
51.   News.pt 130842 
52.   Comment.pt 438297 
53.   Letter.pt 712489 
54.   Review pt 1600963 
55.   Editorial.pt 274165 
56.   50 not (or/51-55) 398 
 
Table C3.2. EMBASE search strategy 05/05/11 
Search Term 
Number  
Retrieved 
1.       Exp lung cancer/ di, dm, dt, ep, rt, rh, su, th 71888 
2.       Exp LUNG CARCINOMA/ di, dm, dt, ep, rt, rh, su, th 43143 
3.       Exp lung non-Small-cell cancer/ di, dm, dt, ep, rt, rh, su, th 25650 
4.       exp small cell carcinoma/ di, dm, dt, ep, rt, rh, su, th 4284 
5.       Or/1-4 75298 
6.       Social Class/ or Socio-economic Factors/ 105019 
7.       Socio-economic status.mp 5032 
8.       Education/ or exp Education, Continuing 264216 
9.       Socio-economic position.mp 254 
10.   Social factors.mp 5735 
11.   Income.mp 60981 
12.   Social Class.mp 24420 
13.   Education.mp 463082 
14.   Exp LOWEST INCOME GROUP/ or exp INCOME/ 54541 
15.   Exp Poverty/ 23046 
16.   Inequality.mp 7552 
17.   Inequalities.mp 6594 
18.   Exp Social Environment/ 224660 
19.   Exp demography/ 114434 
20.   Exp health disparity/ 2317 
21.   Exp Health insurance/ or exp socioeconomics/ or exp Social 
status/ 308865 
22.   Inequity.mp 1106 
23.   Equity.mp 5975 
24.   Exp CULTURAL DEPRIVATION/ or deprivation.mp 53312 
25.   Or/ 6-24 1301033 
26.   surgery.mp 1211103 
27.   treatment.mp 3334976 
28.   treatment disparities.mp 92 
251 
 
29.   exp  “Delivery of Health Care”/ 1383093 
30.   exp Drug Therapy/ 1219237 
31.   Chemotherapy.mp or 357346 
32.   Radiotherapy, Adjuvant/  or Radiotherapy/ 68286 
33.   Radiotherapy.mp  202245 
34.   HEALTH CARE ACCESS/ 27526 
35.   Access.mp 176386 
36.   Care.mp 1749819 
37.   Pattern$.mp 824237 
38.   Health service/ or health care policy/ or equity.mp or health care/ 
or health care delivery 332536 
39.   Quality.mp or HEALTH CARE QUALITY/ 731294 
40.   Health care utilization/ 28472 
41.   Provision.mp 39964 
42.   Attendance.mp 14211 
43.   Receipt.mp 7755 
44.   Terminal care/ 18463 
45.   Or/26-44 7347896 
46.   5 and 25 and 45 1708 
47.   Letter.pt 726344 
48.   Editorial.pt 370622 
49.   Note.pt 440574 
50.   Review.pt 1692350 
51.   46 not (or/47-50) 1208 
52.   51 and article.pt 1080 
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Appendix C4. Population over-lap and paper selection for inclusion 
C4.1 UHCS papers 
Three papers (198, 200, 201) all looked at the same single-year Scottish population and 
presented overlapping results. Two papers examined the same NYCRIS population (78, 
199) but presented different results. 
Four papers used Thames Cancer Registry data where two of the papers used 
overlapping data (202, 213) and one of the papers (158) used a subset population 
included in both other papers. The fourth paper (ref) used more recent data and did 
not overlap the other 3 papers.  
Two papers by the same authors used LUCADA audit data, the first from 2004-2007 
(153) and the second paper had a further year of audit data to 2008 (152). These were 
considered as one population and the paper with the larger population used where 
both were eligible for inclusion. 
Three New Zealand papers all used the same study population (205, 206, 214).   
The size of the UK populations examined ranged from 695 to over 60,000. The non-UK 
papers examined a smaller population size range – from 108 to 6449. 
The majority of the papers used cancer registry data, some supplemented with data 
from medical records, and two used data from a lung cancer audit. Audit data includes 
only a subset of registry patients whose data has been entered into the audit.  
Three UK papers obtained data from Hospital Episode Statistics [HES] and the three 
New Zealand papers included only patients who were admitted to secondary care. 
Papers that used only HES/hospital data were able to look at inequalities in care only 
for those admitted to hospital, not the entire registry population. 
C4.2 Non-UHCS studies 
There is also overlap within the SEER dataset so again only substantially non-
overlapping studies were included in the final meta-analyses. Alternative analyses 
including all eligible studies were also run, as well as analyses including partially 
overlapping studies but not those that were fully a subset of another.  
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C4.3 Choosing the most suitable studies for inclusion in meta-analysis 
Problems did arise where two studies used the same population, or a subset of a 
population, but found slightly different results. Quality score was used as the initial 
selection factor for the most appropriate study to choose for inclusion in the meta-
analysis.  
In some cases the smaller regional analyses were of better quality as they included 
stage and histology, whereas the analysis of the national population did not. For 
example the Berglund (2012) paper looked at patients diagnosed between 2006 and 
2008 in the Thames Cancer Registry region (157). However, Riaz (2012) looked at 
England-wide data diagnosed between 2004 and 2006 (161) and so there is likely to be 
some overlap between these populations for 2006. So although these are clearly 
different populations they are not entirely unique populations. The Berglund study is 
smaller (1826 in the surgery population) compared to Riaz (77,349) but Berglund 
includes stage and co-morbidity and so is the better quality study.  
The two Rich [2011] studies (152, 153) include England-wide data for 2004-2007 
(24,175 patients) and 2004-2008 (34,436 patients) respectively, obtained from the 
LUCADA audit and so these two had clearly overlapping populations where it would 
only be suitable to include one in the meta-analysis. But again some of the same 
patients are likely to be included here that are also found in the Riaz (161) and 
Berglund (157) studies, although different sources have been used [LUCADA rather 
than Registry data]. Therefore, although the overlap may be small, strictly speaking 
only one of these four studies should be included in the final meta-analysis. The quality 
score was therefore used to decide this. Berglund (157) was the smallest study but the 
best quality.  
Sensitivity analyses including all the over-lapping populations meant that three large, 
reasonable quality studies were still able to supply data to the meta-analyses. Further 
analyses were then run where only non-overlapping populations were included and, 
where it was not clear which was the best of the over-lapping populations to include, 
multiple analyses were run using different study combinations, to see if this made any 
difference to the overall outcome. It was therefore possible to examine whether it 
might be better to choose a slightly less-good quality study that contained more data, 
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for example, the larger Rich paper (152) as it contained stage and co-morbidity but did 
not capture everyone diagnosed within the timescale, or the Riaz paper (161) which 
had better population capture but did not include important confounders such as 
stage and co-morbidity. 
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Appendix  C5: Quality Score 
Quality 
Score 
Characteristics of studies 
6 Multi-variable analysis. Population-based sample. Good internal 
validity/reporting/confounding 
5 Multi-variable analysis. Selective population. Good internal 
validity/reporting/confounding 
4 Multi-variable analysis. Population-based sample. Some problems with internal  
validity/reporting/confounding (eg good internal validity/reporting but stage not 
included OR less good internal validity/reporting and stage included) 
3 Multi-variable analysis. Selective population. Some issues with internal 
validity/reporting/confounding (eg good internal validity/reporting but stage not 
included OR less good internal validity/reporting and stage included) 
2 Univariable analysis. Good internal validity/reporting OR multivariable analysis but 
only univariable results reported or no CIs/ different comparator/ stratified by other 
variable 
1 Univariable analysis. Poor internal validity/reporting OR multivariable analysis but 
results for SEP not shown or errors in data 
 
Quality checklist used to derive quality scores 
 
Screening questions:  
Does the study conduct multivariable analysis and report adjusted odds ratios/rates? 
Yes – consider for meta-analysis  
 No – consider for narrative review 
 
What population is included?  
a. Population-based sample: eg total local or national lung cancer population from a cancer 
Registry   
b. Selective population: eg. hospital population from Hospital Episode Statistics (HES) data or 
similar, or from Registry linked to Medicare records (USA) or incomplete audit data   
Section 1: Internal validity 
1. Appropriate, valid and reliable measure of SEP is used (e.g. IMD, Carstairs, Townsend, 
similar local index, income, poverty level, education) 
a. Yes - individual standard measure used     5 
b. Yes - area-based standard measure used    3 
c. Standard measure used but presented as average for PCT/health authority
         1 
d. Non-standard measure used/ measure not reported   0 
2. SEP categorised as 
a. Continuous/Deciles       5 
b. Quintiles/ Quartiles       3 
c. Tertiles/Dichotimised       1 
d. Unknown/ not reported       0 
3. SEP expressed as an OR to 
a. Two decimal places       5 
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b. One decimal place       3 
c. Whole number/ expressed as rate     1 
d. unknown/not reported       0 
4. Outcome measures are valid and reliable 
a. Yes - care/ treatment details obtained from Registry, HES or similar system
         3 
b. Yes - care/treatment details obtained from audit or hospital records 3 
c. Care treatment details obtained from survey/questionnaire/other 1 
d. No/unknown/not reported      0 
Good:  14-18    OK:  13-11   Poor:  0-10 
Section 2: External validity 
1. Population 
a. Study uses multiple Registry or national population(s) or similar  3 
b. Study uses regional population from Registry or HES or similar  2 
c. Study uses only small subset of population (some health boards/PCTs/areas)
         1 
d. Study uses small, random sample from Registry or hospital data /other 1 
e. Population not stated       0 
2. Population date and time period 
a. Multiple years of diagnosis, some post-2000    3 
b. Multiple years of diagnosis, all pre-2000     2 
c. Single year of diagnosis, post -2000     2 
d. Single year of diagnosis, pre-2000     1 
Good:  4-6    Poor:  0-3 
Section 3: Reporting of Study 
1. Outcome measures are clearly defined/reported 
a. Yes         1 
b. No         0 
2. Outcome measure reported 
a. Rates/odds of treatment compared with no treatment   2 
b. Rates/odds of NOT receiving treatment  compared to receiving treatment
         2 
c. Rates/odds of treatment compared with other care   1 
d. Rates/odds of treatment stratified by other variable (sex, race etc) 1 
e. Results presented in some other way     0 
3. Number initially eligible/ number excluded reported 
a. Eligible/excluded/included all reported or able to be calculated  2 
b. Number included reported only      1 
c. Numbers not reported       0 
4. Inclusion/ exclusion criteria detailed 
a. Yes         1 
b. No         0 
257 
 
5. Numbers receiving treatment 
a. Numerator and denominator populations clearly documented  2 
b. Numbers calculable from details given but not clearly specified  1 
c. Numbers not specified       0 
d. Numbers do not add up correctly and need to be checked with authors 0 
6. Other variables that are significant in analysis reported 
a. Yes         2 
b. Yes, but results for only some presented    1 
c. No         0 
7. Death Certificate Only (DCO) excluded 
a. Yes         1 
b. Not applicable (if using HES type data)     1 
c. No/ not reported       0 
8. Confidence interval reported 
a. Yes         1 
b. No         0 
9. P value reported 
a. Overall p value/ p for trend      2 
b. Individual p values       1 
c. Not reported        0 
Good:  11-14  OK:  7-10  Poor:  0-6 
Section 4: Confounding 
1. Multivariable analysis - other important confounders included 
a. Age and sex        3 
b. Age or Sex        2 
c. Univariable analysis only reported     1 
d. Descriptive only/ no analysis      0 
2. Results stratified by stage 
a. Yes, and only eligible- stage patients used for denominator  3 
b. Yes, but all-stage patients used for denominator    2 
c. No, but stage included as a confounder     2 
d. No         0 
3. Results stratified by histology 
a. Yes, and only histologically-verified cases included   3 
b. Yes, but clinically diagnosed and histologically-unknown cases included 2 
c. No, but histology included as a confounder    2 
d. No         0 
4. Other relevant confounders included 
a. Co-morbidity/ performance status     2 
b. Trust/ health board/ hospital/area     1 
c. No         0 
Good:  7-11 (must include age, sex, stage and histology) 
OK: 3-5 (must include age, sex)Poor:  0-2 (univariable analysis)  
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Appendix C6. Assessment of existing quality assessment tools 
The Cochrane tool for assessment of risk of bias is only suitable for randomised 
controlled trials as the tool examines aspects of studies such as randomisation and 
blinding which are not relevant in cohort studies. However, the measures of the four 
different types of biases identified [selection, performance, attrition and detection] 
can be adapted for other types of studies. For example RCTs use randomisation to 
prevent selection bias but in cohort studies controlling for confounders can be 
considered instead (190). Measurement of exposure in cohort studies rather than 
blinding of participants/investigators can be used to check for performance bias. 
Completeness of follow-up to assess attrition bias and blinded outcome assessment for 
detection bias can be examined for cohort studies as they can for RCTs (190). 
Other tools used by Cochrane Review Groups include the Jadad scale (191) which again 
is only suitable for RCTs. The Moncrief scale includes items on external validity and 
reporting of statistical analysis which are not necessarily measures of bias (191). 
The Newcastle-Ottawa scale is recommended by the Musculoskeletal Cochrane Group 
(191).  This scale has been developed for assessing the quality of non-randomised 
studies and so is potentially suitable for cohort studies. Studies are assessed on 
selection, comparability and outcome and so this does appear to be more of a 
measure of the internal validity of a study than some of the other scales examined. The 
scale is divided into: Selection of the cohorts [4 items]; Comparability of the cohorts [1 
item]; and Assessment of outcome [3 items]. ‘High quality’ outcomes are identified 
with a star, with a maximum of 1 star per item in the selection category and 2 stars per 
item in the comparability category [but the number of stars in the outcome category is 
not stated]. These star charts can then be presented alongside the meta-analysis.  
Although published Cochrane reviews do utilise scales and many of their Review 
Groups recommend them (191) their validity has not been demonstrated in empirical 
research. Therefore the validity of the scale is unclear and the definition of ‘good’ and 
‘poor’ scores appears somewhat subjective. Also, the scale does not appear to have 
been published as, after online searching, only a power point presentation was 
available. 
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SIGN, the Scottish Intercollegiate Guidelines Network has a methodology checklist for 
cohort studies (192). This examines internal validity under the following headings: 
selection of subjects, confounding, statistical analysis. Each criterion [for example: ‘The 
outcomes are clearly defined’] is assessed as: well covered, adequately addressed, 
poorly addressed, not addressed, not reported, not applicable. In the overall 
assessment of the study a score of ++, + or – is given for how well has the study 
minimised the risk of bias or confounding and a judgment made on applicability and 
certainty that the overall effect is due to the study intervention.  
A more extensive checklist than SIGN is utilised by the Effective Public Health Practice 
Project [EPHPP] Quality Assessment Tool for Quantitative Studies in Canada (193), 
which looks at selection bias, study design, confounders, blinding, data collection 
methods, withdrawals and drop-outs, intervention integrity and analyses. Each section 
is rated as strong, moderate or weak. Not all of these categories are relevant for the 
type of studies included in this review as all are cohort studies, no blinding takes place 
and as participants are not actively recruited they cannot drop out, but parts of it 
could be adapted and utilised. 
The STROBE [Strengthening the Reporting of Observational Studies in Epidemiology] 
guidelines (194) contain a checklist of 22 items that should be included in cohort 
studies. The quality of reporting on the following criteria can be assessed: study 
design, size, setting, dates, data sources, eligibility criteria, number of participants 
potentially eligible, number actually included, number analysed, missing/incomplete 
data reported, variables included [in terms of outcome, exposure, predictors, 
confounders],  type of statistical analysis carried out, unadjusted and adjusted 
estimates reported, precision [confidence intervals], significance [p values] given, 
limitations of the study, potential bias addressed, external validity of results, funding 
source. 
Although the STROBE guidelines are a checklist measure of good reporting rather than 
‘an instrument to evaluate the quality of observational research’ (194), a number of 
other lung cancer systematic reviews use some of the above items in their scales for 
quality ascertainment (185, 188). However, just because something is not reported 
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does not necessarily mean it was not done. However, in order to determine this it may 
be necessary to contact the authors of the study. 
Conclusion 
Following review of the potential tools identified above, criteria adapted from SIGN, 
EPHPP and STROBE guidelines were used to develop a quality assessment tool for this 
systematic review. 
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Appendix C7: Sensitivity meta-analyses 
Figure C7.1. Meta-analysis of odds of receipt of surgery in low (most deprived) versus high 
(least deprived) SEP. (over-lapping populations; n=16) 
 
 
Figure C7.2. Meta-analysis of odds of receipt of surgery for NSCLC in low (most deprived) 
versus high (least deprived) SEP. (non-overlapping populations; n=8) 
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Figure C7.3. Meta-analysis of odds of receipt of chemotherapy in low (most deprived) versus 
high (least deprived) SEP (over-lapping populations; n=10).  
 
 
Figure C7.4. Meta-analysis of odds of receipt of radiotherapy in low (most deprived) versus 
high (least deprived) SEP (overlapping populations; n=9).  
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Figure C7.5. Meta-analysis of odds of receipt of any type of treatment in low (most deprived) 
versus high (least deprived) SEP (overlapping populations; n=35).  
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Figure C7.6. Meta-analysis of odds of receipt of surgery in low versus high SEP. (partially-
overlapping populations, n=14) 
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14.4 Appendix D: Supplementary tables for chapters 11 and 12 
Table D.1. Odds of FHA within 2 weeks from GP referral (for those with FHA within 1 year of 
GP ref) 1999-2005 
Variables FHA 
within 1 
year 
FHA within 2 
weeks 
Univariable analysis 
 
(n=16,649) 
Multivariable analysis
1
  
 
(n=16,649, R
2
=3.42) 
 N N % OR 95% CI P OR 95% CI P 
IMD 16,649 12,241 73.5    0.28    0.16 
1 1,815 1,357 74.8 1.00    1.00    
2 2,400 1,792 74.7 0.99 0.86 1.14 0.94 0.96 0.83 1.10 0.55 
3 2,796 2,043 73.1 0.92 0.80 1.05 0.20 0.89 0.77 1.02 0.09 
4 3,847 2,793 72.6 0.89 0.79 1.02 0.09 0.86 0.76 0.98 0.03 
5 5,791 4,256 73.5 0.94 0.83 1.06 0.28 0.90 0.80 1.02 0.10 
Age Range 16,649 12,241 73.5    <0.001    <0.001 
<60 2,561 1,970 76.9 1.00    1.00    
60-69 4,707 3,517 74.7 0.89 0.79 0.99 0.04 0.92 0.82 1.03 0.14 
70-79 6,635 4,834 72.9 0.81 0.72 0.90 <0.001 0.86 0.77 0.96 0.01 
80+ 2,746 1,920 69.9 0.70 0.62 0.79 <0.001 0.79 0.69 0.89 <0.001 
Sex 16,649 12,241 73.5    0.76    0.59 
Female 6,909 5,071 73.4 1.00    1.00    
Male 9,740 7,170 73.6 1.01 0.94 1.08 0.76 1.02 0.95 1.10 0.59 
Histology 16,649 12,241 73.5    <0.001    <0.001 
NSCLC 9,865 7,236 73.4 1.00    1.00    
SCLC 2,341 1,905 81.4 1.59 1.42 1.78 <0.001 1.59 1.42 1.79 <0.001 
Other 4,443 3,100 69.8 0.84 0.78 0.91 <0.001 0.88 0.81 0.96 <0.001 
Year of 
Diagnosis 16,649 12,241 73.5    <0.001    <0.001 
1999 2,345 1,608 68.6 1.00    1.00    
2000 2,355 1,714 72.8 1.59 1.41 1.79 <0.001 1.24 1.10 1.41 <0.001 
2001 2,404 1,860 77.4 1.95 1.72 2.20 <0.001 1.60 1.40 1.82 <0.001 
2002 2,379 1,865 78.4 2.49 2.20 2.82 <0.001 1.69 1.48 1.93 <0.001 
2003 2,422 1,954 80.7 2.64 2.33 3.00 <0.001 1.96 1.71 2.24 <0.001 
2004 2,350 1,855 78.9 3.04 2.67 3.46 <0.001 1.76 1.54 2.01 <0.001 
2005 2,394 1,385 57.9 2.73 2.40 3.10 <0.001 0.64 0.57 0.72 <0.001 
Co-morbidity 
score 16,649 12,241 73.5    <0.001    <0.001 
0 2,681 1,888 70.4 1.00    1.00    
1-2 1,151 763 66.3 0.83 0.71 0.96 0.01 0.87 0.75 1.01 0.07 
3+ 175 110 62.9 0.71 0.52 0.98 0.04 0.76 0.55 1.06 0.10 
CCM missing 11,178 8,438 75.5 1.29 1.18 1.42 <0.001 1.29 1.18 1.42 <0.001 
No HES link  1,464 1,042 71.2 1.04 0.90 1.19 0.61 1.19 1.03 1.38 0.02 
1
 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score 
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Table D.2. Odds of receiving any treatment within 31 days of diagnosis (for those treated 
within 1 year of diagnosis) 1999-2005 
 
Treated  
Treated 
within 31 days 
Univariable analysis  
(n=19,510) 
Multivariable analysis
1
   
(n=19,510, R
2
=10.50) 
N N % OR 95% CI P OR 95% CI P 
IMD 19,510 8,457 43.4    0.004    0.001 
1 2,208 1,036 46.9 1.00    1.00    
2 2,828 1,247 44.1 0.89 0.80 1.00 0.05 0.91 0.81 1.03 0.12 
3 3,182 1,371 43.1 0.86 0.77 0.96 0.005 0.88 0.78 0.98 0.03 
4 4,405 1,866 42.4 0.83 0.75 0.92 <0.001 0.83 0.74 0.92 0.001 
5 6,887 2,937 42.7 0.84 0.76 0.93 <0.001 0.82 0.74 0.91 <0.001 
Age Range 19,510 8,457 43.4    <0.001    <0.001 
<60 4,073 2,085 51.2 1.00    1.00    
60-69 6,389 2,886 45.2 0.79 0.73 0.85 <0.001 0.83 0.76 0.90 <0.001 
70-79 7,274 2,887 39.7 0.63 0.58 0.68 <0.001 0.77 0.71 0.84 <0.001 
80+ 1,774 599 33.8 0.49 0.43 0.55 <0.001 0.68 0.60 0.78 <0.001 
Sex 19,510 8,457 43.4    <0.001    0.58 
Female 8,060 3,641 45.2 1.00    1.00    
Male 11,450 4,816 42.1 0.88 0.83 0.93 <0.001 0.98 0.92 1.05 0.58 
Histology 19,510 8,457 43.4    <0.001    <0.001 
NSCLC 12,551 4,269 34.0 1.00    1.00    
SCLC 3,705 2,867 77.4 6.64 6.09 7.23 <0.001 4.76 4.32 5.25 <0.001 
Other 3,254 1,321 40.6 1.33 1.22 1.43 <0.001 1.41 1.30 1.53 <0.001 
Co-morbidity 
score 19,510 8,457 43.4    <0.001    0.28 
0 3,464 1,469 42.4 1.00    1.00    
1-2 1,790 726 40.6 0.93 0.83 1.04 0.20 0.98 0.87 1.12 0.81 
3+ 273 110 40.3 0.92 0.71 1.18 0.50 1.01 0.77 1.32 0.96 
CCM missing 13,210 5,866 44.4 1.08 1.01 1.17 0.04 1.06 0.97 1.15 0.18 
No HES link  773 286 37.0 0.80 0.68 0.94 0.006 1.16 0.98 1.38 0.08 
Diagnosis year 19,510 8,457 43.4    0.10    0.01 
1999 2,844 1,246 43.8 1.00    1.00    
2000 2,901 1,225 42.2 0.94 0.84 1.04 0.23 0.87 0.77 0.97 0.01 
2001 2,776 1,200 43.2 0.98 0.88 1.09 0.66 0.96 0.86 1.08 0.49 
2002 2,766 1,155 41.8 0.92 0.83 1.02 0.12 0.86 0.76 0.96 0.009 
2003 2,705 1,230 45.5 1.07 0.96 1.19 0.21 1.00 0.89 1.12 1.00 
2004 2,701 1,156 42.8 0.96 0.86 1.07 0.45 0.86 0.77 0.97 0.01 
2005 2,817 1,245 44.2 1.02 0.91 1.13 0.77 0.95 0.85 1.07 0.39 
GP referral 19,510 8,457 43.4    <0.001    <0.001 
No GP referral 
date 8,645 4,117 47.6 1.00    1.00    
<=14 days to 
FHA 8,107 3,424 42.2 0.80 0.76 0.85 <0.001 0.79 0.73 0.84 <0.001 
>14 days to 
FHA 2,758 916 33.2 0.55 0.50 0.60 <0.001 0.59 0.54 0.65 <0.001 
Ist treatment 19,510 8,457 43.4    <0.001    <0.001 
Chemotherapy 6,949 4,248 61.1 1.00    1.00    
Surgery 3,430 1,330 38.8 0.40 0.37 0.44 <0.001 0.76 0.69 0.83 <0.0011 
Radiotherapy 9,131 2,879 31.5 0.29 0.27 0.31 <0.001 0.53 0.49 0.58 <0.001 
1
 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, GP referral, first treatment 
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Table D.3. Odds of receiving any treatment within 62 days of GP referral (for those with FHA 
within 1 year of referral, diagnosis within 1 year of FHA and treated within 1 year of 
diagnosis) 1999-2005  
 Treated Treated within 
62 days 
Univariable analysis  
(n=10,844) 
Multivariable analysis
1
   
(n=10,844, R
2
=9.71) 
 N  N  % OR 95% CI P OR 95% CI P 
IMD 10,844 5,326 49.1    0.005    0.0002 
1 1,220 646 53.0 1.00    1.00    
2 1,628 825 50.7 0.91 0.79 1.06 0.23 0.92 0.79 1.08 0.32 
3 1,796 901 50.2 0.89 0.77 1.03 0.13 0.89 0.76 1.04 0.16 
4 2,476 1,173 47.4 0.80 0.70 0.92 0.001 0.78 0.67 0.90 0.001 
5 3,724 1,781 47.8 0.81 0.72 0.93 0.002 0.77 0.67 0.88 <0.001 
Age Range 10,844 5,326 49.1    <0.001    <0.001 
<60 2,146 1,233 57.5 1.00    1.00    
60-69 3,616 1,843 51.0 0.77 0.69 0.86 <0.001 0.82 0.73 0.92 0.001 
70-79 4,054 1,826 45.0 0.61 0.55 0.67 <0.001 0.74 0.66 0.83 <0.001 
80+ 1,028 424 41.3 0.52 0.45 0.60 <0.001 0.70 0.59 0.82 <0.001 
Sex 10,844 5,326 49.1    0.38    0.21 
Female 4,436 2,201 49.6 1.00    1.00    
Male 6,408 3,125 48.8 0.97 0.90 1.04 0.38 1.05 0.97 1.14 0.21 
Histology 10,844 5,326 49.1    <0.001    <0.001 
NSCLC 7,290 3,091 42.4 1.00    1.00    
SCLC 1,911 1,550 81.1 5.83 5.15 6.60 <0.001 3.66 3.19 4.20 <0.001 
Other 1,643 685 41.7 0.97 0.87 1.08 0.60 1.04 0.93 1.16 0.54 
Co-morbidity 
score 10,844 5,326 49.1    <0.001    <0.001 
0 1,824 799 43.8 1.00    1.00    
1-2 729 316 43.4 0.98 0.83 1.17 0.83 1.05 0.87 1.26 0.61 
3+ 97 33 34.0 0.66 0.43 1.02 0.06 0.73 0.46 1.15 0.17 
CCM missing 7,763 3,990 51.4 1.36 1.22 1.50 <0.001 1.32 1.18 1.47 <0.001 
No HES link  431 188 43.6 0.99 0.80 1.23 0.94 1.38 1.11 1.73 0.004 
Diagnosis year 10,844 5,326 49.1    0.01    0.04 
1999 1,541 745 48.4 1.00    1.00    
2000 1,530 697 45.6 0.89 0.78 1.03 0.12 0.86 0.74 1.00 0.05 
2001 1,530 767 50.1 1.07 0.93 1.24 0.32 1.07 0.92 1.25 0.37 
2002 1,552 747 48.1 0.99 0.86 1.14 0.91 0.92 0.79 1.07 0.28 
2003 1,581 778 49.2 1.04 0.90 1.19 0.63 0.96 0.82 1.12 0.60 
2004 1,534 766 49.9 1.07 0.93 1.23 0.38 0.96 0.82 1.12 0.58 
2005 1,576 826 52.4 1.18 1.02 1.35 0.02 1.08 0.93 1.26 0.33 
1
st
 treatment 10,844 5,326 49.1    <0.001    <0.001 
Chemotherapy 3,985 2,732 68.6 1.00    1.00    
Surgery  1,882 619 32.9 0.22 0.20 0.25 <0.001 0.36 0.32 0.41 <0.001 
Radiotherapy 4,977 1,975 39.7 0.30 0.28 0.33 <0.001 0.50 0.45 0.56 <0.001 
1
 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, first treatment 
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Table D.4. Hazard ratio of early first hospital appointment from GP referral (for those 
referred within 1 year) in 2006-2010 cohort with stage recorded 
  Median time 
to FHA (days) 
Univariable analysis 
(n=5100) 
Multivariable analysis  
(n=5100) 
 N N IQR HR 95% CI P HR 95% CI P 
IMD 5100 9 4-14    0.28    0.16 
1 594 8 4-14 1.00    1.00    
2 705 9 5-14 0.93 0.84 1.04 0.21 0.95 0.85 1.06 0.32 
3 839 9 5-15 0.90 0.81 1.00 0.05 0.89 0.80 0.99 0.03 
4 1198 9 5-14 0.91 0.83 1.01 0.07 0.90 0.81 0.99 0.03 
5 1764 9 4-15 0.95 0.87 1.04 0.27 0.93 0.85 1.02 0.13 
Age Range 5100 9 4-14    0.34     
<60 682 9 4-14 1.00    1.00    
60-69 1490 9 5-14 1.01 0.93 1.11 0.75 1.00 0.91 1.10 1.00 
70-79 1876 9 5-15 0.95 0.87 1.04 0.30 0.93 0.85 1.02 0.11 
80+ 1052 8 3-15 0.99 0.90 1.09 0.79 0.91 0.82 1.01 0.07 
Sex 5100 9 4-14    0.18    0.46 
female 2297 9 4-14 1.00    1.00    
male 2803 9 5-15 0.96 0.91 1.02 0.18 0.98 0.93 1.04 0.46 
Histology 5100 9 4-14    <0.001     
NSCLC 3518 9 6-15 1.00    1.00    
SCLC 386 8 4-13 1.23 1.11 1.37 0.00 1.10 0.99 1.22 0.09 
Other 1196 8 1-14 1.14 1.07 1.22 0.00 1.06 0.99 1.14 0.11 
Year of 
Diagnosis 5100 9 4-14    <0.001    <0.001 
2006 395 14 9-23 1.00    1.00    
2007 473 14 8-22 1.03 0.90 1.17 0.70 1.00 0.88 1.15 0.98 
2008 968 7.5 4-12 1.70 1.51 1.92 <0.001 1.64 1.46 1.85 <0.001 
2009 1492 8 3-13 1.68 1.50 1.87 <0.001 1.78 1.56 2.04 <0.001 
2010 1772 8 3-14 1.53 1.37 1.71 <0.001 1.59 1.38 1.82 <0.001 
Co-morbidity 
score 5100 9 4-14    0.005     
0 618 9 5-15 1.00    1.00    
1-2 508 8 3-18 0.93 0.82 1.07 0.31 0.93 0.83 1.05 0.26 
3+ 110 8 2-15 1.05 0.88 1.25 0.59 0.88 0.72 1.08 0.24 
CCM missing 1259 10 6-16 1.03 0.84 1.26 0.77 1.19 1.06 1.32 0.002 
No HES link 2605 8 3-14 1.11 1.02 1.21 0.01 1.02 0.92 1.12 0.75 
Stage 5100 9 4-14    <0.001    <0.001 
I 773 11 7-20 1.00    1.00    
II 399 11 5-16 1.20 1.06 1.35 0.003 1.20 1.06 1.36 0.004 
III 1578 9 6-15 1.26 1.16 1.38 <0.001 1.23 1.12 1.34 <0.001 
IV 2350 8 3-14 1.45 1.33 1.57 <0.001 1.35 1.24 1.47 <0.001 
Performance 
Status 5100 9 4-14    <0.001     
0 1111 11 6-15 1.00    1.00    
1-2 2634 9 5-15 1.05 0.97 1.12 0.22 1.02 0.95 1.10 0.56 
3-4 1016 6 0-13 1.39 1.28 1.51 <0.001 1.32 1.20 1.45 <0.001 
Missing/ 
unknown 339 11 7-18 0.93 0.82 1.05 0.24 1.01 0.89 1.15 0.84 
1
 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage, PS 
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Table D.5. Likelihood of still being alive 2 years after diagnosis, by selected patient, tumour 
and system factors for those diagnosed between 1999 and 2005 (DCO cases excluded)  
1
 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, timely GP referral 
2
 Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, timely GP referral, type of 
treatment  
variable Adjusted – selected
1 
(n=36,477, R
2
=5.80) 
Adjusted – selected
2 
(n=36,477, R
2
=24.60) 
 OR 95% CI P OR 95% CI P 
Deprivation quintile    0.003    0.64 
1 (least deprived) 1.00    1.00    
2 0.97 0.86 1.10 0.68 1.02 0.89 1.18 0.74 
3 0.90 0.80 1.01 0.08 1.01 0.88 1.15 0.94 
4 0.86 0.77 0.96 0.01 0.98 0.86 1.12 0.80 
5 (most deprived) 0.84 0.76 0.94 0.002 1.06 0.94 1.20 0.38 
Age group    <0.001    0.15 
<60 1.00    1.00    
60-69 0.85 0.78 0.93 <0.001 0.99 0.89 1.09 0.78 
70-79 0.61 0.56 0.66 <0.001 0.95 0.86 1.06 0.35 
80+ 0.32 0.29 0.36 <0.001 0.86 0.74 0.99 0.03 
Sex    <0.001    <0.001 
Female 1.00    1.00    
Male 0.74 0.69 0.78 <0.001 0.71 0.66 0.76 <0.001 
Histology    <0.001    <0.001 
NSCLC 1.00    1.00    
SCLC 0.37 0.33 0.41 <0.001 0.59 0.52 0.67 <0.001 
Other 0.59 0.55 0.64 <0.001 1.05 0.96 1.15 0.28 
Year of Diagnosis    <0.001    <0.001 
1999 1.00    1.00    
2000 1.17 1.04 1.32 0.009 1.17 1.02 1.34 0.03 
2001 1.12 0.99 1.26 0.07 1.17 1.02 1.35 0.02 
2002 1.15 1.02 1.29 0.03 1.21 1.05 1.39 0.01 
2003 1.22 1.08 1.37 0.001 1.30 1.13 1.49 <0.001 
2004 1.20 1.07 1.36 0.002 1.32 1.15 1.52 <0.001 
2005 1.18 1.05 1.33 0.01 1.26 1.10 1.44 <0.001 
Co-morbidity score    <0.001    0.18 
0 1.00    1.00    
1-2 0.85 0.75 0.96 0.01 0.98 0.85 1.13 0.77 
3+ 0.67 0.51 0.88 0.004 0.76 0.55 1.04 0.08 
CCM missing 0.82 0.75 0.88 <0.001 0.91 0.83 1.00 0.06 
No HES link 0.46 0.39 0.54 <0.001 0.90 0.76 1.07 0.25 
Timely GP referral    <0.001    <0.001 
No GP referral 1.00    1.00    
FHA<=14 days 1.42 1.32 1.52 <0.001 1.24 1.14 1.34 <0.001 
FHA>14 days 2.08 1.90 2.28 <0.001 1.80 1.62 1.99 <0.001 
Type of treatment        <0.001 
No treatment     1.00    
Surgery     44.34 39.20 50.15 <0.001 
Surgery + 
chemo/radiotherapy     19.90 16.68 23.74 <0.001 
Chemotherapy     2.13 1.82 2.50 <0.001 
Chemotherapy 
+radiotherapy     5.81 5.06 6.68 <0.001 
Radiotherapy     2.73 2.45 3.05 <0.001 
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